The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.

Description

88 parts

›CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of U.S. patent application Ser. No. 15/067,024, filed Mar. 10, 2016, now U.S. Pat. No. 10,392,445, which is a continuation of International Patent Application No. PCT/EP2015/076528, filed Nov. 13, 2015, which claims the benefit of and priority to European Patent Application No. EP 14193260.8, now withdrawn, filed Nov. 14, 2014, European Patent Application No. EP 15183736.6, now abandoned, filed Sep. 3, 2015, and European Patent Application No. EP 15188142.2, now abandoned, filed Oct. 2, 2015, the disclosures of which are incorporated herein by reference in their entirety.

›SEQUENCE LISTING

This application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jul. 23, 2019, is named P32429-US-2_ST25.txt and is 858,163 bytes in size, and updated by a file entitled P32429-US-2_SL_Replacement.txt, created on Apr. 27, 2021, which is 872,614 bytes in size.

›FIELD OF THE INVENTION

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecules are characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof. The invention further relates to methods of producing these molecules and to methods of using the same.

›BACKGROUND · 1 of 2

Ligands interacting with molecules of the TNF (tumor necrosis factor) receptor superfamily have pivotal roles in the organization and function of the immune system. While regulating normal functions such as immune responses, hematopoiesis and morphogenesis, the TNF family ligands (also called cytokines) play a role in tumorgenesis, transplant rejection, septic shock, viral replication, bone resorption, rheumatoid arthritis and diabetes (Aggarwal, 2003). The TNF ligand family comprises 18 genes encoding 19 type II (i.e. intracellular N terminus and extracellular C-terminus) transmembrane proteins, characterized by the presence of a conserved C-terminal domain coined the ‘TNF homology domain’ (THD). This domain is responsible for receptor binding and is thus critical for the biological activity of the TNF ligand family members. The sequence identity between family members is ˜20-30% (Bodmer, 2002). Members of the TNF ligand family exert their biological function as self-assembling, noncovalent trimers (Banner et al, Cell 1993, 73, 431-445). Thus, the TNF family ligands form a trimer that is able to bind to and to activate the corresponding receptors of TNFR superfamily.

4-1BB (CD137), a member of the TNF receptor superfamily, has been first identified as a molecule whose expression is induced by T-cell activation (Kwon and Weissman, 1989). Subsequent studies demonstrated expression of 4-1BB in T- and B-lymphocytes (Snell et al., 2011; Zhang et al., 2010), NK-cells (Lin et al., 2008), NKT-cells (Kim et al., 2008), monocytes (Kienzle and von Kempis, 2000; Schwarz et al., 1995), neutrophils (Heinisch et al., 2000), mast (Nishimoto et al., 2005) and dendritic cells as well as cells of non-hematopoietic origin such as endothelial and smooth muscle cells (Broll et al., 2001; Olofsson et al., 2008). Expression of 4-1BB in different cell types is mostly inducible and driven by various stimulatory signals, such as T-cell receptor (TCR) or B-cell receptor triggering, as well as signaling induced through co-stimulatory molecules or receptors of pro-inflammatory cytokines (Diehl et al., 2002; von Kempis et al., 1997; Zhang et al., 2010).

Expression of 4-1BB ligand (4-1BBL or CD137L) is more restricted and is observed on professional antigen presenting cells (APC) such as B-cells, dendritic cells (DCs) and macrophages. Inducible expression of 4-1BBL is characteristic for T-cells, including both and γδ T-cell subsets, and endothelial cells (reviewed in Shao and Schwarz, 2011).

CD137 signaling is known to stimulate IFNγ secretion and proliferation of NK cells (Buechele et al., 2012; Lin et al., 2008; Melero et al., 1998) as well as to promote DC activation as indicated by their increased survival and capacity to secret cytokines and upregulate co-stimulatory molecules (Choi et al., 2009; Futagawa et al., 2002; Wilcox et al., 2002). However, CD137 is best characterized as a co-stimulatory molecule which modulates TCR-induced activation in both the CD4+ and CD8+ subsets of T-cells. In combination with TCR triggering, agonistic 4-1BB-specific antibodies enhance proliferation of T-cells, stimulate lymphokine secretion and decrease sensitivity of T-lymphocytes to activation-induced cells death (reviewed in (reviewed in Snell et al., 2011).

In line with these co-stimulatory effects of 4-1BB antibodies on T-cells in vitro, their administration to tumor bearing mice leads to potent anti-tumor effects in many experimental tumor models (Melero et al., 1997; Narazaki et al., 2010). However, 4-1BB usually exhibits its potency as an anti-tumor agent only when administered in combination with other immunomodulatory compounds (Curran et al., 2011; Guo et al., 2013; Morales-Kastresana et al., 2013; Teng et al., 2009; Wei et al., 2013), chemotherapeutic reagents (Ju et al., 2008; Kim et al., 2009), tumor-specific vaccination (Cuadros et al., 2005; Lee et al., 2011) or radiotherapy (Shi and Siemann, 2006). In vivo depletion experiments demonstrated that CD8+ T-cells play the most critical role in anti-tumoral effect of 4-1BB-specific antibodies. However, depending on the tumor model or combination therapy, which includes anti-4-1BB, contributions of other types of cells such as DCs, NK-cells or CD4+ T-cells have been reported (Melero et al., 1997; Murillo et al., 2009; Narazaki et al., 2010; Stagg et al., 2011).

In addition to their direct effects on different lymphocyte subsets, 4-1BB agonists can also induce infiltration and retention of activated T-cells in the tumor through 4-1BB-mediated upregulation of intercellular adhesion molecule 1 (ICAM1) and vascular cell adhesion molecule 1 (VCAM1) on tumor vascular endothelium (Palazon et al., 2011).

4-1BB triggering may also reverse the state of T-cell anergy induced by exposure to soluble antigen that may contribute to disruption of immunological tolerance in the tumor micro-environment or during chronic infections (Wilcox et al., 2004).

It appears that the immunomodulatory properties of 4-1BB agonistic antibodies in vivo require the presence of the wild type Fc-portion on the antibody molecule thereby implicating Fc-receptor binding as an important event required for the pharmacological activity of such reagents as has been described for agonistic antibodies specific to other apoptosis-inducing or immunomodulatory members of the TNFR-superfamily (Li and Ravetch, 2011; Teng et al., 2009). However, systemic administration of 4-1BB-specific agonistic antibodies with the functionally active Fc domain also induces expansion of CD8+ T-cells associated with liver toxicity (Dubrot et al., 2010) that is diminished or significantly ameliorated in the absence of functional Fc-receptors in mice. In human clinical trials (ClinicalTrials.gov, NCT00309023), Fc-competent 4-1BB agonistic antibodies (BMS-663513) administered once every three weeks for 12 weeks induced stabilization of the disease in patients with melanoma, ovarian or renal cell carcinoma. However, the same antibody given in another trial (NCT00612664) caused grade 4 hepatitis leading to termination of the trial (Simeone and Ascierto, 2012).

›BACKGROUND · 2 of 2

Collectively, the available pre-clinical and clinical data clearly demonstrate that there is a high clinical need for effective 4-1BB agonists. However, new generation drug candidates should not only effectively engage 4-1BB on the surface of hematopoietic and endothelial cells but also be capable of achieving that through mechanisms other than binding to Fc-receptors in order to avoid uncontrollable side effects. The latter may be accomplished through preferential binding to and oligomerization on tumor-specific or tumor-associated moieties.

Fusion proteins composed of one extracellular domain of a 4-1BB ligand and a single chain antibody fragment (Mueller et al., 2008; Hornig et al., 2012) or a single 4-1BB ligand fused to the C-terminus of a heavy chain (Zhang et al, 2007) have been made. WO 2010/010051 discloses the generation of fusion proteins that consist of three TNF ligand ectodomains linked to each other and fused to an antibody part.

However, there is still a need of new antigen binding molecules that combine a moiety capable of preferred binding to tumor-specific or tumor-associated targets with a moiety capable of forming a costimulatory TNF ligand trimer and that have sufficient stability to be pharmaceutically useful. The antigen binding molecules of the present invention comprise both and surprisingly they provide a trimeric and thus biologically active TNF ligand, although one of the trimerizing TNF ligand ectodomains is located on another polypeptide than the other two TNF ligand ectodomains of the molecule.

›SUMMARY OF THE INVENTION · 1 of 6

In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising

(a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.

In a particular aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising

(a) at least one moiety capable of specific binding to a target cell antigen, (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof, and (c) an Fc domain composed of a first and a second subunit capable of stable association.

In a further aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, comprising

(i) the first polypeptide contains a CH1 or CL domain and the second polypeptide contains a CL or CH1 domain, respectively, wherein the second polypeptide is linked to the first polypeptide by a disulfide bond between the CH1 and CL domain, and wherein the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the CH1 or CL domain by a peptide linker and wherein the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to the CL or CH1 domain of said polypeptide, or (ii) the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, respectively, and wherein the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the C-terminus of the CH3 domain by a peptide linker and wherein the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to C-terminus of the CH3 domain of said polypeptide, or (iii) the first polypeptide contains a VH-CL or a VL-CH1 domain and the second polypeptide contains a VL-CH1 domain or a VH-CL domain, respectively, wherein the second polypeptide is linked to the first polypeptide by a disulfide bond between the CH1 and CL domain, and wherein the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to to VH or VL by a peptide linker and wherein the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to VL or VH of said polypeptide.

In a particular aspect, the TNF ligand family member is one that costimulates human T-cell activation. Thus, the TNF family ligand trimer-containing antigen binding molecule comprises

In one aspect, the TNF ligand family member is 4-1BBL.

In a further aspect, the ectodomain of a TNF ligand family member comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:96, SEQ ID NO: 373, SEQ ID NO:374 and SEQ ID NO:375, particularly the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:96.

In another aspect, the ectodomain of a TNF ligand family member or fragment thereof comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:96, particularly the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:96. More particularly, the ectodomain of a TNF ligand family member comprises the amino acid sequence of SEQ ID NO:96.

In a further aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises

(a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99 and in that the second polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4.

In one aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises

›SUMMARY OF THE INVENTION · 2 of 6

In a further aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises

In yet a further aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises

In another aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises

(a) at least one moiety capable of specific binding to a target cell antigen, (b) a first polypeptide containing a CH1 or CL domain and a second polypeptide containing a CL or CH1 domain, respectively, wherein the second polypeptide is linked to the first polypeptide by a disulfide bond between the CH1 and CL domain, and wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other and to the CH1 or CL domain by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof connected by a peptide linker to the CL or CH1 domain of said polypeptide.

In one aspect, provided is a TNF family ligand trimer-containing antigen binding molecule comprising

(a) at least one moiety capable of specific binding to a target cell antigen, (b) a first polypeptide containing a CH1 domain and a second polypeptide containing a CL domain, wherein the second polypeptide is linked to the first polypeptide by a disulfide bond between the CH1 and CL domain, and wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the CH1 domain by a peptide linker and in that the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to the CL domain of said polypeptide.

In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule comprising

(a) at least one moiety capable of specific binding to a target cell antigen, (b) a first polypeptide containing a CL domain and a second polypeptide containing a CH1 domain, wherein the second polypeptide is linked to the first polypeptide by a disulfide bond between the CH1 and CL domain, and wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the CL domain by a peptide linker and in that the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to the CH1 domain of said polypeptide.

In a further aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule as defined herein before, wherein the moiety capable of specific binding to a target cell antigen is selected from the group consisting of an antibody, an antibody fragment and a scaffold antigen binding protein.

In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule as defined herein before, wherein the moiety capable of specific binding to a target cell antigen is an antibody fragment.

In particular, the moiety capable of specific binding to a target cell antigen is selected from the group consisting of an antibody fragment, a Fab molecule, a crossover Fab molecule, a single chain Fab molecule, a Fv molecule, a scFv molecule, a single domain antibody, an aVH and a scaffold antigen binding protein.

In a particular aspect, the invention is concerned with a TNF family ligand trimer-containing antigen binding molecule as defined above, wherein the moiety capable of specific binding to a target cell antigen is a Fab molecule capable of specific binding to a target cell antigen.

The invention provides a TNF family ligand trimer-containing antigen binding molecule that comprises at least one moiety capable of specific binding to a target cell antigen. In a particular aspect, the TNF family ligand trimer-containing antigen binding molecule comprises one moiety capable of specific binding to a target cell antigen. In another aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising two moieties capable of specific binding to a target cell antigen.

In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule of the invention, wherein the target cell antigen is selected from the group consisting of Fibroblast Activation Protein (FAP), Carcinoembryonic Antigen (CEA), Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP), Epidermal Growth Factor Receptor (EGFR), CD19, CD20 and CD33.

In a particular aspect, the target cell antigen is Fibroblast Activation Protein (FAP).

In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to FAP comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:7 or SEQ ID NO:100, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:101, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:102, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:10 or SEQ ID NO:103, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:11 or SEQ ID NO:104, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:12 or SEQ ID NO:105.

›SUMMARY OF THE INVENTION · 3 of 6

In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to FAP comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:7, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:8 and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:9, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:10, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:11 and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:12.

In a particular aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to FAP comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:100, (ii) CDR-H2 comprising the amino acid sequence SEQ ID NO:101, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:102, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:103, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:104, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:105.

In one aspect, provided is a TNF family ligand trimer-containing antigen binding molecule as defined herein before, wherein the moiety capable of specific binding to FAP comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO:16 and a variable light chain comprising an amino acid sequence of SEQ ID NO:17 or wherein the moiety capable of specific binding to FAP comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO:106 and a variable light chain comprising an amino acid sequence of SEQ ID NO:107.

In a further aspect, provided is a TNF family ligand trimer-containing antigen binding molecule according to the invention, wherein a peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus to the CH1 or CL domain of a heavy chain by a second peptide linker and wherein one ectodomain of said TNF ligand family member or a fragment thereof is fused at the its C-terminus the CL or CH1 domain on a light chain by a third peptide linker.

In a particular aspect, the invention relates to a TNF family ligand trimer-containing antigen binding molecule as defined above, wherein the peptide linker is (G 4 S) 2 , i.e. a peptide linker of SEQ ID NO:13. In one aspect, the first peptide linker is (G 4 S) 2 (SEQ ID NO:13), the second peptide linker is GSPGSSSSGS (SEQ ID NO:57) and the third peptide linker is (G 4 S) 2 (SEQ ID NO:13). In another aspect, the first, the second and the third peptide linker is (G 4 S) 2 (SEQ ID NO:13).

The invention is further concerned with a TNF family ligand trimer-containing antigen binding molecule as defined herein before, comprising an Fc domain composed of a first and a second subunit capable of stable association.

In particular, the TNF family ligand trimer-containing antigen binding molecule of the invention comprising (c) an Fc domain composed of a first and a second subunit capable of stable association further comprises (a) a Fab molecule capable of specific binding to a target cell antigen, wherein the Fab heavy chain is fused at the C-terminus to the N-terminus of a CH2 domain in the Fc domain.

In a further aspect, the Fc domain is an IgG, particularly an IgG1 Fc domain or an IgG4 Fc domain. More particularly, the Fc domain is an IgG1 Fc domain. In a particular aspect, the Fc domain comprises a modification promoting the association of the first and second subunit of the Fc domain.

In another aspect, the invention is concerned with a TNF family ligand trimer-containing antigen binding molecule as defined herein before, comprising (c) an Fc domain composed of a first and a second subunit capable of stable association, wherein the Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor, in particular towards Fcγ receptor.

In particular, the Fc domain comprises amino acid substitutions at positions 234 and 235 (EU numbering) and/or 329 (EU numbering) of the IgG heavy chains. More particularly, provided is a trimeric TNF family ligand-containing antigen binding molecule according to the invention which comprises an IgG1 Fc domain with the amino acid substitutions L234A, L235A and P329G (EU numbering).

In a further aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises

a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to a target cell antigen, a first peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker fused at its C-terminus by a second peptide linker to a second heavy or light chain, and a second peptide comprising one ectodomain of said TNF ligand family member fused at its C-terminus by a third peptide linker to a second light or heavy chain, respectively.

In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the first peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus by a second peptide linker to a CH1 domain that is part of a heavy chain,

and the second peptide comprising one ectodomain of said TNF ligand family member or a fragment thereof is fused at its C-terminus by a third peptide linker to a CL domain that is part of a light chain.

›SUMMARY OF THE INVENTION · 4 of 6

and the second peptide comprising one ectodomain of said TNF ligand family member or a fragment thereof is fused at its C-terminus by a third peptide linker to a CH1 domain that is part of a light chain.

In a further aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the first peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus by a second peptide linker to a VH domain that is part of a heavy chain,

and the second peptide comprising one ectodomain of said TNF ligand family member or a fragment thereof is fused at its C-terminus by a third peptide linker to a VL domain that is part of a light chain.

Provided is further a TNF family ligand trimer-containing antigen binding molecule, wherein in the CL domain adjacent to the TNF ligand family member the amino acid at position 123 (EU numbering) has been replaced by arginine (R) and the amino acid at position 124 (EU numbering) has been substituted by lysine (K), and wherein in the CH1 domain adjacent to the TNF ligand family member the amino acids at position 147 (EU numbering) and at position 213 (EU numbering) have been substituted by glutamic acid (E).

In a further aspect, provided is a TNF family ligand trimer-containing antigen binding molecule as described herein before, wherein the antigen binding molecule comprises

(a) a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to a target cell antigen, (b) a second heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99, and a second light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4.

In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises

(a) a Fab molecule capable of specific binding to FAP, and (b) a second heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99, and a second light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4.

In a particular aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising a moiety capable of specific binding to FAP. In one aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises

(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:16 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:17 or a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:106 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:107, (ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:108, SEQ ID NO:111, SEQ ID NO:113, SEQ ID NO.115, SEQ ID NO:139 and SEQ ID NO:148, and (iii) a second light chain comprising the amino acid sequence of SEQ ID NO:15, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114 and SEQ ID NO:115.

In another aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises

(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:16 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:17 or a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:106 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:107, (ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119 and SEQ ID NO:173, and (iii) a second light chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120 and SEQ ID NO:174.

In yet another aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, comprising

(a) at least one moiety capable of specific binding to a target cell antigen, and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, respectively, and wherein the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the C-terminus of the CH3 domain by a peptide linker and wherein the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to C-terminus of the CH3 domain of said polypeptide.

In particular, such a TNF family ligand trimer-containing antigen binding molecule comprises two moieties capable of specific binding to a target cell antigen.

In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising two moieties capable of specific binding to FAP. In particular, provided is a TNF family ligand trimer-containing antigen binding molecule as described herein before comprises

(i) a first heavy chain comprising the amino acid sequence of SEQ ID NO:121, a second heavy chain comprising the amino acid sequence of SEQ ID NO:122, and two light chains comprising the amino acid sequence of SEQ ID NO:19, or (ii) a first heavy chain comprising the amino acid sequence of SEQ ID NO:123, a second heavy chain comprising the amino acid sequence of SEQ ID NO:124, and two light chains comprising the amino acid sequence of SEQ ID NO:125, or (iii) a first heavy chain comprising the amino acid sequence of SEQ ID NO:126, a second heavy chain comprising the amino acid sequence of SEQ ID NO:127, and two light chains comprising the amino acid sequence of SEQ ID NO:125.

›SUMMARY OF THE INVENTION · 5 of 6

In another particular aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule as described herein before, wherein the target cell antigen is CD19.

In one aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to CD19 comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:195 or SEQ ID NO:252, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:196 or SEQ ID NO:253, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:197 or SEQ ID NO:254, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:198 or SEQ ID NO:249, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:199 or SEQ ID NO:250, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:200 or SEQ ID NO:251.

In a further aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to CD19 comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO:201 and a variable light chain comprising an amino acid sequence of SEQ ID NO:202 or wherein the moiety capable of specific binding to FAP comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO:357 and a variable light chain comprising an amino acid sequence of SEQ ID NO:358.

In a particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises

(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:201 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:202 or a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:357 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:358, (ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:108, SEQ ID NO:111 and SEQ ID NO:113, and (iii) a second light chain comprising the amino acid sequence of SEQ ID NO:15, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:112 and SEQ ID NO:114.

In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises

(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:201 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:202 or a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:357 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:358, (ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119 and SEQ ID NO:173, and (iii) a second light chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120 and SEQ ID NO:174.

In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising two moieties capable of specific binding to CD19. In particular, provided is a TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 14 , 29 , 30 and 32 to 34 , wherein the antigen binding molecule comprises

(i) a first heavy chain comprising the amino acid sequence of SEQ ID NO:209, a second heavy chain comprising the amino acid sequence of SEQ ID NO:210, and two light chains comprising the amino acid sequence of SEQ ID NO:206, or (ii) a first heavy chain comprising the amino acid sequence of SEQ ID NO:213, a second heavy chain comprising the amino acid sequence of SEQ ID NO:214, and two light chains comprising the amino acid sequence of SEQ ID NO:206, or (iii) a first heavy chain comprising the amino acid sequence of SEQ ID NO:309, a second heavy chain comprising the amino acid sequence of SEQ ID NO:310, and two light chains comprising the amino acid sequence of SEQ ID NO:279, or (iv) a first heavy chain comprising the amino acid sequence of SEQ ID NO:313, a second heavy chain comprising the amino acid sequence of SEQ ID NO:314, and two light chains comprising the amino acid sequence of SEQ ID NO:279.

In another particular aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule as described herein before, wherein the target cell antigen is CEA.

In one aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to CEA comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:321, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:322, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:323, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:324, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:325, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:326.

In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to CEA comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO:329 and a variable light chain comprising an amino acid sequence of SEQ ID NO:330.

In one aspect, provided is a TNF family ligand trimer-containing antigen binding molecule as described herein before, wherein the antigen binding molecule comprises

(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:329 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:330, (ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:108, SEQ ID NO:111 and SEQ ID NO:113, and (iii) a second light chain comprising the amino acid sequence of SEQ ID NO:15, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:112 and SEQ ID NO:114.

›SUMMARY OF THE INVENTION · 6 of 6

In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises

(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:329 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:330, (ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119 and SEQ ID NO:173, and (iii) a second light chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120 and SEQ ID NO:174.

In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising two moieties capable of specific binding to CEA. Particularly, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises

(i) a first heavy chain comprising the amino acid sequence of SEQ ID NO:337, a second heavy chain comprising the amino acid sequence of SEQ ID NO:338, and two light chains comprising the amino acid sequence of SEQ ID NO:334, or (ii) a first heavy chain comprising the amino acid sequence of SEQ ID NO:341, a second heavy chain comprising the amino acid sequence of SEQ ID NO:342, and two light chains comprising the amino acid sequence of SEQ ID NO:334.

In a further aspect, provided is aTNF family ligand trimer-containing antigen binding molecule as described herein before, wherein the TNF ligand family member is OX40L. In one aspect, provided is TNF family ligand trimer-containing antigen binding molecule, wherein the ectodomain of a TNF ligand family member comprises the amino acid sequence of SEQ ID NO:53 or SEQ ID NO:54, particularly the amino acid sequence of SEQ ID NO:53.

In a further aspect, provided is a TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 5 , 10 to 24 , 29 , 30 , 32 to 34 , 38 to 40 , 44 and 45 , comprising

In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the target cell antigen is Fibroblast Activation Protein (FAP) and the moiety capable of specific binding to FAP comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:7 or SEQ ID NO:100, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:101, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:102, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:10 or SEQ ID NO:103, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:11 or SEQ ID NO:104, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:12 or SEQ ID NO:105.

Particularly, provided is a TNF family ligand trimer-containing antigen binding molecule as described herein, wherein the antigen binding molecule comprises

(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:16 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:17 or a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:106 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:107, (ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:355, and (iii) a second light chain comprising the amino acid sequence of SEQ ID NO:356.

According to another aspect of the invention, there is provided an isolated polynucleotide encoding a TNF family ligand trimer-containing antigen binding molecule as defined herein before. The invention further provides a vector, particularly an expression vector, comprising the isolated polynucleotide of the invention and a host cell comprising the isolated polynucleotide or the vector of the invention. In some embodiments the host cell is a eukaryotic cell, particularly a mammalian cell.

In another aspect, provided is a method for producing the TNF family ligand trimer-containing antigen binding molecule of the invention, comprising the steps of (i) culturing the host cell of the invention under conditions suitable for expression of the antigen binding molecule, and (ii) recovering the antigen binding molecule. The invention also encompasses a TNF family ligand trimer-containing antigen binding molecule produced by the method of the invention.

The invention further provides a pharmaceutical composition comprising the TNF family ligand trimer-containing antigen binding molecule of the invention and at least one pharmaceutically acceptable excipient.

Also encompassed by the invention is the TNF family ligand trimer-containing antigen binding molecule of the invention, or the pharmaceutical composition of the invention, for use as a medicament. In one aspect is provided the TNF family ligand trimer-containing antigen binding molecule of the invention, or the pharmaceutical composition of the invention, for use in the treatment of a disease in an individual in need thereof. In a specific embodiment, provided is the TNF family ligand trimer-containing antigen binding molecule of the invention, or the pharmaceutical composition of the invention, for use in the treatment of cancer.

Also provided is the use of the TNF family ligand trimer-containing antigen binding molecule of the invention for the manufacture of a medicament for the treatment of a disease in an individual in need thereof, in particular for the manufacture of a medicament for the treatment of cancer, as well as a method of treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising the TNF family ligand trimer-containing antigen binding molecule of the invention in a pharmaceutically acceptable form. In a specific embodiment, the disease is cancer. In any of the above embodiments the individual is preferably a mammal, particularly a human.

›BRIEF DESCRIPTION OF THE DRAWINGS · 1 of 6

FIGS. 1A to 1D show the components for the assembly of split trimeric human 4-1BB ligands including linker GGGGSGGGGS (SEQ ID NO:13). FIG. 1A shows the dimeric ligand that is fused at the C-terminus to a human CH1 or CL domain or a VL or VH domain and FIG. 1B shows the monomeric ligand fused to human CL or CH1 domain or a VL or VH domain.

FIG. 1C shows the dimeric ligand that is fused at the N-terminus to a human CH3 domain and

FIG. 1D shows the monomeric ligand fused at the N-terminus to a human CH3 domain.

FIGS. 2A to 2J show the 4-1BBL-trimer-containing antigen binding molecules Constructs 1.1 to 1.10 of the invention. The preparation and production of these constructs is described in Example 1. The VH and VL domains are those of anti-FAP antibody 28H1, the thick black point stands for the knob-into-hole modification. * symbolizes amino acid modifications in the CH1 and CL domain (so-called charged residues).

FIGS. 3A to 3C show the components for the assembly of split trimeric murine 4-1BB ligands including linker GGGGSGGGGS (SEQ ID NO:13). FIG. 3A shows the dimeric ligand that is fused at the C-terminus to murine CL domain and FIG. 3B shows the monomeric ligand fused at the C-terminus to murine CH1 domain. Components for the assembly of FAP targeted split trimeric murine 4-1BB ligand. FIG. 3C shows the assembled murine 4-1BBL-trimer-containing antigen binding molecules as described in more detail in Example 1.3.

FIGS. 4A to 4F show the 4-1BBL-trimer-containing antigen binding molecules Constructs 2.1 to 2.6 of the invention. The preparation and production of these constructs is described in Example 2. The VH and VL domains are those of anti-FAP antibody 4B9, the thick black point stands for the knob-into-hole modification. * symbolizes amino acid modifications in the CH1 and CL domain (so-called charged residues).

FIGS. 5A and 5B show the “untargeted” variants of Constructs 1.1 and 1.2 comprising a DP47 Fab molecule instead of the anti-FAP Fab molecule. The molecules are named Control A and Control B, respectively. The preparation is described in Example 1.4. FIG. 5C is a drawing of the monomeric 4-1BB Fc(kih) construct as prepared in Example 3.

FIGS. 6A-1 to 6C-2 relate to the binding of FAP-targeted 4-1BB ligand trimer-containing Fc(kih) fusion antigen binding molecule (FAP split 4-1BBL trimer, filled circles) or DP-47 untargeted 4-1BB ligand trimer-containing Fc(kih) fusion antigen binding molecule (DP47 split 4-1BBL trimer, open circles) to resting (naïve) or activated human PMBCs. Specifically, the binding to resting (naïve) or activated human CD8+ T cells is shown in FIGS. 6A-1 and 6A-2 , to resting (naïve) or activated human CD4+ T cells in FIGS. 6B-1 and 6B-2 and to resting (naïve) or activated human NK cells in FIGS. 6 -C 1 and 6 -C 2 . Shown is the binding as Median of fluorescence intensity (MFI) of red macrophytic algae Phycoerythrin (R-PE)-labeled anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment which is used as secondary detection antibody. WI was measured by flow cytometry and baseline corrected by subtracting the WI of the blank control.

FIGS. 7A-1 to 7B-4 show the binding of different FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs to human 4-1BB expressing T cells from PHA-L and Proleukin pre-activated and anti-human CD3/anti-human CD28 re-activated human PBMCs. Binding was detected with R-Phycoerythrin-fluorochrome conjugated anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment. Shown is the median of fluorescence intensity (MFI) versus the concentration of tested Constructs 1.1 to 1.10 of Example 1. For a better display the binding curves are split in four different blots with Construct 1.1 (monovalent FAP-targeted split trimeric human 4-1BB ligand Fc (kih)) and Control B (monovalent untargeted split trimeric human 4-1BB ligand Fc (kih) with CH-CL cross and charged residues) as comparison curves. Binding was monitored on CD3+CD8+ T cells ( FIGS. 7A-1 to 7A-4 ) and CD3+CD4+ T cells ( FIGS. 7B-1 to 7B-4 ). The 4-1BB expression level on CD8 T cells is normally higher than on CD4 T cells. All versions bind with a quite similar affinity to human 4-1BB.

FIGS. 8A-1 to 8B-4 show the binding of different FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs to CD4+ or CD8+ T cells from fresh PBMCs ( FIGS. 8A-1 to 8A-4 ) or to human 4-1BB expressing PHA-L and Proleukin pre-activated and anti-human CD3/anti-human CD28 re-activated human PBMCs ( FIGS. 8B-1 to 8B-4 ). Binding was detected with R-Phycoerythrin-fluorochrome conjugated anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment. Shown is the median of fluorescence intensity (MFI) versus the concentration of tested Constructs 2.1, 2.3, 2.4, 2.5 and 2.6 of Example 2 and control molecules Control B, Control C, Control E and Control F. For a better display the binding curves are split in two different blots with construct 2.1 (monovalent FAP-targeted split trimeric human 4-1BB ligand Fc (kih)) and control B (monovalent untargeted split trimeric human 4-1BB ligand Fc (kih) with CH-CL cross and charged residues) as comparison curves. Binding was monitored on CD45+CD3+CD8+ T cells (blots on the bottom) and CD45+CD3+CD4+ T cells (blots on the top). The 4-1BB expression level on CD8 T cells is normally higher than on CD4 T cells. All constructs bind with a quite similar affinity to human 4-1BB, whereas the bivalent construct 2.3 and its untargeted control C show a lower MFI. This can be due to sterical hindrance of 4-1BB-binding and/or less detection due to the 2nd detection antibody induced by the Fc-conjugated split 4-1BB ligand.

FIGS. 9A and 9B show the binding of FAP-targeted 4-1BB ligand trimer-containing Fc(kih) fusion antigen binding molecules (FAP split 4-1BBL trimer, filled circles) or DP47 untargeted 4-1BB ligand trimer-containing Fc(kih) fusion antigen binding molecules (DP47 split 4-1BBL trimer; open circles) to activated mouse splenocytes. In particular, the binding to activated mouse CD4+ T cells is shown in FIG. 9A and to activated mouse CD8+ T cells in FIG. 9B . An anti-mouse CD137-specific human IgG1 P329G LALA antibody (clone Lob12.3) was used as positive control (Triangles). The binding is characterized by plotting the MFI of R-PE-labeled anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment that is used as secondary detection antibody versus the concentration in nM of the tested split 4-1BBL trimer constructs. MFI was measured by flow cytometry and baseline corrected by subtracting the MFI of the blank control.

›BRIEF DESCRIPTION OF THE DRAWINGS · 2 of 6

FIGS. 10A and 10B show the binding of 4-1BB ligand trimer-containing Fc(kih) fusion antigen binding molecules (filled circles: FAP-targeted 4-1BB ligand trimer-containing Fc(kih) fusion antigen binding molecule Construct 1.1, open circles: DP47 untargeted 4-1BB ligand trimer-containing Fc(kih) fusion antigen binding molecule Control A to fibroblast activation protein (FAP)-expressing human melanoma ( FIG. 10A ) MV-3 cell line and ( FIG. 10B ) WM-266-4 cell line. The binding is characterized by plotting the MFI of R-PE-labeled anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment that is used as secondary detection antibody versus the concentration in nM of tested split 4-1BBL trimer constructs. MFI was measured by flow cytometry and baseline corrected by subtracting the MFI of the blank control.

FIGS. 11A-1 to 11B-2 show the binding of different FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs to human-FAP expressing human melanoma MV-3 cells ( FIGS. 11A-1 to 11A-4 ) and/or NIH/3T3-huFAP clone 39 transfected mouse embryonic fibroblast cells ( FIGS. 11B-1 and 11B-2 ). Binding was detected with R-Phycoerythrin-fluorochrome or fluorescein-fluorochrome conjugated anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragments. Shown is the median of fluorescence intensity (MFI) versus the concentration of tested constructs. For a better display binding curves were distributed to four ( FIGS. 11A-1 to 11A-4 ) or two blots ( FIGS. 11B-1 and 11B-2 ), whereas construct 1.1 (monovalent FAP-targeted split trimeric human 4-1BB ligand Fc (kih)) is used a comparison curve. All constructs bind with a similar affinity to human FAP except the bivalent FAP-targeted constructs (constructs 1.5, 1.7 and 1.8). They showed a tendency to have lower EC50 values and lower median fluorescence intensity. This can be explained with their bivalent targeting (higher avidity, less molecules can bind at the same time due to occupancy of two epitopes resulting in a lower MFI). Structural differences may also explain the difference between Construct 1.8 (complete bivalent targeting) and Constructs 1.5 and 1.7 (only partial bivalent targeting).

FIGS. 12A-1 to 12B-2 show the binding of different FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) Constructs 2.1, 2.3, 2.4, 2.5 and 2.6 to human-FAP expressing human melanoma MV-3 cells ( FIGS. 12A-1 and 12A-2 ) and WM-266-4 cells ( FIGS. 12B-1 and 12B-2 ). Binding was detected with R-Phycoerythrin-fluorochrome conjugated anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragments. Shown is the median of fluorescence intensity (MFI) versus the concentration of tested constructs. For a better display binding curves were distributed to two blots, whereas construct 2.1 (monovalent FAP-targeted split trimeric human 4-1BB ligand Fc (kih)) is used as comparison curve. All constructs bind with a similar affinity to human FAP except the bivalent FAP-targeted construct 2.3. It has a tendency to show lower EC50 values and lower median fluorescence intensity. This can be explained with its bivalent targeting, which results in higher avidity but less occupancy or FAP molecules on the cell surface resulting in a lower MFI.

FIGS. 13A-1 to 13B-2 show the binding of different FAP-targeted or untargeted split trimeric mouse 4-1BB ligand Fc (kih) constructs to CD4+ or CD8+ T cells from fresh splenocytes ( FIGS. 13A-1 and 13A-2 ) or to mouse 4-1BB expressing anti-mouse CD3/anti-mouse CD28 monoclonal agonistic antibodies activated mouse splenocytes ( FIGS. 13B-1 and 13B-2 ). Binding was detected with FITC-fluorochrome conjugated anti-mouse IgG Fcγ-specific goat IgG F(ab′)2 fragment. Shown is the median of fluorescence intensity (MFI) versus the concentration of tested constructs. Binding was monitored on CD3+CD8+ T cells (left blot) and CD3+CD4+ T cells (right blot). The 4-1BB expression level on CD8 T cells is normally higher than on CD4 T cells. All constructs bind with a quite similar affinity to mouse 4-1BB.

FIGS. 14A and 14B show the binding of different FAP-targeted or untargeted split trimeric mouse 4-1BB ligand Fc (kih) constructs to human FAP expressing tumor cells. Binding was detected with FITC-fluorochrome conjugated anti-mouse IgG Fcγ-specific goat IgG F(ab′)2 fragment. Shown is the median of fluorescence intensity (MFI) versus the concentration of tested constructs. Binding was monitored on MV-3 cells ( FIG. 14A ) and WM-266-4 cells ( FIG. 14B ). FAP-targeted split trimeric mouse 4-1BB ligand Fc (kih) constructs M.1 and M.2 bind with a quite similar affinity to FAP.

FIGS. 15A and 15B show a scheme that illustrates the general principal of the NFkB activity assay described in Example 6.1 using a reporter cell line. Shown is the activation assay set up with human 4-1BB expressing HeLa reporter cell line. A crosslinking of 4-1BB expressed on the reporter cells induces NFκB activation and NFκB-mediated Luciferase expression. After lysis of the cells Luciferase can catalyze the oxidation of Luciferin to Oxyluciferin. This chemical reaction correlates positively with the strength of NFκB-mediated luciferase expression and can be measured by the strength of light emission (units of released light). The ratio of FAP-expressing tumor cells to the reporter cell line HeLa-huCD137-NFkB-luc was 5 to 1.

FIGS. 16A to 16C show that the activation of the NFkB signaling pathway by FAP-targeted 4-1BB ligand trimer-containing Fc(kih) fusion antigen binding molecule (Construct 1.1) is strictly dependent on its binding to FAP-expressing target cells. Human CD137 expressing NFkB reporter HeLa cells were co-cultured with the indicated tumor cells exhibiting different levels of cell surface FAP expression. Luciferase activity was assessed as described in Example 6.1 after culturing cells in the absence or presence of 4-1BBL-containing molecules at the indicated concentrations for 6 hours. Filled circles refer to Construct 1.1. Open circles refer to DP47 untargeted 4-1BB ligand trimer-containing Fc(kih) fusion antigen binding molecule (Control A). Cell line NIH/3T3-human FAP clone 39 was used as target cells in 16 A; 16 B shows the activation with MV3 cell line as target cells and 16 C with WM-266-4 cell line as target cells. Activity is characterized by blotting the units of released light (URL) measured during 0.5 s versus the concentration in nM of tested split 4-1BBL trimer constructs. URLs are emitted due to luciferase-mediated oxidation of luciferin to oxyluciferin.

›BRIEF DESCRIPTION OF THE DRAWINGS · 3 of 6

FIGS. 17A-1 to 17C-4 shows the NFκB-activation-induced Luciferase expression and activity as measured with the assay described in Example 6.1. Counts of released light per seconds (CPS) are measured for 0.5 s/well and plotted against the used concentration of FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs. Human 4-1BB-expressing HeLa-reporter cells were incubated for 6 h in the absence ( FIGS. 17A-1 to 17A-4 ) or presence of crosslinking human-FAP expressing human melanoma cell line MV-3 ( FIGS. 17B-1 to 17B-4 ) or WM-266-4 ( FIGS. 17C-1 to 17C-4 ). CPS were measured and blotted against the concentrations of different FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) Constructs. The cell ratio is one human 4-1BB-expressing HeLa reporter cell to five tumor cells. For better display, activation curves were split to four different display-blots with construct 1.1 (monovalent FAP-targeted split trimeric human 4-1BB ligand Fc (kih)) and control B (monovalent untargeted split trimeric human 4-1BB ligand Fc (kih) with CH-CL cross and charged residues) as comparison curves. FIGS. 17A-1 to 17D-4 show the activation without crosslinking FAP-expressing tumor cells, FIGS. 17B-1 to 17B-4 show the activation in the presence of crosslinking FAP-expressing MV-3 tumor cells and FIGS. 17C-1 to 17C-4 show the activation in the presence of crosslinking FAP-expressing WM-266-4 tumor cells.

FIGS. 18A to 18F show the NFκB-activation-induced Luciferase expression and activity as measured for the constructs of Example 2. Units of released light (URL) are measured for 0.5 s/well and plotted against the used concentration of FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs. Human 4-1BB-expressing HeLa-reporter cells were incubated for 6 h in the absence or presence of crosslinking human-FAP expressing human melanoma cell line MV-3 or WM-266-4. URLs were measured and blotted against the concentrations of different FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs 2.1, 2.3, 2.4, 2.5 and 2.6 and Controls B, C, E and F. The cell ratio is one 4-1BB-expressing HeLa reporter cell to five tumor cells. For better display activation curves were split to two different display-blots with construct 2.1 (monovalent FAP-targeted split trimeric human 4-1BB ligand Fc (kih)).

FIGS. 19A and 19B show the activation assay set up with cynomolgus monkey 4-1BB expressing T293-HEK reporter cell line. A crosslinking of cynomolgus monkey 4-1BB expressed on the reporter cells induces NFκB activation and NFκB-mediated Luciferase expression. After lysis of the cells Luciferase can catalyze the oxidation of Luciferin to Oxyluciferin. This chemical reaction correlates positively with the strength of NFκB-mediated luciferase expression and can be measured by the strength of light emission (units of released light).

FIGS. 20A to 20F show the NFκB-activation-induced Luciferase expression and activity. Units of released light (URL) are measured for 0.5 s/well and plotted against the used concentration of FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs. Cynomolgus monkey 4-1BB-expressing T293-HEK-reporter cells were incubated for 6 h in the absence or presence of crosslinking human-FAP expressing human melanoma cell line MV-3 or WM-266-4. URLs were measured and blotted against the concentrations of different FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs. The cell ratio is one 4-1BB-expressing T293-HEK reporter cell to five MV-3 or two WM-266-4 cells. For better display activation curves were split to two different blots with Construct 2.1 as comparison curve.

FIGS. 21A and 21B show a scheme illustrating the principal of the T-cell activation assay described in Example 6.3. Shown is the schematic assay activation set up with HLA-A2-NLV-specific CD8 T cells and NLV-pulsed HLA-A2+ FAP+ human melanoma cell line MV-3 in the presence of different titrated concentration of FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs. Cells were incubated for 28 h, the last 4 h in the presence of monesin-containing Golgi-Stop. The ratio of NLV-specific CD8 T cells to MV-3 tumor cells is 1:8.

FIGS. 22A-1 to 22E-3 and 23A-1 to 23E-3 relate to the Activation assay with HLA-A2-NLV-specific CD8 T cells and NLV-pulsed HLA-A2+ FAP+ human melanoma cell line MV-3 in the presence of different titrated concentration of different FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs as prepared in Example 1. For better display expression curves were split to several different display-blots with Construct 1.1 (monovalent FAP-targeted split trimeric human 4-1BB ligand Fc (kih)) and Control B (monovalent untargeted split trimeric human 4-1BB ligand Fc (kih)) as comparison curves. Results were obtained in four independent similar experiments and show that prolonged IFNγ secretion and CD137 expression of NLV-specific CD8+ T cells is strictly dependent on simultaneous activation of T-cells via recognition of NLV-HLA-A2 complexes (signal 1) and 4-1BB-triggering by FAP-targeted human split 4-1BBL (signal 2). The effect of 4-1BB upregulation is shown in graphs of FIGS. 22A-1 to 22E-3 , whereas the effect of INFγ expression of CD8+ T cells is presented in graphs of FIGS. 23A-1 to 23E-3 . Shown is always the frequency in percentage of positive cells in the total CD8+ T cell population. All FAP-targeted variants induced a similar activation improvement of NLV-peptide activated CD8 T cells shown in FIGS. 22A-1 to 22E-3 as 4-1BB-upregulation (positive feedback loop) and in FIGS. 23A-1 to 23E-3 as IFNγ expression after 24 h of stimulation. Differences of curves lie in the range of normal error deviation and are not significant.

FIGS. 24A-1 to 24B-3 and 25A-1 to 25B-3 refer to the Activation assay with HLA-A2-NLV-specific CD8 T cells and NLV-pulsed HLA-A2+ FAP+ human melanoma cell line MV-3 in the presence of titrated concentration of different FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs of Example 2. For better display expression curves were split to two different display-blots with Construct 2.1 (monovalent FAP-targeted split trimeric human 4-1BB ligand Fc (kih)) and Control B as comparison curves. All FAP-targeted split trimeric human 4-1BB ligand Fc (kih) constructs show a similar activation improvement of HLA-A2-NLV-peptide specific CD8 T cells shown in FIGS. 24A-1 to 24B-3 as 4-1BB-upregulation (positive feedback loop) and in FIGS. 25A-1 to 25B-3 as IFNγ expression after 24 h of stimulation. Differences of curves lie in the range of normal error deviation and are not significant.

›BRIEF DESCRIPTION OF THE DRAWINGS · 4 of 6

FIGS. 26A and 26B show a scheme illustrating the experiment as described in Example 6.4.

FIG. 27 shows the induction of CD8+ T cell proliferation. Shown is the frequency of proliferating CD8+ T cells versus the concentration of tested constructs.

FIG. 28A relates to the single dose PK experiment of Construct 1.2 and Control B in healthy NOG mice. Shown is the decline in Construct concentration over the time. FIG. 28B shows the results of the single dose PK experiment of Constructs 2.1, 2.3, Control B and Control C in tumor bearing NOG mice humaniced with stem cells. FIG. 28C relates to the single dose PK experiment comparing Construct 2.1 and 2.3 in healthy NOG mice.

FIGS. 29A to 29D show components for the assembly of split trimeric human 4-1BB ligands including linker GGGGSGGGGS (SEQ ID NO:13). FIG. 29A shows the dimeric ligand that is fused at the C-terminus to a human CL domain with mutations E123R and Q124K (charged residues) and FIG. 29B shows the monomeric 4-1BB ligand fused to human CH1 domain with mutations K147E and K213E (charged residues). Components for the assembly of bivalent CD19-targeted split trimeric human 4-1BB ligand (71-254) antigen binding molecule (construct 3.3). FIG. 29C shows the dimeric ligand being fused to the C-terminus of human IgG1 Fc hole chain. FIG. 29D shows the monomeric ligand being fused to the C-terminus of human IgG1 Fc knob chain.

FIGS. 30A to 30F show the CD19-targeted 4-1BBL-trimer-containing antigen binding molecules Constructs 3.1 to 3.6 of the invention. The preparation and production of these constructs is described in Example 3. The VH and VL domains are those of anti-CD19 antibody 8B8-018, the thick black point stands for the knob-into-hole modification. * symbolizes amino acid modifications in the CH1 and CL domain (so-called charged residues).

FIGS. 31A-1 to 31A-2 illustrate the randomization strategy for the CDR regions of the parental clone 8B8. Shown are the variable domains of the parental clone 8B8 and the CDR regions (boxed) according to the numbering of Kabat. (X) (SEQ ID NO:202; SEQ ID NO:201) represents the randomized positions. FIGS. 31B-1 to 31B-2 show the schematic description of the library generation strategies. Shown is the PCR amplification and cloning strategy used for the generation of the 8B8-based library with A) randomized CDR1 and CDR2 regions in the light and heavy chain or B) randomized CDR1 and CDR3 regions in the light and CDR3 region in the heavy chain. Respective enzymes used for cloning into the phagemide are indicated.

FIGS. 32A and 32B show the alignment of the parental anti-CD19 clone 8B8 (SEQ ID NO:202; SEQ ID NO:201) with the selected affinity-matured binders. Shown are the sequences of clone 8B8 and all selected affinity-matured binders. CDRs of both heavy and light chains are framed (SEQ ID NOs:231-272).

FIGS. 33A to 33H relate to the SPR analysis of the parental 8B8 clone and its affinity-matured variants. Shown are the sensorgrams of clone 8B8 and its affinity-matured derivatives that are devoid of the LCDR1 N27d and N28 hotspots.

FIG. 34 illustrates the setup of the assay measuring Simultaneous binding of CD19 targeted trimeric split 4-1BBL to hu4-1BB and huCD19 (Example 8.2).

FIGS. 35A-35F show simultaneous binding of the CD19 targeted trimeric 4-1BBL FC fusion antigen binding molecules Constructs 3.1, 3.3, 3.4, 3.5, 3.6 and 4.4 (Analyte 1) to immobilized human 4-1BB and human CD19 (Analyte 2).

FIGS. 36A-1 to 36B-3 show the binding of different CD19-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs to 4-1BB-expressing CD4 and CD8 T cells of PHA-L and Proleukin pre-activated and anti-human CD3/anti-human CD28 re-activated human PBMCs. Binding was detected with R-Phycoerythrin-fluorochrome conjugated anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment. Shown is the median of fluorescence intensity (MFI) versus the concentration of tested constructs. For a better display the binding curves are split in three different blots with construct 3.4 and control F (Isotype control huIgG1 P329G LALA) as comparison curves. Binding was monitored on CD45+CD3+CD8+ T cells ( FIGS. 36A-1 to 36A-3 ) and CD45+CD3+CD4+ T cells ( FIGS. 36B-1 to 36B-3 ). The 4-1BB expression level on CD8 T cells is normally higher than on CD4 T cells. All constructs bind with a quite similar affinity to human 4-1BB.

FIGS. 37A-1 to 37D-3 show the binding of CD19-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) antigen binding molecules to human-CD19 expressing B cell lymphoma cell lines: diffuse large non-Hodgkin B cell lymphoma SU-DHL-8 ( 37 A- 1 to 37 A- 3 ), acute B cell precursor lymphoid leukemia Nalm6 ( 37 B- 1 to 37 B- 3 ), diffuse large cell lymphoblast lymphoma Toledo ( 37 C- 1 to 37 C- 3 ) and diffuse large B cell lymphoma OCI-Ly18 ( 37 D- 1 to 37 D- 3 ). Binding was detected with R-Phycoerythrin-fluorochrome conjugated anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragments. Shown is the median of fluorescence intensity (MFI) versus the concentration of tested constructs. For a better display the binding curves are split in three different blots with construct 3.4 and control F (Isotype control huIgG1 P329G LALA) as comparison curves. All constructs bind with a quite similar affinity to human CD19.

FIGS. 38A to 38C relate to NFκB-activation-induced Luciferase expression and activity of CD19-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) antigen binding molecules. Units of released light (URL) are measured for 0.5 s/well and plotted against the used concentration of CD19-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs 3.1 and 3.3 and control molecules B and C. Human 4-1BB-expressing HeLa-reporter cells were incubated for 7.5 h in the absence presence of crosslinking human-CD19 expressing SU-DHL-8 or Pfeiffer cells. URLs were measured and blotted against the concentrations of different CD19-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs. The cell ratio is one 4-1BB-expressing HeLa reporter cell to 2.5 or five tumor cells.

›BRIEF DESCRIPTION OF THE DRAWINGS · 5 of 6

FIG. 39 shows the binding of different humanized variants of T84.66 IgG on CEA-expressing human gastric adenocarcinoma cells. Based on the data humanized variant 1 was selected for including it into CEA-targeted trimeric human 4-1BB ligand Fc (kih) antigen binding molecules.

FIGS. 40A to 40F show the CEA targeted 4-1BBL-trimer-containing antigen binding molecules Constructs 5.1 to 5.6 of the invention. The preparation and production of these constructs is described in Example 11. The VH and VL domains are those of anti-CEA antibody T84.66-LCHA, the thick black point stands for the knob-into-hole modification. * symbolizes amino acid modifications in the CH1 and CL domain (so-called charged residues).

FIG. 41A shows a schematic description of human NA3B3A2-avi His, the antigen used to assess binding of CEA-targeted trimeric split 4-1BBL Fc (kih) antigen binding molecules. FIG. 41B illustrates the setup of the assay measuring simultaneous binding of CEA-targeted trimeric split 4-1BBL to hu4-1BB and human NA3B3A2 (Example 12.1).

FIGS. 42A to 42D show simultaneous binding of the CEA targeted trimeric 4-1BBL Fc fusion antigen binding molecules Constructs 5.4, 5.6, 5.7 and 5.8 (Analyte 1) to immobilized human 4-1BB and human NA3B3A2 (Analyte 2).

FIGS. 43A to 43D show binding of different CEA-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs to 4-1BB-expressing CD4 and CD8 T cells of PHA-L and Proleukin pre-activated and anti-human CD3/anti-human CD28 re-activated human PBMCs. Binding was detected with R-Phycoerythrin-fluorochrome conjugated anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment. Shown is the median of fluorescence intensity (MFI) versus the concentration of tested constructs. For a better display the binding curves are split in two different blots with construct 5.4 and control F (Isotype control huIgG1 P329G LALA) as comparison curves. Binding was monitored on CD45+CD3+CD8+ T cells (blots on the bottom) and CD45+CD3+CD4+ T cells (blots on the top). The 4-1BB expression level on CD8 T cells is normally higher than on CD4 T cells. All constructs bind with quite similar affinity to human 4-1BB.

FIGS. 44A and 44B show the binding of CEA-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs to human-CEA expressing human gastric cell line MKN-45 ( 44 A) and human colorectal adenocarcinoma cells line LS180 (right 44 B). Binding was detected with R-Phycoerythrin-fluorochrome conjugated anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragments. Shown is the median of fluorescence intensity (MFI) versus the concentration of tested constructs.

FIGS. 45A to 45D relate to NFκB-activation-induced Luciferase expression and activity of CEA-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) antigen binding molecules. Units of released light (URL) are measured for 0.5 s/well and blotted against the used concentration of CEA-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs 5.4, 5.6, 5.7 and 5.8 and control molecules. Human 4-1BB-expressing HeLa-reporter cells were incubated for 6 h in the absence or presence of crosslinking human-CEA expressing human gastric cancer cell line MKN-45. The cell ratio is one 4-1BB-expressing HeLa reporter cell to three tumor cells.

FIGS. 46A and 46B show the components for the assembly of monovalent FAP targeted split trimeric human OX40 ligand (construct 6.1) including linker GGGGSGGGGS (SEQ ID NO:13). FIG. 46A relates to dimeric ligand fused to human IgG1-CL domain, FIG. 46B relates to monomeric ligand fused to human IgG1-CH1 domain. FIG. 46C shows the FAP targeted OX40L-trimer-containing antigen binding molecule Construct 6.1. In FIG. 46D is shown the DP47 “untargeted” human IgG1 PGLALA (control F).

FIG. 47A shows the binding of FAP targeted split trimeric human OX40L to FAP positive WM-266-4 cells. WM-266-4 cells express high levels of human fibroblast activation protein (huFAP). Only FAP targeted OX40 ligand Fc (kih) constructs (filled square) but not control F (filled diamond) bound to WM-266-4 cells. Shown is the binding as median of fluorescence intensity (MFI) of Fluorescein isothiocyanate (FITC)-labeled anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment which is used as secondary detection antibody. MFI was measured by flow cytometry. The x-axis shows the concentration of antibody constructs. FIG. 47B shows the binding of FAP targeted OX40 ligand Fc (kih) construct to human FAP human OX40 negative A549 NucLight™ Red cells. FAP targeted OX40 ligand Fc (kih) construct showed no binding to OX40 negative FAP negative A549 tumor cells. Shown is the binding as median of fluorescence intensity (MFI) of FITC labeled anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment which is used as secondary detection antibody. MFI was measured by flow cytometry and baseline corrected by subtracting the MFI of the blank control.

FIGS. 48A-1 to 48A-2 show the binding of FAP-OX40L to resting and activated human CD4 T cells. OX40 is not expressed on resting human CD4 T cells (left side). In the absence of human OX40 expressing cells no binding was observed ( 48 A- 1 ). After activation of human PBMCs OX40 is up-regulated on CD4+ T cells ( 48 A- 2 ). FAP-OX40L bound to OX40+ activated CD4 T cells. Shown is the binding as median of fluorescence intensity (MFI) of FITC labeled anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment which is used as secondary detection antibody. MFI was measured by flow cytometry and baseline corrected by subtracting the MFI of the blank control. The x-axis shows the concentration of antibody constructs. FIGS. 48B-1 and 48B-2 show that OX40 is not expressed on resting human CD8 T cells (left side). In the absence of human OX40 expressing cells no binding was observed (left graphs). After activation of human PBMCs OX40 is up-regulated on CD8+ T cells (right side). OX40 expression on human CD8+ T cells is lower than on CD4+ T cells and varies between donors and time points. Expression of OX40 was low on the depicted CD8 T cells. FAP-OX40L bound to OX40+ activated CD8 T cells. Shown is the binding as median of fluorescence intensity (MFI) of FITC labeled anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment which is used as secondary detection antibody. MFI was measured by flow cytometry and baseline corrected by subtracting the MFI of the blank control. The x-axis shows the concentration of antibody constructs.

›BRIEF DESCRIPTION OF THE DRAWINGS · 6 of 6

In FIGS. 49A and 49B , the activation of NFκB signaling pathway by the FAP targeted split trimeric human OX40L antigen binding molecule (FAP-OX40L) in HeLa_hOx40_NFkB_Luc1 reporter cells is demonstrated. Shown is the activation with ( 49 B) or without ( 49 A) crosslinking by secondary antibody. The reporter cells were cultured for 5 hours in the presence of FAP-OX40L at the indicated concentrations with or without crosslinking secondary poly-clonal anti-huIgG1 Fcγ-specific goat IgG F(ab)2 fragment in a 1:2 ratio. Luciferase activity was assessed as described in Example 6.1. Activity is characterized by blotting the units of released light (URL) measured during 0.5 s versus the concentration in nM of tested construct. URLs are emitted due to luciferase-mediated oxidation of luciferin to oxyluciferin.

FIG. 50A shows the activation of NFκB by FAP-OX40L in HeLa_hOx40_NFkB_Luc1 reporter cells in the presence of FAP positive cells. Shown is the activation of NFκB signaling pathway in the reporter cells by FAP-OX40L in the presence of low FAP expressing NIH-3T3 human FAP cells (ratio 3 FAP+ tumor cells to 1 reporter cell). The NFκB-mediated luciferase activity was characterized by blotting the units of released light (URL), measured during 0.5 s, versus the concentration in nM of tested compounds. URLs are emitted due to luciferase-mediated oxidation of luciferin to oxyluciferin. Values are baseline corrected by subtracting the URLs of the blank control. For a better comparison the area under the curve of the respective blotted dose-response curves were quantified as a marker for the agonistic capacity of each construct. The comparison is illustrated in FIG. 50B . The area was calculated using GraphPad Prism. Values are baseline corrected by subtracting the value of the blank control.

FIGS. 51A to 51D show the OX40 mediated costimulation of suboptimally TCR triggered resting human PBMC (Example 15.5). Hyper-crosslinking of FAP-OX40L by the present NIH/3T3-huFAP clone 39 cells strongly promoted survival and proliferation in human CD4 and CD8 T cells. Shown is the event count of vital CD4+( 51 A and 51 C) and CD8+( 51 B and 51 D) T cells. Baseline values of samples containing only the anti-human CD3 (clone V9, huIgG1), resting human PBMC and NIH/3T3-huFAP clone 39 were subtracted. Thus the enhancing effect of OX40 co-stimulation but not the effect of suboptimal anti-CD3 stimulation per se is shown here. In FIGS. 51A to 51D on the bottom the rescue of suboptimal TCR stimulation of resting human PBMC with cell surface immobilized FAP-OX40L—Proliferation is shown.

DETAILED DESCRIPTION OF THE INVENTION

›Definitions · 1 of 34

Unless defined otherwise, technical and scientific terms used herein have the same meaning as generally used in the art to which this invention belongs. For purposes of interpreting this specification, the following definitions will apply and whenever appropriate, terms used in the singular will also include the plural and vice versa.

As used herein, the term “antigen binding molecule” refers in its broadest sense to a molecule that specifically binds an antigenic determinant. Examples of antigen binding molecules are antibodies, antibody fragments and scaffold antigen binding proteins.

As used herein, the term “moiety capable of specific binding to a target cell antigen” refers to a polypeptide molecule that specifically binds to an antigenic determinant. In one aspect, the antigen binding moiety is able to activate signaling through its target cell antigen. In a particular aspect, the antigen binding moiety is able to direct the entity to which it is attached (e.g. the TNF family ligand trimer) to a target site, for example to a specific type of tumor cell or tumor stroma bearing the antigenic determinant. Moieties capable of specific binding to a target cell antigen include antibodies and fragments thereof as further defined herein. In addition, moieties capable of specific binding to a target cell antigen include scaffold antigen binding proteins as further defined herein, e.g. binding domains which are based on designed repeat proteins or designed repeat domains (see e.g. WO 2002/020565).

In relation to an antibody or fragment thereof, the term “moiety capable of specific binding to a target cell antigen” refers to the part of the molecule that comprises the area which specifically binds to and is complementary to part or all of an antigen. A moiety capable of specific antigen binding may be provided, for example, by one or more antibody variable domains (also called antibody variable regions). Particularly, a moiety capable of specific antigen binding comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH).

The term “antibody” herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, monospecific and multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.

The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g. containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen.

The term “monospecific” antibody as used herein denotes an antibody that has one or more binding sites each of which bind to the same epitope of the same antigen. The term “bispecific” means that the antigen binding molecule is able to specifically bind to at least two distinct antigenic determinants. Typically, a bispecific antigen binding molecule comprises two antigen binding sites, each of which is specific for a different antigenic determinant. In certain embodiments the bispecific antigen binding molecule is capable of simultaneously binding two antigenic determinants, particularly two antigenic determinants expressed on two distinct cells.

The term “valent” as used within the current application denotes the presence of a specified number of binding sites in an antigen binding molecule. As such, the terms “bivalent”, “tetravalent”, and “hexavalent” denote the presence of two binding sites, four binding sites, and six binding sites, respectively, in an antigen binding molecule.

The terms “full length antibody”, “intact antibody”, and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure. “Native antibodies” refer to naturally occurring immunoglobulin molecules with varying structures. For example, native IgG-class antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two light chains and two heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3), also called a heavy chain constant region. Similarly, from N- to C-terminus, each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a light chain constant domain (CL), also called a light chain constant region. The heavy chain of an antibody may be assigned to one of five types, called α (IgA), δ (IgD), ε (IgE), γ (IgG), or μ (IgM), some of which may be further divided into subtypes, e.g. γ1 (IgG1), γ2 (IgG2), γ3 (IgG3), γ4 (IgG4), α1 (IgA1) and α2 (IgA2). The light chain of an antibody may be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.

An “antibody fragment” refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab′, Fab′-SH, F(ab′) 2 ; diabodies, triabodies, tetrabodies, cross-Fab fragments; linear antibodies; single-chain antibody molecules (e.g. scFv); and single domain antibodies. For a review of certain antibody fragments, see Hudson et al., Nat Med 9, 129-134 (2003). For a review of scFv fragments, see e.g. Plückthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994); see also WO 93/16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. For discussion of Fab and F(ab′)2 fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Pat. No. 5,869,046. Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific, see, for example, EP 404,097; WO 1993/01161; Hudson et al., Nat Med 9, 129-134 (2003); and Hollinger et al., Proc Natl Acad Sci USA 90, 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat Med 9, 129-134 (2003). Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, Mass.; see e.g. U.S. Pat. No. 6,248,516 B1). Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g. E. coli or phage), as described herein.

›Definitions · 2 of 34

Papain digestion of intact antibodies produces two identical antigen-binding fragments, called “Fab” fragments containing each the heavy- and light-chain variable domains and also the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. As used herein, Thus, the term “Fab fragment” refers to an antibody fragment comprising a light chain fragment comprising a VL domain and a constant domain of a light chain (CL), and a VH domain and a first constant domain (CH1) of a heavy chain. Fab′ fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteins from the antibody hinge region. Fab′-SH are Fab′ fragments in which the cysteine residue(s) of the constant domains bear a free thiol group. Pepsin treatment yields an F(ab′) 2 fragment that has two antigen-combining sites (two Fab fragments) and a part of the Fc region.

The term “cross-Fab fragment” or “xFab fragment” or “crossover Fab fragment” refers to a Fab fragment, wherein either the variable regions or the constant regions of the heavy and light chain are exchanged. Two different chain compositions of a crossover Fab molecule are possible and comprised in the bispecific antibodies of the invention: On the one hand, the variable regions of the Fab heavy and light chain are exchanged, i.e. the crossover Fab molecule comprises a peptide chain composed of the light chain variable region (VL) and the heavy chain constant region (CH1), and a peptide chain composed of the heavy chain variable region (VH) and the light chain constant region (CL). This crossover Fab molecule is also referred to as CrossFab (VLVH) . On the other hand, when the constant regions of the Fab heavy and light chain are exchanged, the crossover Fab molecule comprises a peptide chain composed of the heavy chain variable region (VH) and the light chain constant region (CL), and a peptide chain composed of the light chain variable region (VL) and the heavy chain constant region (CH1). This crossover Fab molecule is also referred to as CrossFab (CLCH1) .

A “single chain Fab fragment” or “scFab” is a polypeptide consisting of an antibody heavy chain variable domain (VH), an antibody constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL) and a linker, wherein said antibody domains and said linker have one of the following orders in N-terminal to C-terminal direction: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1 or d) VL-CH1-linker-VH-CL; and wherein said linker is a polypeptide of at least 30 amino acids, preferably between 32 and 50 amino acids. Said single chain Fab fragments are stabilized via the natural disulfide bond between the CL domain and the CH1 domain. In addition, these single chain Fab molecules might be further stabilized by generation of interchain disulfide bonds via insertion of cysteine residues (e.g. position 44 in the variable heavy chain and position 100 in the variable light chain according to Kabat numbering).

A “crossover single chain Fab fragment” or “x-scFab” is a is a polypeptide consisting of an antibody heavy chain variable domain (VH), an antibody constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL) and a linker, wherein said antibody domains and said linker have one of the following orders in N-terminal to C-terminal direction: a) VH-CL-linker-VL-CH1 and b) VL-CH1-linker-VH-CL; wherein VH and VL form together an antigen-binding site which binds specifically to an antigen and wherein said linker is a polypeptide of at least 30 amino acids. In addition, these x-scFab molecules might be further stabilized by generation of interchain disulfide bonds via insertion of cysteine residues (e.g. position 44 in the variable heavy chain and position 100 in the variable light chain according to Kabat numbering).

A “single-chain variable fragment (scFv)” is a fusion protein of the variable regions of the heavy (VH) and light chains (VL) of an antibody, connected with a short linker peptide of ten to about 25 amino acids. The linker is usually rich in glycine for flexibility, as well as serine or threonine for solubility, and can either connect the N-terminus of the VH with the C-terminus of the VL, or vice versa. This protein retains the specificity of the original antibody, despite removal of the constant regions and the introduction of the linker. scFv antibodies are, e.g. described in Houston, J.S., Methods in Enzymol. 203 (1991) 46-96). In addition, antibody fragments comprise single chain polypeptides having the characteristics of a VH domain, namely being able to assemble together with a VL domain, or of a VL domain, namely being able to assemble together with a VH domain to a functional antigen binding site and thereby providing the antigen binding property of full length antibodies.

“Scaffold antigen binding proteins” are known in the art, for example, fibronectin and designed ankyrin repeat proteins (DARPINs®) have been used as alternative scaffolds for antigen-binding domains, see, e.g., Gebauer and Skerra, Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 13:245-255 (2009) and Stumpp et al., Darpins: A new generation of protein therapeutics. Drug Discovery Today 13: 695-701 (2008). In one aspect of the invention, a scaffold antigen binding protein is selected from the group consisting of CTLA-4 (Evibody), Lipocalins (ANTICALIN®), a Protein A-derived molecule such as Z-domain of Protein A (AFFIBODY®), an A-domain (Avimer/Maxibody), a serum transferrin (trans-body); a designed ankyrin repeat protein (DARPIN®), a variable domain of antibody light chain or heavy chain (single-domain antibody, sdAb), a variable domain of antibody heavy chain (nanobody, aVH), VNAR fragments, a fibronectin (AdNectin), a C-type lectin domain (Tetranectin); a variable domain of a new antigen receptor beta-lactamase (VNAR fragments), a human gamma-crystallin or ubiquitin (AFFILIN® molecules); a kunitz type domain of human protease inhibitors, microbodies such as the proteins from the knottin family, peptide aptamers and fibronectin (adnectin).

›Definitions · 3 of 34

CTLA-4 (Cytotoxic T Lymphocyte-associated Antigen 4) is a CD28-family receptor expressed on mainly CD4+ T-cells. Its extracellular domain has a variable domain-like Ig fold. Loops corresponding to CDRs of antibodies can be substituted with heterologous sequence to confer different binding properties. CTLA-4 molecules engineered to have different binding specificities are also known as Evibodies (e.g. U.S. Pat. No. 7,166,697B1). Evibodies are around the same size as the isolated variable region of an antibody (e.g. a domain antibody). For further details see Journal of Immunological Methods 248 (1-2), 31-45 (2001).

Lipocalins are a family of extracellular proteins which transport small hydrophobic molecules such as steroids, bilins, retinoids and lipids. They have a rigid beta-sheet secondary structure with a number of loops at the open end of the conical structure which can be engineered to bind to different target antigens. ANTICALINs® are between 160-180 amino acids in size, and are derived from lipocalins. For further details see Biochim Biophys Acta 1482: 337-350 (2000), U.S. Pat. No. 7,250,297B1 and US20070224633 (U.S. Pat. No. 7,585,940B2).

An AFFIBODY® is a scaffold derived from Protein A of Staphylococcus aureus which can be engineered to bind to antigen. The domain consists of a three-helical bundle of approximately 58 amino acids. Libraries have been generated by randomization of surface residues. For further details see Protein Eng. Des. Sel. 17, 455-462 (2004) and EP 1641818A1.

Avimers are multidomain proteins derived from the A-domain scaffold family. The native domains of approximately 35 amino acids adopt a defined disulfide bonded structure. Diversity is generated by shuffling of the natural variation exhibited by the family of A-domains. For further details see Nature Biotechnology 23(12), 1556-1561 (2005) and Expert Opinion on Investigational Drugs 16(6), 909-917 (June 2007).

A transferrin is a monomeric serum transport glycoprotein. Transferrins can be engineered to bind different target antigens by insertion of peptide sequences in a permissive surface loop. Examples of engineered transferrin scaffolds include the Trans-body. For further details see J. Biol. Chem 274, 24066-24073 (1999).

Designed Ankyrin Repeat Proteins (DARPINs®) are derived from Ankyrin which is a family of proteins that mediate attachment of integral membrane proteins to the cytoskeleton. A single ankyrin repeat is a 33 residue motif consisting of two alpha-helices and a beta-turn. They can be engineered to bind different target antigens by randomizing residues in the first alpha-helix and a beta-turn of each repeat. Their binding interface can be increased by increasing the number of modules (a method of affinity maturation). For further details see J. Mol. Biol. 332, 489-503 (2003), PNAS 100(4), 1700-1705 (2003) and J. Mol. Biol. 369, 1015-1028 (2007) and US20040132028A1 (U.S. Pat. No. 7,417,130B2).

A single-domain antibody is an antibody fragment consisting of a single monomeric variable antibody domain. The first single domain were derived from the variable domain of the antibody heavy chain from camelids (nanobodies or V H H fragments). Furthermore, the term single-domain antibody includes an autonomous human heavy chain variable domain (aVH) or VNAR fragments derived from sharks.

Fibronectin is a scaffold which can be engineered to bind to antigen. Adnectins consists of a backbone of the natural amino acid sequence of the 10th domain of the 15 repeating units of human fibronectin type III (FN3). Three loops at one end of the .beta.-sandwich can be engineered to enable an Adnectin to specifically recognize a therapeutic target of interest. For further details see Protein Eng. Des. Sel. 18, 435-444 (2005), US20080139791, WO2005056764 and U.S. Pat. No. 6,818,418B1.

Peptide aptamers are combinatorial recognition molecules that consist of a constant scaffold protein, typically thioredoxin (TrxA) which contains a constrained variable peptide loop inserted at the active site. For further details see Expert Opin. Biol. Ther. 5, 783-797 (2005).

Microbodies are derived from naturally occurring microproteins of 25-50 amino acids in length which contain 3-4 cysteine bridges—examples of microproteins include KalataBI and conotoxin and knottins. The microproteins have a loop which can be engineered to include upto 25 amino acids without affecting the overall fold of the microprotein. For further details of engineered knottin domains, see WO2008098796.

An “antigen binding molecule that binds to the same epitope” as a reference molecule refers to an antigen binding molecule that blocks binding of the reference molecule to its antigen in a competition assay by 50% or more, and conversely, the reference molecule blocks binding of the antigen binding molecule to its antigen in a competition assay by 50% or more.

The term “antigen binding domain” refers to the part of an antigen binding molecule that comprises the area which specifically binds to and is complementary to part or all of an antigen. Where an antigen is large, an antigen binding molecule may only bind to a particular part of the antigen, which part is termed an epitope. An antigen binding domain may be provided by, for example, one or more variable domains (also called variable regions). Preferably, an antigen binding domain comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH).

As used herein, the term “antigenic determinant” is synonymous with “antigen” and “epitope,” and refers to a site (e.g. a contiguous stretch of amino acids or a conformational configuration made up of different regions of non-contiguous amino acids) on a polypeptide macromolecule to which an antigen binding moiety binds, forming an antigen binding moiety-antigen complex. Useful antigenic determinants can be found, for example, on the surfaces of tumor cells, on the surfaces of virus-infected cells, on the surfaces of other diseased cells, on the surface of immune cells, free in blood serum, and/or in the extracellular matrix (ECM). The proteins useful as antigens herein can be any native form the proteins from any vertebrate source, including mammals such as primates (e.g. humans) and rodents (e.g. mice and rats), unless otherwise indicated. In a particular embodiment the antigen is a human protein. Where reference is made to a specific protein herein, the term encompasses the “full-length”, unprocessed protein as well as any form of the protein that results from processing in the cell. The term also encompasses naturally occurring variants of the protein, e.g. splice variants or allelic variants.

›Definitions · 4 of 34

By “specific binding” is meant that the binding is selective for the antigen and can be discriminated from unwanted or non-specific interactions. The ability of an antigen binding molecule to bind to a specific antigen can be measured either through an enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to one of skill in the art, e.g. Surface Plasmon Resonance (SPR) technique (analyzed on a BIACORE® instrument) (Liljeblad et al., Glyco J 17, 323-329 (2000)), and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)). In one embodiment, the extent of binding of an antigen binding molecule to an unrelated protein is less than about 10% of the binding of the antigen binding molecule to the antigen as measured, e.g. by SPR. In certain embodiments, an molecule that binds to the antigen has a dissociation constant (Kd) of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g. 10 −8 M or less, e.g. from 10 −8 M to 10 −13 M, e.g. from 10 −9 M to 10 −13 M).

“Affinity” or “binding affinity” refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g. an antibody) and its binding partner (e.g. an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g. antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Kd), which is the ratio of dissociation and association rate constants (koff and kon, respectively). Thus, equivalent affinities may comprise different rate constants, as long as the ratio of the rate constants remains the same. Affinity can be measured by common methods known in the art, including those described herein. A particular method for measuring affinity is Surface Plasmon Resonance (SPR).

A “target cell antigen” as used herein refers to an antigenic determinant presented on the surface of a target cell, for example a cell in a tumor such as a cancer cell or a cell of the tumor stroma. In certain embodiments, the target cell antigen is an antigen on the surface of a tumor cell. In one embodiment, target cell antigen is selected from the group consisting of Fibroblast Activation Protein (FAP), Carcinoembryonic Antigen (CEA), Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP), Epidermal Growth Factor Receptor (EGFR), CD19, CD20 and CD33. In particular, the target cell antigen is Fibroblast Activation Protein (FAP).

The term “Fibroblast activation protein (FAP)”, also known as Prolyl endopeptidase FAP or Seprase (EC 3.4.21), refers to any native FAP from any vertebrate source, including mammals such as primates (e.g. humans) non-human primates (e.g. cynomolgus monkeys) and rodents (e.g. mice and rats), unless otherwise indicated. The term encompasses “full-length,” unprocessed FAP as well as any form of FAP which results from processing in the cell. The term also encompasses naturally occurring variants of FAP, e.g., splice variants or allelic variants. In one embodiment, the antigen binding molecule of the invention is capable of specific binding to human, mouse and/or cynomolgus FAP. The amino acid sequence of human FAP is shown in UniProt accession no. Q12884 (version 149, SEQ ID NO:20), or NCBI RefSeq NP_004451.2. The extracellular domain (ECD) of human FAP extends from amino acid position 26 to 760. The amino acid and nucleotide sequences of a His-tagged human FAP ECD is shown in SEQ ID NOs 15 and 16, respectively. The amino acid sequence of mouse FAP is shown in UniProt accession no. P97321 (version 126, SEQ ID NO:23), or NCBI RefSeq NP 032012.1. The extracellular domain (ECD) of mouse FAP extends from amino acid position 26 to 761. SEQ ID NOs 24 and 25 show the amino acid and nucleotide sequences, respectively, of a His-tagged mouse FAP ECD. SEQ ID NOs 26 and 27 show the amino acid and nucleotide sequences, respectively, of a His-tagged cynomolgus FAP ECD. Preferably, an anti-FAP binding molecule of the invention binds to the extracellular domain of FAP. Exemplary anti-FAP binding molecules are described in International Patent Application No. WO 2012/020006 A2.

The term “Carcinoembroynic antigen (CEA)”, also known as Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), refers to any native CEA from any vertebrate source, including mammals such as primates (e.g. humans) non-human primates (e.g. cynomolgus monkeys) and rodents (e.g. mice and rats), unless otherwise indicated. The amino acid sequence of human CEA is shown in UniProt accession no. P06731 (version 151, SEQ ID NO:28). CEA has long been identified as a tumor-associated antigen (Gold and Freedman, J Exp Med., 121:439-462, 1965; Berinstein N. L., J Clin Oncol., 20:2197-2207, 2002). Originally classified as a protein expressed only in fetal tissue, CEA has now been identified in several normal adult tissues. These tissues are primarily epithelial in origin, including cells of the gastrointestinal, respiratory, and urogential tracts, and cells of colon, cervix, sweat glands, and prostate (Nap et al., Tumour Biol., 9(2-3):145-53, 1988; Nap et al., Cancer Res., 52(8):2329-23339, 1992). Tumors of epithelial origin, as well as their metastases, contain CEA as a tumor associated antigen. While the presence of CEA itself does not indicate transformation to a cancerous cell, the distribution of CEA is indicative. In normal tissue, CEA is generally expressed on the apical surface of the cell (Hammarström S., Semin Cancer Biol. 9(2):67-81 (1999)), making it inaccessible to antibody in the blood stream. In contrast to normal tissue, CEA tends to be expressed over the entire surface of cancerous cells (Hammarström S., Semin Cancer Biol. 9(2):67-81 (1999)). This change of expression pattern makes CEA accessible to antibody binding in cancerous cells. In addition, CEA expression increases in cancerous cells. Furthermore, increased CEA expression promotes increased intercellular adhesions, which may lead to metastasis (Marshall J., Semin Oncol., 30 (a Suppl. 8):30-6, 2003). The prevalence of CEA expression in various tumor entities is generally very high. In concordance with published data, own analyses performed in tissue samples confirmed its high prevalence, with approximately 95% in colorectal carcinoma (CRC), 90% in pancreatic cancer, 80% in gastric cancer, 60% in non-small cell lung cancer (NSCLC, where it is co-expressed with HER3), and 40% in breast cancer; low expression was found in small cell lung cancer and glioblastoma.

›Definitions · 5 of 34

CEA is readily cleaved from the cell surface and shed into the blood stream from tumors, either directly or via the lymphatics. Because of this property, the level of serum CEA has been used as a clinical marker for diagnosis of cancers and screening for recurrence of cancers, particularly colorectal cancer (Goldenberg D M., The International Journal of Biological Markers, 7:183-188, 1992; Chau I., et al., J Clin Oncol., 22:1420-1429, 2004; Flamini et al., Clin Cancer Res; 12(23):6985-6988, 2006).

The term “Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)”, also known as Chondroitin Sulfate Proteoglycan 4 (CSPG4) refers to any native MCSP from any vertebrate source, including mammals such as primates (e.g. humans) non-human primates (e.g. cynomolgus monkeys) and rodents (e.g. mice and rats), unless otherwise indicated. The amino acid sequence of human MCSP is shown in UniProt accession no. Q6UVK1 (version 103, SEQ ID NO:29). The term “Epidermal Growth Factor Receptor (EGFR)”, also named Proto-oncogene c-ErbB-1 or Receptor tyrosine-protein kinase erbB-1, refers to any native EGFR from any vertebrate source, including mammals such as primates (e.g. humans) non-human primates (e.g. cynomolgus monkeys) and rodents (e.g. mice and rats), unless otherwise indicated. The amino acid sequence of human EGFR is shown in UniProt accession no. P00533 (version 211, SEQ ID NO:30).

The term “CD19” refers to B-lymphocyte antigen CD19, also known as B-lymphocyte surface antigen B4 or T-cell surface antigen Leu-12 and includes any native CD19 from any vertebrate source, including mammals such as primates (e.g. humans) non-human primates (e.g. cynomolgus monkeys) and rodents (e.g. mice and rats), unless otherwise indicated. The amino acid sequence of human CD19 is shown in Uniprot accession no. P15391 (version 160, SEQ ID NO:31). The term encompasses “full-length” unprocessed human CD19 as well as any form of human CD19 that results from processing in the cell as long as the antibody as reported herein binds thereto. CD19 is a structurally distinct cell surface receptor expressed on the surface of human B cells, including, but not limited to, pre-B cells, B cells in early development {i.e., immature B cells), mature B cells through terminal differentiation into plasma cells, and malignant B cells. CD19 is expressed by most pre-B acute lymphoblastic leukemias (ALL), non-Hodgkin's lymphomas, B cell chronic lymphocytic leukemias (CLL), pro-lymphocytic leukemias, hairy cell leukemias, common acute lymphocytic leukemias, and some Null-acute lymphoblastic leukemias. The expression of CD19 on plasma cells further suggests it may be expressed on differentiated B cell tumors such as multiple myeloma. Therefore, the CD19 antigen is a target for immunotherapy in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

“CD20” refers to B-lymphocyte antigen CD20, also known as membrane-spanning 4-domains subfamily A member 1 (MS4A1), B-lymphocyte surface antigen B1 or Leukocyte surface antigen Leu-16, and includes any native CD20 from any vertebrate source, including mammals such as primates (e.g. humans) non-human primates (e.g. cynomolgus monkeys) and rodents (e.g. mice and rats), unless otherwise indicated. The amino acid sequence of human CD20 is shown in Uniprot accession no. P11836 (version 149, SEQ ID NO:32). “CD33” refers to Myeloid cell surface antigen CD33, also known as SIGLEC3 or gp67, and includes any native CD33 from any vertebrate source, including mammals such as primates (e.g. humans) non-human primates (e.g. cynomolgus monkeys) and rodents (e.g. mice and rats), unless otherwise indicated. The amino acid sequence of human CD33 is shown in Uniprot accession no. P20138 (version 157, SEQ ID NO:33).

The term “variable region” or “variable domain” refers to the domain of an antibody heavy or light chain that is involved in binding the antigen binding molecule to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). See, e.g., Kindt et al., Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity.

The term “hypervariable region” or “HVR,” as used herein refers to each of the regions of an antibody variable domain which are hypervariable in sequence and/or form structurally defined loops (“hypervariable loops”). Generally, native four-chain antibodies comprise six HVRs; three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3). HVRs generally comprise amino acid residues from the hypervariable loops and/or from the “complementarity determining regions” (CDRs), the latter being of highest sequence variability and/or involved in antigen recognition. Exemplary hypervariable loops occur at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3). (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987).) Exemplary CDRs (CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3) occur at amino acid residues 24-34 of L1, 50-56 of L2, 89-97 of L3, 31-35B of H1, 50-65 of H2, and 95-102 of H3. (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991).) Hypervariable regions (HVRs) are also referred to as complementarity determining regions (CDRs), and these terms are used herein interchangeably in reference to portions of the variable region that form the antigen binding regions. This particular region has been described by Kabat et al., U.S. Dept. of Health and Human Services, “Sequences of Proteins of Immunological Interest” (1983) and by Chothia et al., J. Mol. Biol. 196:901-917 (1987), where the definitions include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either definition to refer to a CDR of an antibody or variants thereof is intended to be within the scope of the term as defined and used herein. The appropriate amino acid residues which encompass the CDRs as defined by each of the above cited references are set forth below in Table A as a comparison. The exact residue numbers which encompass a particular CDR will vary depending on the sequence and size of the CDR. Those skilled in the art can routinely determine which residues comprise a particular CDR given the variable region amino acid sequence of the antibody.

›Definitions · 6 of 34

Kabat et al. also defined a numbering system for variable region sequences that is applicable to any antibody. One of ordinary skill in the art can unambiguously assign this system of “Kabat numbering” to any variable region sequence, without reliance on any experimental data beyond the sequence itself. As used herein, “Kabat numbering” refers to the numbering system set forth by Kabat et al., U.S. Dept. of Health and Human Services, “Sequence of Proteins of Immunological Interest” (1983). Unless otherwise specified, references to the numbering of specific amino acid residue positions in an antibody variable region are according to the Kabat numbering system.

With the exception of CDR1 in VH, CDRs generally comprise the amino acid residues that form the hypervariable loops. CDRs also comprise “specificity determining residues,” or “SDRs,” which are residues that contact antigen. SDRs are contained within regions of the CDRs called abbreviated-CDRs, or a-CDRs. Exemplary a-CDRs (a-CDR-L1, a-CDR-L2, a-CDR-L3, a-CDR-H1, a-CDR-H2, and a-CDR-H3) occur at amino acid residues 31-34 of L1, 50-55 of L2, 89-96 of L3, 31-35B of H1, 50-58 of H2, and 95-102 of H3. (See Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008).) Unless otherwise indicated, HVR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kabat et al., supra.

As used herein, the term “affinity matured” in the context of antigen binding molecules (e.g., antibodies) refers to an antigen binding molecule that is derived from a reference antigen binding molecule, e.g., by mutation, binds to the same antigen, preferably binds to the same epitope, as the reference antibody; and has a higher affinity for the antigen than that of the reference antigen binding molecule. Affinity maturation generally involves modification of one or more amino acid residues in one or more CDRs of the antigen binding molecule. Typically, the affinity matured antigen binding molecule binds to the same epitope as the initial reference antigen binding molecule.

“Framework” or “FR” refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.

An “acceptor human framework” for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework “derived from” a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence.

The term “chimeric” antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.

The “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g. IgG 1 , IgG 2 , IgG 3 , IgG 4 , IgA 1 , and IgA 2 . The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and μ respectively.

A “humanized” antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A “humanized form” of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization. Other forms of “humanized antibodies” encompassed by the present invention are those in which the constant region has been additionally modified or changed from that of the original antibody to generate the properties according to the invention, especially in regard to C1q binding and/or Fc receptor (FcR) binding.

A “human” antibody is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.

The term “Fc domain” or “Fc region” herein is used to define a C-terminal region of an antibody heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. An IgG Fc region comprises an IgG CH2 and an IgG CH3 domain. The “CH2 domain” of a human IgG Fc region usually extends from an amino acid residue at about position 231 to an amino acid residue at about position 340. In one embodiment, a carbohydrate chain is attached to the CH2 domain. The CH2 domain herein may be a native sequence CH2 domain or variant CH2 domain. The “CH3 domain” comprises the stretch of residues C-terminal to a CH2 domain in an Fc region (i.e. from an amino acid residue at about position 341 to an amino acid residue at about position 447 of an IgG). The CH3 region herein may be a native sequence CH3 domain or a variant CH3 domain (e.g. a CH3 domain with an introduced “protuberance” (“knob”) in one chain thereof and a corresponding introduced “cavity” (“hole”) in the other chain thereof; see U.S. Pat. No. 5,821,333, expressly incorporated herein by reference). Such variant CH3 domains may be used to promote heterodimerization of two non-identical antibody heavy chains as herein described. In one embodiment, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991.

›Definitions · 7 of 34

The “knob-into-hole” technology is described e.g. in U.S. Pat. Nos. 5,731,168; 7,695,936; Ridgway et al., Prot Eng 9, 617-621 (1996) and Carter, J Immunol Meth 248, 7-15 (2001). Generally, the method involves introducing a protuberance (“knob”) at the interface of a first polypeptide and a corresponding cavity (“hole”) in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heterodimer formation and hinder homodimer formation. Protuberances are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory cavities of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). The protuberance and cavity can be made by altering the nucleic acid encoding the polypeptides, e.g. by site-specific mutagenesis, or by peptide synthesis. In a specific embodiment a knob modification comprises the amino acid substitution T366W in one of the two subunits of the Fc domain, and the hole modification comprises the amino acid substitutions T366S, L368A and Y407V in the other one of the two subunits of the Fc domain. In a further specific embodiment, the subunit of the Fc domain comprising the knob modification additionally comprises the amino acid substitution S354C, and the subunit of the Fc domain comprising the hole modification additionally comprises the amino acid substitution Y349C. Introduction of these two cysteine residues results in the formation of a disulfide bridge between the two subunits of the Fc region, thus further stabilizing the dimer (Carter, J Immunol Methods 248, 7-15 (2001)). The numbering is according to EU index of Kabat et al, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991.

A “region equivalent to the Fc region of an immunoglobulin” is intended to include naturally occurring allelic variants of the Fc region of an immunoglobulin as well as variants having alterations which produce substitutions, additions, or deletions but which do not decrease substantially the ability of the immunoglobulin to mediate effector functions (such as antibody-dependent cellular cytotoxicity). For example, one or more amino acids can be deleted from the N-terminus or C-terminus of the Fc region of an immunoglobulin without substantial loss of biological function. Such variants can be selected according to general rules known in the art so as to have minimal effect on activity (see, e.g., Bowie, J. U. et al., Science 247:1306-10 (1990)).

The term “effector functions” refers to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), cytokine secretion, immune complex-mediated antigen uptake by antigen presenting cells, down regulation of cell surface receptors (e.g. B cell receptor), and B cell activation.

An “activating Fc receptor” is an Fc receptor that following engagement by an Fc region of an antibody elicits signaling events that stimulate the receptor-bearing cell to perform effector functions. Activating Fc receptors include FcγRIIIa (CD16a), FcγRI (CD64), FcγRIIa (CD32), and FcαRI (CD89). A particular activating Fc receptor is human FcγRIIIa (see UniProt accession no. P08637, version 141).

The term “TNF ligand family member” or “TNF family ligand” refers to a proinflammatory cytokine. Cytokines in general, and in particular the members of the TNF ligand family, play a crucial role in the stimulation and coordination of the immune system. At present, nineteen cyctokines have been identified as members of the TNF (tumour necrosis factor) ligand superfamily on the basis of sequence, functional, and structural similarities. All these ligands are type II transmembrane proteins with a C-terminal extracellular domain (ectodomain), N-terminal intracellular domain and a single transmembrane domain. The C-terminal extracellular domain, known as TNF homology domain (THD), has 20-30% amino acid identity between the superfamily members and is responsible for binding to the receptor. The TNF ectodomain is also responsible for the TNF ligands to form trimeric complexes that are recognized by their specific receptors.

Members of the TNF ligand family are selected from the group consisting of Lymphotoxin a (also known as LTA or TNFSF1), TNF (also known as TNFSF2), LTβ (also known as TNFSF3), OX40L (also known as TNFSF4), CD40L (also known as CD154 or TNFSF5), FasL (also known as CD95L, CD178 or TNFSF6), CD27L (also known as CD70 or TNFSF7), CD30L (also known as CD153 or TNFSF8), 4-1BBL (also known as TNFSF9), TRAIL (also known as APO2L, CD253 or TNFSF10), RANKL (also known as CD254 or TNFSF11), TWEAK (also known as TNFSF12), APRIL (also known as CD256 or TNFSF13), BAFF (also known as CD257 or TNFSF13B), LIGHT (also known as CD258 or TNFSF14), TL1A (also known as VEGI or TNFSF15), GITRL (also known as TNFSF18), EDA-A1 (also known as ectodysplasin A1) and EDA-A2 (also known as ectodysplasin A2). The term refers to any native TNF family ligand from any vertebrate source, including mammals such as primates (e.g. humans), non-human primates (e.g. cynomolgus monkeys) and rodents (e.g. mice and rats), unless otherwise indicated. In specific embodiments of the invention, the TNF ligand family member is selected from the group consisting of OX40L, FasL, CD27L, TRAIL, 4-1BBL, CD40L and GITRL. In a particular embodiment, the TNF ligand family member is selected from 4-1BBL and OX40L.

Further information, in particular sequences, of the TNF ligand family members may be obtained from publically accessible databases such as Uniprot. For instance, the human TNF ligands have the following amino acid sequences: human Lymphotoxin a (UniProt accession no. P01374, SEQ ID NO:34), human TNF (UniProt accession no. P01375, SEQ ID NO:35), human Lymphotoxin β (UniProt accession no. Q06643, SEQ ID NO:36), human OX40L (UniProt accession no. P23510, SEQ ID NO:37), human CD40L (UniProt accession no. P29965, SEQ ID NO:38), human FasL (UniProt accession no. P48023, SEQ ID NO:39), human CD27L (UniProt accession no. P32970, SEQ ID NO:40), human CD30L (UniProt accession no. P32971, SEQ ID NO:41), 4-1BBL (UniProt accession no. P41273, SEQ ID NO:42), TRAIL (UniProt accession no. P50591, SEQ ID NO:43), RANKL (UniProt accession no. 014788, SEQ ID NO:44), TWEAK (UniProt accession no. 043508, SEQ ID NO:45), APRIL (UniProt accession no. 075888, SEQ ID NO:46), BAFF (UniProt accession no. Q9Y275, SEQ ID NO:47), LIGHT (UniProt accession no. 043557, SEQ ID NO:48), TL1A (UniProt accession no. 095150, SEQ ID NO:49), GITRL (UniProt accession no. Q9UNG2, SEQ ID NO:50) and ectodysplasin A (UniProt accession no. Q92838, SEQ ID NO:51).

›Definitions · 8 of 34

An “ectodomain” is the domain of a membrane protein that extends into the extracellular space (i.e. the space outside the target cell). Ectodomains are usually the parts of proteins that initiate contact with surfaces, which leads to signal transduction. The ectodomain of TNF ligand family member as defined herein thus refers to the part of the TNF ligand protein that extends into the extracellular space (the extracellular domain), but also includes shorter parts or fragments thereof that are responsible for the trimerization and for the binding to the corresponding TNF receptor. The term “ectodomain of a TNF ligand family member or a fragment thereof” thus refers to the extracellular domain of the TNF ligand family member that forms the extracellular domain or to parts thereof that are still able to bind to the receptor (receptor binding domain).

The term “costimulatory TNF ligand family member” or “costimulatory TNF family ligand” refers to a subgroup of TNF ligand family members, which are able to costimulate proliferation and cytokine production of T-cells. These TNF family ligands can costimulate TCR signals upon interaction with their corresponding TNF receptors and the interaction with their receptors leads to recruitment of TNFR-associated factors (TRAF), which initiate signalling cascades that result in T-cell activation. Costimulatory TNF family ligands are selected from the group consisting of 4-1BBL, OX40L, GITRL, CD70, CD30L and LIGHT, more particularly the costimulatory TNF ligand family member is selected from 4-1BBL and OX40L.

As described herein before, 4-1BBL is a type II transmembrane protein and one member of the TNF ligand family. Complete or full length 4-1BBL having the amino acid sequence of SEQ ID NO:42 has been described to form trimers on the surface of cells. The formation of trimers is enabled by specific motives of the ectodomain of 4-1BBL. Said motives are designated herein as “trimerization region”. The amino acids 50-254 of the human 4-1BBL sequence (SEQ ID NO:52) form the extracellular domain of 4-1BBL, but even fragments thereof are able to form the trimers. In specific embodiments of the invention, the term “ectodomain of 4-1BBL or a fragment thereof” refers to a polypeptide having an amino acid sequence selected from SEQ ID NO:4 (amino acids 52-254 of human 4-1BBL), SEQ ID NO:1 (amino acids 71-254 of human 4-1BBL), SEQ ID NO:3 (amino acids 80-254 of human 4-1BBL) and SEQ ID NO:2 (amino acids 85-254 of human 4-1BBL) or a polypeptide having an amino acid sequence selected from SEQ ID NO:96 (amino acids 71-248 of human 4-1BBL), SEQ ID NO:375 (amino acids 52-248 of human 4-1BBL), SEQ ID NO:374 (amino acids 80-248 of human 4-1BBL) and SEQ ID NO:373 (amino acids 85-248 of human 4-1BBL), but also other fragments of the ectodomain capable of trimerization are included herein.

As described herein before, OX40L is another type II transmembrane protein and a further member of the TNF ligand family. Complete or full length human OX40L has the amino acid sequence of SEQ ID NO:37. The amino acids 51-183 of the human OX40L sequence (SEQ ID NO:53) form the extracellular domain of OX40L, but even fragments thereof that are able to form the trimers. In specific embodiments of the invention, the term “ectodomain of OX40L or a fragment thereof” refers to a polypeptide having an amino acid sequence selected from SEQ ID NO:53 (amino acids 51-183 of human OX40L) or SEQ ID NO:54 (amino acids 52-183 of human OX40L), but also other fragments of the ectodomain capable of trimerization are included herein.

The term “peptide linker” refers to a peptide comprising one or more amino acids, typically about 2 to 20 amino acids. Peptide linkers are known in the art or are described herein. Suitable, non-immunogenic linker peptides are, for example, (G 4 S) n (SEQ ID NO: 390), (SG 4 ) n (SEQ ID NO: 391) or G 4 (SG 4 ) n (SEQ ID NO: 392) peptide linkers, wherein “n” is generally a number between 1 and 10, typically between 1 and 4, in particular 2, i.e. the peptides selected from the group consisting of GGGGS (SEQ ID NO:128), GGGGSGGGGS (SEQ ID NO:13), SGGGGSGGGG (SEQ ID NO:55) and GGGGSGGGGSGGGG (SEQ ID NO:56), but also include the sequences GSPGSSSSGS (SEQ ID NO:57), GSGSGSGS (SEQ ID NO:394), GSGSGNGS (SEQ ID NO:59), GGSGSGSG (SEQ ID NO:60), GGSGSG (SEQ ID NO:61), GGSG (SEQ ID NO:62), GGSGNGSG (SEQ ID NO:63), GGNGSGSG (SEQ ID NO:64) and GGNGSG (SEQ ID NO:65). Peptide linkers of particular interest are (G 4 S) 1 or GGGGS (SEQ ID NO:128), (G 4 S) 2 or GGGGSGGGGS (SEQ ID NO:13) and GSPGSSSSGS (SEQ ID NO:57), more particularly (G 4 S) 2 or GGGGSGGGGS (SEQ ID NO:13) and GSPGSSSSGS (SEQ ID NO:57).

The term “amino acid” as used within this application denotes the group of naturally occurring carboxy a-amino acids comprising alanine (three letter code: ala, one letter code: A), arginine (arg, R), asparagine (asn, N), aspartic acid (asp, D), cysteine (cys, C), glutamine (gln, Q), glutamic acid (glu, E), glycine (gly, G), histidine (his, H), isoleucine (ile, I), leucine (leu, L), lysine (lys, K), methionine (met, M), phenylalanine (phe, F), proline (pro, P), serine (ser, S), threonine (thr, T), tryptophan (trp, W), tyrosine (tyr, Y), and valine (val, V).

A “single chain fusion protein” as used herein refers to a single chain polypeptide composed of one or two ectodomains of said TNF ligand family member fused to a part of antigen binding moiety or Fc part. The fusion may occur by directly linking the N or C-terminal amino acid of the antigen binding moiety via a peptide linker to the C- or N-terminal amino acid of the ectodomain of said TNF ligand family member.

By “fused” or “connected” is meant that the components (e.g. a polypeptide and an ectodomain of said TNF ligand family member) are linked by peptide bonds, either directly or via one or more peptide linkers.

“Percent (%) amino acid sequence identity” with respect to a reference polypeptide (protein) sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN. SAWI or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, Calif., or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary. In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

›Definitions · 9 of 34

100 times the fraction X/Y

where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

In certain embodiments, amino acid sequence variants of the TNF ligand trimer-containing antigen binding molecules provided herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the TNF ligand trimer-containing antigen binding molecules. Amino acid sequence variants of the TNF ligand trimer-containing antigen binding molecules may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the molecules, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding. Sites of interest for substitutional mutagenesis include the HVRs and Framework (FRs). Conservative substitutions are provided in Table B under the heading “Preferred Substitutions” and further described below in reference to amino acid side chain classes (1) to (6). Amino acid substitutions may be introduced into the molecule of interest and the products screened for a desired activity, e.g., retained/improved antigen binding, decreased immunogenicity, or improved ADCC or CDC.

Amino acids may be grouped according to common side-chain properties:

(1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another class.

The term “amino acid sequence variants” includes substantial variants wherein there are amino acid substitutions in one or more hypervariable region residues of a parent antigen binding molecule (e.g. a humanized or human antibody). Generally, the resulting variant(s) selected for further study will have modifications (e.g., improvements) in certain biological properties (e.g., increased affinity, reduced immunogenicity) relative to the parent antigen binding molecule and/or will have substantially retained certain biological properties of the parent antigen binding molecule. An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated, e.g., using phage display-based affinity maturation techniques such as those described herein. Briefly, one or more HVR residues are mutated and the variant antigen binding molecules displayed on phage and screened for a particular biological activity (e.g. binding affinity). In certain embodiments, substitutions, insertions, or deletions may occur within one or more HVRs so long as such alterations do not substantially reduce the ability of the antigen binding molecule to bind antigen. For example, conservative alterations (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in HVRs. A useful method for identification of residues or regions of an antibody that may be targeted for mutagenesis is called “alanine scanning mutagenesis” as described by Cunningham and Wells (1989) Science, 244:1081-1085. In this method, a residue or group of target residues (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) are identified and replaced by a neutral or negatively charged amino acid (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with antigen is affected. Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions. Alternatively, or additionally, a crystal structure of an antigen-antigen binding molecule complex to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution. Variants may be screened to determine whether they contain the desired properties.

Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include TNF family ligand trimer-containing antigen binding molecule with an N-terminal methionyl residue. Other insertional variants of the molecule include the fusion to the N- or C-terminus to a polypeptide which increases the serum half-life of the TNF ligand trimer-containing antigen binding molecules.

In certain embodiments, the TNF family ligand trimer-containing antigen binding molecules provided herein are altered to increase or decrease the extent to which the antibody is glycosylated. Glycosylation variants of the molecules may be conveniently obtained by altering the amino acid sequence such that one or more glycosylation sites is created or removed. Where the TNF ligand trimer-containing antigen binding molecule comprises an Fc region, the carbohydrate attached thereto may be altered. Native antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached by an N-linkage to Asn297 of the CH2 domain of the Fc region. See, e.g., Wright et al. TIBTECH 15:26-32 (1997). The oligosaccharide may include various carbohydrates, e.g., mannose, N-acetyl glucosamine (GlcNAc), galactose, and sialic acid, as well as a fucose attached to a GlcNAc in the “stem” of the biantennary oligosaccharide structure. In some embodiments, modifications of the oligosaccharide in TNF family ligand trimer-containing antigen binding molecule may be made in order to create variants with certain improved properties. In one aspect, variants of TNF family ligand trimer-containing antigen binding molecules are provided having a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region. Such fucosylation variants may have improved ADCC function, see e.g. US Patent Publication Nos. US 2003/0157108 (Presta, L.) or US 2004/0093621 (Kyowa Hakko Kogyo Co., Ltd). Further variants of the TNF family ligand trimer-containing antigen binding molecules of the invention include those with bisected oligosaccharides, e.g., in which a biantennary oligosaccharide attached to the Fc region is bisected by GlcNAc. Such variants may have reduced fucosylation and/or improved ADCC function., see for example WO 2003/011878 (Jean-Mairet et al.); U.S. Pat. No. 6,602,684 (Umana et al.); and US 2005/0123546 (Umana et al., U.S. Pat. No. 9,296,820B2). Variants with at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such antibody variants may have improved CDC function and are described, e.g., in WO 1997/30087 (Patel et al.); WO 1998/58964 (Raju, S.); and WO 1999/22764 (Raju, S.).

›Definitions · 10 of 34

In certain embodiments, it may be desirable to create cysteine engineered variants of the TNF family ligand trimer-containing antigen binding molecule of the invention, e.g., “thioMAbs,” in which one or more residues of the molecule are substituted with cysteine residues. In particular embodiments, the substituted residues occur at accessible sites of the molecule. By substituting those residues with cysteine, reactive thiol groups are thereby positioned at accessible sites of the antibody and may be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to create an immunoconjugate. In certain embodiments, any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and 5400 (EU numbering) of the heavy chain Fc region. Cysteine engineered antigen binding molecules may be generated as described, e.g., in U.S. Pat. No. 7,521,541.

In certain aspects, the TNF family ligand trimer-containing antigen binding molecules provided herein may be further modified to contain additional non-proteinaceous moieties that are known in the art and readily available. The moieties suitable for derivatization of the antibody include but are not limited to water soluble polymers. Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propropylene glycol homopolymers, prolypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may be of any molecular weight, and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the bispecific antibody derivative will be used in a therapy under defined conditions, etc. In another aspect, conjugates of an antibody and non-proteinaceous moiety that may be selectively heated by exposure to radiation are provided. In one embodiment, the non-proteinaceous moiety is a carbon nanotube (Kam, N. W. et al., Proc. Natl. Acad. Sci. USA 102 (2005) 11600-11605). The radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the non-proteinaceous moiety to a temperature at which cells proximal to the antibody-non-proteinaceous moiety are killed.

In another aspect, immunoconjugates of the TNF family ligand trimer-containing antigen binding molecules provided herein may be obtained. An “immunoconjugate” is an antibody conjugated to one or more heterologous molecule(s), including but not limited to a cytotoxic agent.

The term “polynucleotide” refers to an isolated nucleic acid molecule or construct, e.g. messenger RNA (mRNA), virally-derived RNA, or plasmid DNA (pDNA). A polynucleotide may comprise a conventional phosphodiester bond or a non-conventional bond (e.g. an amide bond, such as found in peptide nucleic acids (PNA). The term “nucleic acid molecule” refers to any one or more nucleic acid segments, e.g. DNA or RNA fragments, present in a polynucleotide.

By “isolated” nucleic acid molecule or polynucleotide is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, a recombinant polynucleotide encoding a polypeptide contained in a vector is considered isolated for the purposes of the present invention. Further examples of an isolated polynucleotide include recombinant polynucleotides maintained in heterologous host cells or purified (partially or substantially) polynucleotides in solution. An isolated polynucleotide includes a polynucleotide molecule contained in cells that ordinarily contain the polynucleotide molecule, but the polynucleotide molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the present invention, as well as positive and negative strand forms, and double-stranded forms. Isolated polynucleotides or nucleic acids according to the present invention further include such molecules produced synthetically. In addition, a polynucleotide or a nucleic acid may be or may include a regulatory element such as a promoter, ribosome binding site, or a transcription terminator.

By a nucleic acid or polynucleotide having a nucleotide sequence at least, for example, 95% “identical” to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the 5′ or 3′ terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence. As a practical matter, whether any particular polynucleotide sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs, such as the ones discussed above for polypeptides (e.g. ALIGN-2).

›Definitions · 11 of 34

The term “expression cassette” refers to a polynucleotide generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a target cell. The recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment.

Typically, the recombinant expression cassette portion of an expression vector includes, among other sequences, a nucleic acid sequence to be transcribed and a promoter. In certain embodiments, the expression cassette of the invention comprises polynucleotide sequences that encode bispecific antigen binding molecules of the invention or fragments thereof.

The term “vector” or “expression vector” is synonymous with “expression construct” and refers to a DNA molecule that is used to introduce and direct the expression of a specific gene to which it is operably associated in a target cell. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. The expression vector of the present invention comprises an expression cassette. Expression vectors allow transcription of large amounts of stable mRNA. Once the expression vector is inside the target cell, the ribonucleic acid molecule or protein that is encoded by the gene is produced by the cellular transcription and/or translation machinery. In one embodiment, the expression vector of the invention comprises an expression cassette that comprises polynucleotide sequences that encode bispecific antigen binding molecules of the invention or fragments thereof.

The terms “host cell”, “host cell line,” and “host cell culture” are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein. A host cell is any type of cellular system that can be used to generate the bispecific antigen binding molecules of the present invention. Host cells include cultured cells, e.g. mammalian cultured cells, such as CHO cells, BHK cells, NS0 cells, SP2/0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells or hybridoma cells, yeast cells, insect cells, and plant cells, to name only a few, but also cells comprised within a transgenic animal, transgenic plant or cultured plant or animal tissue.

An “effective amount” of an agent refers to the amount that is necessary to result in a physiological change in the cell or tissue to which it is administered.

A “therapeutically effective amount” of an agent, e.g. a pharmaceutical composition, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result. A therapeutically effective amount of an agent for example eliminates, decreases, delays, minimizes or prevents adverse effects of a disease.

An “individual” or “subject” is a mammal. Mammals include, but are not limited to, domesticated animals (e.g. cows, sheep, cats, dogs, and horses), primates (e.g. humans and non-human primates such as monkeys), rabbits, and rodents (e.g. mice and rats). Particularly, the individual or subject is a human.

The term “pharmaceutical composition” refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.

A “pharmaceutically acceptable excipient” refers to an ingredient in a pharmaceutical composition, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable excipient includes, but is not limited to, a buffer, a stabilizer, or a preservative.

The term “package insert” is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.

As used herein, “treatment” (and grammatical variations thereof such as “treat” or “treating”) refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, the molecules of the invention are used to delay development of a disease or to slow the progression of a disease.

The term “cancer” as used herein refers to proliferative diseases, such as lymphomas, carcinoma, lymphoma, blastoma, sarcoma, leukemia, lymphocytic leukemias, lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colorectal cancer (CRC), pancreatic cancer, breast cancer, triple-negative breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, mesothelioma, hepatocellular cancer, biliary cancer, neoplasms of the central nervous system (CNS), spinal axis tumors, brain stem glioma, glioblastoma multiforme, astrocytomas, schwanomas, ependymonas, medulloblastomas, meningiomas, squamous cell carcinomas, pituitary adenoma and Ewings sarcoma, melanoma, multiple myeloma, B-cell cancer (lymphoma), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), hairy cell leukemia, chronic myeloblastic leukemia, including refractory versions of any of the above cancers, or a combination of one or more of the above cancers.

›Definitions · 12 of 34

TNF Family Ligand Trimer-Containing Antigen Binding Molecules of the Invention

The invention provides novel TNF family ligand trimer-containing antigen binding molecules with particularly advantageous properties such as producibility, stability, binding affinity, biological activity, targeting efficiency and reduced toxicity.

In a first aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising

In a particular aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising

In a particular aspect, the TNF family ligand trimer-containing antigen binding molecule comprises (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof, wherein the TNF ligand family member is costimulates human T-cell activation.

In another particular aspect, the TNF family ligand trimer-containing antigen binding molecule comprises (a) at least one moiety capable of specific binding to a target cell antigen and

(b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof, wherein the ectodomains of a TNF ligand family member are identical in all instances.

In a further aspect, provided is a TNF family ligand trimer-containing antigen binding molecule of claim 1 , comprising

In a particular aspect, the TNF family ligand trimer-containing antigen binding molecule comprises a TNF ligand family member that costimulates human T-cell activation which is selected from 4-1BBL and OX40L. More particularly, the TNF ligand family member is 4-1BBL.

In another aspect, wherein the ectodomain of a TNF ligand family member comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:96, SEQ ID NO: 373, SEQ ID NO:374 and SEQ ID NO:375, particularly the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:96. In one aspect, the ectodomain of a TNF ligand family member or fragment thereof comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:96, particularly the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:96. In a particular aspect, the ectodomain of a TNF ligand family member or fragment thereof comprises the amino acid sequence of SEQ ID NO:96.

›Definitions · 13 of 34

In a further aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises

(a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99 and in that the second polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4. In a particular aspect, the first polypeptide comprises the amino acid sequence of SEQ ID NO:97 and the second polypeptide comprises the amino acid sequence of SEQ ID NO:96.

In one aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises

In a further aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises

In yet a further aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises

In another aspect, the TNF ligand family member is OX40L. In a particular aspect, provided is TNF family ligand trimer-containing antigen binding molecule, wherein the ectodomain of a TNF ligand family member comprises the amino acid sequence of SEQ ID NO:53 or SEQ ID NO:54, particularly the amino acid sequence of SEQ ID NO:53.

In one aspect, the invention relates to a TNF family ligand trimer-containing antigen binding molecule comprising

In one aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises

(a) at least one moiety capable of specific binding to a target cell antigen, (b) a first polypeptide containing a CH1 or CL domain and a second polypeptide containing a CL or CH1 domain, respectively, wherein the second polypeptide is linked to the first polypeptide by a disulfide bond between the CH1 and CL domain, and wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the CH1 or CL domain by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to the CL or CH1 domain of said polypeptide.

In one aspect, provided is a TNF family ligand trimer-containing antigen binding molecule comprising

In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule comprising

In another aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising

(a) one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.

›Definitions · 14 of 34

In yet another aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising

(a) more than one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to said polypeptide.

In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising

(a) two moities capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.

In a particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, comprising

(a) at least one moiety capable of specific binding to a target cell antigen, and (b) a first and a second polypeptide that are linked to each other by a disulfide bond,

wherein the antigen binding molecule is characterized in that the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, respectively, and wherein the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the C-terminus of the CH3 domain by a peptide linker and wherein the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to C-terminus of the CH3 domain of said polypeptide. Particularly, such TNF family ligand trimer-containing antigen binding molecule comprises two moieties capable of specific binding to a target cell antigen.

In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising

(a) two moities capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof, wherein the two moieties capable of specific binding to a target cell antigen bind to two different target cell antigens.

In one aspect, provided is a TNF family ligand trimer-containing antigen binding molecule as described herein before, wherein the moiety capable of specific binding to a target cell antigen is selected from the group consisting of an antibody fragment, a Fab molecule, a crossover Fab molecule, a single chain Fab molecule, a Fv molecule, a scFv molecule, a single domain antibody, an aVH and a scaffold antigen binding protein. In one aspect, the moiety capable of specific binding to a target cell antigen is an aVH or a scaffold antigen binding protein. In one aspect, the moiety capable of specific binding to a target cell antigen is a scaffold antigen binding protein capable of specific binding to a target cell antigen.

In particular, the TNF family ligand trimer-containing antigen binding molecule comprises one or two moieties capable of specific binding to a target cell antigen.

In a particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to a target cell antigen is a Fab molecule or a crossover Fab molecule capable of specific binding to a target cell antigen. In particular, the moiety capable of specific binding to a target cell antigen is a Fab capable of specific binding to a target cell antigen.

Furthermore, provided is TNF family ligand trimer-containing antigen binding molecule as described herein, wherein the target cell antigen is selected from the group consisting of Fibroblast Activation Protein (FAP), Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP), Epidermal Growth Factor Receptor (EGFR), Carcinoembryonic Antigen (CEA), CD19, CD20 and CD33.

In a further aspect, provided is a TNF family ligand trimer-containing antigen binding molecule according to the invention, wherein a peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus to the CH1 domain of a heavy chain by a second peptide linker and wherein one ectodomain of said TNF ligand family member or a fragment thereof is fused at the its C-terminus to the CL domain on a light chain by a third peptide linker.

In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule according to the invention, wherein a peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus to the CL domain of a heavy chain by a second peptide linker and wherein one ectodomain of said TNF ligand family member or a fragment thereof is fused at the its C-terminus to the CH1 domain on a light chain by a third peptide linker.

›Definitions · 15 of 34

In a further aspect, the invention is concerned with a TNF family ligand trimer-containing antigen binding molecule according to the invention, wherein a peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus to the CL domain of a light chain by a second peptide linker and wherein one ectodomain of said TNF ligand family member or a fragment thereof is fused at the its C-terminus to the CH1 domain of the heavy chain by a third peptide linker.

In a particular aspect, the invention relates to a TNF family ligand trimer-containing antigen binding molecule as defined above, wherein the peptide linker is (G 4 S) 2 (SEQ ID NO:13). In one aspect, the first peptide linker is (G 4 S) 2 (SEQ ID NO:13), the second peptide linker is GSPGSSSSGS (SEQ ID NO:57) and the third peptide linker is (G 4 S) 2 (SEQ ID NO:13). In particular, the invention relates to a TNF ligand trimer-containing antigen binding molecule as defined above, wherein the first peptide linker is (G 4 S) 2 (SEQ ID NO:13), the second peptide linker is (G 4 S) 2 (SEQ ID NO:13), and the third peptide linker is (G 4 S) 2 (SEQ ID NO:13).

In another aspect, the TNF family ligand trimer-containing antigen binding molecule as defined herein before comprises an Fc domain composed of a first and a second subunit capable of stable association.

In particular, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises (a) a Fab molecule capable of specific binding to a target cell antigen, wherein the Fab heavy chain is fused at the C-terminus to the N-terminus of a CH2 domain in the Fc domain and (c) an Fc domain composed of a first and a second subunit capable of stable association.

Fc Domain Modifications Reducing Fc Receptor Binding and/or Effector Function

The Fc domain of the TNF family ligand trimer-containing antigen binding molecules of the invention consists of a pair of polypeptide chains comprising heavy chain domains of an immunoglobulin molecule. For example, the Fc domain of an immunoglobulin G (IgG) molecule is a dimer, each subunit of which comprises the CH2 and CH3 IgG heavy chain constant domains. The two subunits of the Fc domain are capable of stable association with each other.

The Fc domain confers favorable pharmacokinetic properties to the antigen binding molecules of the invention, including a long serum half-life which contributes to good accumulation in the target tissue and a favorable tissue-blood distribution ratio. At the same time it may, however, lead to undesirable targeting of the bispecific antibodies of the invention to cells expressing Fc receptors rather than to the preferred antigen-bearing cells. Accordingly, in particular aspects, the Fc domain of the TNF family ligand trimer-containing antigen binding molecule of the invention exhibits reduced binding affinity to an Fc receptor and/or reduced effector function, as compared to a native IgG1 Fc domain. In one aspect, the Fc does not substantially bind to an Fc receptor and/or does not induce effector function. In a particular aspect the Fc receptor is an Fcγ receptor. In one aspect, the Fc receptor is a human Fc receptor. In a specific aspect, the Fc receptor is an activating human Fcγ receptor, more specifically human FcγRIIIa, FcγRI or FcγRIIa, most specifically human FcγRIIIa. In one aspect, the Fc domain does not induce effector function. The reduced effector function can include, but is not limited to, one or more of the following: reduced complement dependent cytotoxicity (CDC), reduced antibody-dependent cell-mediated cytotoxicity (ADCC), reduced antibody-dependent cellular phagocytosis (ADCP), reduced cytokine secretion, reduced immune complex-mediated antigen uptake by antigen-presenting cells, reduced binding to NK cells, reduced binding to macrophages, reduced binding to monocytes, reduced binding to polymorphonuclear cells, reduced direct signaling inducing apoptosis, reduced dendritic cell maturation, or reduced T cell priming.

In certain aspects, one or more amino acid modifications may be introduced into the Fc region of a TNF family ligand trimer-containing antigen binding molecule provided herein, thereby generating an Fc region variant. The Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g. a substitution) at one or more amino acid positions.

In a particular aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising

In one aspect, the Fc domain of the TNF family ligand trimer-containing antigen binding molecule of the invention comprises one or more amino acid mutation that reduces the binding affinity of the Fc domain to an Fc receptor and/or effector function. Typically, the same one or more amino acid mutation is present in each of the two subunits of the Fc domain. In particular, the Fc domain comprises an amino acid substitution at a position of E233, L234, L235, N297, P331 and P329 (EU numbering). In particular, the Fc domain comprises amino acid substitutions at positions 234 and 235 (EU numbering) and/or 329 (EU numbering) of the IgG heavy chains. More particularly, provided is a trimeric TNF family ligand-containing antigen binding molecule according to the invention which comprises an Fc domain with the amino acid substitutions L234A, L235A and P329G (“P329G LALA”, EU numbering) in the IgG heavy chains. The amino acid substitutions L234A and L235A refer to the so-called LALA mutation. The “P329G LALA” combination of amino acid substitutions almost completely abolishes Fcγ receptor binding of a human IgG1 Fc domain and is described in International Patent Appl. Publ. No. WO 2012/130831 A1 which also describes methods of preparing such mutant Fc domains and methods for determining its properties such as Fc receptor binding or effector functions. “EU numbering” refers to the numbering according to EU index of Kabat et al, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991.

›Definitions · 16 of 34

Fc domains with reduced Fc receptor binding and/or effector function also include those with substitution of one or more of Fc domain residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Pat. No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called “DANA” Fc mutant with substitution of residues 265 and 297 to alanine (U.S. Pat. No. 7,332,581).

In another aspect, the Fc domain is an IgG4 Fc domain. IgG4 antibodies exhibit reduced binding affinity to Fc receptors and reduced effector functions as compared to IgG1 antibodies. In a more specific aspect, the Fc domain is an IgG4 Fc domain comprising an amino acid substitution at position 5228 (Kabat numbering), particularly the amino acid substitution S228P. In a more specific aspect, the Fc domain is an IgG4 Fc domain comprising amino acid substitutions L235E and S228P and P329G (EU numbering). Such IgG4 Fc domain mutants and their Fcγ receptor binding properties are also described in WO 2012/130831.

Mutant Fc domains can be prepared by amino acid deletion, substitution, insertion or modification using genetic or chemical methods well known in the art. Genetic methods may include site-specific mutagenesis of the encoding DNA sequence, PCR, gene synthesis, and the like. The correct nucleotide changes can be verified for example by sequencing.

Binding to Fc receptors can be easily determined e.g. by ELISA, or by Surface Plasmon Resonance (SPR) using standard instrumentation such as a BIACORE® instrument (GE Healthcare), and Fc receptors such as may be obtained by recombinant expression. A suitable such binding assay is described herein. Alternatively, binding affinity of Fc domains or cell activating bispecific antigen binding molecules comprising an Fc domain for Fc receptors may be evaluated using cell lines known to express particular Fc receptors, such as human NK cells expressing FcγIIIa receptor.

Effector function of an Fc domain, or bispecific antibodies of the invention comprising an Fc domain, can be measured by methods known in the art. A suitable assay for measuring ADCC is described herein. Other examples of in vitro assays to assess ADCC activity of a molecule of interest are described in U.S. Pat. No. 5,500,362; Hellstrom et al. Proc Natl Acad Sci USA 83, 7059-7063 (1986) and Hellstrom et al., Proc Natl Acad Sci USA 82, 1499-1502 (1985); U.S. Pat. No. 5,821,337; Bruggemann et al., J Exp Med 166, 1351-1361 (1987). Alternatively, non-radioactive assays methods may be employed (see, for example, ACTI™ non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, Calif.); and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, Wis.)). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g. in a animal model such as that disclosed in Clynes et al., Proc Natl Acad Sci USA 95, 652-656 (1998).

In some embodiments, binding of the Fc domain to a complement component, specifically to C1q, is reduced. Accordingly, in some embodiments wherein the Fc domain is engineered to have reduced effector function, said reduced effector function includes reduced CDC. C1q binding assays may be carried out to determine whether the bispecific antibodies of the invention is able to bind C1q and hence has CDC activity. See e.g., C1q and C3c binding ELISA in WO 2006/029879 and WO 2005/100402. To assess complement activation, a CDC assay may be performed (see, for example, Gazzano-Santoro et al., J Immunol Methods 202, 163 (1996); Cragg et al., Blood 101, 1045-1052 (2003); and Cragg and Glennie, Blood 103, 2738-2743 (2004)).

In a particular aspect, the Fc domain comprises a modification promoting the association of the first and second subunit of the Fc domain.

Fc Domain Modifications Promoting Heterodimerization

In one aspect, the TNF family ligand trimer-containing antigen binding molecules of the invention comprise (a) at least one moiety capable of specific binding to a target cell antigen, (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof, and (c) an Fc domain composed of a first and a second subunit capable of stable association, wherein the Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor, in particular towards Fcγ receptor. Thus, they comprise different moieties, fused to one or the other of the two subunits of the Fc domain that are typically comprised in two non-identical polypeptide chains (“heavy chains”). Recombinant co-expression of these polypeptides and subsequent dimerization leads to several possible combinations of the two polypeptides. To improve the yield and purity of the TNF family ligand trimer-containing antigen binding molecules in recombinant production, it will thus be advantageous to introduce in the Fc domain of the TNF family ligand trimer-containing antigen binding molecules of the invention a modification promoting the association of the desired polypeptides.

Accordingly, the Fc domain of the TNF family ligand trimer-containing antigen binding molecules of the invention comprises a modification promoting the association of the first and the second subunit of the Fc domain. The site of most extensive protein-protein interaction between the two subunits of a human IgG Fc domain is in the CH3 domain of the Fc domain. Thus, said modification is particularly in the CH3 domain of the Fc domain.

In a specific aspect, said modification is a so-called “knob-into-hole” modification, comprising a “knob” modification in one of the two subunits of the Fc domain and a “hole” modification in the other one of the two subunits of the Fc domain. Thus, in a particular aspect, the invention relates to a TNF family ligand trimer-containing antigen binding molecule as described herein before which comprises an IgG molecule, wherein the Fc part of the first heavy chain comprises a first dimerization module and the Fc part of the second heavy chain comprises a second dimerization module allowing a heterodimerization of the two heavy chains of the IgG molecule and the first dimerization module comprises knobs and the second dimerization module comprises holes according to the knob into hole technology.

›Definitions · 17 of 34

The knob-into-hole technology is described e.g. in U.S. Pat. Nos. 5,731,168; 7,695,936; Ridgway et al., Prot Eng 9, 617-621 (1996) and Carter, J Immunol Meth 248, 7-15 (2001). Generally, the method involves introducing a protuberance (“knob”) at the interface of a first polypeptide and a corresponding cavity (“hole”) in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heterodimer formation and hinder homodimer formation. Protuberances are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory cavities of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine).

Accordingly, in a particular aspect, in the CH3 domain of the first subunit of the Fc domain of the TNF family ligand trimer-containing antigen binding molecules of the invention an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance within the CH3 domain of the first subunit which is positionable in a cavity within the CH3 domain of the second subunit, and in the CH3 domain of the second subunit of the Fc domain an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the CH3 domain of the second subunit within which the protuberance within the CH3 domain of the first subunit is positionable.

The protuberance and cavity can be made by altering the nucleic acid encoding the polypeptides, e.g. by site-specific mutagenesis, or by peptide synthesis.

In a specific aspect, in the CH3 domain of the first subunit of the Fc domain the threonine residue at position 366 is replaced with a tryptophan residue (T366W), and in the CH3 domain of the second subunit of the Fc domain the tyrosine residue at position 407 is replaced with a valine residue (Y407V). More particularly, in the second subunit of the Fc domain additionally the threonine residue at position 366 is replaced with a serine residue (T366S) and the leucine residue at position 368 is replaced with an alanine residue (L368A). More particularly, in the first subunit of the Fc domain additionally the serine residue at position 354 is replaced with a cysteine residue (S354C), and in the second subunit of the Fc domain additionally the tyrosine residue at position 349 is replaced by a cysteine residue (Y349C). The introduction of these two cysteine residues results in the formation of a disulfide bridge between the two subunits of the Fc domain. The disulfide bridge further stabilizes the dimer (Carter, J Immunol Methods 248, 7-15 (2001)).

In an alternative aspect, a modification promoting association of the first and the second subunit of the Fc domain comprises a modification mediating electrostatic steering effects, e.g. as described in PCT publication WO 2009/089004. Generally, this method involves replacement of one or more amino acid residues at the interface of the two Fc domain subunits by charged amino acid residues so that homodimer formation becomes electrostatically unfavorable but heterodimerization electrostatically favorable.

Modifications in the CH1/CL Domains

To further improve correct pairing, the TNF family ligand trimer-containing antigen binding molecules can contain different charged amino acid substitutions (so-called “charged residues”). These modifications are introduced in the crossed or non-crossed CH1 and CL domains. In a particular aspect, the invention relates to a TNF family ligand trimer-containing antigen binding molecule, wherein in one of CL domains the amino acid at position 123 (EU numbering) has been replaced by arginine (R) and the amino acid at position 124 (EU numbering) has been substituted by lysine (K) and wherein in one of the CH1 domains the amino acids at position 147 (EU numbering) and at position 213 (EU numbering) have been substituted by glutamic acid (E).

More particularly, the invention relates to a TNF family ligand trimer-containing antigen binding molecule, wherein in the CL domain adjacent to the TNF ligand family member the amino acid at position 123 (EU numbering) has been replaced by arginine (R) and the amino acid at position 124 (EU numbering) has been substituted by lysine (K), and wherein in the CH1 domain adjacent to the TNF ligand family member the amino acids at position 147 (EU numbering) and at position 213 (EU numbering) have been substituted by glutamic acid (E).

Particular TNF Family Ligand Trimer-Containing Antigen Binding Molecules

In another aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises

In a further aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the first peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus by a second peptide linker to a CH1 domain that is part of a heavy chain, and the second peptide comprising one ectodomain of said TNF ligand family member or a fragment thereof is fused at its C-terminus by a third peptide linker to a CL domain that is part of a light chain.

In yet another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the first peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus by a second peptide linker to a CL domain that is part of a heavy chain, and the second peptide comprising one ectodomain of said TNF ligand family member or a fragment thereof that is fused at its C-terminus by a third peptide linker to a CH1 domain that is part of a light chain.

›Definitions · 18 of 34

In a further aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the first peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus by a second peptide linker to a VH domain that is part of a heavy chain, and the second peptide comprising one ectodomain of said TNF ligand family member or a fragment thereof is fused at its C-terminus by a third peptide linker to a VL domain that is part of a light chain.

In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule of claims 21 to 23 , wherein in the CL domain adjacent to the TNF ligand family member the amino acid at position 123 (EU numbering) has been replaced by arginine (R) and the amino acid at position 124 (EU numbering) has been substituted by lysine (K), and wherein in the CH1 domain adjacent to the TNF ligand family member the amino acids at position 147 (EU numbering) and at position 213 (EU numbering) have been substituted by glutamic acid (E). These modifications lead to so-called charged residues with advantageous properties that avoid undesired effects such as for example mispairing.

TNF family ligand trimer-containing antigen binding molecules, wherein the target cell antigen is FAP

In a particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the target cell antigen is Fibroblast Activation Protein (FAP).

In a particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule of the invention, wherein the moiety capable of specific binding to a target cell antigen is a Fab molecule capable of specific binding to FAP and comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:7, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:8 and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:9, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:10, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:11 and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:12.

In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule of the invention, wherein the moiety capable of specific binding to a target cell antigen is a Fab molecule capable of specific binding to FAP and comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:100, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:101 and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:102, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:103, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:104 and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:105.

In a further aspect, the moiety capable of specific binding to FAP comprises a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:16 and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:17.

In another aspect, the moiety capable of specific binding to FAP comprises a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:106 and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:107.

In one aspect, the moiety capable of specific binding to FAP comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO:16 and a variable light chain comprising an amino acid sequence of SEQ ID NO:17 or a variable heavy chain comprising an amino acid sequence of SEQ ID NO:106 and a variable light chain comprising an amino acid sequence of SEQ ID NO:107.

In a particular aspect, the moiety capable of specific binding to FAP comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:16 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:17. In another particular aspect, the moiety capable of specific binding to FAP comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:106 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:107. In a specific aspect, the moiety capable of specific binding to FAP comprises a VH domain consisting of amino acid sequence of SEQ ID NO:106 and a VL domain consisting of the amino acid sequence of SEQ ID NO:107.

In a further aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises

›Definitions · 19 of 34

(a) at least one moiety capable of specific binding to a target cell antigen comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:16 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:17, and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99 and in that the second polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4.

In a particular aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises

(a) at least one moiety capable of specific binding to a target cell antigen comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:16 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:17, and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises the the amino acid sequence of SEQ ID NO:97 and the second polypeptide comprises the amino acid sequence of SEQ ID NO:96.

In another aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises

(a) at least one moiety capable of specific binding to a target cell antigen comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:106 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:107, and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99 and in that the second polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4.

In a particular aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises

(a) at least one moiety capable of specific binding to a target cell antigen comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:106 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:107, and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises the the amino acid sequence of SEQ ID NO:97 and the second polypeptide comprises the amino acid sequence of SEQ ID NO:96.

In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to a target cell antigen,

a second heavy chain comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker that is fused at its C-terminus by a second peptide linker to a CH1 domain, and a second light chain comprising one ectodomain of said TNF ligand family member or a fragment thereof is fused at its C-terminus by a third peptide linker to a CL domain, and wherein the antigen binding molecule comprises (i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:16 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:17 or a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:106 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:107, (ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:108, SEQ ID NO:111 and SEQ ID NO:113, and (iii) a second light chain comprising the amino acid sequence of SEQ ID NO:15, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:112 and SEQ ID NO:114.

In a further particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, and wherein the antigen binding molecule comprises

a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to a target cell antigen, a second heavy chain comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus by a second peptide linker to a CL domain, and a second light chain comprising one ectodomain of said TNF ligand family member or a fragment thereof that is fused at its C-terminus by a third peptide linker to a CH1 domain, and wherein the molecule comprises (i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:16 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:17 or a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:106 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:107, (ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119 and SEQ ID NO:173, and (iii) a second light chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120 and SEQ ID NO:174.

More particularly, provided is a TNF family ligand trimer-containing antigen binding molecule comprising

(a) a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to a target cell antigen, wherein the first heavy chain comprises the VH domain comprising the amino acid sequence of SEQ ID NO:106 and the first light chain comprises the VL domain comprising the amino acid sequence of SEQ ID NO:107, and (b) a second heavy chain comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus by a second peptide linker to a CL domain, and a second light chain comprising one ectodomain of said TNF ligand family member or a fragment thereof that is fused at its C-terminus by a third peptide linker to a CH1 domain, wherein the second heavy chain comprises the amino acid sequence of SEQ ID NO:119 or SEQ ID NO:173, and the second light chain comprises the amino acid sequence of SEQ ID NO:120 or SEQ ID NO:174. In particular, the second heavy chain comprises the amino acid sequence of SEQ ID NO:119 and the second light chain comprises the amino acid sequence of SEQ ID NO:120.

›Definitions · 20 of 34

Furthermore, the invention provides a TNF family ligand trimer-containing antigen binding molecule, comprising

In a particular aspect, such a TNF family ligand trimer-containing antigen binding molecule comprises two moieties capable of specific binding to a target cell antigen.

More particular, such TNF family ligand trimer-containing antigen binding molecule comprises

In a further aspect, the invention relates to a TNF family ligand trimer-containing antigen binding molecule, selected from the group consisting of:

a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:18, a first light chain comprising the amino acid sequence of SEQ ID NO:19, a second heavy chain comprising the amino acid sequence of SEQ ID NO:14 and a second light chain comprising the amino acid sequence of SEQ ID NO:15;

b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:18, a first light chain comprising the amino acid sequence of SEQ ID NO:19, a second heavy chain comprising the amino acid sequence of SEQ ID NO:115 and a second light chain comprising the amino acid sequence of SEQ ID NO:116;

c) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:135, a first light chain comprising the amino acid sequence of SEQ ID NO:136, a second heavy chain comprising the amino acid sequence of SEQ ID NO:108 and a second light chain comprising the amino acid sequence of SEQ ID NO:109;

d) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:18, a first light chain comprising the amino acid sequence of SEQ ID NO:19, a second heavy chain comprising the amino acid sequence of SEQ ID NO:139 and a second light chain comprising the amino acid sequence of SEQ ID NO:140;

e) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:19, a first heavy chain comprising the amino acid sequence of SEQ ID NO:121 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:122;

f) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:18, a first light chain comprising the amino acid sequence of SEQ ID NO:19, a second heavy chain comprising the amino acid sequence of SEQ ID NO:108 and a second light chain comprising the amino acid sequence of SEQ ID NO:110;

g) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:145, a first light chain comprising the amino acid sequence of SEQ ID NO:19, a second heavy chain comprising the amino acid sequence of SEQ ID NO:115 and a second light chain comprising the amino acid sequence of SEQ ID NO:116;

h) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:18, a first light chain comprising the amino acid sequence of SEQ ID NO:19, a second heavy chain comprising the amino acid sequence of SEQ ID NO:148 and a second light chain comprising the amino acid sequence of SEQ ID NO:149;

i) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:18, a first light chain comprising the amino acid sequence of SEQ ID NO:19, a second heavy chain comprising the amino acid sequence of SEQ ID NO:111 and a second light chain comprising the amino acid sequence of SEQ ID NO:112; and

j) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:18, a first light chain comprising the amino acid sequence of SEQ ID NO:19, a second heavy chain comprising the amino acid sequence of SEQ ID NO:113 and a second light chain comprising the amino acid sequence of SEQ ID NO:114.

In another aspect, the invention relates to a TNF family ligand trimer-containing antigen binding molecule, selected from the group consisting of:

a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:164, a first light chain comprising the amino acid sequence of SEQ ID NO:125, a second heavy chain comprising the amino acid sequence of SEQ ID NO:115 and a second light chain comprising the amino acid sequence of SEQ ID NO:116;

b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:164, a first light chain comprising the amino acid sequence of SEQ ID NO:125, a second heavy chain comprising the amino acid sequence of SEQ ID NO:117 and a second light chain comprising the amino acid sequence of SEQ ID NO:118;

c) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:125, a first heavy chain comprising the amino acid sequence of SEQ ID NO:123 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:124;

›Definitions · 21 of 34

d) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:164, a first light chain comprising the amino acid sequence of SEQ ID NO:125, a second heavy chain comprising the amino acid sequence of SEQ ID NO:119 and a second light chain comprising the amino acid sequence of SEQ ID NO:120;

e) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:164, a first light chain comprising the amino acid sequence of SEQ ID NO:125, a second heavy chain comprising the amino acid sequence of SEQ ID NO:173 and a second light chain comprising the amino acid sequence of SEQ ID NO:174; and

f) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:125, a first heavy chain comprising the amino acid sequence of SEQ ID NO:126 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:127.

In particular, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:164, a first light chain comprising the amino acid sequence of SEQ ID NO:125, a second heavy chain comprising the amino acid sequence of SEQ ID NO:119 and a second light chain comprising the amino acid sequence of SEQ ID NO:120.

In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the TNF ligand family member is OX40L and wherein the target cell antigen is Fibroblast Activation Protein (FAP) and the moiety capable of specific binding to FAP comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:7 or SEQ ID NO:100, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:101, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:102, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:10 or SEQ ID NO:103, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:11 or SEQ ID NO:104, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:12 or SEQ ID NO:105.

In a particular aspect, the TNF family ligand trimer-containing antigen binding molecule of comprises

(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:16 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:17 or a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:106 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:107, (ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:355, and (iii) a second light chain comprising the amino acid sequence of SEQ ID NO:356.

TNF family ligand trimer-containing antigen binding molecules, wherein the target cell antigen is CD19

In a particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the target cell antigen is CD19.

In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to CD19 comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:195 or SEQ ID NO:252, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:196 or SEQ ID NO:253, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:197 or SEQ ID NO:254, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:198 or SEQ ID NO:249, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:199 or SEQ ID NO:250, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:200 or SEQ ID NO:251.

In a particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule of the invention, wherein the moiety capable of specific binding to a target cell antigen is a Fab molecule capable of specific binding to CD19 and comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:195, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:196 and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:197, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:198, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:199 and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:200.

In a further aspect, provided is a TNF family ligand trimer-containing antigen binding molecule of the invention, wherein the moiety capable of specific binding to a target cell antigen is a Fab molecule capable of specific binding to CD19 and comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:252, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:253 and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:254, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:249, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:250 and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:251.

In another aspect, the moiety capable of specific binding to CD19 comprises a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:201 and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:202.

In a further aspect, the moiety capable of specific binding to CD19 comprises a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:357 and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:358.

›Definitions · 22 of 34

In one aspect, the moiety capable of specific binding to CD19 comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO:201 and a variable light chain comprising an amino acid sequence of SEQ ID NO:202 or wherein the moiety capable of specific binding to CD19 comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO:357 and a variable light chain comprising an amino acid sequence of SEQ ID NO:358.

In a particular aspect, the moiety capable of specific binding to CD19 comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:201 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:202. In another particular aspect, the moiety capable of specific binding to CD19 comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:357 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:358.

In another aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises

(a) at least one moiety capable of specific binding to a target cell antigen comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:201 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:202, and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99 and in that the second polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4.

In a particular aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises

(a) at least one moiety capable of specific binding to a target cell antigen comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:201 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:202, and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises the the amino acid sequence of SEQ ID NO:97 and the second polypeptide comprises the amino acid sequence of SEQ ID NO:96.

In another aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises

(a) at least one moiety capable of specific binding to a target cell antigen comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:357 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:358, and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99 and in that the second polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4.

In a particular aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises

(a) at least one moiety capable of specific binding to a target cell antigen comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:357 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:358, and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises the the amino acid sequence of SEQ ID NO:97 and the second polypeptide comprises the amino acid sequence of SEQ ID NO:96.

In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises

a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to a target cell antigen, a second heavy chain comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker that is fused at its C-terminus by a second peptide linker to a CH1 domain, and a second light chain comprising one ectodomain of said TNF ligand family member or a fragment thereof is fused at its C-terminus by a third peptide linker to a CL domain, and wherein the antigen binding molecule comprises (i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:201 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:202 or a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:357 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:358, (ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:108, SEQ ID NO:111 and SEQ ID NO:113, and (iii) a second light chain comprising the amino acid sequence of SEQ ID NO:15, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:112 and SEQ ID NO:114.

In a further particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, and wherein the antigen binding molecule comprises

a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to a target cell antigen, a second heavy chain comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus by a second peptide linker to a CL domain, and a second light chain comprising one ectodomain of said TNF ligand family member or a fragment thereof that is fused at its C-terminus by a third peptide linker to a CH1 domain, and wherein the molecule comprises (i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:201 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:202 or a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:357 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:358, (ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119 and SEQ ID NO:173, and (iii) a second light chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120 and SEQ ID NO:174.

›Definitions · 23 of 34

Furthermore, the invention provides a TNF family ligand trimer-containing antigen binding molecule, comprising

In a particular aspect, such a TNF family ligand trimer-containing antigen binding molecule comprises two moieties capable of specific binding to a target cell antigen.

More particular, such TNF family ligand trimer-containing antigen binding molecule comprises

In a further aspect, the invention relates to a TNF family ligand trimer-containing antigen binding molecule, selected from the group consisting of:

a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:205, a first light chain comprising the amino acid sequence of SEQ ID NO:206, a second heavy chain comprising the amino acid sequence of SEQ ID NO:115 and a second light chain comprising the amino acid sequence of SEQ ID NO:116;

b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:205, a first light chain comprising the amino acid sequence of SEQ ID NO:206, a second heavy chain comprising the amino acid sequence of SEQ ID NO:117 and a second light chain comprising the amino acid sequence of SEQ ID NO:118;

c) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:206, a first heavy chain comprising the amino acid sequence of SEQ ID NO:209 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:210;

d) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:205, a first light chain comprising the amino acid sequence of SEQ ID NO:206, a second heavy chain comprising the amino acid sequence of SEQ ID NO:119 and a second light chain comprising the amino acid sequence of SEQ ID NO:120;

e) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:205, a first light chain comprising the amino acid sequence of SEQ ID NO:206, a second heavy chain comprising the amino acid sequence of SEQ ID NO:173 and a second light chain comprising the amino acid sequence of SEQ ID NO:174; and

f) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:206, a first heavy chain comprising the amino acid sequence of SEQ ID NO:213 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:214.

In particular, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:205, a first light chain comprising the amino acid sequence of SEQ ID NO:206, a second heavy chain comprising the amino acid sequence of SEQ ID NO:119 and a second light chain comprising the amino acid sequence of SEQ ID NO:120.

In another aspect, the invention relates to a TNF family ligand trimer-containing antigen binding molecule, selected from the group consisting of:

a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:357, a first light chain comprising the amino acid sequence of SEQ ID NO:358, a second heavy chain comprising the amino acid sequence of SEQ ID NO:115 and a second light chain comprising the amino acid sequence of SEQ ID NO:116;

b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:357, a first light chain comprising the amino acid sequence of SEQ ID NO:358, a second heavy chain comprising the amino acid sequence of SEQ ID NO:117 and a second light chain comprising the amino acid sequence of SEQ ID NO:118;

c) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:358, a first heavy chain comprising the amino acid sequence of SEQ ID NO:209 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:210;

d) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:357, a first light chain comprising the amino acid sequence of SEQ ID NO:358, a second heavy chain comprising the amino acid sequence of SEQ ID NO:119 and a second light chain comprising the amino acid sequence of SEQ ID NO:120;

e) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:357, a first light chain comprising the amino acid sequence of SEQ ID NO:358, a second heavy chain comprising the amino acid sequence of SEQ ID NO:173 and a second light chain comprising the amino acid sequence of SEQ ID NO:174; and

›Definitions · 24 of 34

f) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:358, a first heavy chain comprising the amino acid sequence of SEQ ID NO:213 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:214.

In particular, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:357, a first light chain comprising the amino acid sequence of SEQ ID NO:358, a second heavy chain comprising the amino acid sequence of SEQ ID NO:119 and a second light chain comprising the amino acid sequence of SEQ ID NO:120.

TNF family ligand trimer-containing antigen binding molecules, wherein the target cell antigen is CEA.

In a particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the target cell antigen is CEA.

In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to CD19 comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:321, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:322, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:323, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:324, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:325, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:326.

In a particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule of the invention, wherein the moiety capable of specific binding to a target cell antigen is a Fab molecule capable of specific binding to CEA and comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:321, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:322 and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:323, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:324, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:325 and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:326.

In a further aspect, the moiety capable of specific binding to CEA comprises a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:327 and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:328.

In one aspect, the moiety capable of specific binding to CEA comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO:327 and a variable light chain comprising an amino acid sequence of SEQ ID NO:328.

In a further aspect, the moiety capable of specific binding to CEA comprises a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:329 and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:330.

In one aspect, the moiety capable of specific binding to CEA comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO:329 and a variable light chain comprising an amino acid sequence of SEQ ID NO:330.

In another aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises

(a) at least one moiety capable of specific binding to a target cell antigen comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:329 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:330, and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99 and in that the second polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4.

In a particular aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises

(a) at least one moiety capable of specific binding to a target cell antigen comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:329 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:330, and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises the the amino acid sequence of SEQ ID NO:97 and the second polypeptide comprises the amino acid sequence of SEQ ID NO:96.

In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises

a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to a target cell antigen, a second heavy chain comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker that is fused at its C-terminus by a second peptide linker to a CH1 domain, and a second light chain comprising one ectodomain of said TNF ligand family member or a fragment thereof is fused at its C-terminus by a third peptide linker to a CL domain, and wherein the antigen binding molecule comprises (i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:329 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:330, (ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:108, SEQ ID NO:111 and SEQ ID NO:113, and (iii) a second light chain comprising the amino acid sequence of SEQ ID NO:15, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:112 and SEQ ID NO:114.

›Definitions · 25 of 34

In a further particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, and wherein the antigen binding molecule comprises

a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to a target cell antigen, a second heavy chain comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus by a second peptide linker to a CL domain, and a second light chain comprising one ectodomain of said TNF ligand family member or a fragment thereof that is fused at its C-terminus by a third peptide linker to a CH1 domain, and wherein the molecule comprises i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:329 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:330, (ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119 and SEQ ID NO:173, and (iii) a second light chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120 and SEQ ID NO:174.

Furthermore, the invention provides a TNF family ligand trimer-containing antigen binding molecule, comprising

In a particular aspect, such a TNF family ligand trimer-containing antigen binding molecule comprises two moieties capable of specific binding to a target cell antigen.

More particular, such TNF family ligand trimer-containing antigen binding molecule comprises

In a further aspect, the invention relates to a TNF family ligand trimer-containing antigen binding molecule, selected from the group consisting of:

a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:333, a first light chain comprising the amino acid sequence of SEQ ID NO:334, a second heavy chain comprising the amino acid sequence of SEQ ID NO:115 and a second light chain comprising the amino acid sequence of SEQ ID NO:116;

b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:333, a first light chain comprising the amino acid sequence of SEQ ID NO:334, a second heavy chain comprising the amino acid sequence of SEQ ID NO:117 and a second light chain comprising the amino acid sequence of SEQ ID NO:118;

c) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:334, a first heavy chain comprising the amino acid sequence of SEQ ID NO:337 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:338;

d) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:333, a first light chain comprising the amino acid sequence of SEQ ID NO:334, a second heavy chain comprising the amino acid sequence of SEQ ID NO:119 and a second light chain comprising the amino acid sequence of SEQ ID NO:120;

e) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:333, a first light chain comprising the amino acid sequence of SEQ ID NO:334, a second heavy chain comprising the amino acid sequence of SEQ ID NO:173 and a second light chain comprising the amino acid sequence of SEQ ID NO:174; and

f) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:334, a first heavy chain comprising the amino acid sequence of SEQ ID NO:341 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:342.

In particular, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:333, a first light chain comprising the amino acid sequence of SEQ ID NO:334, a second heavy chain comprising the amino acid sequence of SEQ ID NO:119 and a second light chain comprising the amino acid sequence of SEQ ID NO:120.

Polynucleotides

The invention further provides isolated polynucleotides encoding a TNF family ligand trimer-containing antigen binding molecule as described herein or a fragment thereof.

The isolated polynucleotides encoding TNF ligand trimer-containing antigen binding molecules of the invention may be expressed as a single polynucleotide that encodes the entire antigen binding molecule or as multiple (e.g., two or more) polynucleotides that are co-expressed. Polypeptides encoded by polynucleotides that are co-expressed may associate through, e.g., disulfide bonds or other means to form a functional antigen binding molecule. For example, the light chain portion of an immunoglobulin may be encoded by a separate polynucleotide from the heavy chain portion of the immunoglobulin. When co-expressed, the heavy chain polypeptides will associate with the light chain polypeptides to form the immunoglobulin.

›Definitions · 26 of 34

In some aspects, the isolated polynucleotide encodes the entire TNF family ligand trimer-containing antigen binding molecule according to the invention as described herein. In particular, the isolated polynucleotide encodes a polypeptide comprised in the TNF family ligand trimer-containing antigen binding molecule according to the invention as described herein.

In one aspect, the present invention is directed to an isolated polynucleotide encoding a TNF family ligand trimer-containing antigen binding molecule, wherein the polynucleotide comprises (a) a sequence that encodes a moiety capable of specific binding to a target cell antigen, (b) a sequence that encodes a polypeptide comprising two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and (c) a sequence that encodes a polypeptide comprising one ectodomain of said TNF ligand family member or a fragment thereof.

In another aspect, provided is an isolated polynucleotide encoding a 4-1BB ligand trimer-containing antigen binding molecule, wherein the polynucleotide comprises (a) a sequence that encodes a moiety capable of specific binding to a target cell antigen, (b) a sequence that encodes a polypeptide comprising two ectodomains of 4-1BBL or two fragments thereof that are connected to each other by a peptide linker and (c) a sequence that encodes a polypeptide comprising one ectodomain of 4-1BBL or a fragment thereof.

In a further aspect, the invention is directed to an isolated polynucleotide comprising a sequence that encodes a polypeptide comprising two 4-1BBL fragments comprising an amino acid sequence that is at least about 90%, 95%, 98% or 100% identical to an amino acid sequence shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:96, and to a polynucleotide comprising a sequence that encodes a polypeptide comprising one 4-1BBL fragment comprising an amino acid sequence that is at least about 90%, 95%, 98% or 100% identical to an amino acid sequence shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:96.

Furthermore, provided is an isolated polynucleotide encoding a OX40 ligand trimer-containing antigen binding molecule, wherein the polynucleotide comprises (a) a sequence that encodes a moiety capable of specific binding to a target cell antigen, (b) a sequence that encodes a polypeptide comprising two ectodomains of OX40L or two fragments thereof that are connected to each other by a peptide linker and (c) a sequence that encodes a polypeptide comprising one ectodomain of OX40L or a fragment thereof.

In another aspect, the invention is directed to an isolated polynucleotide comprising a sequence that encodes a polypeptide comprising two 4-1BBL fragments comprising an amino acid sequence that is at least about 90%, 95%, 98% or 100% identical to an amino acid sequence shown in SEQ ID NO:53 or SEQ ID NO:54, and to a polynucleotide comprising a sequence that encodes a polypeptide comprising one 4-1BBL fragment comprising an amino acid sequence that is at least about 90%, 95%, 98% or 100% identical to an amino acid sequence shown in SEQ ID NO:53 or SEQ ID NO:54.

In further aspects, the invention relates to the polynucleotides comprising a sequence that is at least about 90%, 95%, 98% or 100% identical to the specific cDNA sequences disclosed herein. In a particular aspect, the invention relates to a polynucleotide comprising a sequence that is identical to one of the specific cDNA sequences disclosed herein.

In other aspects, the nucleic acid molecule comprises or consists of a nucleotide sequence that encodes an amino acid sequence as set forth in any one of SEQ ID NOs: 5, 6, 97, 98, 99, 183, 184 or 185. In a further aspect, the nucleic acid molecule comprises or consists of a nucleotide sequence that encodes an amino acid sequence as set forth in any one of SEQ ID NOs:14, 15, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 173 or 174.

In still other aspects, the nucleic acid molecule comprises or consists of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 66, 67, 68, 69, 129, 130, 131, 132, 133, 134, 137, 138, 141, 142, 143, 144, 146, 147, 150, 151, 152, 153, 162, 163, 165, 166, 167, 168, 169, 170, 171, 172, 175, 176, 177, 178, 203, 204, 207, 208, 211, 212, 215, 216, 273, 274, 277, 278, 281, 282, 285, 286, 289, 290, 293, 294, 297, 298, 301, 302, 305, 307, 308, 311, 312, 315, 316, 331, 332, 335, 336, 339, 340, 343, 344, 347, 348, 353 or 354.

In certain aspects, the polynucleotide or nucleic acid is DNA. In other embodiments, a polynucleotide of the present invention is RNA, for example, in the form of messenger RNA (mRNA). RNA of the present invention may be single stranded or double stranded.

Recombinant Methods

TNF family ligand trimer-containing antigen binding molecules of the invention may be obtained, for example, by solid-state peptide synthesis (e.g. Merrifield solid phase synthesis) or recombinant production. For recombinant production one or more polynucleotide encoding the TNF family ligand trimer-containing antigen binding molecule or polypeptide fragments thereof, e.g., as described above, is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such polynucleotide may be readily isolated and sequenced using conventional procedures. In one aspect of the invention, a vector, preferably an expression vector, comprising one or more of the polynucleotides of the invention is provided. Methods which are well known to those skilled in the art can be used to construct expression vectors containing the coding sequence of the TNF family ligand trimer-containing antigen binding molecule (fragment) along with appropriate transcriptional/translational control signals. These methods include in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination/genetic recombination. See, for example, the techniques described in Maniatis et al., MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory, N.Y. (1989); and Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing Associates and Wiley Interscience, N.Y. (1989). The expression vector can be part of a plasmid, virus, or may be a nucleic acid fragment. The expression vector includes an expression cassette into which the polynucleotide encoding the TNF family ligand trimer-containing antigen binding molecule or polypeptide fragments thereof (i.e. the coding region) is cloned in operable association with a promoter and/or other transcription or translation control elements. As used herein, a “coding region” is a portion of nucleic acid which consists of codons translated into amino acids. Although a “stop codon” (TAG, TGA, or TAA) is not translated into an amino acid, it may be considered to be part of a coding region, if present, but any flanking sequences, for example promoters, ribosome binding sites, transcriptional terminators, introns, 5′ and 3′ untranslated regions, and the like, are not part of a coding region. Two or more coding regions can be present in a single polynucleotide construct, e.g. on a single vector, or in separate polynucleotide constructs, e.g. on separate (different) vectors. Furthermore, any vector may contain a single coding region, or may comprise two or more coding regions, e.g. a vector of the present invention may encode one or more polypeptides, which are post- or co-translationally separated into the final proteins via proteolytic cleavage. In addition, a vector, polynucleotide, or nucleic acid of the invention may encode heterologous coding regions, either fused or unfused to a polynucleotide encoding the TNF family ligand trimer-containing antigen binding molecule of the invention or polypeptide fragments thereof, or variants or derivatives thereof. Heterologous coding regions include without limitation specialized elements or motifs, such as a secretory signal peptide or a heterologous functional domain. An operable association is when a coding region for a gene product, e.g. a polypeptide, is associated with one or more regulatory sequences in such a way as to place expression of the gene product under the influence or control of the regulatory sequence(s). Two DNA fragments (such as a polypeptide coding region and a promoter associated therewith) are “operably associated” if induction of promoter function results in the transcription of mRNA encoding the desired gene product and if the nature of the linkage between the two DNA fragments does not interfere with the ability of the expression regulatory sequences to direct the expression of the gene product or interfere with the ability of the DNA template to be transcribed. Thus, a promoter region would be operably associated with a nucleic acid encoding a polypeptide if the promoter was capable of effecting transcription of that nucleic acid. The promoter may be a cell-specific promoter that directs substantial transcription of the DNA only in predetermined cells. Other transcription control elements, besides a promoter, for example enhancers, operators, repressors, and transcription termination signals, can be operably associated with the polynucleotide to direct cell-specific transcription.

›Definitions · 27 of 34

Suitable promoters and other transcription control regions are disclosed herein. A variety of transcription control regions are known to those skilled in the art. These include, without limitation, transcription control regions, which function in vertebrate cells, such as, but not limited to, promoter and enhancer segments from cytomegaloviruses (e.g. the immediate early promoter, in conjunction with intron-A), simian virus 40 (e.g. the early promoter), and retroviruses (such as, e.g. Rous sarcoma virus). Other transcription control regions include those derived from vertebrate genes such as actin, heat shock protein, bovine growth hormone and rabbit â.-globin, as well as other sequences capable of controlling gene expression in eukaryotic cells. Additional suitable transcription control regions include tissue-specific promoters and enhancers as well as inducible promoters (e.g. promoters inducible tetracyclins). Similarly, a variety of translation control elements are known to those of ordinary skill in the art. These include, but are not limited to ribosome binding sites, translation initiation and termination codons, and elements derived from viral systems (particularly an internal ribosome entry site, or IRES, also referred to as a CITE sequence). The expression cassette may also include other features such as an origin of replication, and/or chromosome integration elements such as retroviral long terminal repeats (LTRs), or adeno-associated viral (AAV) inverted terminal repeats (ITRs).

Polynucleotide and nucleic acid coding regions of the present invention may be associated with additional coding regions which encode secretory or signal peptides, which direct the secretion of a polypeptide encoded by a polynucleotide of the present invention. For example, if secretion of the TNF family ligand trimer-containing antigen binding molecule or polypeptide fragments thereof is desired, DNA encoding a signal sequence may be placed upstream of the nucleic acid encoding a TNF family ligand trimer-containing antigen binding molecule of the invention or polypeptide fragments thereof. According to the signal hypothesis, proteins secreted by mammalian cells have a signal peptide or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Those of ordinary skill in the art are aware that polypeptides secreted by vertebrate cells generally have a signal peptide fused to the N-terminus of the polypeptide, which is cleaved from the translated polypeptide to produce a secreted or “mature” form of the polypeptide. In certain embodiments, the native signal peptide, e.g. an immunoglobulin heavy chain or light chain signal peptide is used, or a functional derivative of that sequence that retains the ability to direct the secretion of the polypeptide that is operably associated with it. Alternatively, a heterologous mammalian signal peptide, or a functional derivative thereof, may be used. For example, the wild-type leader sequence may be substituted with the leader sequence of human tissue plasminogen activator (TPA) or mouse β-glucuronidase.

DNA encoding a short protein sequence that could be used to facilitate later purification (e.g. a histidine tag) or assist in labeling the fusion protein may be included within or at the ends of the polynucleotide encoding a TNF family ligand trimer-containing antigen binding molecule of the invention or polypeptide fragments thereof.

In a further aspect of the invention, a host cell comprising one or more polynucleotides of the invention is provided. In certain embodiments a host cell comprising one or more vectors of the invention is provided. The polynucleotides and vectors may incorporate any of the features, singly or in combination, described herein in relation to polynucleotides and vectors, respectively. In one aspect, a host cell comprises (e.g. has been transformed or transfected with) a vector comprising a polynucleotide that encodes (part of) a TNF family ligand trimer-containing antigen binding molecule of the invention of the invention. As used herein, the term “host cell” refers to any kind of cellular system which can be engineered to generate the fusion proteins of the invention or fragments thereof. Host cells suitable for replicating and for supporting expression of antigen binding molecules are well known in the art. Such cells may be transfected or transduced as appropriate with the particular expression vector and large quantities of vector containing cells can be grown for seeding large scale fermenters to obtain sufficient quantities of the antigen binding molecule for clinical applications. Suitable host cells include prokaryotic microorganisms, such as E. coli , or various eukaryotic cells, such as Chinese hamster ovary cells (CHO), insect cells, or the like. For example, polypeptides may be produced in bacteria in particular when glycosylation is not needed. After expression, the polypeptide may be isolated from the bacterial cell paste in a soluble fraction and can be further purified. In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for polypeptide-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized”, resulting in the production of a polypeptide with a partially or fully human glycosylation pattern. See Gerngross, Nat Biotech 22, 1409-1414 (2004), and Li et al., Nat Biotech 24, 210-215 (2006).

Suitable host cells for the expression of (glycosylated) polypeptides are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells. Plant cell cultures can also be utilized as hosts. See e.g. U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES™ technology for producing antibodies in transgenic plants). Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293T cells as described, e.g., in Graham et al., J Gen Virol 36, 59 (1977)), baby hamster kidney cells (BHK), mouse sertoli cells (TM4 cells as described, e.g., in Mather, Biol Reprod 23, 243-251 (1980)), monkey kidney cells (CV1), African green monkey kidney cells (VERO-76), human cervical carcinoma cells (HELA), canine kidney cells (MDCK), buffalo rat liver cells (BRL 3A), human lung cells (W138), human liver cells (Hep G2), mouse mammary tumor cells (MMT 060562), TRI cells (as described, e.g., in Mather et al., Annals N.Y. Acad Sci 383, 44-68 (1982)), MRC 5 cells, and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including dhfr-CHO cells (Urlaub et al., Proc Natl Acad Sci USA 77, 4216 (1980)); and myeloma cell lines such as YO, NS0, P3X63 and Sp2/0. For a review of certain mammalian host cell lines suitable for protein production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, N.J.), pp. 255-268 (2003). Host cells include cultured cells, e.g., mammalian cultured cells, yeast cells, insect cells, bacterial cells and plant cells, to name only a few, but also cells comprised within a transgenic animal, transgenic plant or cultured plant or animal tissue. In one embodiment, the host cell is a eukaryotic cell, preferably a mammalian cell, such as a Chinese Hamster Ovary (CHO) cell, a human embryonic kidney (HEK) cell or a lymphoid cell (e.g., YO, NS0, Sp20 cell). Standard technologies are known in the art to express foreign genes in these systems. Cells expressing a polypeptide comprising either the heavy or the light chain of an immunoglobulin, may be engineered so as to also express the other of the immunoglobulin chains such that the expressed product is an immunoglobulin that has both a heavy and a light chain.

›Definitions · 28 of 34

In one aspect, a method of producing a TNF family ligand trimer-containing antigen binding molecule of the invention or polypeptide fragments thereof is provided, wherein the method comprises culturing a host cell comprising polynucleotides encoding the TNF family ligand trimer-containing antigen binding molecule of the invention or polypeptide fragments thereof, as provided herein, under conditions suitable for expression of the TNF family ligand trimer-containing antigen binding molecule of the invention or polypeptide fragments thereof, and recovering the TNF family ligand trimer-containing antigen binding molecule of the invention or polypeptide fragments thereof from the host cell (or host cell culture medium).

In the TNF family ligand trimer-containing antigen binding molecule of the invention, the components (at least one moiety capable of specific binding to a target cell antigen, one polypeptide comprising two ectodomains of a TNF ligand family member or fragments thereof and a polypeptide comprising one ectodomain of said TNF family ligand family member or a fragment thereof) are not genetically fused to each other. The polypeptides are designed such that its components (two ectodomains of a TNF ligand family member or fragments thereof and other components such as CH or CL) are fused to each other directly or through a linker sequence. The composition and length of the linker may be determined in accordance with methods well known in the art and may be tested for efficacy. Examples of linker sequences between different components of the antigen binding molecules of the invention are found in the sequences provided herein. Additional sequences may also be included to incorporate a cleavage site to separate the individual components of the fusion protein if desired, for example an endopeptidase recognition sequence.

In certain embodiments the moieties capable of specific binding to a target cell antigen (e.g. Fab fragments) forming part of the antigen binding molecule comprise at least an immunoglobulin variable region capable of binding to an antigen. Variable regions can form part of and be derived from naturally or non-naturally occurring antibodies and fragments thereof. Methods to produce polyclonal antibodies and monoclonal antibodies are well known in the art (see e.g. Harlow and Lane, “Antibodies, a laboratory manual”, Cold Spring Harbor Laboratory, 1988). Non-naturally occurring antibodies can be constructed using solid phase-peptide synthesis, can be produced recombinantly (e.g. as described in U.S. Pat. No. 4,186,567) or can be obtained, for example, by screening combinatorial libraries comprising variable heavy chains and variable light chains (see e.g. U.S. Pat. No. 5,969,108 to McCafferty).

Any animal species of immunoglobulin can be used in the invention. Non-limiting immunoglobulins useful in the present invention can be of murine, primate, or human origin. If the fusion protein is intended for human use, a chimeric form of immunoglobulin may be used wherein the constant regions of the immunoglobulin are from a human. A humanized or fully human form of the immunoglobulin can also be prepared in accordance with methods well known in the art (see e. g. U.S. Pat. No. 5,565,332 to Winter). Humanization may be achieved by various methods including, but not limited to (a) grafting the non-human (e.g., donor antibody) CDRs onto human (e.g. recipient antibody) framework and constant regions with or without retention of critical framework residues (e.g. those that are important for retaining good antigen binding affinity or antibody functions), (b) grafting only the non-human specificity-determining regions (SDRs or a-CDRs; the residues critical for the antibody-antigen interaction) onto human framework and constant regions, or (c) transplanting the entire non-human variable domains, but “cloaking” them with a human-like section by replacement of surface residues. Humanized antibodies and methods of making them are reviewed, e.g., in Almagro and Fransson, Front Biosci 13, 1619-1633 (2008), and are further described, e.g., in Riechmann et al., Nature 332, 323-329 (1988); Queen et al., Proc Natl Acad Sci USA 86, 10029-10033 (1989); U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Jones et al., Nature 321, 522-525 (1986); Morrison et al., Proc Natl Acad Sci 81, 6851-6855 (1984); Morrison and Oi, Adv Immunol 44, 65-92 (1988); Verhoeyen et al., Science 239, 1534-1536 (1988); Padlan, Molec Immun 31(3), 169-217 (1994); Kashmiri et al., Methods 36, 25-34 (2005) (describing SDR (a-CDR) grafting); Padlan, Mol Immunol 28, 489-498 (1991) (describing “resurfacing”); Dall'Acqua et al., Methods 36, 43-60 (2005) (describing “FR shuffling”); and Osbourn et al., Methods 36, 61-68 (2005) and Klimka et al., Br J Cancer 83, 252-260 (2000) (describing the “guided selection” approach to FR shuffling). Particular immunoglobulins according to the invention are human immunoglobulins. Human antibodies and human variable regions can be produced using various techniques known in the art. Human antibodies are described generally in van Dijk and van de Winkel, Curr Opin Pharmacol 5, 368-74 (2001) and Lonberg, Curr Opin Immunol 20, 450-459 (2008). Human variable regions can form part of and be derived from human monoclonal antibodies made by the hybridoma method (see e.g. Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)). Human antibodies and human variable regions may also be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge (see e.g. Lonberg, Nat Biotech 23, 1117-1125 (2005). Human antibodies and human variable regions may also be generated by isolating Fv clone variable region sequences selected from human-derived phage display libraries (see e.g., Hoogenboom et al. in Methods in Molecular Biology 178, 1-37 (O'Brien et al., ed., Human Press, Totowa, N.J., 2001); and McCafferty et al., Nature 348, 552-554; Clackson et al., Nature 352, 624-628 (1991)). Phage typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments.

›Definitions · 29 of 34

In certain aspects, the moieties capable of specific binding to a target cell antigen (e.g. Fab fragments) comprised in the antigen binding molecules of the present invention are engineered to have enhanced binding affinity according to, for example, the methods disclosed in PCT publication WO 2012/020006 (see Examples relating to affinity maturation) or U.S. Pat. Appl. Publ. No. 2004/0132066 (U.S. Pat. No. 7,432,063B2). The ability of the antigen binding molecules of the invention to bind to a specific antigenic determinant can be measured either through an enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to one of skill in the art, e.g. surface plasmon resonance technique (Liljeblad, et al., Glyco J 17, 323-329 (2000)), and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)). Competition assays may be used to identify an antigen binding molecule that competes with a reference antibody for binding to a particular antigen. In certain embodiments, such a competing antigen binding molecule binds to the same epitope (e.g. a linear or a conformational epitope) that is bound by the reference antigen binding molecule. Detailed exemplary methods for mapping an epitope to which an antigen binding molecule binds are provided in Morris (1996) “Epitope Mapping Protocols”, in Methods in Molecular Biology vol. 66 (Humana Press, Totowa, N.J.). In an exemplary competition assay, immobilized antigen is incubated in a solution comprising a first labeled antigen binding molecule that binds to the antigen and a second unlabeled antigen binding molecule that is being tested for its ability to compete with the first antigen binding molecule for binding to the antigen. The second antigen binding molecule may be present in a hybridoma supernatant. As a control, immobilized antigen is incubated in a solution comprising the first labeled antigen binding molecule but not the second unlabeled antigen binding molecule. After incubation under conditions permissive for binding of the first antibody to the antigen, excess unbound antibody is removed, and the amount of label associated with immobilized antigen is measured. If the amount of label associated with immobilized antigen is substantially reduced in the test sample relative to the control sample, then that indicates that the second antigen binding molecule is competing with the first antigen binding molecule for binding to the antigen. See Harlow and Lane (1988) Antibodies: A Laboratory Manual ch.14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).

TNF ligand trimer-containing antigen binding molecules of the invention prepared as described herein may be purified by art-known techniques such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, and the like. The actual conditions used to purify a particular protein will depend, in part, on factors such as net charge, hydrophobicity, hydrophilicity etc., and will be apparent to those having skill in the art. For affinity chromatography purification an antibody, ligand, receptor or antigen can be used to which the TNF ligand trimer-containing antigen binding molecule binds. For example, for affinity chromatography purification of fusion proteins of the invention, a matrix with protein A or protein G may be used. Sequential Protein A or G affinity chromatography and size exclusion chromatography can be used to isolate an antigen binding molecule essentially as described in the Examples. The purity of the TNF ligand trimer-containing antigen binding molecule or fragments thereof can be determined by any of a variety of well-known analytical methods including gel electrophoresis, high pressure liquid chromatography, and the like. For example, the TNF ligand trimer-containing antigen binding molecules expressed as described in the Examples were shown to be intact and properly assembled as demonstrated by reducing and non-reducing SDS-PAGE.

Assays

The antigen binding molecules provided herein may be identified, screened for, or characterized for their physical/chemical properties and/or biological activities by various assays known in the art.

1. Affinity Assays

The affinity of the TNF family ligand trimer-containing antigen binding molecule provided herein for the corresponding TNF receptor can be determined in accordance with the methods set forth in the Examples by surface plasmon resonance (SPR), using standard instrumentation such as a BIACORE® instrument (GE Healthcare), and receptors or target proteins such as may be obtained by recombinant expression. The affinity of the TNF family ligand trimer-containing antigen binding molecule for the target cell antigen can also be determined by surface plasmon resonance (SPR), using standard instrumentation such as a BIACORE® instrument (GE Healthcare), and receptors or target proteins such as may be obtained by recombinant expression. A specific illustrative and exemplary embodiment for measuring binding affinity is described in Example 4. According to one aspect, KD is measured by surface plasmon resonance using a BIACORE® T100 machine (GE Healthcare) at 25° C.

2. Binding Assays and Other Assays

Binding of the TNF family ligand trimer-containing antigen binding molecule provided herein to the corresponding receptor expressing cells may be evaluated using cell lines expressing the particular receptor or target antigen, for example by flow cytometry (FACS). In one aspect, fresh peripheral blood mononuclear cells (PBMCs) expressing the TNF receptor are used in the binding assay. These cells are used directly after isolation (naïve PMBCs) or after stimulation (activated PMBCs). In another aspect, activated mouse splenocytes (expressing the TNF receptor molecule) were used to demonstrate the binding of the TNF family ligand trimer-containing antigen binding molecule of the invention to the corresponding TNF receptor expressing cells.

In a further aspect, cancer cell lines expressing the target cell antigen, for example FAP, were used to demonstrate the binding of the antigen binding molecules to the target cell antigen.

›Definitions · 30 of 34

In another aspect, competition assays may be used to identify an antigen binding molecule that competes with a specific antibody or antigen binding molecule for binding to the target or TNF receptor, respectively. In certain embodiments, such a competing antigen binding molecule binds to the same epitope (e.g., a linear or a conformational epitope) that is bound by a specific anti-target antibody or a specific anti-TNF receptor antibody. Detailed exemplary methods for mapping an epitope to which an antibody binds are provided in Morris (1996) “Epitope Mapping Protocols,” in Methods in Molecular Biology vol. 66 (Humana Press, Totowa, N.J.).

3. Activity Assays

In one aspect, assays are provided for identifying TNF family ligand trimer-containing antigen binding molecules that bind to a specific target cell antigen and to a specific TNF receptor having biological activity. Biological activity may include, e.g., agonistic signalling through the TNF receptor on cells expressing the target cell antigen. TNF family ligand trimer-containing antigen binding molecules identified by the assays as having such biological activity in vitro are also provided.

In certain aspects, a TNF family ligand trimer-containing antigen binding molecule of the invention is tested for such biological activity. Assays for detecting the biological activity of the molecules of the invention are those described in Example 6. Furthermore, assays for detecting cell lysis (e.g. by measurement of LDH release), induced apoptosis kinetics (e.g. by measurement of Caspase 3/7 activity) or apoptosis (e.g. using the TUNEL assay) are well known in the art. In addition the biological activity of such complexes can be assessed by evaluating their effects on survival, proliferation and lymphokine secretion of various lymphocyte subsets such as NK cells, NKT-cells or γδ T-cells or assessing their capacity to modulate phenotype and function of antigen presenting cells such as dendritic cells, monocytes/macrophages or B-cells.

Pharmaceutical Compositions, Formulations and Routes of Administration

In a further aspect, the invention provides pharmaceutical compositions comprising any of the TNF family ligand trimer-containing antigen binding molecules provided herein, e.g., for use in any of the below therapeutic methods. In one embodiment, a pharmaceutical composition comprises any of the TNF family ligand trimer-containing antigen binding molecules provided herein and at least one pharmaceutically acceptable excipient. In another embodiment, a pharmaceutical composition comprises any of the TNF family ligand trimer-containing antigen binding molecules provided herein and at least one additional therapeutic agent, e.g., as described below.

Pharmaceutical compositions of the present invention comprise a therapeutically effective amount of one or more TNF family ligand trimer-containing antigen binding molecules dissolved or dispersed in a pharmaceutically acceptable excipient. The phrases “pharmaceutical or pharmacologically acceptable” refers to molecular entities and compositions that are generally non-toxic to recipients at the dosages and concentrations employed, i.e. do not produce an adverse, allergic or other untoward reaction when administered to an animal, such as, for example, a human, as appropriate. The preparation of a pharmaceutical composition that contains at least one TNF family ligand trimer-containing antigen binding molecule and optionally an additional active ingredient will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, incorporated herein by reference. In particular, the compositions are lyophilized formulations or aqueous solutions. As used herein, “pharmaceutically acceptable excipient” includes any and all solvents, buffers, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g. antibacterial agents, antifungal agents), isotonic agents, salts, stabilizers and combinations thereof, as would be known to one of ordinary skill in the art.

Parenteral compositions include those designed for administration by injection, e.g. subcutaneous, intradermal, intralesional, intravenous, intraarterial intramuscular, intrathecal or intraperitoneal injection. For injection, the TNF family ligand trimer-containing antigen binding molecules of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer. The solution may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the fusion proteins may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. Sterile injectable solutions are prepared by incorporating the fusion proteins of the invention in the required amount in the appropriate solvent with various of the other ingredients enumerated below, as required. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and/or the other ingredients. In the case of sterile powders for the preparation of sterile injectable solutions, suspensions or emulsion, the preferred methods of preparation are vacuum-drying or freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered liquid medium thereof. The liquid medium should be suitably buffered if necessary and the liquid diluent first rendered isotonic prior to injection with sufficient saline or glucose. The composition must be stable under the conditions of manufacture and storage, and preserved against the contaminating action of microorganisms, such as bacteria and fungi. It will be appreciated that endotoxin contamination should be kept minimally at a safe level, for example, less that 0.5 ng/mg protein. Suitable pharmaceutically acceptable excipients include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as polyethylene glycol (PEG). Aqueous injection suspensions may contain compounds which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, dextran, or the like. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl cleats or triglycerides, or liposomes.

›Definitions · 31 of 34

Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences (18th Ed. Mack Printing Company, 1990). Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide, which matrices are in the form of shaped articles, e.g. films, or microcapsules. In particular embodiments, prolonged absorption of an injectable composition can be brought about by the use in the compositions of agents delaying absorption, such as, for example, aluminum monostearate, gelatin or combinations thereof.

Exemplary pharmaceutically acceptable excipients herein further include insterstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX®, Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in US Patent Publication Nos. 2005/0260186 (U.S. Pat. No. 7,871,607B2) and 2006/0104968. In one aspect, a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.

Exemplary lyophilized antibody formulations are described in U.S. Pat. No. 6,267,958. Aqueous antibody formulations include those described in U.S. Pat. No. 6,171,586 and WO2006/044908, the latter formulations including a histidine-acetate buffer.

In addition to the compositions described previously, the fusion proteins may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the fusion proteins may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Pharmaceutical compositions comprising the fusion proteins of the invention may be manufactured by means of conventional mixing, dissolving, emulsifying, encapsulating, entrapping or lyophilizing processes. Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the proteins into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

The TNF family ligand trimer-containing antigen binding molecules may be formulated into a composition in a free acid or base, neutral or salt form. Pharmaceutically acceptable salts are salts that substantially retain the biological activity of the free acid or base. These include the acid addition salts, e.g. those formed with the free amino groups of a proteinaceous composition, or which are formed with inorganic acids such as for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric or mandelic acid. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as for example, sodium, potassium, ammonium, calcium or ferric hydroxides; or such organic bases as isopropylamine, trimethylamine, histidine or procaine. Pharmaceutical salts tend to be more soluble in aqueous and other protic solvents than are the corresponding free base forms.

The composition herein may also contain more than one active ingredients as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such active ingredients are suitably present in combination in amounts that are effective for the purpose intended.

The formulations to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.

Therapeutic Methods and Compositions

Any of the TNF family ligand trimer-containing antigen binding molecules provided herein may be used in therapeutic methods.

For use in therapeutic methods, TNF family ligand trimer-containing antigen binding molecules of the invention can be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.

In one aspect, TNF family ligand trimer-containing antigen binding molecules of the invention for use as a medicament are provided. In further aspects, TNF family ligand trimer-containing antigen binding molecules of the invention for use in treating a disease, in particular for use in the treatment of cancer, are provided. In certain aspects, TNF family ligand trimer-containing antigen binding molecules of the invention for use in a method of treatment are provided. In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule as described herein for use in the treatment of a disease in an individual in need thereof. In certain aspects, the invention provides a TNF family ligand trimer-containing antigen binding molecule for use in a method of treating an individual having a disease comprising administering to the individual a therapeutically effective amount of the fusion protein. In certain aspects, the disease to be treated is cancer. Examples of cancers include solid tumors, bladder cancer, renal cell carcinoma, brain cancer, head and neck cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, esophageal cancer, colon cancer, colorectal cancer, rectal cancer, gastric cancer, prostate cancer, blood cancer, skin cancer, squamous cell carcinoma, bone cancer, and kidney cancer, melanoma, B-cell lymphoma, B-cell leukemia, non-Hodgkin lymphoma and acute lymphoblastic leukemia. Thus, a TNF family ligand trimer-containing antigen binding molecule as described herein for use in the treatment of cancer is provided. The subject, patient, or “individual” in need of treatment is typically a mammal, more specifically a human.

›Definitions · 32 of 34

In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule as described herein for use in the treatment of infectious diseases, in particular for the treatment of viral infections. In a further aspect, provided is a TNF family ligand trimer-containing antigen binding molecule as described herein for use in the treatment of autoimmune diseases such as for example Lupus disease.

In one aspect, provided is a TNF family ligand trimer-containing antigen binding molecule according to the invention for use in treating head and neck squamous cell carcinoma (HNSCC), breast cancer, colorectal cancer (CRC), pancreatic cancer (PAC), gastric cancer, non-small-cell lung carcinoma (NSCLC) and Mesothelioma, wherein the target cell antigen is FAP.

In a further aspect, the invention relates to the use of a TNF family ligand trimer-containing antigen binding molecule in the manufacture or preparation of a medicament for the treatment of a disease in an individual in need thereof. In one aspect, the medicament is for use in a method of treating a disease comprising administering to an individual having the disease a therapeutically effective amount of the medicament. In certain embodiments the disease to be treated is a proliferative disorder, particularly cancer. Thus, in one aspect, the invention relates to the use of a TNF family ligand trimer-containing antigen binding molecule of the invention in the manufacture or preparation of a medicament for the treatment of cancer. Examples of cancers include solid tumors, bladder cancer, renal cell carcinoma, brain cancer, head and neck cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, esophageal cancer, colon cancer, colorectal cancer, rectal cancer, gastric cancer, prostate cancer, blood cancer, skin cancer, squamous cell carcinoma, bone cancer, and kidney cancer, melanoma, B-cell lymphoma, B-cell leukemia, non-Hodgkin lymphoma and acute lymphoblastic leukemia. Other cell proliferation disorders that can be treated using a TNF family ligand trimer-containing antigen binding molecule of the present invention include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous system (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic region, and urogenital system. Also included are pre-cancerous conditions or lesions and cancer metastases. In certain embodiments the cancer is chosen from the group consisting of renal cell cancer, skin cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, head and neck cancer. A skilled artisan may recognize that in some cases the TNF family ligand trimer-containing antigen binding molecule may not provide a cure but may only provide partial benefit. In some aspects, a physiological change having some benefit is also considered therapeutically beneficial. Thus, in some aspects, an amount of TNF family ligand trimer-containing antigen binding molecule that provides a physiological change is considered an “effective amount” or a “therapeutically effective amount”.

In a further aspect, the invention relates to the use of a TNF family ligand trimer-containing antigen binding molecule as described herein in the manufacture or preparation of a medicament for the treatment of infectious diseases, in particular for the treatment of viral infections or for the treatment of autoimmune diseases, for example Lupus disease.

In a further aspect, the invention provides a method for treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of a TNF family ligand trimer-containing antigen binding molecule of the invention. In one aspect a composition is administered to said individual, comprising a fusion protein of the invention in a pharmaceutically acceptable form. In certain aspects, the disease to be treated is a proliferative disorder. In a particular aspect, the disease is cancer. In another aspect, the disease is an infectious disease or an autoimmune disease. In certain aspects, the method further comprises administering to the individual a therapeutically effective amount of at least one additional therapeutic agent, e.g. an anti-cancer agent if the disease to be treated is cancer. An “individual” according to any of the above embodiments may be a mammal, preferably a human.

For the prevention or treatment of disease, the appropriate dosage of a TNF family ligand trimer-containing antigen binding molecule of the invention (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the route of administration, the body weight of the patient, the type of fusion protein, the severity and course of the disease, whether the fusion protein is administered for preventive or therapeutic purposes, previous or concurrent therapeutic interventions, the patient's clinical history and response to the fusion protein, and the discretion of the attending physician. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject. Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.

The TNF family ligand trimer-containing antigen binding molecule is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 μg/kg to 15 mg/kg (e.g. 0.1 mg/kg-10 mg/kg) of TNF family ligand trimer-containing antigen binding molecule can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. One typical daily dosage might range from about 1 μg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment would generally be sustained until a desired suppression of disease symptoms occurs. One exemplary dosage of the fusion protein would be in the range from about 0.005 mg/kg to about 10 mg/kg. In other examples, a dose may also comprise from about 1 μg/kg body weight, about 5 μg/kg body weight, about 10 μg/kg body weight, about 50 μg/kg body weight, about 100 μg/kg body weight, about 200 μg/kg body weight, about 350 μg/kg body weight, about 500 μg/kg body weight, about 1 mg/kg body weight, about 5 mg/kg body weight, about 10 mg/kg body weight, about 50 mg/kg body weight, about 100 mg/kg body weight, about 200 mg/kg body weight, about 350 mg/kg body weight, about 500 mg/kg body weight, to about 1000 mg/kg body weight or more per administration, and any range derivable therein. In examples of a derivable range from the numbers listed herein, a range of about 5 mg/kg body weight to about 100 mg/kg body weight, about 5 μg/kg body weight to about 500 mg/kg body weight etc., can be administered, based on the numbers described above. Thus, one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 5.0 mg/kg or 10 mg/kg (or any combination thereof) may be administered to the patient. Such doses may be administered intermittently, e.g. every week or every three weeks (e.g. such that the patient receives from about two to about twenty, or e.g. about six doses of the fusion protein). An initial higher loading dose, followed by one or more lower doses may be administered. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.

›Definitions · 33 of 34

The TNF family ligand trimer-containing antigen binding molecules of the invention will generally be used in an amount effective to achieve the intended purpose. For use to treat or prevent a disease condition, the TNF family ligand trimer-containing antigen binding molecules of the invention, or pharmaceutical compositions thereof, are administered or applied in a therapeutically effective amount. Determination of a therapeutically effective amount is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure provided herein.

For systemic administration, a therapeutically effective dose can be estimated initially from in vitro assays, such as cell culture assays. A dose can then be formulated in animal models to achieve a circulating concentration range that includes the IC 50 as determined in cell culture. Such information can be used to more accurately determine useful doses in humans.

Initial dosages can also be estimated from in vivo data, e.g., animal models, using techniques that are well known in the art. One having ordinary skill in the art could readily optimize administration to humans based on animal data.

Dosage amount and interval may be adjusted individually to provide plasma levels of the TNF family ligand trimer-containing antigen binding molecules which are sufficient to maintain therapeutic effect. Usual patient dosages for administration by injection range from about 0.1 to 50 mg/kg/day, typically from about 0.5 to 1 mg/kg/day. Therapeutically effective plasma levels may be achieved by administering multiple doses each day. Levels in plasma may be measured, for example, by HPLC.

In cases of local administration or selective uptake, the effective local concentration of the TNF family ligand trimer-containing antigen binding molecule may not be related to plasma concentration. One skilled in the art will be able to optimize therapeutically effective local dosages without undue experimentation.

A therapeutically effective dose of the TNF family ligand trimer-containing antigen binding molecules described herein will generally provide therapeutic benefit without causing substantial toxicity. Toxicity and therapeutic efficacy of a fusion protein can be determined by standard pharmaceutical procedures in cell culture or experimental animals. Cell culture assays and animal studies can be used to determine the LD 50 (the dose lethal to 50% of a population) and the ED 50 (the dose therapeutically effective in 50% of a population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the ratio LD 50 /ED 50 . TNF family ligand trimer-containing antigen binding molecules that exhibit large therapeutic indices are preferred. In one embodiment, the TNF family ligand trimer-containing antigen binding molecule according to the present invention exhibits a high therapeutic index. The data obtained from cell culture assays and animal studies can be used in formulating a range of dosages suitable for use in humans. The dosage lies preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity. The dosage may vary within this range depending upon a variety of factors, e.g., the dosage form employed, the route of administration utilized, the condition of the subject, and the like. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition (see, e.g., Fingl et al., 1975, in: The Pharmacological Basis of Therapeutics, Ch. 1, p. 1, incorporated herein by reference in its entirety).

The attending physician for patients treated with fusion proteins of the invention would know how and when to terminate, interrupt, or adjust administration due to toxicity, organ dysfunction, and the like. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity). The magnitude of an administered dose in the management of the disorder of interest will vary with the severity of the condition to be treated, with the route of administration, and the like. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency will also vary according to the age, body weight, and response of the individual patient.

Other Agents and Treatments

The TNF family ligand trimer-containing antigen binding molecules of the invention may be administered in combination with one or more other agents in therapy. For instance, a fusion protein of the invention may be co-administered with at least one additional therapeutic agent. The term “therapeutic agent” encompasses any agent that can be administered for treating a symptom or disease in an individual in need of such treatment. Such additional therapeutic agent may comprise any active ingredients suitable for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. In certain embodiments, an additional therapeutic agent is another anti-cancer agent.

Such other agents are suitably present in combination in amounts that are effective for the purpose intended. The effective amount of such other agents depends on the amount of fusion protein used, the type of disorder or treatment, and other factors discussed above. The TNF family ligand trimer-containing antigen binding molecules are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate.

Such combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate compositions), and separate administration, in which case, administration of the TNF family ligand trimer-containing antigen binding molecule of the invention can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent and/or adjuvant.

›Definitions · 34 of 34

Articles of Manufacture

In another aspect of the invention, an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above is provided. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper that is pierceable by a hypodermic injection needle). At least one active agent in the composition is a TNF ligand trimer-containing antigen binding molecule of the invention.

The label or package insert indicates that the composition is used for treating the condition of choice. Moreover, the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises a TNF ligand trimer-containing antigen binding molecule of the invention; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent. The article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition.

Alternatively, or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

General information regarding the nucleotide sequences of human immunoglobulins light and heavy chains is given in: Kabat, E. A., et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991). Amino acids of antibody chains are numbered and referred to according to the EU numbering systems according to Kabat (Kabat, E. A., et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991)) as defined above.

›EXAMPLES

The following are examples of methods and compositions of the invention. It is understood that various other embodiments may be practiced, given the general description provided above.

Recombinant DNA Techniques

Standard methods were used to manipulate DNA as described in Sambrook et al., Molecular cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989. The molecular biological reagents were used according to the manufacturer's instructions. General information regarding the nucleotide sequences of human immunoglobulin light and heavy chains is given in: Kabat, E. A. et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Ed., NIH Publication No 91-3242.

DNA Sequencing

DNA sequences were determined by double strand sequencing.

Gene Synthesis

Desired gene segments were either generated by PCR using appropriate templates or were synthesized by Geneart AG (Regensburg, Germany) from synthetic oligonucleotides and PCR products by automated gene synthesis. In cases where no exact gene sequence was available, oligonucleotide primers were designed based on sequences from closest homologues and the genes were isolated by RT-PCR from RNA originating from the appropriate tissue. The gene segments flanked by singular restriction endonuclease cleavage sites were cloned into standard cloning/sequencing vectors. The plasmid DNA was purified from transformed bacteria and concentration determined by UV spectroscopy. The DNA sequence of the subcloned gene fragments was confirmed by DNA sequencing. Gene segments were designed with suitable restriction sites to allow sub-cloning into the respective expression vectors. All constructs were designed with a 5′-end DNA sequence coding for a leader peptide which targets proteins for secretion in eukaryotic cells.

Cell Culture Techniques

Standard cell culture techniques were used as described in Current Protocols in Cell Biology (2000), Bonifacino, J. S., Dasso, M., Harford, J. B., Lippincott-Schwartz, J. and Yamada, K. M. (eds.), John Wiley & Sons, Inc.

Protein Purification

Proteins were purified from filtered cell culture supernatants referring to standard protocols. In brief, antibodies were applied to a Protein A Sepharose column (GE healthcare) and washed with PBS. Elution of antibodies was achieved at pH 2.8 followed by immediate neutralization of the sample. Aggregated protein was separated from monomeric antibodies by size exclusion chromatography (Superdex 200, GE Healthcare) in PBS or in 20 mM Histidine, 150 mM NaCl pH 6.0. Monomeric antibody fractions were pooled, concentrated (if required) using e.g., a MILLIPORE Amicon Ultra (30 MWCO) centrifugal concentrator, frozen and stored at −20° C. or −80° C. Part of the samples were provided for subsequent protein analytics and analytical characterization e.g. by SDS-PAGE, size exclusion chromatography (SEC) or mass spectrometry.

›SDS-PAGE

The NuPAGE® Pre-Cast gel system (Invitrogen) was used according to the manufacturer's instruction. In particular, 10% or 4-12% NuPAGE® Novex® Bis-TRIS Pre-Cast gels (pH 6.4) and a NuPAGE® MES (reduced gels, with NuPAGE® Antioxidant running buffer additive) or MOPS (non-reduced gels) running buffer was used.

Analytical Size Exclusion Chromatography

Size exclusion chromatography (SEC) for the determination of the aggregation and oligomeric state of antibodies was performed by HPLC chromatography. Briefly, Protein A purified antibodies were applied to a Tosoh TSKGEL® G3000SW column in 300 mM NaCl, 50 mM KH 2 PO 4 /K 2 HPO 4 , pH 7.5 on an Agilent HPLC 1100 system or to a Superdex 200 column (GE Healthcare) in 2×PBS on a Dionex HPLC-System. The eluted protein was quantified by UV absorbance and integration of peak areas. BioRad Gel Filtration Standard 151-1901 served as a standard.

Mass Spectrometry

This section describes the characterization of the multispecific antibodies with VH/VL exchange (VH/VL CrossMabs) with emphasis on their correct assembly. The expected primary structures were analyzed by electrospray ionization mass spectrometry (ESI-MS) of the deglycosylated intact CrossMabs and deglycosylated/plasmin digested or alternatively deglycosylated/limited LysC digested CrossMabs.

The VH/VL CrossMabs were deglycosylated with N-Glycosidase F in a phosphate or Tris buffer at 37° C. for up to 17 h at a protein concentration of 1 mg/ml. The plasmin or limited LysC (Roche) digestions were performed with 100 μs deglycosylated VH/VL CrossMabs in a Tris buffer pH 8 at room temperature for 120 hours and at 37° C. for 40 min, respectively. Prior to mass spectrometry the samples were desalted via HPLC on a Sephadex G25 column (GE Healthcare). The total mass was determined via ESI-MS on a maXis 4G UHR-QTOF MS system (Bruker Daltonik) equipped with a TriVersa NanoMate source (Advion).

Determination of binding and binding affinity of multispecific antibodies to the respective antigens using surface plasmon resonance (SPR) (BIACORE®)

Binding of the generated antibodies to the respective antigens is investigated by surface plasmon resonance using a BIACORE® instrument (GE Healthcare Biosciences AB, Uppsala, Sweden). Briefly, for affinity measurements Goat-Anti-Human IgG, JIR 109-005-098 antibodies are immobilized on a CM5 chip via amine coupling for presentation of the antibodies against the respective antigen. Binding is measured in HBS buffer (HBS-P (10 mM HEPES, 150 mM NaCl, 0.005% Tween 20, ph 7.4), 25° C. (or alternatively at 37° C.). Antigen (R&D Systems or in house purified) was added in various concentrations in solution. Association was measured by an antigen injection of 80 seconds to 3 minutes; dissociation was measured by washing the chip surface with HBS buffer for 3-10 minutes and a KD value was estimated using a 1:1 Langmuir binding model. Negative control data (e.g. buffer curves) are subtracted from sample curves for correction of system intrinsic baseline drift and for noise signal reduction. The respective Biacore Evaluation Software is used for analysis of sensorgrams and for calculation of affinity data.

›Examples34

›Example 1 · 1 of 3

1.1 Preparation of Targeted Human 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules

Different fragments of the DNA sequence encoding part of the ectodomain (amino acids 71-254, 52-254 and 80-254) of human 4-1BB ligand were synthetized according to the P41273 sequence of Uniprot database (SEQ ID NO:42).

As components for the assembly of a TNF ligand trimer-containing antigen binding molecule a polypeptide comprising two ectodomains of 4-1BB ligand, separated by (G 4 S) 2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CH1 or CL domain, was cloned as depicted in FIG. 1A (human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human CH1 or CL) or as depicted in FIG. 1C (human CH3, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand).

A polypeptide comprising one ectodomain of 4-1BB ligand and fused to the human IgG1-CL or CH1 domain, was cloned as described in FIG. 1B (human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human CL or CH1) or as depicted in FIG. 1D (human CH3, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand).

The polypeptides were subcloned in frame with the human IgG1 heavy chain CH2 and CH3 domains with optional peptide linkers, for example for construct 1 the polypeptide encoding the dimeric 4-1BB ligand fused to a human CH1 domain was subcloned in frame with the human IgG1 heavy chain CH2 and CH3 domains on the knob (Merchant, Zhu et al. 1998) using a linker (G 4 S) 2 of SEQ ID NO:13 or GSPGSSSSGS of SEQ ID NO:57.

The variable region of heavy and light chain DNA sequences encoding a binder specific for fibroblast activation protein (FAP), i.e. 28H1, were subcloned in frame with either the constant heavy chain of the hole (Carter, J. Immunol. Methods (2001), 248, 7-15) or the constant light chain of human IgG1. The generation and preparation of the FAP binders is described in WO 2012/020006 A2, which is incorporated herein by reference.

Table 1 summarizes the characteristics of the constructs produced. The constructs 1 to 10 differ in their geometry, valency for FAP, 4-1BB ligand ectodomain, crossover of the CH1 and CL domain (CrossMab technology), mutations in the CH1 and CL domains and different peptide linkers in the polypeptide comprising one ectodomain of 4-1BB ligand (monomeric 4-1BBL chain).

In order to avoid mispairing, in most of the constructs one pair of CH1 and CL domains was replaced by each other (domain crossover) as described in WO 2009/080253 A1.

To further improve correct pairing, different charged amino acid substitutions were introduced in the crossed or non-crossed CH1 and CL domains as charged residues in constructs 2 to 4 and 6 to 10. In the human CL domain the mutations E123R and Q124K were introduced, whereas the mutations K147E and K213E were cloned into the human CH1 domain.

For all constructs the knobs into holes heterodimerization technology was used with the S354C/T366W mutations in the CH3 domain of the knob chain and the corresponding Y349C/T366S/L368A/Y407V mutations in the CH3 domain of the hole chain (Carter, J Immunol Methods 248, 7-15 (2001)).

For example, in construct 1 the combination of the ligand-Fc knob chain containing the S354C/T366W mutations in the first CH3 domain, with the targeted anti-FAP-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations in the second CH3 domain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a FAP binding Fab ( FIG. 2A , Construct 1.1).

Table 2 shows the cDNA and amino acid sequences of the monovalent FAP-targeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecule (Construct 1.1).

Table 3 shows the cDNA and amino acid sequences of acid sequences of the monovalent FAP-targeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecule ( FIG. 2B , Construct 1.2) with CH1-CL crossover and charged residues.

Table 4 shows the cDNA and amino acid sequences of the monovalent FAP-targeted 4-1BB ligand trimer-containing Fc (kih) fusion molecule Construct 1.3 ( FIG. 2C ) (FAP split trimer with CH1-CL crossover in anti-FAP Fab and charged residues on the 4-1BBL containing chains).

Table 5 shows the cDNA and amino acid sequences of the monovalent FAP-targeted 4-1BB ligand trimer-containing Fc (kih) fusion molecule Construct 1.4 ( FIG. 2D ) (FAP split trimer with anti-FAP Fab, monomeric 4-1BB ligand fused to CH1-knob chain and charged residues on the 4-1BBL containing chains).

Table 6 shows the cDNA and amino acid sequences of the bivalent FAP-targeted 4-1BB ligand trimer-containing Fc (kih) fusion molecule Construct 1.5 ( FIG. 2E ) (FAP split trimer with 2 anti-FAP Fabs, dimeric and monomeric 4-1BB ligand fused at the C-terminus of each heavy chain, respectively).

Table 7 shows the cDNA and amino acid sequences of the monovalent FAP-targeted 4-1BB ligand trimer-containing Fc (kih) fusion molecule Construct 1.6 ( FIG. 2F ) (FAP split trimer with anti-FAP Fab, monomeric 4-1BB ligand fused to CL* via a (G 4 S)-linker (SEQ ID NO: 128)).

Table 8 shows the cDNA and amino acid sequences of the bivalent FAP-targeted 4-1BB ligand trimer-containing Fc (kih) fusion molecule Construct 1.7 ( FIG. 2G ) (FAP split trimer with double anti-FAP on the N-terminus of Fc hole chain and charged residues on crossed CH1 and CL fused to 4-1BB ligands).

Table 9 shows the cDNA and amino acid sequences of the bivalent FAP-targeted 4-1BB ligand trimer-containing Fc (kih) fusion molecule Construct 1.8 ( FIG. 2H ) (FAP split trimer with 4-1BB ligands fused to anti-FAP CrossFab, with charged residues, on knob chain).

Table 10 shows the cDNA and amino acid sequences of the monovalent FAP-targeted 4-1BB ligand (52-254) trimer-containing Fc (kih) fusion molecule Construct 1.9 ( FIG. 2I ) (FAP split trimer with 4-1BBL ectodomain amino acids 52-254 and charged residues on ligand chains).

›Example 1 · 2 of 3

Table 11 shows the cDNA and amino acid sequences of the monovalent FAP-targeted 4-1BB ligand (80-254) trimer-containing Fc (kih) fusion molecule Construct 1.10 ( FIG. 2J ) (FAP split trimer with 4-1BBL ectodomain amino acids 80-254 and charged residues on ligand chains).

1.2 Production of FAP (28H1) Targeted Split Trimeric 4-1BB Ligand Fc Fusion Constructs

The targeted TNF ligand trimer-containing Fc (kih) fusion antigen binding molecule encoding sequences were cloned into a plasmid vector, which drives expression of the insert from an MPSV promoter and contains a synthetic polyA sequence located at the 3′ end of the CDS. In addition, the vector contains an EBV OriP sequence for episomal maintenance of the plasmid.

The targeted TNF ligand trimer-containing Fc (kih) fusion antigen binding molecule was produced by co-transfecting HEK293-EBNA cells with the mammalian expression vectors using polyethylenimine. The cells were transfected with the corresponding expression vectors at a 1:1:1:1 ratio (e.g. “vector dimeric ligand-(CH1 or CL)-knob chain”: “vector monomeric ligand fusion-(CL or CH1)”: “vector anti-FAP Fab-hole heavy chain”: “vector anti-FAP light chain”) for the Constructs 1, 2, 3, 4, 6, 7, 8, 9, 10. For the bivalent Construct 5, a 1:1:1 ratio (“vector hole heavy chain”: “vector knob heavy chain”: “vector anti-FAP light chain”) was used.

For production in 500 mL shake flasks, 300 million HEK293 EBNA cells were seeded 24 hours before transfection. For transfection cells were centrifuged for 10 minutes at 210×g, and the supernatant was replaced by 20 mL pre-warmed CD CHO medium. Expression vectors (200 μg of total DNA) were mixed in 20 mL CD CHO medium. After addition of 540 μL PEI, the solution was vortexed for 15 seconds and incubated for 10 minutes at room temperature. Afterwards, cells were mixed with the DNA/PEI solution, transferred to a 500 mL shake flask and incubated for 3 hours at 37° C. in an incubator with a 5% CO 2 atmosphere. After the incubation, 160 mL of Excell medium supplemented with 6 mM L-Glutamine, 5 g/L PEPSOY and 1.2 mM valproic acid was added and cells were cultured for 24 hours. One day after transfection 12% Feed 7 and Glucose (final concentration 3 g/L) were added. After culturing for 7 days, the supernatant was collected by centrifugation for 30-40 minutes at 400×g. The solution was sterile filtered (0.22 μm filter), supplemented with sodium azide to a final concentration of 0.01% (w/v), and kept at 4° C.

The targeted TNF ligand trimer-containing Fc (kih) fusion antigen binding molecule was purified from cell culture supernatants by affinity chromatography using Protein A, followed by size exclusion chromatography. For affinity chromatography, the supernatant was loaded on a MABSELECT SURE® column (CV=5-15 mL, resin from GE Healthcare) equilibrated with 20 mM sodium phosphate, 20 mM sodium citrate buffer (pH 7.5). Unbound protein was removed by washing with at least 6 column volumes of the same buffer. The bound protein was eluted using either a linear gradient (20 CV) or a step elution (8 CV) with 20 mM sodium citrate, 100 mM Sodium chloride, 100 mM Glycine buffer (pH 3.0). For the linear gradient an additional 4 column volumes step elution was applied.

The pH of collected fractions was adjusted by adding 1/10 (v/v) of 0.5M sodium phosphate, pH 8.0. The protein was concentrated prior to loading on a HILOAD® Superdex 200 column (GE Healthcare) equilibrated with 20 mM Histidine, 140 mM sodium chloride, 0.01% (v/v) TWEEN® 20 (polysorbate 20) solution of pH 6.0.

The protein concentration was determined by measuring the optical density (OD) at 280 nm, using a molar extinction coefficient calculated on the basis of the amino acid sequence. Purity and molecular weight of the targeted TNF ligand trimer-containing Fc (kih) fusion antigen binding molecule was analyzed by SDS-PAGE in the presence and absence of a reducing agent (5 mM 1,4-dithiotreitol) and staining with Coomassie SIMPLYBLUE™ SafeStain (Invitrogen USA) or CE-SDS using Caliper LabChip GXII (Perkin Elmer). The aggregate content of samples was analyzed using a TSKGEL® G3000 SW XL analytical size-exclusion column (Tosoh) equilibrated in 25 mM K 2 HPO 4 , 125 mM NaCl, 200 mM L-Arginine Monohydrocloride, 0.02% (w/v) NaN 3 , pH 6.7 running buffer at 25° C.

Table 12 summarizes the yield and final monomer content of the FAP-targeted 4-1BBL trimer-containing Fc (kih) fusion antigen binding molecules.

1.3 Preparation of Targeted Murine 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules

Similarly to targeted human 4-1BB ligand trimer-containing Fc fusion antigen binding molecules, murine FAP-targeted 4-1BBL trimer-containing Fc fusion antigen binding molecules were prepared.

The DNA sequence encoding part of the ectodomain (amino acids 104-309) of murine 4-1BB ligand was synthetized according to the Q3U1Z9-1 sequence of Uniprot database (SEQ ID NO:70). For Construct M.1 the cysteines at positions 137, 160 and 246 were mutated to Serine by standard PCR methods, whereas for Construct M.2 the cysteine at position 160 was mutated to Serine (C160S).

The murine ligand was assembled as described for the human 4-1BBL and as depicted in FIGS. 3A and 3B . The dimeric 4-1BBL, separated by (G 4 S) 2 (SEQ ID NO:13) linkers, was fused to the murine IgG1-CL domain ( FIG. 3A ) and the monomeric 4-1BBL was fused to murine IgG1-CH domain ( FIG. 3B ). The polypeptide encoding the dimeric 4-1BB ligand fused to murine CL domain was subcloned in frame with the murine IgG1 heavy chain CH2 and CH3 domains to build the Constructs as depicted in FIG. 3C .

For the murine constructs, mutations Lys392Asp and Lys409Asp (DD) were introduced in the heavy chain containing the murine 4-1BBL and mutations Glu356Lys and Asp399Lys (KK) were introduced in the heavy chain containing the anti-FAP Fab to obtain asymmetric molecules (Gunasekaran K. et al, J Biol. Chem., 2010, Jun. 18; 285(25):19637-46).

Mutations Asp265Ala and Pro329Gly (DAPG) were introduced in the constant region of the heavy chains to abrogate binding to Fc gamma receptors.

›Example 1 · 3 of 3

Table 13 shows, respectively, the cDNA and amino acid sequences of the FAP-targeted murine 4-1BB ligand trimer-containing Fc fusion antigen binding molecule Construct M.1.

Table 14 shows, respectively, the cDNA and amino acid sequences of the untargeted (DP47) murine 4-1 BB ligand trimer-containing Fc fusion antigen binding molecule Control M.1.

Table 15 shows the cDNA and amino acid sequences of the FAP-targeted murine 4-1BB ligand trimer-containing Fc fusion antigen binding molecule Construct M.2.

Table 16 shows the cDNA and amino acid sequences of the DP47-untargeted murine 4-1BB ligand trimer-containing Fc fusion antigen binding molecule Construct Control M.2.

The murine 4-1BB ligand trimer-containing Fc fusion antigen binding molecules were produced and purified as described herein before for the human 4-1BBL constructs.

Table 17 summarizes the yield and final monomer content of the FAP-targeted and untargeted murine 4-1BBL trimer-containing Fc fusion antigen binding molecule.

1.4 Preparation and Purification of Untargeted Human 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules (Control Molecules)

The control molecules were prepared as described above for the FAP-targeted Constructs 1 and 2, with the only difference that the anti-FAP binder (VH-VL) was replaced by a germline control, termed DP47, not binding to the antigen. The control is an untargeted monovalent split trimeric human 4-1BB ligand Fc (kih) (Control A, FIG. 5A ) and for Control B, the construct also contains a CH-CL crossover with charged residues ( FIG. 5B ). The variable region of heavy and light chain DNA sequences of the FAP binder were replaced with those of the germline control (DP47) and subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1.

The untargeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules were produced as described above for the FAP-targeted constructs. The cells were transfected with the corresponding expression vectors at a 1:1:1:1 ratio (“vector dimeric ligand-CH1 or CL*-knob chain”: “vector monomeric ligand fusion-CL or CH1*”: “vector DP47 Fab-hole chain”: “vector DP47 light chain”).

Table 18 shows, respectively, the cDNA and amino acid sequences of the DP47-untargeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecule Control A.

Table 19 shows the cDNA and amino acid sequences of the DP47-untargeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecule with CH1-CL crossover and charged residues in the 4-1BB ligand containing arms (Control B).

Table 20 summarizes the yield and final monomer content of the DP47 untargeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules.

›Example 2 · 1 of 4

2.1 Preparation of FAP (4B9) Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules

Different fragments of the DNA sequence encoding part of the ectodomain (amino acid 71-254 and 71-248) of human 4-1BB ligand were synthetized according to the P41273 sequence of Uniprot database (SEQ ID NO:42).

2.1.1 Preparation of Monovalent FAP (4B9) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains with Charged Residues (Construct 2.1)

A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the human IgG1-CH1 domain, was cloned as described in FIG. 1B : human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human CH.

To improve correct pairing the following mutations have been introduced in the crossed CH-CL. In the dimeric 4-1BB ligand fused to human CL the mutations E123R and Q124K were introduced. In the monomeric 4-1BB ligand fused to human CH1, the mutations K147E and K213E were cloned into the human CH1 domain.

The variable region of heavy and light chain DNA sequences encoding a binder specific for fibroblast activation protein (FAP), clone 4B9, were subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1.

The generation and preparation of the FAP binders is described in WO 2012/020006 A2, which is incorporated herein by reference.

For all constructs the knobs into hole heterodimerization technology was used with the S354C/T366W mutations in the knob chain and the corresponding Y349C/T366S/L368A/Y407V mutations in the hole chain.

Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-FAP-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-FAP light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a FAP binding Fab ( FIG. 4A , Construct 2.1).

Table 21 shows the cDNA and amino acid sequences of the monovalent FAP (4B9)-human 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule containing CH1-CL crossover and charged residues (Construct 2.1).

2.1.2 Preparation of Monovalent FAP (4B9) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains without Charged Residues (Construct 2.2)

The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors (WO 2012/130831).

Table 22 shows the cDNA and amino acid sequences of the monovalent FAP (4B9)-human 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule containing CH1-CL crossover without charged residues (Construct 2.2).

2.1.3 Preparation of Bivalent FAP (4B9) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with the Dimeric and Monomeric 4-1BB Ligands Fused at the C-Terminus of Each Heavy Chain (Construct 2.3)

A polypeptide containing two ectodomains of 4-1BB ligand (71-254), separated by (G 4 S) 2 (SEQ ID NO:13) linkers was fused to the C-terminus of human IgG1 Fc hole chain, as depicted in FIG. 1C : human IgG1 Fc hole, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand. A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the C-terminus of human IgG1 Fc knob chain as described in FIG. 1D : human IgG1 Fc knob, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand.

The polypeptide encoding the dimeric 4-1BB ligand was subcloned in frame at the C-terminus of human IgG1 heavy chain CH2 and CH3 domains on the hole (Merchant, Zhu et al. 1998) using a (G 4 S) 2 (SEQ ID NO:13) connector. The polypeptide encoding the monomeric 4-1BB ligand was subcloned in frame at the C-terminus of human IgG1 heavy chain CH2 and CH3 domains on the knob (Merchant, Zhu et al. 1998) using a (G 4 S) 2 (SEQ ID NO:13) connector.

›Example 2 · 2 of 4

Combination of the anti-FAP huIgG1 hole dimeric ligand chain containing the Y349C/T366S/L368A/Y407V mutations, the anti-FAP huIgG1 knob monomeric ligand chain containing the S354C/T366W mutations and the anti-FAP light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and two FAP binding Fabs ( FIG. 4C , Construct 2.3)

Table 23 shows the cDNA and amino acid sequences of the bivalent FAP (4B9)-targeted 4-1BB ligand trimer-containing Fc (kih) fusion molecule Construct 2.3 (FAP split trimer with 2 anti-FAP Fabs, dimeric and monomeric 4-1BB ligand fused at the C-terminus of each heavy chain, respectively).

2.1.4 Preparation of Monovalent FAP (4B9) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains with Charged Residues (Construct 2.4)

A polypeptide containing two ectodomains of 4-1BB ligand (71-248), separated by (G 4 S) 2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CL domain, was cloned as depicted in FIG. 1A : human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human CL. A polypeptide containing one ectodomain of 4-1BB ligand (71-248) and fused to the human IgG1-CH domain, was cloned as described in FIG. 1B : human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human CH.

The polypeptide encoding the dimeric 4-1BB ligand fused to human CL domain was subcloned in frame with the human IgG1 heavy chain CH2 and CH3 domains on the knob (Merchant, Zhu et al. 1998) using a linker (G 4 S) 2 (SEQ ID NO:13) or, alternatively, GSPGSSSSGS (SEQ ID NO:57). To improve correct pairing the following mutations have been introduced in the crossed CH-CL. In the dimeric 4-1BB ligand fused to human CL, E123R and Q124K. In the monomeric 4-1BB ligand fused to human CH1, K147E and K213E.

Table 24 shows the cDNA and amino acid sequences of the monovalent FAP (4B9)-human 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule containing CH1-CL crossover with charged residues (Construct 2.4).

2.1.5 Preparation of Monovalent FAP (4B9) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains without Charged Residues (Construct 2.5)

Table 25 shows the cDNA and amino acid sequences of the monovalent FAP (4B9)-human 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule containing CH1-CL crossover without charged residues (Construct 2.5).

2.1.6 Preparation of Bivalent FAP (4B9) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with the Dimeric and Monomeric 4-1BB Ligands Fused at the C-Terminus of Each Heavy Chain (Construct 2.6)

A polypeptide containing two ectodomains of 4-1BB ligand (71-248), separated by (G 4 S) 2 (SEQ ID NO:13) linkers was fused to the C-terminus of human IgG1 Fc hole chain, as depicted in FIG. 1C : human IgG1 Fc hole, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand. A polypeptide containing one ectodomain of 4-1BB ligand (71-248) and fused to the C-terminus of human IgG1 Fc knob chain as described in FIG. 1D : human IgG1 Fc knob, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand.

›Example 2 · 3 of 4

Table 26 shows the cDNA and amino acid sequences of the bivalent FAP (4B9)-targeted 4-1BB ligand trimer-containing Fc (kih) fusion molecule Construct 2.6 (FAP split trimer with 2 anti-FAP Fabs, dimeric and monomeric 4-1BB ligand fused at the C-terminus of each heavy chain, respectively).

2.2 Preparation of Untargeted Human 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules (Control Molecules)

Further control molecules were prepared as described in Example 1.4 above for Control A and B. A bivalent variant Control C was prepared in analogy to the bivalent Construct 2.3 and 2.6 and a monovalent variant Control E was prepared in analogy to Construct 2.5 (containing a 4-1BB ligand (71-248) trimer), with the only difference that the anti-FAP binder (VH-VL) was replaced by a germline control, termed DP47, not binding to the antigen.

Table 27 shows the cDNA and amino acid sequences of the bivalent DP47-untargeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion molecule Control C. Table 28 shows the cDNA and amino acid sequences of the monovalent DP47-untargeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion molecule Control E.

2.3 Preparation of Untargeted Human IgG1 as Control F

An additional control molecule used in the assays was an untargeted DP47, germline control, human IgG1, containing the Pro329Gly, Leu234Ala and Leu235Ala mutations, to abrogate binding to Fc gamma receptors according to the method described in International Patent Appl. Publ. No. WO 2012/130831).

Table 29 shows the cDNA and amino acid sequences of the cDNA and amino acid sequences of the untargeted DP47 huIgG1 PGLALA (Control F).

2.4 Production of Monovalent and Bivalent FAP (4B9) Targeted Split Trimeric 4-1BB Ligand Fc Fusion Constructs and Control Molecules

The targeted and untargeted split trimeric 4-1BB ligand Fc (kih) fusion encoding sequences were cloned into a plasmid vector, which drives expression of the insert from an MPSV promoter and contains a synthetic polyA sequence located at the 3′ end of the CDS. In addition, the vector contains an EBV OriP sequence for episomal maintenance of the plasmid.

The split trimeric 4-1BB ligand Fc (kih) fusion was produced by co-transfecting HEK293-EBNA cells with the mammalian expression vectors using polyethylenimine. The cells were transfected with the corresponding expression vectors. For Constructs 2.1, 2.2., 2.4 and 2.5 and corresponding control molecules, a 1:1:1:1 ratio (e.g.“vector dimeric ligand-CL-knob chain”: “vector monomeric ligand fusion-CH1”: “vector anti-FAP Fab-hole chain”: “vector anti-FAP light chain”) was used. For Constructs 2.3 and 2.6 and its control molecule, a 1:1:1 ratio (“vector huIgG1 Fc hole dimeric ligand chain”: “vector huIgG1 Fc knob monomeric ligand chain”: “vector anti-FAP light chain”) was taken. Human IgGs, used as control in the assay, were produced as for the bispecific constructs (for transfection only a vector for light and a vector for heavy chain were used.

For production in 500 mL shake flasks, 300 million HEK293 EBNA cells were seeded 24 hours before transfection. For transfection cells were centrifuged for 10 minutes at 210×g, and the supernatant was replaced by 20 mL pre-warmed CD CHO medium. Expression vectors (200 μg of total DNA) were mixed in 20 mL CD CHO medium. After addition of 540 μL PEI, the solution was vortexed for 15 seconds and incubated for 10 minutes at room temperature. Afterwards, cells were mixed with the DNA/PEI solution, transferred to a 500 mL shake flask and incubated for 3 hours at 37° C. in an incubator with a 5% CO 2 atmosphere. After the incubation, 160 mL of Excell medium supplemented with 6 mM L-Glutamine, 5 g/L PEPSOY and 1.2 mM valproic acid was added and cells were cultured for 24 hours. One day after transfection 12% Feed 7 and Glucose (final conc. 3 g/L) were added. After culturing for 7 days, the supernatant was collected by centrifugation for 30-40 minutes at least 400×g. The solution was sterile filtered (0.22 μm filter), supplemented with sodium azide to a final concentration of 0.01% (w/v), and kept at 4° C.

The targeted and untargeted TNF ligand trimer-containing Fc (kih) fusion antigen binding molecules and the human IgG1 were purified from cell culture supernatants by affinity chromatography using Protein A, followed by size exclusion chromatography. For affinity chromatography, the supernatant was loaded on a MAB SELECT SURE® column (CV=5-15 mL, resin from GE Healthcare) equilibrated with Sodium Phosphate (20 mM), Sodium Citrate (20 mM) buffer (pH 7.5). Unbound protein was removed by washing with at least 6 column volumes of the same buffer. The bound protein was eluted using either a linear gradient (20 CV) or a step elution (8 CV) with 20 mM sodium citrate, 100 mM Sodium chloride, 100 mM Glycine buffer (pH 3.0). For the linear gradient an additional 4 column volumes step elution was applied.

›Example 2 · 4 of 4

The pH of collected fractions was adjusted by adding 1/10 (v/v) of 0.5M sodium phosphate, pH8.0. The protein was concentrated prior to loading on a HILOAD® Superdex 200 column (GE Healthcare) equilibrated with 20 mM Histidine, 140 mM sodium chloride, 0.01% (v/v) TWEEN® 20 (polysorbate 20) solution of pH 6.0.

The protein concentration was determined by measuring the optical density (OD) at 280 nm, using a molar extinction coefficient calculated on the basis of the amino acid sequence. Purity and molecular weight of the targeted trimeric 4-1BB ligand Fc (kih) fusion was analyzed by SDS-PAGE in the presence and absence of a reducing agent (5 mM 1,4-dithiotreitol) and staining with Coomassie SIMPLYBLUE™ SafeStain (Invitrogen USA) or CE-SDS using Caliper LabChip GXII (Perkin Elmer). The aggregate content of samples was analyzed using a TSKGEL® G3000 SW XL analytical size-exclusion column (Tosoh) equilibrated in 25 mM K 2 HPO 4 , 125 mM NaCl, 200 mM L-Arginine Monohydrocloride, 0.02% (w/v) NaN3, pH 6.7 running buffer at 25° C.

Table 30 summarizes the yield and final monomer content of the FAP (4B9) targeted and untargeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules and control molecules.

›Example 3

Preparation, Purification and Characterization of 4-1BB

DNA sequences encoding the ectodomains of human, mouse or cynomolgus 4-1BB (Table 31) were subcloned in frame with the human IgG1 heavy chain CH2 and CH3 domains on the knob (Merchant et al., 1998). An AcTEV protease cleavage site was introduced between an antigen ectodomain and the Fc of human IgG1. An Avi tag for directed biotinylation was introduced at the C-terminus of the antigen-Fc knob. Combination of the antigen-Fc knob chain containing the S354C/T366W mutations, with a Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations allows generation of a heterodimer which includes a single copy of 4-1BB ectodomain containing chain, thus creating a monomeric form of Fc-linked antigen ( FIG. 5C ). Table 32 shows the cDNA and amino acid sequences of the antigen Fc-fusion constructs.

All 4-1BB-Fc-fusion molecule encoding sequences were cloned into a plasmid vector, which drives expression of the insert from an MPSV promoter and contains a synthetic polyA signal sequence located at the 3′ end of the CDS. In addition, the vector contains an EBV OriP sequence for episomal maintenance of the plasmid.

For preparation of the biotinylated monomeric antigen/Fc fusion molecules, exponentially growing suspension HEK293 EBNA cells were co-transfected with three vectors encoding the two components of fusion protein (knob and hole chains) as well as BirA, an enzyme necessary for the biotinylation reaction. The corresponding vectors were used at a 2:1:0.05 ratio (“antigen ECD-AcTEV-Fc knob”: “Fc hole”: “BirA”).

For protein production in 500 ml shake flasks, 400 million HEK293 EBNA cells were seeded 24 hours before transfection. For transfection cells were centrifuged for 5 minutes at 210 g, and the supernatant was replaced by pre-warmed CD CHO medium. Expression vectors were resuspended in 20 mL of CD CHO medium containing 200 μg of vector DNA. After addition of 540 μL of polyethylenimine (PEI), the solution was vortexed for 15 seconds and incubated for 10 minutes at room temperature. Afterwards, cells were mixed with the DNA/PEI solution, transferred to a 500 mL shake flask and incubated for 3 hours at 37° C. in an incubator with a 5% CO 2 atmosphere. After the incubation, 160 mL of F17 medium was added and cells were cultured for 24 hours. The production medium was supplemented with 5 μM kifunensine. One day after transfection, 1 mM valproic acid and 7% Feed 1 with supplements were added to the culture. After 7 days of culturing, the cell supernatant was collected by spinning down cells for 15 min at 210 g. The solution was sterile filtered (0.22 μm filter), supplemented with sodium azide to a final concentration of 0.01% (w/v), and kept at 4° C.

Secreted proteins were purified from cell culture supernatants by affinity chromatography using Protein A, followed by size exclusion chromatography. For affinity chromatography, the supernatant was loaded on a HITRAP® ProteinA HP column (CV=5 mL, GE Healthcare) equilibrated with 40 mL 20 mM sodium phosphate, 20 mM sodium citrate pH 7.5. Unbound protein was removed by washing with at least 10 column volumes of 20 mM sodium phosphate, 20 mM sodium citrate, 0.5 M sodium chloride containing buffer (pH 7.5). The bound protein was eluted using a linear pH-gradient of sodium chloride (from 0 to 500 mM) created over 20 column volumes of 20 mM sodium citrate, 0.01% (v/v) TWEEN® 20 (polysorbate 20), pH 3.0. The column was then washed with 10 column volumes of 20 mM sodium citrate, 500 mM sodium chloride, 0.01% (v/v) TWEEN® 20 (polysorbate 20), pH 3.0.

The pH of collected fractions was adjusted by adding 1/40 (v/v) of 2M Tris, pH8.0. The protein was concentrated and filtered prior to loading on a HILOAD® Superdex 200 column (GE Healthcare) equilibrated with 2 mM MOPS, 150 mM sodium chloride, 0.02% (w/v) sodium azide solution of pH 7.4.

For affinity determination to the human receptor, the ectodomain of human 4-1BB was also subcloned in frame with an avi (SEQ ID NO: 376; GLNDIFEAQKIEWHE) and a hexahistidine tag (SEQ ID NO: 393).

Protein production was performed as described above for the Fc-fusion protein. Secreted proteins were purified from cell culture supernatants by chelating chromatography, followed by size exclusion chromatography. The first chromatographic step was performed on a Ni-NTA SUPERFLOW™ Cartridge (5 ml, Qiagen) equilibrated in 20 mM sodium phosphate, 500 nM sodium chloride, pH7.4. Elution was performed by applying a gradient over 12 column volume from 5% to 45% of elution buffer (20 mM sodium phosphate, 500 nM sodium chloride, 500 mM Imidazole, pH7.4). The protein was concentrated and filtered prior to loading on a HILOAD® Superdex 75 column (GE Healthcare) equilibrated with 2 mM MOPS, 150 mM sodium chloride, 0.02% (w/v) sodium azide solution of pH 7.4 (Table 33).

›Example 4

Biochemical Characterization of FAP-Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecule by Surface Plasmon Resonance

The binding of FAP-targeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules to recombinant 4-1BB was assessed by surface plasmon resonance (SPR). All SPR experiments were performed on a BIACORE® instrument T100 at 25° C. with HBS-EP as a running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% Surfactant P20, Biacore, Freiburg/Germany).

The avidity of the interaction between the FAP-targeted or untargeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules and recombinant 4-1BB (human, cyno and murine) was determined as described below. The data demonstrated that both targeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules as well as untargeted DP47 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules bind with comparable avidities to human and cynomolgus 4-1BB but negligibly to the mouse homolog.

Recombinant biotinylated human, cynomolgus and murine 4-1BB Fc(kih) fusion molecules were directly coupled on a SA chip using the standard coupling instruction (Biacore, Freiburg/Germany). The immobilization level was about 30 RU. FAP-targeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules, or the DP47 untargeted controls, were passed at a concentration range from 0.39 to 200 nM with a flow of 30 μL/minutes through the flow cells over 120 seconds. The dissociation was monitored for 180 seconds. Bulk refractive index differences were corrected for by subtracting the response obtained on a reference empty flow cell.

For affinity measurement, direct coupling of around 7200 resonance units (RU) of an anti-human Fc specific antibody was performed on a CM5 chip at pH 5.0 using the standard amine coupling kit (GE Healthcare). FAP-targeted or untargeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules, at 50 nM were captured with a flow rate of 30 μl/min for 60 sec on flow cell 2. A dilution series (1.95 to 1000 nM) of human 4-1BB-avi-His was passed on both flow cells at 30 μl/min for 180 sec to record the association phase. The dissociation phase was monitored for 180 s and triggered by switching from the sample solution to HBS-EP. The chip surface was regenerated after every cycle using a double injection of 60 sec 10 mM Glycine-HCl pH 2.1. Bulk refractive index differences were corrected for by subtracting the response obtained on reference flow cell 1. For the interaction between the 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules and hu4-1BB avi His, the affinity constants were derived from the rate constants by fitting to a 1:1 Langmuir binding curve using the Biaeval software (GE Healthcare).

›Example 5 · 1 of 4

Functional Characterization of the Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules

5.1. Binding on Naïve Versus Activated Human PMBCs of the FAP-Targeted 4-1BB Ligand Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecules

Buffy coats were obtained from the Zurich blood donation center. To isolate fresh peripheral blood mononuclear cells (PBMCs) the buffy coat was diluted with the same volume of DPBS (Gibco by Life Technologies, Cat. No. 14190 326). 50 mL polypropylene centrifuge tubes (TPP, Cat.-No. 91050) were supplied with 15 mL HISTOPAQUE® reagent 1077 (SIGMA Life Science, Cat.-No. 10771, polysucrose and sodium diatrizoate, adjusted to a density of 1.077 g/mL) and the diluted buffy coat solution was layered above the HISTOPAQUE® reagent 1077. The tubes were centrifuged for 30 min at 400×g. PBMCs were then collected from the interface, washed three times with DPBS and resuspended in T cell medium consisting of RPMI 1640 medium (Gibco by Life Technology, Cat. No. 42401-042) supplied with 10% Fetal Bovine Serum (FBS, Gibco by Life Technology, Cat. No. 16000-044, Lot 941273, gamma-irradiated, mycoplasma-free and heat inactivated at 56° C. for 35 min), 1% (v/v) GlutaMAX-I (GIBCO by Life Technologies, Cat. No. 35050 038), 1 mM Sodium Pyruvate (SIGMA, Cat. No. S8636), 1% (v/v) MEM non-essential amino acids (SIGMA, Cat.-No. M7145) and 50 μM β-Mercaptoethanol (SIGMA, M3148).

PBMCs were used directly after isolation or stimulated to induce 4-1BB expression at the cell surface of T and NK cells by culturing for 4 days in T cell medium supplemented with 200 U/mL Proleukin (Novartis Pharma Schweiz AG, CHCLB-P-476-700-10340) and 2 μg/mL PHA-L (SIGMA Cat.-No. L2769) in a 6-well tissue culture plate and then 1 day in a 6-well tissue culture plate coated with 10 ug/mL anti-human CD3 (clone OKT3, BioLegend, Cat.-No. 317315) and 2 μg/mL anti-human CD28 (clone CD28.2, BioLegend, Cat.-No.: 302928) in T cell medium at 37° C. and 5% CO 2 .

To determine binding of 4-1BBL trimer-containing Fc fusion antigen binding molecules to human PBMCs, 0.1×10 6 naïve or activated PBMCs were added to each well of a round-bottom suspension cell 96-well plates (Greiner bio-one, cellstar, Cat. No. 650185). Plates were centrifuged 4 minutes with 400×g and at 4° C. Supernatant was discarded. Afterwards cells were stained in 100 μL/well DPBS containing 1:1000 diluted LIVE/DEAD® Fixable Blue Dead Cell Stain Kit, for UV excitation (Life Technologies, Molecular Probes, L-23105) or Fixable Viability Dye eF660 (eBioscience 65-0864-18) or LIVE/DEAD® Fixable Green Dead Cell Stain Kit (Life Technologies, Molecular Probes, L-23101) for 30 minutes at 4° C. in the dark. If DAPI was used as Live/Death stain, this staining step was skipped. Cells were washed once with 200 μL cold FACS buffer (DPBS supplied with 2% (v/v) FBS, 5 mM EDTA pH8 (Amresco, Cat. No. E177) and 7.5 mM sodium azide (Sigma-Aldrich S2002).

Next, 50 μL/well of 4° C. cold FACS buffer containing different titrated concentrations of 4-1BBL trimer-containing Fc fusion antigen binding molecules were added and cells were incubated for 120 minutes at 4° C., washed four times with 200 μL/well 4° C. FACS buffer and resuspended. Cells were further stained with 50 μL/well of 4° C. cold FACS buffer containing 0.67 μg/mL anti-human CD3-PerCP-Cy5.5 (clone UCHT1, mouse IgG1κ, BioLegend, Cat.-No. 300430) or 0.16 μL anti-human CD3-PE/Cy7 (clone SP34-2, mouse IgG1 κ, BD Pharmingen, Cat.-No. 557749, Lot 33324597), 0.67 μg/mL anti-human CD45-AF488 (clone HI30, mouse IgG1κ, BioLegend, Cat.-No. 304017) or 0.12 μg/mL anti-human CD56-FITC (clone NCAM16.2, mouse IgG2bκ, BD Pharmingen, Cat.-No. 345811) or 1 μL anti-human CD56-APC (clone B159, mouse IgG1 κ, BD Pharmingen, Cat.-No. 555518, Lot 3098894), 0.25 μg/mL anti-human CD4-BV421 (clone RPA-T4, mouse IgG1κ, BioLegend, Cat.-No. 300532) or 0.23 μg/mL anti-human CD4-BV421 (clone OKT4, mouse IgG2bκ, BioLegend, Cat.-No. 317434), 0.25 μL anti-human CD8a-APC (clone RPA-T8, mouse IgG1κ, BD Pharmingen, Cat.-No. 555369) or 0.67 μL anti-human CD8a-APC/Cy7 (clone RPA-T8, mouse IgG1κ, BioLegend, Cat.-No. 301016) or 0.83 ng/mL anti-human CD8a-BV711 (clone RPA-T8, mouse IgG1κ, BD Pharmingen, Cat.-No. 301044) and 5 μg/mL PE-conjugated AffiniPure anti-human IgG Fcγ-fragment-specific goat IgG F(ab′)2 fragment (Jackson ImmunoResearch, Cat. No. 109 116 098 or 109 116 170). Cells were washed twice with FACS-buffer. If cells were stained with fixable viability dyes, they were fixed with 50 μL/well DPBS containing 1% formaldehyde (Sigma, HT501320-9.5L). Cells were resuspended in FACS buffer and acquired the next or the same day using a 5-laser LSR-FORTESSA® (BD Bioscience with DIVA software) or 3-laser Miltenyi Quant Analyzer 10 (Mitenyi Biotec) and Flow Jo (FlowJo X 10.0.7). If DAPI staining was used to detect dead cells, they were resuspended in 80 μL/well FACS buffer containing 0.2 μg/mL DAPI (Santa Cruz Biotec, Cat. No. Sc-3598) and acquired the same day using a 5-laser LSR-FORTESSA® (BD Bioscience with DIVA software).

As shown in FIGS. 6A-1 to 6C-2 , both FAP-targeted or untargeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules did not bind to resting human CD4+ T cells and showed no detectable binding to resting CD8+ T cells and NK cells. In contrast, both constructs bound strongly to activated NK, CD8+ or CD4+ T cells, although the latter showed approximately 10 fold lower intensity of specific fluorescence as compared to the NK cells and 20 fold decreased intensity of specific fluorescence as compared to CD8+ T cells.

FIGS. 7A-1 to 7A-4 and 7B-1 to 7B-4 show the binding of Constructs 1.1 to 1.10 as prepared in Example 1 on 4-1BB-expressing activated human CD3+CD8+ T cells and 4-1BB-expressing activated human CD3+CD4+ T cells, respectively. Table 35 shows the EC50 values as measured for Constructs 1.1 to 1.10.

FIGS. 8A-1 to 8A-4 and 8B-1 to 8B-4 show the binding of Constructs 2.1, 2.3, 2.4, 2.5 and 2.6 as prepared in Example 2 on CD4+ and CD8+ from fresh human blood and on activated 4-1BB-expressing CD4+ T cells and CD8+ T cells, respectively. Gates were set on living CD45+CD3+CD4+ or CD45+CD3+CD8+ T cells and MFI of PE-conjugated AffiniPure anti-human IgG IgG Fcγ-fragment-specific goat F(ab′)2 fragment were blotted against the titrated concentration of targeted split trimeric 4-1BB ligand Fc fusion variants. Table 36 shows the EC 50 values as measured for Constructs 2.1, 2.3, 2.4, 2.5 and 2.6.

›Example 5 · 2 of 4

5.2 Binding of FAP-Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecule to Activated Mouse Splenocytes

Mouse spleens were collected in 3 mL PBS and a single cell suspension was generated using gentle MACS tubes (Miltenyi Biotec Cat.-No. 130-096-334) and gentleMACS Octo Dissociator (Miltenyi Biotec). Afterwards splenocytes were filtered through a 30 μm Pre-Separation Filters (Miltenyi Biotec Cat.-No. 130-041-407) and centrifuged for 7 min at 350×g and 4° C. Supernatant was aspirated and cells were resuspended in RPMI 1640 medium supplied with 10% (v/v) FBS, 1% (v/v) GlutaMAX-I, 1 mM Sodium-Pyruvate, 1% (v/v) MEM non-essential amino acids, 50 μM β-Mercaptoethanol and 10% Penicillin-Streptomycin (SIGMA, Cat.-No. P4333). 10 6 cells/mL were cultured for 2 days in a 6-well tissue culture plate coated with 10 μg/mL anti-mouse CD3ε Armenian Hamster IgG (clone 145-2C11, BioLegend, Cat.-No. 100331) and 2 μg/mL anti-mouse CD28 Syrian Hamster IgG (clone 37.51, BioLegend, Cat.-No. 102102).

Activated mouse splenocytes were harvested, washed in DPBS, counted and 0.1×10 6 cells were transferred to each well of a 96 U-bottom non-tissue culture treated well plate. Supernatant was removed and cells were stained in 100 uL/well DPBS containing 1:5000 diluted Fixable Viability Dye eF660 (Bioscience, Cat-No. 65-0864-18) for 30 min at 4° C. Cells were washed with PBS and stained in 50 uL FACS buffer containing different concentration of FAP-targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules (FAP split 4-1BBL trimer), untargeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules (DP47 split 4-1BBL trimer) or anti-mouse CD137 human IgG1 P329G LALA mAb (clone Lob.12.3, BioXcell Catalog #: BE0169). Cells were incubated for 120 min at 4° C. Cells were washed four times with FACS buffer and stained in 50 FACS buffer containing 10 μg/mL purified anti-mouse CD16/CD32 rat IgG-Fc-Block (BD Pharmingen, Cat.-No. 553142 clone 2.4G2), 5 μg/mL anti-mouse CD8b rat IgG2bκ-FITC (BioLegend, Cat.-No. 126606, clone YTS156.7.7), 0.67 μg/mL anti-mouse CD3 rat IgG2bκ-APC-Cy7 (BioLegend, Cat.-No. 100222, clone 17A2), 0.67 μg/mL anti-mouse CD4 rat IgG2bκ-PE-Cy7 (BioLegend, Cat.-No. 100422, clone GK1.5), 2 μg/mL anti-mouse NK1.1 Mouse (C3H×BALB/c) IgG2aκ-PerCp-Cy5.5 (BioLegend, Cat.-No. 108728, clone PK136) and 10 μg/mL PE-conjugated AffiniPure polyclonal F(ab′)2 Fragment goat anti-human IgG, Fey fragment specific, minimal cross-reactive to bovine mouse and rabbit serum proteins (Jackson ImmunoResearch, Cat.-No. 109-116-170) for 30 min at 4° C. Cells were washed twice with 200 μL/well cold FACS buffer. Cells were fixed with 50 DPBS containing 1% formaldehyde. Cells were resuspended in FACS-buffer and acquired the next day using a 5-laser LSR-FORTESSA® (BD Bioscience with DIVA software).

As shown in FIGS. 9A and 9B , FAP-targeted hu4-1BB ligand trimer-containing Fc fusion antigen binding molecules (FAP split hu4-1BBL trimer) and untargeted hu4-1BB ligand trimer-containing Fc fusion antigen binding molecules (DP47 split hu4-1BBL trimer) do not bind to mouse 4-1BB. Therefore activity cannot be tested in immune competent mice. For in vivo mode of action studies either humanized mouse models in immune incompetent mice or surrogates containing mouse 4-1BBL trimers as shown in FIGS. 3A to 3C have to be used.

5.3 Binding to FAP-Expressing Tumor Cells

For binding assays on FAP expressing cells, the human melanoma cell line MV-3 (see Ruiter et al., Int. J. Cancer 1991, 48(1), 85-91), WM-266-4 (ATTC CRL-1676) or NIH/3T3-huFAP clone 39 cell line were used. To generate the latter cell line, NIH/3T3 cells were transfected with human FAP (NIH/3T3-huFAP clone 39). The cells were generated by transfection of mouse embryonic fibroblast NIH/3T3 cells (ATCC CRL-1658) with the expression pETR4921 plasmid encoding human FAP under a CMV promoter. Cells were maintained in the presence of 1.5 μg/mL puromycin (InvivoGen, Cat.-No.: ant-pr-5). 0.1×10 6 of FAP expressing tumor cells were added to each well of a round-bottom suspension cell 96-well plates (Greiner bio-one, cellstar, Cat.-No. 650185). Cells were washed once with 200 μL DPBS and pellets were resuspended. 100 μL/well of 4° C. cold DPBS buffer containing 1:5000 diluted Fixable Viability Dye EFLUOR® 450 (eBioscience, Cat.-No. 65-0863-18) or Fixable Viability Dye EFLUOR® 660 (eBioscience, Cat.-No. 65-0864-18) were added and plates were incubated for 30 minutes at 4° C. Cells were washed once with 200 μL 4° C. cold DPBS buffer and resuspended in 50 μL/well of 4° C. cold FACS buffer (DPBS supplied with 2% (v/v) FBS, 5 mM EDTA pH 8 (Amresco, Cat.-No. E177) and 7.5 mM Sodium azide (Sigma-Aldrich 52002) containing different concentrations of titrated 4-1BBL trimer-containing Fc fusion antigen binding molecules, followed by incubation for 1 hour at 4° C. After washing four times with with 200 μL/well, cells were stained with 50 μL/well of 4° C. cold FACS buffer containing 30 μg/mL FITC-conjugated AffiniPure anti-human IgG Fcγ-fragment-specific goat F(ab′) 2 fragment (Jackson ImmunoResearch, Cat.-No. 109-096-098) or 5 μg/mL PE-conjugated AffiniPure anti-human IgG Fgγ-fragment-specific goat F(ab′)2 fragment (Jackson ImmunoResearch, Cat. No. 109-116-098 or 109-116-170) for 30 minutes at 4° C. Cells were washed twice with 200 μL 4° C. FACS buffer and then resuspended in 50 μL/well DPBS containing 1% formaldehyde. The same or the next day cells were resuspended in 100 μL FACS-buffer and acquired using 5-laser LSR-FORTESSA® (BD Bioscience with DIVA software) or 3-laser Miltenyi Quant Analyzer 10 (Mitenyi Biotec) and Flow Jo (FlowJo X 10.0.7).

As shown in FIGS. 10A and 10B , the FAP-targeted 4-1BB ligand trimer-containing Fc(kih) fusion antigen binding molecule (FAP split 4-1BBL trimer) Construct 1.1, but not the untargeted, DP47-Fab-containing construct (DP47 split 4-1BBL trimer) Control A, efficiently bound to human fibroblast activation protein (FAP)-expressing melanoma (10A) MV-3 cells or (10B) WM-266-4 cells.

›Example 5 · 3 of 4

FIGS. 11A-1 to 11A-4 shows the binding of Constructs 1.1 to 1.10 as prepared in Example 1 to human-FAP expressing human melanoma MV-3 cells and in FIGS. 11B-1 and 11B-2 the binding of Construct 1.1, 1.2, 1.3 and 1.5 to human FAP expressing NIH/3T3-huFAP clone 39 transfected mouse embryonic fibroblast cells is presented. Table 37 shows the EC 50 values as measured for Constructs 1.1 to 1.10.

FIGS. 12A-1 to 12B-2 shows the binding of different FAP (4B9)-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs to human-FAP expressing human melanoma MV-3 cells ( FIGS. 12A-1 and 12A-2 ) and WM-266-4 cells ( FIGS. 12B-1 and 12B-2 ). The constructs 2.1, 2.3, 2.4, 2.5 and 2.6 were prepared as described in Example 2 and Controls were prepared as described herein before. Gates were set on living tumor cells and MFI of PE-conjugated AffiniPure anti-human IgG Fcγ-fragment-specific goat F(ab′) 2 fragment were blotted against the titrated concentration of targeted split trimeric 4-1BB ligand Fc fusion constructs. Table 38 shows the EC 50 values as measured.

5.4 Functional Characterization of the Murine Targeted 4-1BB Ligand Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecules

5.4.1 Binding to Activated Mouse Splenocytes

For binding on fresh mouse splenocytes cells were used directly. To induce mouse 4-1BB expression on T cells, mouse splenocytes were activated as following: 10 6 cells/mL were cultured for 2 days in a 6-well tissue culture plate coated with 10 μg/mL anti-mouse CD3c Armenian Hamster IgG (clone 145-2C11, BioLegend, Cat.-No. 100331) and 2 μg/mL anti-mouse CD28 Syrian Hamster IgG (clone 37.51, BioLegend, Cat.-No. 102102).

Fresh mouse splenocytes or activated mouse splenocytes were collected, washed in DPBS (Gibco life technologies, Cat.-No. 14190-136), counted and 0.1×10 6 cells were transferred to each well of a 96 U-bottom non-tissue culture treated well plate (Greiner bio-one, cell star, Cat.-No. 650185). Supernatant was removed and cells were stained in 100 uL/well 4° C. cold DPBS containing 1:1000 diluted LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit (Life Technologies, L34957) for 30 min at 4° C. Cells were washed with cold DPBS and stained in 50 uL/well cold FACS buffer (DPBS supplied with 2% (v/v) FBS, 5 mM EDTA pH8 (Amresco, Cat. No. E177) and 7.5 mM Sodium azide (Sigma-Aldrich S2002)) containing different concentration of mouse 4-1BB ligand trimer-containing Fc(kih) fusion molecules or mouse IgG1 Isotype control (BioLegend, Cat.-No. 400153, clone MOPC-21). Cells were incubated for 120 min at 4° C., washed four times with cold DPBS and stained in 50 μL/well cold FACS buffer containing 30 μg/mL FITC-conjugated anti-mouse IgG Fc-gamma-specific goat IgG F(ab′)2 (Jackson Immunoresearch, Cat.-No. 115-096-071) for 30 min at 4° C. Afterwards cells were washed twice with cold DPBS and stained with 50 μL/well FACS buffer supplied with 10 μg/mL purified anti-mouse CD16/CD32 rat IgG-Fc-Block (BD Pharmingen, Cat.-No. 553142 clone 2.4G2), 0.67 μg/mL anti-mouse CD8a-APC-Cy7 (BioLegend, Cat.-No. 100714, clone 53-6.7), 0.67 μg/mL anti-mouse CD3c-PerCP-Cy5.5 (BioLegend, Cat.-No. 100328, clone 145-2C11), 0.67 μg/mL anti-mouse CD4 rat IgG2bκ-PE-Cy7 (BioLegend, Cat.-No. 100422, clone GK1.5) for 30 min at 4° C. Cells were washed twice with 200 μL/well cold DPBS, fixed with 50 μL/well DPBS containing 1% Formaldehyde and resuspended in FACS-buffer. Cells were acquired using 3-laser MACSQuant Analyzer 10 (Miltenyi Biotech) and Flow Jo v10.0.7 (FlowJo LLC). Gates were set on CD3 + CD8 + or CD3 + CD4 + T cells and the median florescence intensity (MFI) of FITC-conjugated anti-mouse IgG Fc-gamma-specific goat IgG F(ab′)2 was analyzed and normalized by the subtraction of the MFI of the blank control (no addition of mouse 4-1BB ligand trimer-containing Fc(kih) fusion molecule). The MFI was blotted against the concentration of used mouse 4-1BB ligand trimer-containing Fc(kih) fusion molecules to display the binding to mouse 4-1BB cell-bound molecule.

As can be seen in FIGS. 13A-1 to 13B-2 , the murine 4-1BBL Constructs M.1 and M.2 as well as corresponding control molecules Control M.1 and Control M.2 bind with a quite similar affinity to mouse 4-1BB. Table 39 shows the EC50 values as measured for Constructs M.1 and M.2 and the control molecules.

5.4.2 Binding on FAP-Expressing Tumor Cells

For binding assays on FAP expressing cells, the human melanoma cell line MV-3 (see Ruiter et al., Int. J. Cancer 1991, 48(1), 85-91) and WM-266-4 (ATTC CRL-1676) were used (anti-FAP specific clone 28H1 is mouse/human-crossreactive). 0.1×10 6 of FAP expressing tumor cells were added to each well of a round-bottom suspension cell 96-well plates (Greiner bio-one, cellstar, Cat.-No. 650185). Cells were washed once with 200 μL cold DPBS and pellets were resuspended in 100 μL/well of 4° C. cold DPBS buffer containing 1:1000 diluted LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit (Life Technologies, L34957) and incubated for 30 min at 4° C. Cells were washed once with 200 μL cold DPBS buffer and resuspended in 50 μL/well of cold FACS buffer (DPBS supplied with 2% (v/v) FBS, 5 mM EDTA pH8 (Amresco, Cat. No. E177) and 7.5 mM Sodium azide (Sigma-Aldrich S2002)) containing murine 4-1BB ligand trimer-containing Fc(kih) fusion molecules at a series of concentrations followed by incubation for 1 hour at 4° C. After washing four times with 200 μL DPBS/well, cells were stained with 50 μL/well of 4° C. cold FACS buffer containing 30 μg/mL FITC-conjugated anti-mouse IgG Fc-gamma-specific goat IgG F(ab′)2 (Jackson Immunoresearch, Cat.-No. 115-096-071) for 30 min at 4° C. Cells were washed twice with 200 μL/well cold DPBS buffer, fixed with 50 μL/well DPBS containing 1% Formaldehyde and resuspended in FACS-buffer. Cells were acquired using 3-laser MACSQuant Analyzer 10 (Miltenyi Biotech) and Flow Jo v10.0.7 (FlowJo LLC). Gates were set on living cells and the median florescence intensity (MFI) of FITC-conjugated anti-mouse IgG Fc-gamma-specific goat IgG F(ab′)2 was analyzed and normalized by the subtraction of the MFI of the blank control (no addition of mouse 4-1BB ligand trimer-containing Fc(kih) fusion molecule). The MFI was blotted against the concentration of used murine 4-1BB ligand trimer-containing Fc(kih) fusion molecules to display the binding to murine 4-1BB cell-bound molecule. As expected, the murine 4-1BBL constructs M.1 and M.2 bind with a quite similar affinity to FAP whereas the control molecules do not bind.

›Example 5 · 4 of 4

FIGS. 14 and 14B shows the binding of the FAP-targeted or untargeted split trimeric murine 4-1BB ligand Fc (kih) Constructs M.1 and M.2 to human-FAP expressing human melanoma MV-3 cells ( FIG. 14A ) and WM-266-4 cells ( FIG. 14B ). Table 40 shows the EC 50 values as measured.

›Example 6 · 1 of 5

Biological Activity of the Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules

6.1. NF-κB Activation in HeLa Cells Expressing Human 4-1BB

Generation of HeLa Cells Expressing Human 4-1BB and NF-κB-Luciferase

The cervix carcinoma cell line HeLa (ATCC CCL-2) was transduced with a plasmid based on the expression vector pETR10829, which contains the sequence of human 4-1BB (Uniprot accession Q07011) under control of a CMV-promoter and a puromycin resistance gene. Cells were cultured in DMEM medium supplemented with 10% (v/v) FBS, 1% (v/v) GlutaMAX-I and 3 μg/mL Puromycin.

4-1BB-transduced HeLa cells were tested for 4-1BB expression by flow cytometry: 0.2×10 6 living cells were resuspended in 100 μL FACS buffer containing 0.1 μs PerCP/Cy5.5 conjugated anti-human 4-1BB mouse IgG1κ clone 4B4-1 (BioLegend Cat.-No. 309814) or its isotype control (PerCP/Cy5.5 conjugated mouse IgG1κ isotype control antibody clone MOPC-21, BioLegend Cat.-No. 400150) and incubated for 30 minutes at 4° C. Cells were washed twice with FACS buffer, resuspended in 300 μL FACS buffer containing 0.06 μg DAPI (Santa Cruz Biotec, Cat. No. Sc-3598) and acquired using a 5-laser LSR-FORTESSA® (BD Bioscience, DIVA software). Limited dilutions were performed to generate single clones as described: human-4-1BB-transduced HeLa cells were resuspended in medium to a density of 10, 5 and 2.5 cells/ml and 200 μl of cell suspensions were transferred to round bottom tissue-culture treated 96-well plates (6 plates/cell concentration, TPP Cat.-No. 92697). Single clones were harvested, expanded and tested for 4-1BB expression as described above. The clone with the highest expression of 4-1BB (clone 5) was chosen for subsequent transfection with the NF-κB-luciferase expression-vector 5495p Tranlucent HygB. The vector confers transfected cells both with resistance to Hygromycin B and capacity to express luciferase under control of NF-kB-response element (back bone vector Panomics, Cat.-No. LR0051 with introduced HyB resistance). Human-4-1BB HeLa clone 5 cells were cultured to 70% confluence. 50 μg (40 μL) linearized (restriction enzymes AseI and SalI) 5495p Tranlucent HygB expression vector were added to a sterile 0.4 cm Gene Pulser/MicroPulser Cuvette (Biorad, Cat.-No, 165-2081). 2.5×10 6 human-4-1BB HeLa clone 5 cells in 400 μl supplement-free DMEM medium were added and mixed carefully with the plasmid solution. Transfection of cells was performed using a Gene Pulser Xcell total system (Biorad, Cat-No. 165-2660) under the following settings: exponential pulse, capacitance 500 g, voltage 160 V, resistance ∞. Immediately after the pulse transfected cells were transferred to a 75 cm 2 tissue culture flask (TPP, Cat.-No. 90075) with 15 mL 37° C. warm DMEM medium supplied with 10% (v/v) FBS and 1% (v/v) GlutaMAX-I. Next day, culture medium containing 3 μg/mL Puromycin and 200 μg/mL Hygromycin B (Roche, Cat.-No. 10843555001) was added. Surviving cells were expanded and limited dilution was performed as described above to generate single clones.

Clones were tested for 4-1BB expression as described above and for NF-κB-Luciferase activity as following: Clones were harvested in selection medium and counted using a Cell Counter Vi-cell xr 2.03 (Beckman Coulter, Cat.-No. 731050). Cells were set to a cell density of 0.33×10 6 cells/mL and 150 μL of this cell suspension were transferred to each well of a sterile white 96-well flat bottom tissue culture plate with lid (greiner bio-one, Cat.-No. 655083) and—as a control—to normal 96-well flat bottom tissue culture plate (TPP Cat.-No. 92096) to test survival and cell density the next day. Cells were incubated at 37° C. and 5% CO 2 overnight. The next day 50 μL of medium containing different concentrations of recombinant human tumor necrosis factor alpha (rhTNF-α, PeproTech, Cat.-No. 300-01A) were added to each well of a 96-well plate resulting in final concentration of rhTNF-α of 100, 50, 25, 12.5, 6.25 and 0 ng/well. Cells were incubated for 6 hours at 37° C. and 5% CO 2 and then washed three times with 200 μL/well DPBS. Reporter Lysis Buffer (Promega, Cat-No: E3971) was added to each well (40 μl) and the plates were stored over night at −20° C. The next day frozen cell plates and Detection Buffer (Luciferase 1000 Assay System, Promega, Cat.-No. E4550) were thawed to room temperature. 100 uL of detection buffer were added to each well and the plate was measured as fast as possible using a SpectraMax M5/M5e microplate reader and the SoftMax Pro Software (Molecular Devices). Measured units of released light for 500 ms/well (URLs) above control (no rhTNF-α added) were taken as luciferase activity. The NF-κB-luc-4-1BB-HeLa clone 26 exhibiting the highest luciferase activity and a considerable level of 4-1BB-expression and was chosen for further use.

NF-κB Activation in Hela Cells Expressing Human 4-1BB Co-Cultured with FAP-Expressing Tumor Cells

NF-κB-luciferase human-4-1BB HeLa cells were harvested and resuspended in DMEM medium supplied with 10% (v/v) FBS and 1% (v/v) GlutaMAX-I to a concentration of 0.2×10 6 cells/ml. 100 μl (2×10 4 cells) of this cell suspension were transferred to each well of a sterile white 96-well flat bottom tissue culture plate with lid (greiner bio-one, Cat. No. 655083) and the plate were incubated at 37° C. and 5% CO 2 overnight. The next day 50 μL of medium containing titrated concentrations of FAP-targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules (FAP split 4-1BBL trimer) or DP47-untargeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules (DP47 split 4-1BBL trimer) were added. FAP-expressing tumor cells (MV3, WM-266-4 or NIH/3T3-huFAP clone 39) were resuspended in DMEM medium supplied with 10% (v/v) FBS and 1% (v/v) GlutaMAX-I to a concentration of 2×10 6 cells/ml.

Suspension of FAP-expressing tumor cell (50 final ratio 1:5) or only medium were added to each well and plates were incubated for 6 hours at 37° C. and 5% C 0 2. Cells were washed two times with 200 μL/well DPBS. 40 μl freshly prepared Reporter Lysis Buffer (Promega, Cat-No: E3971) were added to each well and the plate were stored over night at −20° C. The next day frozen cell plate and Detection Buffer (Luciferase 1000 Assay System, Promega, Cat. No. E4550) were thawed at room temperature. 100 μL of detection buffer were added to each well and luciferase activity was measured as fast as possible using a SpectraMax M5/M5e microplate reader and a SoftMax Pro Software (Molecular Devices) counting light emission in URL (units of released light for 0.5 s/well) or Victor3 1420 multilabel counter plate reader (Perkin Elmer) and the Perkin Elmer 2030 Manager Software counting light emission as counts per seconds (CPS) and blotted against the concentration of tested constructs.

›Example 6 · 2 of 5

FAP-targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecule (FAP split 4-1BBL trimer) triggered activation of the NFκB signaling pathway in the reporter cell line in the presence of FAP-expressing tumor cells. In contrast, the untargeted variant of the same molecule failed to trigger such an effect at any of the tested concentrations ( FIGS. 16A to 16C ). This activity of targeted 4-1BBL was strictly dependent on the expression of FAP at the cell surface of tumor cells as no NF-kB activation could be detected upon culturing of the NF-kB reporter cell line with FAP-negative tumor cells even in the presence of FAP-targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecule. The activities as measured for Constructs 1.1 to 1.10 are shown in FIGS. 17A-1 to 17C-4 and the data as measured for Constructs 2.1, 2.4 and 2.5 are presented in FIGS. 18A to 18F .

6.2. NFκB Activation in HEK T293 Cells Expressing Cynomolgus Monkey 4-1BB

Generation of HEK T293 Cells Expressing Cynomolgus Monkey 4-1BB and NFκB-Luciferase

For the production of viral-like particles (VLP) the Human Embryonic Kidney (HEK) T293/17 (ATCC CRL-11268) was transfected using Lipofectamine® LTX Reagent with PLUS™ Reagent (Life Technologies, Cat.-No. 15338100) with the vector pETR14372 encoding a NFκB-luciferase-IRIS-GFP reporter gene cassette (NFκB-luc-GFP) accordingly to the manufacture's protocol. 6 hours later DMEM supplied with 10% FBS medium replacement was performed and VLP were harvested 4 days later. Fresh HEK 293T cells were transduced at a confluency of 70-80% with the produced pETR14372-VLP and 4 μg/mL polybrene. Cells were cultured for 24 h and a medium exchange was performed. The transduced HEK T293/17 cells were harvested and a limited dilution of 1 cell/well was performed to screen for stable single clones. The single clones were stimulated with 25 ng/mL TNF-α (PeproTech Inc. Cat.-No. 300-01A) in the medium and were screened for a positive GFP signal over time using the Incuyte Zoom Fluorescence Microscope System (Essen Bioscience). After GFP signal recording cells were tested for luciferase activity using the NANO GLO® Luciferase Kit (Promega, N1120) accordingly to the manufacture's protocol. Luciferase activity was measured using Victor3 1420 multilabel counter plate reader (Perkin Elmer) and the Perkin Elmer 2030 Manager Software. Light emission was counted in counts per seconds (CPS) for 0.5 sec/well. The clone 61 showed the highest expression of GFP and Luciferase after TNF-α activation and was further used for the reporter cell line generation.

As described above, new VLP were produced using the vector pETR14879 encoding cynomolgus monkey 4-1BB and a puromycine resistance and the HEK 293T NFκB-fluc-GFP clone 61 cell line was transduced at a confluency of 70-80% with the produced pETR14879-VLP and 4 μg/mL polybrene. Cells were cultured for 24 h and a medium exchange was performed. Four days after transduction the cells were stained with PE-conjugated anti-human cynomolgus-crossreactive 4-1BB antibody (mouse IgG1κ, clone MOPC-21, BioLegend, Cat.-No. 309804) in DPBS containing 1% FBS, were sorted by FACS (ARIA, BD) and seeded with 5 cells/well in DMEM supplied with 10% FBS medium containing 1 μg/mL Puromycine (InvivoGen, Cat.-No. ant-pr). Growing clones were tested as described for GFP and Luciferase activity after TNF-α stimulation and for high cynomolgus monkey 4-1BB expression by flow cytometry. Double positive clones were chosen and tested for Luficerase activity in the presence of monovalent FAP-targeted Construct 2.1 or Control B and FAP-expressing MV-3 or WM-266-4 cells. HEK T293/17-NF-κB-luc-GFP-cy4-1BB expressing Clone 61-13 was chosen to be used for all further experiments.

NFκB Activation of HEK T293/17 Reporter Cells Expressing Cynomolgus Monkey 4-1BB Co-Cultured with FAP-Expressing Tumor Cells

HEK T293/17-NFκB-luc-GFP-cy4-1BB expressing Clone 61-13 cells were harvested and resuspended in DMEM medium supplied with 10% (v/v) FBS and 1% (v/v) GlutaMAX-I to a concentration of 0.2×10 6 cells/mL. 100 μl (2×10 4 cells) of this cell suspension were transferred to each well of a sterile white 96-well flat bottom tissue culture plate with lid (greiner bio-one, Cat. No. 655083) and the plate were incubated at 37° C. and 5% CO 2 overnight. The next day 50 μL of medium containing different titrated concentrations of FAP-targeted or untargeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules were added. FAP-expressing tumor cells (MV3 and WM-266-4) were resuspended in medium to a concentration of 2×10 6 cells/ml. Suspension of FAP-expressing tumor cell (50 μl) was added to each well and plates were incubated for 6 hours at 37° C. and 5% C 0 2. The principle of the assay is shown in FIGS. 19A and 19B . After incubation cells were washed three times with 200 μL/well DPBS. 40 μl freshly prepared Reporter Lysis Buffer (Promega, Cat-No: E3971) were added to each well and plates were stored over night at −20° C. The next day frozen cell plates and detection buffer (Luciferase 1000 Assay System, Promega, Cat. No. E4550) were thawed to room temperature. 100 μL of detection buffer were added to each well and luciferase activity was measured as fast as possible using SpectraMax M5/M5e (Molecular Devices) microplate reader (500 ms integration time, no filter collecting all wavelength). Light emission was counted in units of released light (URL) for 0.5 sec/well and blotted against the concentration of tested FAP-targeted or untargeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules. The results for Constructs of Example 2 are shown in FIGS. 20A to 20F .

6.3 Antigen-Specific CD8+ T Cell-Based Assay

Isolation and Culture of Antigen-Specific CD8 T Cells

Fresh blood was obtained from a HLA-A2+ CMV-infected volunteer. PBMCs were isolated as described above. CD8 T cells were purified from PBMCs using a negative selection human CD8 T cell isolation Kit according to manufacturer's recommendations (Miltenyi Biotec, Cat. No. 130-094-156). Ten million of isolated CD8 T cells were resuspended in 1 mL sterile DPBS supplemented with 1% (v/v) FBS along with 50 μL of PE-labeled HLA-A2-pentamer containing the CMV-derived NLVPMVATV peptide (SEQ ID NO: 377) (ProImmune, Cat. No. F008-2B) and incubated for 10 min at room temperature. Cells were washed twice with 3 mL sterile DPBS supplied with 1% (v/v) FBS. Cells were resuspended in 1 mL cells DPBS supplied with 1% (v/v) FBS containing 1 μg/mL anti-human CD8-FITC (clone LT8, Abcam, Cat. No. Ab28010) and incubated for 30 minutes at 4° C. Cells were washed twice, resuspended to a concentration of 5×10 6 cells/mL in DPBS supplied with 1% (v/v) FBS, and filtrated through a 30 μm pre-separation nylon-net cell strainer (Miltenyi Biotec, Cat. No. 130-041-407). NLV-peptide-specific CD8+ T cells were isolated by FACS sorting using an ARIA cell sorter (BD Bioscience with DIVA software) with the following settings: 100 μm nozzle and purity sort mask. Sorted cells were collected in a 15 ml polypropylene centrifuge tube (TPP, Cat. No. 91015) containing 5 ml RPMI 1640 medium supplied with 10% (v/v) FBS, 1% (v/v) GlutaMAX-I and 400 U/mL Proleukin. Sorted cells were centrifuged for 7 minutes at 350×g at room temperature and resuspended in same medium to a concentration of 0.53×10 6 cells/mL. 100 μL/well of this cell suspension were added to each well of a previously prepared feeder plate.

›Example 6 · 3 of 5

PHA-L-activated irradiated allogeneic feeder cells were prepared from PBMCs as previously described (Levitsky et al., 1998) and distributed to 96 well culture plates at 2×10 5 feeder cells per well.

After one day of culturing 100 μL medium/well were removed from well containing sorted CD8+ T-cells and replaced by new RPMI 1640 medium supplemented with 10% (v/v) FBS and 1% (v/v) GlutaMAX-I and 400 U/mL Proleukin, this was repeated during culture on a regular basis (every 2-4 days). As soon as cells start to proliferate, they were transferred to 24-well flat-bottom tissue culture plate (TPP, 92024). Cells were expanded/split and reactivated with new feeder cell preparation on a regular basis.

Activation Assay of Antigen-Specific CD8+ T Cells

MV3 cells were harvested and washed with DPBS and 2×10 7 cells were resuspended in 250 μL C diluent of the PKH-26 Red Fluorescence Cell linker Kit (Sigma, Cat.-No. PKH26GL). 1 μL PKH26-Red-stain solution was diluted with 250 μL C diluent and added to the suspension of MV3 cells which were then incubated for 5 min at room temperature in the dark. This was followed by addition of 0.5 mL FBS and cells were incubated for 1 minute and washed once with T cell medium consisting of RPMI 1640 medium supplemented with 10% (v/v) FBS, 1% (v/v) GlutaMAX-I, 1 mM Sodium-Pyruvate, 1% (v/v) MEM non-essential amino acids and 50 μM β-Mercaptoethanol. 1×10 6 MV3 cells/mL were resuspended in T cell medium and separated into three tubes. Synthetic NLVPMVATV peptide (SEQ ID NO: 377) (obtained from thinkpeptides) was added to a final concentration of 1×10 −9 M or 1×10 −8 M and cells were incubated for 90 min. MV3 cells were washed once with T cell medium and resuspended to a density of 0.5×10 6 cells/mL, distributed (100 μL/well) to a 96-well round bottom cell-suspension plate (Greiner bio-one, cellstar, Cat.-No. 650185) and incubated over night at 37° C. and 5% CO 2 . The principle of the assay is shown in FIGS. 21A and 21B .

The next day, 50 μL/well T cell medium containing different titrated concentrations of targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules were added. NLV-specific CD8 T cells were harvested, CFDA-SE (5(6)-Carboxyfluoresceindiacetate-N-succinimidylester, SIGMA-Aldrich, Cat.-No. 21888-25MG-F) was added to a final concentration of 40 nM and cells were incubated under rotation for 15 min at 37° C. Labeling was stopped by adding FBS, cells were washed and resuspended in T cell medium to a final concentration of 0.125×10 6 cells/mL. 50 μL of this CFSE-labeled CD8 T cell suspension were added to each well (final E:T ratio=1:8). Cell plates were incubated for 24 h, 50 μL/well were removed and 50 μL T cell medium containing 2.64 μL/mL Golgi stop (Protein Transport Inhibitor containing Monesin, BD Bioscience, Cat.-No. 554724) were added to each well (final concentration 0.66 μL/mL). Cells were incubated for 4 h and then plates were washed with 200 μL/well DPBS and stained with 100 μL/well 4° C. DPBS containing 1:5000 diluted Fixable Viability Dye-eF450 (eBioscience, Cat.-No. 65-0864) for 30 minutes at 4° C. Cell plates were washed with 200 μL/well DPBS followed by staining with fluorescent dye-conjugated antibodies: anti-human CD137-PerCP/Cy5.5 (clone 4B4-1, mouse IgG1κ, BioLegend, Cat.-No. 309814), anti-human CD8-BV605 (clone RPA-T8, mouse IgG1κ, BioLegend, Cat.-No. 301012) or 0.67 μg/mL anti-human CD8a-APC/Cy7 (clone RPA-T8, mouse IgG1κ, BioLegend, Cat.-No. 301016) and anti-human CD25 PE/Cy7 (clone BC96, mouse IgG1κ, BioLegend, Cat.-No. 302612). After incubation for 30 min at 4° C., cells were washed twice with 200 μL/well FACS buffer, resuspended in 50 μL/well freshly prepared FoxP3 Fix/Perm buffer (eBioscience Cat.-No. 00-5123 and 00-5223) and incubated for 30 min at 4° C. Plates were washed twice with 200 μL/well Perm-Buffer (DPBS supplied with 2% (v/v) FBS, 1% (w/v) saponin (Sigma Life Science, 57900) and 1% (w/v) sodium azide (Sigma-Aldrich, 52002) and stained with 50 μL/well Perm-Buffer (eBioscience, Cat.-No. 00-8333-56) containing 0.25 μg/mL anti-human IFNγ-APC (clone B27, mouse IgG1κ, BioLegend, Cat.-No. 506510) or 0.33 μg/mL anti-human IFNγ-BV510 (clone 4S.B3, mouse IgG1κ, BioLegend, Cat.-No. 502543). Plates were incubated for 1 h at 4° C. and washed twice with 200 μL/well Perm-Buffer. For fixation, 50 μL/well DPBS containing 1% formaldehyde were added. The same or the next day, cells were resuspended in 100 μL/well FACS buffer and acquired using a 5-laser FORTESSA® flow cytometer (BD Bioscience with DIVA software) or 3-laser Miltenyi Quant Analyzer 10 (Miltenyi Biotec) and Flow Jo (FlowJo X 10.0.7).

As shown in FIGS. 22A-1 to 22E-3 and FIGS. 23A-1 to 23E-3 for Constructs 1.1 to 1.10 and in FIGS. 24A-1 to 24B-3 and 25A-1 to 25B-3 for Constructs 2.1, 2.3 and 2.4, antigen-specific CD8+ T cells, but not unstimulated controls, exhibited increased levels of surface 4-1BB expression in the presence of FAP-targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecule (FAP split 4-1BBL trimer). This effect of 4-1BBL was dose dependent and required FAP-targeting as addition of the untargeted control molecule did not affect the level of 4-1BB expression. Furthermore, T-cells activated at the higher peptide concentration (1×10 −8 M) showed sustained secretion of INFγ in the presence of FAP-targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecule (FAP split 4-1BBL trimer). Collectively, these data demonstrate that the antigen-targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecule modulates the surface phenotype and responsiveness of antigen specific T-cells in a targeting dependent manner.

6.4 Comparison of Cell-Targeted and Untargeted Mouse 4-1BBL Fc Fusion Antigen Binding Molecules

Targeted and untargeted mouse 4-1BB ligand trimer-containing Fc fusion antigen binding molecules (FAP split mouse 4-1BBL trimer and DP47 split mouse 4-1BBL trimer) were prepared as described in Example 1.3.

To compare the bioactivity of cell-targeted and untargeted mouse 4-1BB ligand trimer-containing Fc fusion antigen binding molecules, Proliferation Dye EFLUOR® 670-labeled (eBioscience, Cat.-No. 65-0840-90) or CellTrace Violet Cell Proliferation dye-labeled (Cell tracer, Cat.-No. C34557) fresh mouse splenocytes were cocultured for 3-4 days in 96 well tissue culture U-bottom plates (TTP, Cat.-No. 92097) with adherent 50 Gy irradiated NIH/3T3-huFAP clone 39 cells (generation see 5.3) in RPMI 1640 medium (Gibco, Cat.-No. 42401-042) supplied with 10% (v/v) FBS, 1% (v/v) GlutaMAX-I, 1 mM Sodium-Pyruvate, 1% (v/v) MEM non-essential amino acids and 50 μM β-Mercaptoethanolin the presence of 0.5 μg/mL anti-mouse CD3 Syrian hamster IgG (clone 145-2C11, BD, Cat.-No. 553057) and the indicated drug candidate molecule added at a range of concentrations ( FIGS. 26A and 26B ). After three or four days, cells were washed with FACS buffer and stained for 30 min at 4° C. in 25 uL FACS buffer/well containing anti-mouse CD8 ratIgG2a-BV711 (BioLegend, Cat.-No. 100747, clone 53-6.7,) and anti-mouse CD4 ratIgG2a-BV421 (BioLegend, Cat.-No. 100544, clone RM4-5) and 0.67 μg/mL anti-mouse CD137 (4-1BB) Syrian hamster IgG-PE (BioLegend, Cat.-No. 106106, clone 17B5) and anti-mouse CD25-PErCP-Cy5.5 ratIgG2b (BioLegend, Cat.-No. 1019112). Cells were washed and incubated for 1 h at room temperature in prepared Fix/Perm Buffer (Foxp3/Transcription Factor Staining Buffer Set, eBioscience, Cat.-Ni. 00-5523-00). Cells were washed twice with freshly prepared Perm buffer and co-stained with 25 μL/well Perm-buffer containing fluorescently-labeled antibodies against the cytotoxic lineage transcription factor Eomes, i.e. anti-mouse Eomes ratIgG2a-ALEXA FLUOR® 488 (eBioscience, Cat.-No. 534875, clone Dan1 1mag) and—if CD137 was not stained—against the cytotoxic effector molecule granzyme B, i.e. anti-mouse ratIgG2a granzyme B-PE (eBioscience, Cat.-No. 128822, clone 16G6) for 1 h at room temperature. Cells were then washed twice, resuspended in FACS buffer and acquired using laser FORTESSA® flow cytometer (BD Bioscience with DIVA software) or the 3-laser MACSQuant Analyzer 10 (Miltenyi Biotech) and Flow Jo v10.0.7 (FlowJo LLC). Gates were set on living CD8+ T cells and CD4+ T cells and the frequency of proliferating cells was determined as well as the expression levels of CD25, Eomes and granzyme B or CD137. The proliferation frequency and frequencys and MFIs of activation markers were blotted against the concentration of used mouse 4-1BB ligand trimer-containing Fc(kih) fusion molecules to display the functional activity. As can be seen in FIG. 27 , an increase in proliferating CD8+ T cells could be observed for Constructs M.1 and M.2.

›Example 6 · 4 of 5

6.5 Liver Changes in Mice Treated with Anti-Murine 4-1BB Antibody Lob 12.3 (MmIgG1 Wt) or with Construct M.2

C57BL/6 mice bearing MC38-muFAP (murine colorectal cancer model) s.c. were treated once per week for 3 weeks with agonistic anti-murine 4-1BB antibodies targeted to FAP (Efficacy Study 020-GA1401: “Experiment to show efficacy of 4-1BB targeted therapy in combination with a-PD-L1 in MC38-muFAP s.c. model in C57B6 mice.”). Antibodies used were Lob 12.3 muIgG1 Wt (with “wildtype” Fc, clone Lob 12.3 from BioXcell Catalog #: BE0169) or Construct M.2 with DAPG mutation (inactive Fc). The two antibodies were administered once weekly for three consecutive weeks. Four animals/group were sacrificed 7 days after last treatment and livers examined microscopically.

Liver changes were observed only in animals receiving Lob 12.3 muIgG1 Wt, consisting in foci of hepatocellular degeneration with accumulation of F4/80 positive macrophages and a lower amount of mixed population of inflammatory cells (mainly lymphocytes) frequently showing a vasocentric distribution. Occasionally single cell necrosis of hepatocytes, and perivascular mononuclear cell infiltrates in portal spaces were noted. No treatment related findings were observed in the liver of animals receiving Construct M.2 (Table 41).

Hepatitis, attributed to crosslinking by FcγRs in the liver, has been observed in patients treated with Urelumab BMS-663513 (Ascierto P. A. et al. 2010) and in mouse using the mouse surrogate. The absence of liver findings in animals treated with an antibody with inactive Fc support this hypothesis.

6.6 Determination of Pharmacokinetic Parameters of Human 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules

In order to test if the human 4-1BB ligand trimer-containing Fc fusion antigen binding molecules of the invention are suitable for pharmaceutical use, the pharmacokinetic parameters (PK data) such as clearance, volume of distribution or elimination half-time (t 1/2 ) in mice were determined. Thus, the following experiments were carried out:

Experiment A: Single Dose PK of Construct 1.2 and Control B in Healthy NOG Mice

NOG female mice at an average age of 8 to 10 weeks at start of experiment (purchased from Taconic, SOPF facility) were maintained under specific-pathogen-free condition with daily cycles of 12 h light/12 h darkness according to committed guidelines (GV-Solas; Felasa; TierschG). Experimental study protocol was reviewed and approved by local government (P 2011128). After arrival animals were maintained for one week to get accustomed to new environment and for observation. Continuous health monitoring was carried out on regular basis.

A single dose pharmacokinetic study (SDPK) was performed to evaluate exposure of Construct 1.2 and Control B. An i.v. bolus administration of 2.5 mg/kg was administered to NOG mice and blood samples were taken at selected time points for pharmacokinetic evaluation. Mouse serum samples were analyzed by ELISA. Biotinylated human 4-1BB, test samples, Digoxygenin labelled anti-huCH1 antibody and anti-Digoxygenin detection antibody (POD) were added stepwise to a 96-well streptavidin-coated microtiter plate and incubated after every step for 1 h at room temperature. The plate was washed three times after each step to remove unbound substances. Finally, the peroxidase-bound complex was visualized by adding ABTS substrate solution to form a colored reaction product. The reaction product intensity which was photometrically determined at 405 nm (with reference wavelength at 490 nm) is proportional to the analyte concentration in the serum sample. The calibration range of the standard curve for the constructs was 0.156 to 10 ng/ml, where 3 ng/ml is the lower limit of quantification (LLOQ). FIG. 28A shows the decrease in concentration over the time as observed in this experiment.

Experiment B: Single Dose PK of Constructs 2.1, 2.3, Control B and Control C in Tumor Bearing NOG Mice Humaniced with Stem Cells

A single dose pharmacokinetic study (SDPK) was performed to evaluate exposure of Construct 2.1, 2.3, Control B and Control C. NSG female mice transferred with human stem cells were delivered by Jackson Laboratories. Mice were maintained under specific-pathogen-free condition with daily cycles of 12 h light/12 h darkness according to committed guidelines (GV-Solas; Felasa; TierschG). Experimental study protocol was reviewed and approved by local government (ZH193-2014). After arrival animals were maintained for one week to get accustomed to new environment and for observation. Continuous health monitoring was carried out on regular basis.

Human MKN45 cells (human gastric carcinoma) were originally obtained from ATCC and after expansion deposited in the Glycart internal cell bank. Cells were cultured in DMEM containing 10% FCS. Cells were cultured at 37° C. in a water-saturated atmosphere at 5% C 0 2. In vitro passage 9 was used for subcutaneous injection, at a viability of 97%. Human fibroblasts NIH-3T3 were engineered at Roche Nutley to express human FAP. Clone 39 was used at an in vitro passage number 12 and at a viability of 98%. 50 microliters cell suspension (1×106 MKN45 cells+1×106 3T3-huFAP) mixed with 50 microliters Matrigel were injected subcutaneously in the flank of anaesthetized mice. An i.v. bolus administration of 10 mg/kg was administered to humaniced mice when tumor reached an average size of 190 mm 3 . Blood samples were taken at selected time points for pharmacokinetic evaluation. Mouse serum samples were analyzed by ELISA. Biotinylated human 4-1BB, test samples, Digoxygenin labelled anti-huCH1 antibody and anti-Digoxygenin detection antibody (POD) were added stepwise to a 96-well streptavidin-coated microtiter plate and incubated after every step for 1 h at room temperature. The plate was washed three times after each step to remove unbound substances. Finally, the peroxidase-bound complex is visualized by adding ABTS substrate solution to form a colored reaction product. The reaction product intensity which was photometrically determined at 405 nm (with reference wavelength at 490 nm) is proportional to the analyte concentration in the serum sample. The calibration range of the standard curve for the constructs was 0.156 to 10 ng/ml, where 3 ng/ml is the lower limit of quantification (LLOQ). FIG. 28B shows the decrease in concentration of the constructs over the time as observed in this experiment.

›Example 6 · 5 of 5

Experiment C: Single Dose PK of Construct 2.1 and 2.3 in Healthy NOG Mice

NOG female mice at an average ager of 8-10 weeks at start of experiment (purchased from Taconic, SOPF facility) were maintained under specific-pathogen-free condition with daily cycles of 12 h light/12 h darkness according to committed guidelines (GV-Solas; Felasa; TierschG). Experimental study protocol was reviewed and approved by local government (P 2011128). After arrival animals were maintained for one week to get accustomed to new environment and for observation. Continuous health monitoring was carried out on regular basis.

A single dose pharmacokinetic study (SDPK) was performed to evaluate exposure of Construct 2.1 and 2.3. An i.v. bolus administration of 2.5 mg/kg was administered to NOG mice and blood samples were taken at selected time points for pharmacokinetic evaluation. Mouse serum samples were analyzed by ELISA. Biotinylated human 4-1BB, test samples, Digoxygenin labelled anti-huCH1 antibody and anti-Digoxygenin detection antibody (POD) were added stepwise to a 96-well streptavidin-coated microtiter plate and incubated after every step for 1 h at room temperature. The plate is washed three times after each step to remove unbound substances. Finally, the peroxidase-bound complex is visualized by adding ABTS substrate solution to form a colored reaction product. The reaction product intensity, which is photometrically determined at 405 nm (with reference wavelength at 490 nm), is proportional to the analyte concentration in the serum sample. The calibration range of the standard curve for the constructs was 0.156 to 10 ng/ml, where 3 ng/ml is the lower limit of quantification (LLOQ). FIG. 28C shows the observed decrease in concentration over the time.

The tested constructs 2.1 and 2.3 are stable enough in the body and possess PK parameters in a suitable range for pharmaceutical development. It can also be concluded from the results that construct 2.1 is slightly more stable.

6.7 FAP Prevalence in Human Tumors

The prevalence of FAP in human tumors was evaluated as described in WO 2014/161845 to get an understanding on possible clinical use of FAP-targeted constructs.

Rat anti-human Seprase antibody (IgG2a, clone D8) from Vitatex (MABS1001) was used to immunostain 2,5 μm FFPET sections from various tumour indications on the Ventana Benchmark XT. Sections were subjected to standard CC1 treatment followed by antibody incubation for 60′ at 37° C. at a concentration of 5 μg/mL in Dako antibody diluent (S3022) and positive staining was detected using the Ultraview DAB detection system (Ventana #760-4456). Matched isotype antibody from Abcam (ab18450) was used as the negative control. FAP+ stromal infiltrate was present in human tumors of different indications including head and neck squamous cell carcinoma (HNSCC), breast cancer, colorectal cancer (CRC), pancreatic cancer (PAC), gastric cancer, non-small-cell lung carcinoma (NSCLC) and Mesothelioma marking potentially interesting clinical indications for a FAP-targeted constructs (Table 42).

›Example 7 · 1 of 8

7.1 Preparation of CD19 (8B8-018) Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules

7.1.1 Preparation, Purification and Characterization of CD19 Antigen Fc Fusion for Phage Display Campaign

In order to express and purify the human and cynomolgus CD19 ectodomain in a monomeric state (human CD19 see SEQ ID NO:31), the respective DNA fragment was fused to a human IgG1 Fc gene segment containing the “knob” mutations (human: SEQ ID NO: 186; cynomolgus: SEQ ID NO: 188) and was transfected with an “Fc-hole” (SEQ ID NO: 86) counterpart (Merchant et al., 1998). An IgA cleavage site (PTPPTP; SEQ ID NO: 378) was introduced between an antigen ectodomain and the Fc knob chain. An Avi tag for directed biotinylation was introduced at the C-terminus of the antigen-Fc knob chain and mutations H435R and Y436F were introduced in the Fc hole for purification purposes (Jendeberg L. et al, J. Immunological methods, 1997). Combination of the antigen-Fc knob chain containing the S354C/T366W mutations (human: SEQ ID NO: 187; cynomolgus: SEQ ID NO: 189), with a Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations (SEQ ID NO: 90) allows generation of a heterodimeric Fc fusion fragment which includes a single copy of the CD19 ectodomain (in analogy to the 4-1BB construct in FIG. 5C ). Table 43 lists the cDNA and amino acid sequences of the antigen Fc-fusion construct.

For the production of the monomeric antigen/Fc fusion molecules, exponentially growing suspension CHO cells were co-transfected with two plasmids encoding the two components of fusion protein (knob and hole chains) using standard methods.

Secreted protein was purified from cell culture supernatant by affinity chromatography using Protein A, followed by size exclusion chromatography. For affinity chromatography, the supernatant was loaded on a MABSELECT SURE® column volume (CV)=5-15 mL, resin from GE Healthcare) equilibrated with Sodium Phosphate (20 mM), Sodium Citrate (20 mM), 0.5M sodium chloride buffer (pH 7.5). Unbound protein was removed by washing with at least 6 column volumes of the same buffer. The bound protein was eluted using a linear gradient; step 1, 10 CV from 0 to 60% elution buffer (20 mM sodium citrate, 500 mM Sodium chloride buffer (pH 2.5)); step 2, 2 CV from 60 to 100% elution buffer. For the linear gradient an additional 2 column volumes step elution with 100% elution buffer was applied.

Table 44 summarizes the yield and final monomer content of monomeric human and cynomolgus CD19 antigen Fc(kih) fusion protein.

Part of the purified antigen was in vitro biotinylated using the BirA biotin-protein ligase standard reaction kit (Avidity, Cat. #BirA500) according to the manufacturer's instructions. The biotinylation degree for the human CD19-containing fusion was 94%, for the respective cynomolgus CD19 construct 100%. The biotinylated protein was then used for selection, screening and characterization of affinity-matured 8B8-derived clones devoid of the de-amidation hotspots N27d and N28.

7.1.2 Generation of Anti-CD19 Clone 8B8-018

7.1.2.1 Immunization and Generation of Mouse Anti-Human CD19 Antibodies (Hybridomas)

Balb/c mice were immunized six times and boosted with CD19-transfected HEK293 cells (mean receptor density 35,000 per cell). The immune response was monitored by testing serum samples with a CD19-cell-ELISA on human CD19-transfected NIH-3T3 cells. Spleen cells from mice with sufficient titers of anti-human CD19 antibody were used for immortalization by fusion with mouse myeloma cell line P3X63 Ag8.653. Three fusions were carried out and hybridoma supernatants screened by cell-ELISA on human CD19-transfected NIH-3T3 cells and FACS binding assay using Daudi (CD19+) and CD19-cells for anti-human CD19 specific antibodies (see Example 1 of WO 2011/147834).

7.1.2.2 Hybridoma Screening and Cell Biological Functional Evaluation of Anti-CD19 Antibody

Cell-ELISA for Screening Antibodies Against Human CD19

A cell ELISA was applied for screening of hybridomas, and to identify those hybridomas that secrete antibodies against human-CD19. NIH3T3 cells transfected with human-CD19 were used as positive cells; non-transfected NIH3T3 cells were used as negative control cells. For the assessment of the positive hybridomas the OD ratio between transfected and non-transfected NIH3T3 cells was quantified.

Culture Medium: DMEM high glucose (4.5 mg/ml), 10% FCS, Na-Pyruvate, NEAA, Glutamine Antibodies positive control: anti CD19 monoclonal antibody (IgG1) Pharmingen Cat #555409 c=1 mg/ml Detection antibody: Goat anti-Mouse IgG (H+L) HRP Conjugate Bio-Rad Cat #170-06516 Dilution 1:2000 in 1×ELISA Blocking Reagent Other reagents: Fibronectin Roche Cat #838039 c=1 mg/ml Glutardialdehyde: 25% stock solution//Grade Agar Scientific #R102 final concentration:

0.05% in PBS

ELISA Blocking Reagent: 10×stock solution//Roche Cat #1112589 TMB substrate: Roche Cat #11432559 Stop Solution: 1 M H2SO4 BioRad Cat #170-6516 Dilution 1:2000 in 1×ELISA Blocking Reagent

Day 1:

Fibronectin coating: 5 μg/cm 2 in PBS; 96 well plate=32 cm 2 ; 160 μg/plate in 6 ml PBS, 50 μL/well incubate 45 min at RT, aspirate coating solution Seed 1.25×104 cells/well in 50 μl culture medium in a 96 well plate incubate 40 hours at 37° C. add to upper half of the plate: NIH3T3 cells expressing CD19 add to lower half of the plate: non-transfected NIH3T3 cells

Day 3:

Addition of positive control antibody or samples (supernatant or mouse serum) in 50 μl culture medium incubate for 2 h at 4° C. Remove medium, fix cells with 100 μl Glutardialdehyde (0.05% in PBS) Wash two times with 200 μl PBS Addition of detection antibody 1:2000, 50 μl/well incubate 2 h at RT wash three times with 200 μl PBS add 50 μl TMB, incubate for 30 min. at RT, stop by addition of 25 μl 1 M H2SO4; read extinction at 450 nm/620 nm Calculation of results: ratio OD NIH3T3 CD19: OD NIH3T3 non-transfected

›Example 7 · 2 of 8

The selected antibody demonstrated specific binding to CD19 transfected NIH3T3 cells as compared to untransfected NIH3T3 cells (see Example 2 of WO 2011/147834).

7.1.2.3 Humanization of Anti-CD19 Antibody

The CD19 binding specificity of the murine antibody was transferred onto a human acceptor framework to eliminate potential immunogenicity issues arising from sequence stretches that the human body will recognize as foreign. This was done by engrafting the entire complementary determining regions (CDR) of the murine (donor) antibody onto a human (acceptor) antibody framework, and is called CDR-grafting or antibody humanization.

The murine amino acid sequence was aligned with a collection of human germ-line antibody V genes, and sorted according to sequence identity and homology. Before selecting one particular acceptor sequence, the so-called canonical loop structures of the donor antibody have to be determined (Morea, V., et al., Methods, Vol 20, Issue 3 (2000) 267-279). These canonical loop structures are determined by the type of residues present at the so-called canonical positions. These positions lie (partially) outside of the CDR regions, and have to be kept functionally equivalent in the final construct in order to retain the CDR conformation of the parental (donor) antibody. The human germ-line sequence VBASE_VH1_1 was chosen as the acceptor for the heavy chain and sequence VBASE_VK2_5 was chosen for the light chain.

7.1.2.4 Removal of Deamidation Hotspots

It has been found that the wild-type humanized anti-human CD19 antibody has three deamidation hotspots in the HVR-L1: N S N G N T (SEQ ID NO: 190). Additionally it has been found that in the HVR-H2 a further deamidation hotspot is present: KF N G (SEQ ID NO: 191). To address the deamidation hotspot in the HVR-H2 an N (Asn) to Q (Gln) point mutation at position 64 (numbering according to Kabat) has been introduced. Thus, the antibody as reported herein has a HVR-H2 comprising the amino acid sequence TEKFQGRVTM (SEQ ID NO: 192).

To address the deamidation hotspots in the light chain and to obtain a humanized anti-human CD19 antibody with improved deamidation stability individual mutations at Kabat position 27d, 27e, 28 and 29 and a double mutation at positions 27e and 28 (numbering according to Kabat) were introduced. In total 9 variants (var.1 to var.9) of the wild-type humanized antibody (var.0) have been generated (see Table 45A and Table 45B).

It has been found that with a single mutation at position 27e according to Kabat from S (serine) to P (proline) all deamidation hotspots in the HVR-L1 can be addressed. This is a mutation not of the deamidation prone N (asparagine) residue but of a neighboring residue.

Thus, the antibody as reported herein has a HVR-L1 comprising the amino acid sequence LENPNGNT (SEQ ID NO: 193). In one embodiment the humanized anti-human CD19 antibody comprises a HVR-L1 that has the amino acid sequence LENPSGNT (SEQ ID NO: 194).

Additionally these antibodies maintain the cross-reactivity to cynomolgus CD19 as shown in the following Table 46.

The wild-type humanized anti-human CD19 antibody (var.0) shows after purification approx. 7.5% deamidation. After storage for two weeks at pH 7.4 the amount of deamidated antibody is increased to approx. 18.5%. The variant antibody with an S27eP mutation (var.5) shows approx. 2% deamidation and 2% succinimide formation after purification. During storage at pH 7.4 for two weeks only approx. 7.5% deamidated antibody is present. Var. 5 is named clone 8B8-018 and was elected for the preparation of CD19-targeted TNF family ligand trimer-containing antigen binding molecules.

7.1.3 Preparation of Monovalent CD19(8B8-018) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains with Charged Residues (Construct 3.1)

A polypeptide containing two ectodomains of 4-1BB ligand (71-254), separated by (G 4 S) 2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CL domain, was cloned as depicted in FIG. 29A : human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human CL. A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the human IgG1-CH domain, was cloned as described in FIG. 29B : human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human CH.

The polypeptide encoding the dimeric 4-1BB ligand fused to human CL domain was subcloned in frame with the human IgG1 heavy chain CH2 and CH3 domains on the knob (Merchant, Zhu et al. 1998). To improve correct pairing the following mutations have been introduced in the crossed CH-CL. In the dimeric 4-1BB ligand fused to human CL, E123R and Q124K. In the monomeric 4-1BB ligand fused to human CH1, K147E and K213E.

Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-CD19-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-CD19 light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a CD19 binding Fab ( FIG. 30A , Construct 3.1).

Table 47 shows the cDNA and amino acid sequences of the monovalent CD19(8B8-018) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule with crossed CH-CL and charged residues (construct 3.1).

7.1.4 Preparation of Monovalent CD19(8B8-018) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains without Charged Residues (Construct 3.2)

›Example 7 · 3 of 8

A polypeptide containing two ectodomains of 4-1BB ligand (71-254), separated by (G 4 S) 2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CL domain, was cloned in analogy as depicted in FIG. 29A , but without amino acid mutations in the CL domain: human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human CL. A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the human IgG1-CH1 domain, was cloned in analogy as depicted in FIG. 29B , but without amino acid mutations in the CH1 domain: human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human CH1.

The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831. Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-CD19-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-CD19 light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a CD19-binding Fab ( FIG. 30B , Construct 3.2).

Table 48 shows the cDNA and amino acid sequences of the monovalent CD19(8B8-018) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule containing crossed CH-CL cross without charged residues (construct 3.2).

7.1.5 Preparation of Bivalent CD19(8B8-018) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding (Construct 3.3)

A polypeptide containing two ectodomains of 4-1BB ligand (71-254), separated by (G 4 S) 2 (SEQ ID NO:13) linkers was fused to the C-terminus of human IgG1 Fc hole chain, as depicted in FIG. 29C : human IgG1 Fc hole, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand. A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the C-terminus of human IgG1 Fc knob chain as described in FIG. 29D : human IgG1 Fc knob, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand.

The variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-018, were subcloned in frame with either the constant heavy chain of the hole, the knob or the constant light chain of human IgG1. The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831. Combination of the anti-CD19 huIgG1 hole dimeric ligand chain containing the Y349C/T366S/L368A/Y407V mutations, the anti-CD19 huIgG1 knob monomeric ligand chain containing the S354C/T366W mutations and the anti-CD19 light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and two CD19 binding Fabs ( FIG. 30C , construct 3.3).

Table 49 shows the cDNA and amino acid sequences of the bivalent CD19(8B8-018) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule (construct 3.3).

7.1.6 Preparation of Monovalent CD19 (8B8-018) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains with Charged Residues (Construct 3.4)

A polypeptide containing two ectodomains of 4-1BB ligand (71-248), separated by (G 4 S) 2 (SEQ ID NO: 13) linkers, and fused to the human IgG1-CL domain, was cloned in analogy to the one depicted in FIG. 29A : human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human CL. A polypeptide containing one ectodomain of 4-1BB ligand (71-248) and fused to the human IgG1-CH domain, was cloned in nalogy to the one described in FIG. 29B : human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human CH.

The polypeptide encoding the dimeric 4-1BB ligand fused to human CL domain was subcloned in frame with the human IgG1 heavy chain CH2 and CH3 domains on the knob (Merchant, Zhu et al. 1998). To improve correct pairing the following mutations have been introduced in the crossed CH-CL. In the dimeric 4-1BB ligand fused to human CL, E123R and Q124K. In the monomeric 4-1BB ligand fused to human CH1, K147E and K213E.

The variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-018, were subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1. The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831. Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-CD19-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-CD19 light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a CD19 binding Fab ( FIG. 30D , construct 3.4).

Table 50 shows the cDNA and amino acid sequences of the monovalent CD19(8B8-018) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule with crossed CH-CL and charged residues (construct 3.4).

7.1.7 Preparation of Monovalent CD19(8B8-018) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains without Charged Residues (Construct 3.5)

A polypeptide containing two ectodomains of 4-1BB ligand (71-248), separated by (G 4 S) 2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CL domain, was cloned in analogy as depicted in FIG. 29A , but without amino acid mutations in the CL domain: human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human CL. A polypeptide containing one ectodomain of 4-1BB ligand (71-248) and fused to the human IgG1-CH1 domain, was cloned in analogy as depicted in FIG. 29B , but without amino acid mutations in the CH1 domain: human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human CH1.

›Example 7 · 4 of 8

The variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-018, were subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1. The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831. Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-CD19-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-CD19 light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a CD19-binding Fab ( FIG. 30E , Construct 3.5).

Table 51 shows the cDNA and amino acid sequences of the monovalent CD19(8B8-018) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule containing crossed CH-CL cross without charged residues (construct 3.5).

7.1.8 Preparation of Bivalent CD19(8B8-018) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding (Construct 3.6)

A polypeptide containing two ectodomains of 4-1BB ligand (71-248), separated by (G 4 S) 2 (SEQ ID NO:13) linkers was fused to the C-terminus of human IgG1 Fc hole chain, as depicted in FIG. 29C : human IgG1 Fc hole, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand. A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the C-terminus of human IgG1 Fc knob chain as described in FIG. 29D : human IgG1 Fc knob, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand.

Table 52 shows the cDNA and amino acid sequences of the bivalent CD19(8B8-018) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule (construct 3.6).

7.2 Preparation of CD19 (8B8-Derived Affinity Matured) Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules and Corresponding Control Molecules

7.2.1 Generation of 8B8-Derived Affinity-Matured Anti-CD19 Binders Devoid of Hotspots

7.2.1.1 Selection of Affinity Matured CD19-Specific Antibodies

De-amidation of the asparagine residues at positions 27d and 28, located in CDR1 of the light chain of the humanized clone 8B8, leads to a significant reduction in the biological activity. Therefore, 2 phage display libraries were generated in which a) both asparagine residues at positions 27d and 28 were eliminated and b) additional CDRs of heavy and light chain were randomized in order to select for 8B8 variants with an improved affinity.

7.2.1.2 Generation of 8B8 affinity maturation libraries devoid of LCDR1 hotspots

Generation of affinity-matured 8B8-derived antibodies without the de-amidation sites N27d and N28, located in LCDR1, was carried out by phage display using standard protocols (Silacci et al, 2005). In a first step, the VL and VH DNA sequences of the humanized parental clone 8B8 (SEQ ID NO: 215 and SEQ ID NO: 216) were cloned into our phagemid which was then used as a template for randomization. In a next step, two libraries were generated for the selection of favourable clones by phage display. In order to eliminate the above-mentioned hotspot positions, a LCDR1 randomization primer (SEQ ID NO: 217) that only allowed amino acids S T Q E at positions 27d and 28 was used for both libraries. Maturation library 1 was randomized in CDR1 and 2 of both the light and the heavy chain, while maturation library 2 was randomized in CDR1 and 3 of the light chain and in CDR3 of the heavy chain. The randomized positions in the respective CDR regions are shown in FIGS. 31A-1 to 31A-2 . For the generation of the maturation library 1, randomized in CDR1 and 2 of both the light and the heavy chain, three fragments were assembled by “splicing by overlapping extension” (SOE) PCR and cloned into the phage vector ( FIGS. 31B-1 to 31B-2 ). The following primer combinations were used to generate the library fragments: fragment 1 (LMB3 (SEQ ID NO: 222) and CD19 L1 reverse random (SEQ ID NO: 217), fragment 2 (CD19 L2 forward random (SEQ ID NO: 218) and CD19 H1 reverse random (SEQ ID NO: 219), and fragment 3 (CD19 H2 forward random (SEQ ID NO: 220) and CD19 H3 reverse constant (SEQ ID NO: 221) (Table 53). After assembly of sufficient amounts of full length randomized fragment, it was digested with NcoI/NheI alongside with identically treated acceptor phagemid vector. A 3-fold molar excess of library insert was ligated with 10 μg of phagemid vector. Purified ligations were used for 20 transformations resulting in 2×10 exp9 transformants. Phagemid particles displaying the 8B8 affinity maturation library were rescued and purified by PEG/NaCl purification to be used for selections.

The generation of the second library, randomized in CDR1 and 3 of the light chain and in CDR3 of the heavy chain, was done similarly. The following primer combinations were used to generate the library fragments: fragment 1 (LMB3 (SEQ ID NO: 222) and CD19 L1 reverse random (SEQ ID NO: 217), fragment 2 (CD19 L1 forward constant (SEQ ID NO 223) and CD19 L3 reverse random (SEQ ID NO 224), and fragment 3 (CD19 L3 forward constant (SEQ ID NO: 225) and CD19 H3 reverse random (SEQ ID NO: 226) (Table 54). After assembly of sufficient amounts of full length randomized fragment, it was digested with NcoI/KpnI alongside with identically treated acceptor phagemid vector. A 3-fold molar excess of library insert was ligated with 20 ug of phagemid vector. Purified ligations were used for 40 transformations resulting in 2×10 exp9 transformants. Phagemid particles displaying the 8B8 affinity maturation library were rescued and purified by PEG/NaCl purification to be used for selections.

›Example 7 · 5 of 8

7.2.1.3 Selection of Affinity Matured 8B8-Derived Clones Devoid of LCDR1 Hotspots N27d and N28

For the selection of affinity-matured clones devoid of the LCDR1 hotspots N27d and N28, two selection approaches by phage display were performed:

In the first approach, the selection was executed on human CD19-Fc fusion protein using both phage display libraries. Panning rounds were performed in solution according to the following pattern: 1. binding of ˜10 12 phagemid particles to 30 nM biotinylated CD19-Fc protein for 0.5 h in a total volume of 1 ml, 2. capture of biotinylated CD19-Fc protein and specifically bound phage particles by addition of 5.4×10 7 streptavidin-coated magnetic beads for 10 min, 3. washing of beads using 5×1 ml PBS/TWEEN® 20 (polysorbate 20) and 5×1 ml PBS, 4. elution of phage particles by addition of 1 ml 100 mM TEA for 10 min and neutralization by adding 500 ul M Tris/HCl pH 7.4, 5. re-infection of exponentially growing E. coli TG1 bacteria, and 6.infection with helperphage VCSM13 and subsequent PEG/NaCl precipitation of phagemid particles to be used in subsequent selection rounds. Selections were carried out over 3 rounds using decreasing antigen concentrations (30×10 −9 M, 10×10 −9 M, and 3×10 −9 M). In round 2 and 3, capture of antigen:phage complexes was performed using neutravidin plates instead of streptavidin beads. Neutravidin plates were washed with 5×PBS/TWEEN® 20 (polysorbate 20) and 5×PBS. In round 3, the neutravidin plate was incubated overnight in 2 liters PBS for an “off-rate” selection before phage was eluted from the plate. Furthermore, cynomolgus CD19-Fc protein was used in round 2 in order to enrich cross-reactive binders.

In the second selection approach, the phage panning was executed on cells transiently expressing either the human or cynomolgus CD19 ECD on the cell surface. For the transient transfection of HEK cells, expression plasmids were generated that harbor the DNA sequences (from 5′ to 3′) for the following protein segments: A Flag tag, a SNAP tag, the CD19 ECD of either human or cynomolgus origin, and the transmembrane region of the Platelet-derived growth factor receptor (PDGFR) (SEQ ID NOs: 227 and 228). The expression of the respective proteins (SEQ ID NOs: 229 and 230) on the cell surface was confirmed by flow cytometry using an anti-Flag antibody for detection. Both libraries were exposed in the first selection round to cells either expressing the human or cynomolgus CD19 ECD-containing protein fusion. For the subsequent panning rounds, the species of the CD19 ECD was alternated accordingly. Cells transiently transfected with an irrelevant membrane protein were used for pre-clearing.

Panning rounds were performed according to the following pattern:

1. Transfection of HEK cells with constructs expressing either CD19 ECD or an irrelevant transmembrane protein according to the standard procedure described before,

2. Incubation of the cells for total 48 h at 37° C. in an incubator with a 5% CO 2 atmosphere, 3. Isolation of cells by centrifugation (3 min at 250×g) and re-suspension of 1×10E7 CD19 ECD-positive cells and 1×10E7 negative cells in PBS/5% BSA, respectively,

3. Pre-clearing of unspecific phage by incubating the phage library with 1×107 CD19-negative cells for 60 min at 4° C. using a gently rotating tube rotator,

4. Centrifugation of cells at 250×g for 3 min and transfer of supernatant into a fresh tube and addition of 1×10E7 CD19-positive cells and incubation for 60 min at 4° C. by gentle rotation on a tube rotator,

5. Washing of cells by centrifugation for 1 min at 250×g, aspiration of the supernatant, and re-suspension in 1 ml PBS (8 times),

6. Phage elution with 1 ml 100 mM TEA, incubation for 5 min at RT, and neutralization of the eluate with 500 ul 1M Tris-HCl, pH7.6,

7. re-infection of exponentially growing E. coli TG1 bacteria, and

8.infection with helperphage VCSM13 and subsequent PEG/NaCl precipitation of phagemid particles to be used in subsequent selection rounds. Selections were carried out over 3 rounds.

For both selection approaches, specific binders were identified by ELISA as follows: 100 ul of 30 nM biotinylated CD19-Fc protein per well were coated on neutravidin plates. Fab-containing bacterial supernatants were added and binding Fabs were detected via their Flag-tags using an anti-Flag/HRP secondary antibody.

Clones that were ELISA-positive on recombinant human CD19 were further tested in a cell-based ELISA using cells that were transiently transfected with the human CD19 ECD-containing expression plasmid (SEQ ID NO: 227). This analysis was performed as follows: 48 h after transfection, HEK cells were harvested and centrifuged at 250×g for 5 min. Cells were then re suspended in ice-cold PBS BSA 2% to 4×10 6 cells/ml and incubated for 20 min on ice to block unspecific binding sites. 4×10 5 cells in 100 ul were distributed to each well of a 96 well plate and centrifuged at 250×g and 4° C. for 3 min. Supernatant was aspirated off and 50 ul bacterial supernatant containing soluble Fab fragments was diluted with 50 ul ice-cold PBS/BSA 2%, added to the plate, mixed with the cells and incubated for 1 h at 4° C. Afterwards, cells were washed 3 times with ice cold PBS before 100 ul PBS BSA 2% per well containing a 1:2000 dilution of anti-Fab-HRP antibody were added. After an incubation time of 1 h, cells were washed again 3 times with ice-cold PBS. For the development, 100 ul “1-step ultra TMB-ELISA” substrate was added per well. After an incubation time of 10 minutes, supernatant was transferred to a new 96-well plate containing 40 ul H2504 1M per well and absorbance was measured 450 nM. Clones exhibiting significant signals over background were subjected to a kinetic screening experiment by SPR-analysis using ProteOn XPR36.

7.2.1.4 Identification of Affinity-Matured 8B8-Derived Variants by SPR

In order to further characterize the ELISA-positive clones, the off-rate was measured by surface plasmon resonance and compared with the parental humanized clone 8B8.

›Example 7 · 6 of 8

For this experiment, 7000 RU of polyclonal anti-human Fab antibody were immobilized on all 6 channels of a GLM chip by Amine coupling (NaAcetate pH4.5, 25 μl/min, 240 s) (vertical orientation). Each antibody-containing bacterial supernatant was filtered and 2-fold diluted with PBS, and then injected for 360 s at 25 μl/minute to achieve immobilization levels of between 100 and 400 response units (RU) in vertical orientation. Injection of monomeric CD19-Fc: For one-shot kinetics measurements, injection direction was changed to horizontal orientation, three-fold dilution series of purified monomeric CD19-Fc (varying concentration ranges between 150 and 6 nM) were injected simultaneously at 50 μl/min along separate channels 1-4, with association times of 180 s, and dissociation times of 300 s. A human IgG Fc fragment (150 nM) was injected in channel 5 as a negative control for specific binding to monomeric CD19-Fc Buffer (PBST) was injected along the sixth channel to provide an “in-line” blank for referencing. Regeneration was performed by two pulses of 10 mM glycine pH 1.5 and 50 mM NaOH for 30 s at 90 ul/min (horizontal orientation). Dissociation rate constants (k off ) were calculated using a simple one-to-one Langmuir binding model in ProteOn Manager v3.1 software by simultaneously fitting the sensorgrams. Clones expressing Fabs with the slowest dissociation rate constants were identified (Table 55). Of note, the dissociation rate constants of clones 5A07 and 5B08 could not be determined due to inadequate fitting. Nevertheless, both clones were selected because results obtained suggested a very slow dissociation. The variable domains of the corresponding phagemids were sequenced. Importantly, both asparagine residue in LCDR1 (position 27d and 28) were replaced by a serine or a threonine, demonstrating that both de-amidation sites were removed. An alignment is shown in FIGS. 32A and 32B . The CDRs of the best clones are listed in Table 56 (variable regions of the light chain) and Table 57 (variable regions of the heavy chain) (clone 5H09: (SEQ ID NO:231-236); clone 7H07: (SEQ ID NO:237-242); clone 2B03: (SEQ ID NO: 243-248); clone 2B11: (SEQ ID NO:249-254); clone 5A07: (SEQ ID NO:255-260); clone 5B08: (SEQ ID NO:261-266); clone 5D08: (SEQ ID NO:267-272).

7.2.2 Characterization of Affinity-Matured 8B8-Derived Antibodies

7.2.2.1 Cloning of Variable Antibody Domains into Expression Vectors

The variable regions of heavy and light chain DNA sequences of the selected anti-CD19 binders were subcloned in frame with either the constant heavy chain or the constant light chain of human IgG1. In the heavy chain, Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in order to abrogate binding to Fc gamma receptors according to the method described in International Patent Appl. Publ. No. WO 2012/130831 A1.

The cDNA and amino acid sequences of the anti-CD19 IgGs are shown in Table 58 and Table 59, respectively. All antibody-encoding sequences were cloned into an expression vector, which drives transcription of the insert with a chimeric MPSV promoter and contains a synthetic polyA signal sequence located at the 3′ end of the CDS. In addition, the vector contains an EBV OriP sequence for episomal maintenance of the plasmid.

7.2.2.2 Affinity Determination of Selected Antibodies by SPR

For the exact determination of the affinities by SPR, the selected anti-CD19 antibodies were produced by co-transfecting HEK293-EBNA cells with the mammalian expression vectors using polyethylenimine. The cells were transfected with the corresponding expression vectors in a 1:1 ratio (“vector heavy chain”: “vector light chain”) according to the standard procedure. 7 days after transfection, the antibody titer in the supernatant was measured and all titers were equilibrated to 10 μg/ml.

The Affinity (K D ) of the parental antibody 8B8 as well as it derivatives was measured by SPR using a ProteOn XPR36 instrument (Biorad) at 25° C. 7000 RU of polyclonal anti-human Fab antibody were immobilized on all 6 channels of a GLM chip by Amine coupling (NaAcetate pH4.5, 25 ul/min, 240 s) (vertical orientation). Each antibody-containing HEK supernatant was filtered, diluted with PBST (10 mM phosphate, 150 mM sodium chloride pH 7.4, 0.005% Tween 20) to a concentration of 10 ug/ml, and then injected at a for 360 s at 25 μl/minute to achieve immobilization levels between 500 and 800 response units (RU) in vertical orientation. Injection of monomeric CD19-Fc: For one-shot kinetics measurements, injection direction was changed to horizontal orientation, three-fold dilution series of purified monomeric CD19-Fc (varying concentration ranges between 150 and 6 nM) were injected simultaneously at 50 μl/min along separate channels 1-4, with association times of 180 s, and dissociation times of 300 s. A human IgG Fc fragment (150 nM) was injected in channel 5 as a negative control for specific binding to monomeric CD19-Fc. Buffer (PBST) was injected along the sixth channel to provide an “in-line” blank for referencing. An overview of the respective sensorgrams is shown in FIGS. 33A-33H . Regeneration was performed by two pulses of 10 mM glycine pH 1.5 and 50 mM NaOH for 30 s at 90 ul/min (vertical orientation). Association rate constants (k on ) and dissociation rate constants (k off ) were calculated using a simple one-to-one Langmuir binding model in ProteOn Manager v3.1 software by simultaneously fitting the association and dissociation sensorgrams. The equilibrium dissociation constant (K D ) was calculated as the ratio k off /k on . A summary of the kinetic and thermodynamic data is shown in Table 60. The dissociation constant of all affinity-matured clones was improved compared to their parental clone 8B8.

7.2.2.3 Preparation and Purification of Anti-CD19 IgG1 P329G LALA

The selected anti-CD19 antibodies were produced by co-transfecting HEK293-EBNA cells with the mammalian expression vectors using polyethylenimine. The cells were transfected with the corresponding expression vectors in a 1:1 ratio (“vector heavy chain”: “vector light chain”).

›Example 7 · 7 of 8

For the production in 500 mL shake flasks, 400 million HEK293 EBNA cells were seeded 24 hours before transfection. Before the transfection, cells were centrifuged for 5 minutes at 210×g, and the supernatant was replaced by pre-warmed CD CHO medium. Expression vectors (200 μg of total DNA) were mixed in 20 mL CD CHO medium. After addition of 540 μL PEI, the solution was vortexed for 15 seconds and incubated for 10 minutes at room temperature. Afterwards, cells were mixed with the DNA/PEI solution, transferred to a 500 mL shake flask and incubated for 3 hours at 37° C. in an incubator with a 5% CO 2 atmosphere. After the incubation, 160 mL of F17 medium was added and cells were cultured for 24 hours. One day after transfection 1 mM valproic acid and 7% Feed with supplements were added. After culturing for 7 days, the supernatant was collected by centrifugation for 15 minutes at 210×g. The solution was sterile filtered (0.22 μm filter), supplemented with sodium azide to a final concentration of 0.01% (w/v), and kept at 4° C.

Purification of antibody molecules from cell culture supernatants was carried out by affinity chromatography using Protein A as described above for purification of antigen Fc fusions. The protein was concentrated and filtered prior to loading on a HILOAD® Superdex 200 column (GE Healthcare) equilibrated with 20 mM Histidine, 140 mM NaCl solution of pH 6.0.

The protein concentration of purified antibodies was determined by measuring the OD at 280 nm, using the molar extinction coefficient calculated on the basis of the amino acid sequence. Purity and molecular weight of the antibodies were analyzed by CE-SDS in the presence and absence of a reducing agent (Invitrogen, USA) using a LabChipGXII (Caliper). The aggregate content of antibody samples was analyzed using a TSKGEL® G3000 SW XL analytical size-exclusion column (Tosoh) equilibrated in a 25 mM K 2 HPO 4 , 125 mM NaCl, 200 mM L-Arginine Monohydrocloride, 0.02% (w/v) NaN 3 , pH 6.7 running buffer at 25° C. (Table 61).

For the preparation of bispecific constructs clone 2B11 was chosen because it lacks the three deamidation hotspots.

The DNA sequence encoding part of the ectodomain (amino acid 71-254 and 71-248) of human 4-1BB ligand was synthetized according to the P41273 sequence of Uniprot database.

7.2.3 Preparation of Monovalent CD19 (8B8-2B11) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains with Charged Residues (Construct 4.1)

The construct 4.1 was prepared as described for construct 3.1 ( FIG. 30A ), but using the variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-2B11.

Table 62 shows the cDNA and amino acid sequences of the monovalent CD19(8B8-2B11) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule with crossed CH-CL and charged residues (construct 4.1).

7.2.4 Preparation of Monovalent CD19(8B8-2B11) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains without Charged Residues (Construct 4.2)

The construct 4.2 was prepared as described for construct 3.2 ( FIG. 30B ), but using the variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-2B11.

Table 63 shows the cDNA and amino acid sequences of the monovalent CD19(8B8-2B11) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule containing crossed CH-CL cross without charged residues (construct 4.2).

7.2.5 Preparation of Bivalent CD19(8B8-2B11) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding (Construct 4.3)

The construct 4.3 was prepared as described for construct 3.3 ( FIG. 30C ), but using the variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-2B11.

Table 64 shows the cDNA and amino acid sequences of the bivalent CD19 (8B8-2B11) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule (construct 4.3).

7.2.6 Preparation of Monovalent CD19(8B8-2B11) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains with Charged Residues (Construct 4.4)

The construct 4.4 was prepared as described for construct 3.4 ( FIG. 30D ), but using the variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-2B11.

Table 65 shows the cDNA and amino acid sequences of the monovalent CD19(8B8-2B11) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule with crossed CH-CL and charged residues (construct 4.4).

7.2.7 Preparation of Monovalent CD19(8B8-2B11) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains without Charged Residues (Construct 4.5)

The construct 4.5 was prepared as described for construct 3.5 ( FIG. 30E ), but using the variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-2B11.

Table 66 shows the cDNA and amino acid sequences of the monovalent CD19(8B8-2B11) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule containing crossed CH-CL cross without charged residues (construct 4.5).

7.2.8 Preparation of Bivalent CD19(8B8-2B11) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding (Construct 4.6)

The construct 4.6 was prepared as described for construct 3.6 ( FIG. 30F ), but using the variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-2B11.

Table 67 shows the cDNA and amino acid sequences of the bivalent CD19(8B8-2B11) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule (construct 3.6).

7.3 Preparation of Untargeted Split Trimeric 4-1BB Ligand Fc Fusion and Human IgG as Control Molecules

7.3.1 Preparation of Untargeted Human 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules (Control Molecules)

›Example 7 · 8 of 8

These control molecules were prepared as described above for the CD19 targeted construct 3.1 (termed control B), 3.3 (termed control C), 3.4 (termed control D) and 3.5 (termed control E) with the only difference that the anti-CD19 binder (VH-VL) was replaced by a germline control, termed DP47, not binding to the antigen (see FIGS. 30A-F ).

Table 68 shows, respectively, the cDNA and amino acid sequences of the monovalent DP47-untargeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion containing crossed CH-CL with charged residues, control B.

Table 69 shows, respectively, the cDNA and amino acid sequences of the bivalent DP47-untargeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion, control C.

Table 70 shows, respectively, the cDNA and amino acid sequences of the monovalent DP47-untargeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion containing CH-CL cross with charged residues, control D.

Table 71 shows, respectively, the cDNA and amino acid sequences of the monovalent DP47-untargeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion without charged residues in the CH-CL cross, control E.

7.3.2 Antibodies as Control Molecules

Two control human IgG1 containing PGLALA were prepared.

Table 72 shows the cDNA and amino acid sequences of the anti-CD19 huIgG1 PGLALA (clone 8B8-018), i.e. control G.

Table 73 shows the cDNA and amino acid sequences of germline control DP47 huIgG1 PGLALA (control F).

7.4 Production of CD19-Targeted Split Trimeric 4-1BB Ligand Fc Fusion Antigen Binding Molecules and their Control Molecules

The targeted and untargeted split trimeric 4-1BB ligand Fc (kih) fusion antigen binding molecule encoding sequences were cloned into a plasmid vector, which drives expression of the insert from an MPSV promoter and contains a synthetic polyA sequence located at the 3′ end of the CDS. In addition, the vector contains an EBV OriP sequence for episomal maintenance of the plasmid.

The split trimeric 4-1BB ligand Fc (kih) fusion antigen binding molecule was produced by co-transfecting HEK293-EBNA cells with the mammalian expression vectors using polyethylenimine. The cells were transfected with the corresponding expression vectors. For variants 1,2,4,5 and it's control B, D and E, at a 1:1:1:1 ratio (“vector dimeric ligand-CL-knob chain”: “vector monomeric ligand fusion-CH1”: “vector anti-CD19 Fab-hole chain”: “vector anti-CD19 light chain”). For variant 3, 6 and it's control C, at a 1:1:1 ratio (“vector huIgG1 Fc hole dimeric ligand chain”: “vector huIgG1 Fc knob monomeric ligand chain”: “vector anti-CD19 light chain”). Human IgGs, used as control in the assay, were produced as for the bispecific construct (for transfection only a vector for light and a vector for heavy chain were used at a 1:1 ratio).

For production in 500 mL shake flasks, 300 million HEK293 EBNA cells were seeded 24 hours before transfection. For transfection cells were centrifuged for 10 minutes at 210×g, and the supernatant was replaced by 20 mL pre-warmed CD CHO medium. Expression vectors (200 μg of total DNA) were mixed in 20 mL CD CHO medium. After addition of 540 μL PEI, the solution was vortexed for 15 seconds and incubated for 10 minutes at room temperature. Afterwards, cells were mixed with the DNA/PEI solution, transferred to a 500 mL shake flask and incubated for 3 hours at 37° C. in an incubator with a 5% CO 2 atmosphere. After the incubation, 160 mL of Excell medium supplemented with 6 mM L-Glutamine, 5 g/L PEPSOY and 1.2 mM valproic acid was added and cells were cultured for 24 hours. One day after transfection 12% Feed (amino acid and glucose) were added. After culturing for 7 days, the supernatant was collected by centrifugation for 30-40 minutes at least 400×g. The solution was sterile filtered (0.22 μm filter), supplemented with sodium azide to a final concentration of 0.01% (w/v), and kept at 4° C.

The split trimeric 4-1BB ligand Fc (kih) fusion antigen binding molecule, as well as the IgG, was purified from cell culture supernatants by affinity chromatography using Protein A, followed by size exclusion chromatography. For affinity chromatography, the supernatant was loaded on a MABSELECT SURE® column (CV=5-15 mL, resin from GE Healthcare) equilibrated with sodium phosphate (20 mM), sodium sitrate (20 mM) buffer (pH 7.5). Unbound protein was removed by washing with at least 6 column volumes of the same buffer. The bound protein was eluted using either a linear gradient (20 CV) or a step elution (8 CV) with 20 mM sodium citrate, 100 mM sodium chloride, 100 mM glycine buffer (pH 3.0). For the linear gradient an additional 4 column volumes step elution was applied.

The pH of collected fractions was adjusted by adding 1/10 (v/v) of 0.5M sodium phosphate, pH8.0. The protein was concentrated prior to loading on a HILOAD® Superdex 200 column (GE Healthcare) equilibrated with 20 mM histidine, 140 mM sodium chloride, 0.01% (v/v) TWEEN® 20 (polysorbate 20) solution of pH 6.0.

The protein concentration was determined by measuring the optical density (OD) at 280 nm, using a molar extinction coefficient calculated on the basis of the amino acid sequence. Purity and molecular weight of the targeted trimeric 4-1BB ligand Fc (kih) fusion was analyzed by SDS-PAGE in the presence and absence of a reducing agent (5 mM 1,4-dithiotreitol) and staining with Coomassie SIMPLYBLUE™ SafeStain (Invitrogen USA). The aggregate content of samples was analyzed using a TSKGEL® G3000 SW XL analytical size-exclusion column (Tosoh) equilibrated in 25 mM K 2 HPO 4 , 125 mM NaCl, 200 mM L-arginine monohydrochloride, 0.02% (w/v) NaN 3 , pH 6.7 running buffer at 25° C.

Table 74 summarizes the yield and final monomer content of the CD19 targeted split trimeric 4-1BB ligand Fc (kih) fusion antigen molecules.

Table 75 summarizes the yield and final monomer content of the DP47 untargeted split trimeric 4-1BB ligand Fc (kih) fusion, both monovalent (control B, D and E) and bivalent (control C).

Table 76 summarizes the yield and final monomer content of anti-CD19 (8B8-018) and germline DP47 human IgG1 PGLALA (control F).

›Example 8

Functional Characterization of the CD19 Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules

8.1. Surface Plasmon Resonance (Affinity)

Binding of CD19 targeted split trimeric 4-1BB ligand Fc fusion antigen binding molecules (constructs 3.4 and 3.6) to the recombinant 4-1BB Fc(kih) and CD19 was assessed by surface plasmon resonance (SPR). All SPR experiments were performed on a BIACORE® T200 instrument at 25° C. with HBS-EP as running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% Surfactant P20, Biacore, Freiburg/Germany).

Interaction with Human and Cynomolgus 4-1BB

Anti-human Fab antibody (Biacore, Freiburg/Germany) was directly coupled on a CM5 chip at pH 5.0 using the standard amine coupling kit (Biacore, Freiburg/Germany). The immobilization level was approximately 8000 RU. The CD19 targeted split trimeric 4-1BB ligand Fc fusions were captured for 60 seconds at 2 and 5 nM (control D was also injected). Recombinant human or cynomolgus 4-1BB avi His was passed at a concentration range from 2.7 to 2000 nM (3-fold dilution) with a flow of 30 μL/minutes through the flow cells over 120 seconds. The dissociation was monitored for 180 seconds. Bulk refractive index differences were corrected for by subtracting the response obtained on reference flow cell. Here, the antigens were flown over a surface with immobilized anti-human Fab antibody but on which HBS-EP has been injected rather than the antibodies.

Interaction with Human CD19

Anti-human Fab antibody (Biacore, Freiburg/Germany) was directly coupled on a CM5 chip at pH 5.0 using the standard amine coupling kit (Biacore, Freiburg/Germany). The immobilization level was approximately 8000 RU. The CD19 targeted split trimeric 4-1BB ligand Fc fusions, or the control antibody (anti-CD19(8B8-018) huIgG1 PGLALA) were captured for 60 seconds at 20 nM. Recombinant human CD19-Fc(kih) was passed at a concentration range from 7.8 to 500 nM (2-fold dilution) with a flow of 30 μL/minutes through the flow cells over 120 seconds. The dissociation was monitored for 120/1800 seconds. Bulk refractive index differences were corrected for by subtracting the response obtained on reference flow cell. Here, the antigens were flown over a surface with immobilized anti-human Fab antibody but on which HBS-EP has been injected rather than the antibodies.

Kinetic constants were derived using the Biacore T200 Evaluation Software (vAA, Biacore AB, Uppsala/Sweden), to fit rate equations for 1:1 Langmuir binding by numerical integration.

The bispecific constructs 3.4, 3.6 and control D bind similarly to 4-1BB. Table 77 shows the average with standard deviation (in parenthesis) from the two experiments (using the construct capture solution either at 2 nM or 5 nM). The bispecific constructs 3.4 and 3.6 bind human CD19 with a similar affinity as the IgG. Affinity constants for the interaction were determined by fitting to a 1:1 Langmuir binding. For measurements with hu4-1BB and cy4-1BB, average and standard deviation (in parenthesis) are shown (two experiments with 2 or 5 nM capture solution).

8.2. Surface Plasmon Resonance (Simultaneous Binding)

The capacity of binding simultaneously human 4-1BB Fc(kih) and human CD19 was assessed by surface plasmon resonance (SPR). All SPR experiments were performed on a BIACORE® T200 instrument at 25° C. with HBS-EP as running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% Surfactant P20, Biacore, Freiburg/Germany). Biotinylated human 4-1BB Fc(kih) was directly coupled to a flow cell of a streptavidin (SA) sensor chip. Immobilization levels up to 250 resonance units (RU) were used.

The CD19 targeted trimeric split 4-1BBL constructs (constructs 3.1, 3.3, 3.4, 3.5, 3.6, 4.4) were passed at a concentration range of 200 nM with a flow of 30 μL/minute through the flow cells over 90 seconds and dissociation was set to zero sec. Human CD19 was injected as second analyte with a flow of 30 μL/minute through the flow cells over 90 seconds at a concentration of 500 nM ( FIG. 34 ). The dissociation was monitored for 120 sec. Bulk refractive index differences were corrected for by subtracting the response obtained in a reference flow cell, where no protein was immobilized.

As can be seen in the graphs of FIGS. 35A to 35F , all bispecific constructs could bind simultaneously human 4-1BB and human CD19.

›Example 9

Functional Characterization of the CD-19 Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules

9.1. Binding on Activated Human PMBCs of the CD19-Targeted 4-1BB Ligand Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecules

To determine binding of 4-1BBL trimer-containing Fc fusion antigen binding molecules to human PBMCs, different titrated concentrations of the CD19-targeted 4-1BBL trimer-containing Fc fusion antigen binding molecules were used in the assay as described in Example 5.2.

FIGS. 36A-1 to 36A-3 and 36B-1 to 36B-3 show the binding of Constructs 3.1, 3.3, 3.4, 3.5 and 3.6 as prepared in Example 7 on activated 4-1BB-expressing CD4+ T cells and CD8+ T cells, respectively. Gates were set on living CD45+ CD3+ CD4+ or CD45+ CD3+ CD8+ T cells and MFI of PE-conjugated AffiniPure anti-human IgG IgG Fcγ-fragment-specific goat F(ab′)2 fragment were blotted against the titrated concentration of targeted split trimeric 4-1BB ligand Fc fusion variants. Table 78 shows the EC 50 values as measured for Constructs 3.1, 3.3. 3.4, 3.5 and 3.6 and control molecules.

9.2 Binding to CD19-Expressing Tumor Cells

For binding assays on CD19-expressing tumor cells, the following human CD19-expressing lymphoma cell lines were used: diffuse large non-Hodgkin B cell lymphoma (B-NHL) cell line SU-DHL-8 (DSMZ ACC573), acute B cell precursor lymphoid leukemia cell line Nalm6 (DSMZ ACC-128), diffuse large cell lymphoblast lymphoma cell line Toledo (ATCC CRL-2631) and diffuse large B cell lymphoma cell line OCI-Ly18 (DSMZ ACC-699). The assays were preformed as described for the FAP-expressing MV-3 and WM-266-4 tumor cell lines in Example 5.3.

Gates were set on living tumor cells and MFI of PE-conjugated AffiniPure anti-human IgG IgG Fcγ-fragment-specific goat F(ab′)2 fragment were blotted against the titrated concentration of targeted split trimeric 4-1BB ligand Fc fusion constructs.

FIGS. 37A-1 to 37A-3 show the binding of Constructs 3.1, 3.3, 3.4, 3.5 and 3.6 as prepared in Example 7.1 to diffuse large non-Hodgkin B cell lymphoma (B-NHL) cell line SU-DHL-8 and in FIGS. 37B-1 to 37B-3 the binding of Constructs 3.1, 3.3, 3.4, 3.5 and 3.6 to acute B cell precursor lymphoid leukemia cell line Nalm6 is presented. FIGS. 37C-1 to 37C-3 show the binding of Constructs 3.1, 3.3, 3.4, 3.5 and 3.6 to diffuse large cell lymphoblast lymphoma cell line Toledo and FIGS. 37D-1 to 37D-3 show the binding of Constructs 3.1, 3.3, 3.4, 3.5 and 3.6 to diffuse large B cell lymphoma cell line OCI-Ly18. Table 79 shows the EC50 values as measured for Constructs 3.1, 3.3, 3.4, 3.5 and 3.6 and control molecules.

›Example 10

Biological Activity of the CD19-Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules

10.1. NF-κB Activation in HeLa Cells Expressing Human 4-1BB

HeLa cells expressing human 4-1BB and NF-κB-luciferase were generated as described in Example 6.1.

NF-κB Activation in Hela Cells Expressing Human 4-1BB Co-Cultured with CD19-Expressing Tumor Cells

NF-κB-luciferase human-4-1BB HeLa cells were harvested and resuspended in DMEM medium supplied with 10% (v/v) FBS and 1% (v/v) GlutaMAX-I to a concentration of 0.2×10 6 cells/ml. 100 μl (2×10 4 cells) of this cell suspension were transferred to each well of a sterile white 96-well flat bottom tissue culture plate with lid (greiner bio-one, Cat. No. 655083) and the plate were incubated at 37° C. and 5% CO 2 overnight. The next day 50 μL of medium containing titrated concentrations of CD19-targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules (CD19 split 4-1BBL trimer) or DP47-untargeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules (DP47 split 4-1BBL trimer) were added. CD19-expressing B cell lymphoma cell lines (diffuse large non-Hodgkin B cell lymphoma (B-NHL) cell line SU-DHL-8 (DSMZ ACC573) and human non-Hodgkin's B cell lymphoma cell line Pfeiffer (ATCC CRL-2632)) were resuspended in DMEM medium supplied with 10% (v/v) FBS and 1% (v/v) GlutaMAX-I to a concentration of 2×10 6 cells/ml.

Suspension of CD19-expressing B cell lymphoma cell (50 final ratio 1:5) or only medium were added to each well and plates were incubated for 6 hours at 37° C. and 5% CO 2 . Cells were washed two times with 200 μL/well DPBS. 40 μl freshly prepared Reporter Lysis Buffer (Promega, Cat-No: E3971) were added to each well and the plate were stored over night at −20° C. The next day frozen cell plate and Detection Buffer (Luciferase 1000 Assay System, Promega, Cat. No. E4550) were thawed at room temperature. 100 μL of detection buffer were added to each well and luciferase activity was measured as fast as possible using a SpectraMax M5/M5e microplate reader and a SoftMax Pro Software (Molecular Devices) counting light emission in URL (units of released light for 0.5 s/well) or Victor3 1420 multilabel counter plate reader (Perkin Elmer) and the Perkin Elmer 2030 Manager Software counting light emission as counts per seconds (CPS) and blotted against the concentration of tested constructs.

CD19-targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules Constructs 3.1 and 3.3 triggered activation of the NF-kB signaling pathway in the reporter cell line in the presence of CD19-expressing B cell lymphoma cells. In contrast, the untargeted control molecules failed to trigger such an effect at any of the tested concentrations ( FIGS. 38A to 38C ).

›Example 11 · 1 of 4

11.1 Preparation of CEA (T84.66-LCHA) Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules

11.1.1 Humanization of Anti-CEA Clone T84.66

Novel humanized variants of the murine antibody T84.66 (Wagener et al., J Immunol 130, 2308 (1983), Neumaier et al., J Immunol 135, 3604 (1985)) were developed by grafting of the CDRs onto human germline framework acceptor sequences.

Humanization of an antibody from non-human origin consists essentially of transplanting the CDR residues from the non-human antibody (donor) onto the framework of a human (acceptor) antibody. Normally the acceptor framework is selected by aligning the sequence of the donor to a collection of potential acceptor sequences and choosing one that has either reasonable homology to the donor, or shows similar amino acids at some positions critical for structure and activity. In the present case, the search for the antibody acceptor framework was performed by aligning the mouse T84.66 protein (NCBI Acc No: CAA36980 for the heavy chain (SEQ ID NO:317), and CAA36979 (SEQ ID NO:318) for the light chain) sequence to a collection of human germ-line sequences and picking that human sequence that showed high sequence identity. Here, the sequence IGHV1-69*08 from the IMGT database was chosen as the heavy chain framework acceptor sequence (IMGT Acc No. Z14309, SEQ ID NO:319), and the IGKV3-11*01 sequence (IMGT Acc No. X01668, SEQ ID NO:320) was chosen to be the framework acceptor for the light chain. Onto these two acceptor frameworks, the three complementary determining regions (CDRs) of the mouse heavy and light variable domains were grafted. Since the framework 4 (FR4) region is not part of the variable region of the germ line V gene, the alignment for that position was done individually. The JH4 sequence was chosen for the heavy chain, and the JK2 sequence was chosen for the light chain.

11.1.2 Binding of Different Humanized Variants of T84.66 IgG to Cells

The binding of different humanized variants of T84.66 IgG was tested on CEA-expressing human gastric adenocarcinoma cells (MKN45, DSMZ ACC 409).

Cells were harvested, counted, checked for viability and re-suspended at 2×10 6 cells/ml in FACS buffer (100 μl PBS 0.1% BSA). 100 μl of cell suspension (containing 0.2×10 6 cells) were incubated in round-bottom 96-well plate for 30 min at 4° C. with increasing concentrations of the CEA IgG (4 ng/ml-60 μg/ml), washed twice with cold PBS 0.1% BSA, re-incubated for further 30 min at 4° C. with the PE-conjugated AffiniPure F(ab′)2 Fragment goat anti-human IgG Fcg Fragment Specific secondary antibody (Jackson Immuno Research Lab PE #109-116-170), washed twice with cold PBS 0.1% BSA and immediately analyzed by FACS using a FACS CantoII (Software FACS Diva). Binding curves and EC50 values were obtained and calculated using GraphPadPrism5.

FIG. 39 shows the different binding pattern of selected humanized variants of the T84.66 IgG to human CEA, expressed on MKN45 cells. Based on the calculated EC50 binding values (Table 80), the humanized variant 1 was selected for further evaluation.

Humanized variant 1 is termed in the following T84.66-LCHA. The amino acid sequences of its CDRs and of the VH and VL as well as the amino acid sequences of the VH and VL domain of the parental chimeric T84.66 clone are shown in Table 81.

11.2 Preparation of CEA (T84.66-LCHA) Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules

11.2.1 Preparation of Monovalent CEA (T84.66-LCHA) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains with Charged Residues (Construct 5.1)

To improve correct pairing the following mutations have been introduced in the crossed CH-CL. In the dimeric 4-1BB ligand fused to human CL, E123R and Q124K. In the monomeric 4-1BB ligand fused to human CH1, K147E and K213E.

Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-CEA-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-CEA light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a CEA binding Fab ( FIG. 40A , Construct 5.1).

Table 82 shows the cDNA and amino acid sequences of the monovalent CEA (T84.66-LCHA) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule with crossed CH-CL and charged residues (construct 5.1).

11.2.2 Preparation of Monovalent CEA (T84.66-LCHA) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains without Charged Residues (Construct 5.2)

›Example 11 · 2 of 4

The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831. Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-CEA-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-CEA light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a CEA-binding Fab ( FIG. 40B , Construct 5.2).

Table 83 shows the cDNA and amino acid sequences of the monovalent CEA (T84.66-LCHA) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule containing crossed CH-CL cross without charged residues (construct 5.2).

11.2.3 Preparation of Bivalent CEA(T84.66-LCHA) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding (Construct 5.3)

A polypeptide containing two ectodomains of 4-1BB ligand (71-254), separated by (G 4 S) 2 (SEQ ID NO:13) linkers was fused to the C-terminus of human IgG1 Fc hole chain, as depicted in FIG. 29C : human IgG1 Fc hole, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand. A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the C-terminus of human IgG1 Fc knob chain as described in FIG. 29D : human IgG1 Fc knob, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand.

The variable region of heavy and light chain DNA sequences encoding a binder specific for CEA, clone T84.66-LCHA, were subcloned in frame with either the constant heavy chain of the hole, the knob or the constant light chain of human IgG1. The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831. Combination of the anti-CEA huIgG1 hole dimeric ligand chain containing the Y349C/T366S/L368A/Y407V mutations, the anti-CEA huIgG1 knob monomeric ligand chain containing the S354C/T366W mutations and the anti-CEA light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and two CEA binding Fabs ( FIG. 40C , construct 5.3).

Table 84 shows the cDNA and amino acid sequences of the bivalent CEA(T84.66-LCHA) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule (construct 5.3).

11.2.4 Preparation of Monovalent CEA(T84.66-LCHA) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains with Charged Residues (Construct 5.4)

A polypeptide containing two ectodomains of 4-1BB ligand (71-248), separated by (G 4 S) 2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CL domain, was cloned in analogy to the one depicted in FIG. 29A : human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human CL. A polypeptide containing one ectodomain of 4-1BB ligand (71-248) and fused to the human IgG1-CH domain, was cloned in analogy to the one described in FIG. 29B : human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human CH.

The polypeptide encoding the dimeric 4-1BB ligand fused to human CL domain was subcloned in frame with the human IgG1 heavy chain CH2 and CH3 domains on the knob (Merchant, Zhu et al. 1998). To improve correct pairing the following mutations have been introduced in the crossed CH-CL. In the dimeric 4-1BB ligand fused to human CL, E123R and Q124K. In the monomeric 4-1BB ligand fused to human CH1, K147E and K213E.

The variable region of heavy and light chain DNA sequences encoding a binder specific for CEA, clone T84.66-LCHA, were subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1. The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831. Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-CD19-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-CD19 light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a CEA binding Fab ( FIG. 40D , construct 5.4).

Table 85 shows the cDNA and amino acid sequences of the monovalent CEA(T84.66-LCHA) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule with crossed CH-CL and charged residues (construct 5.4).

11.2.5 Preparation of Monovalent CEA(T84.66-LCHA) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains without Charged Residues (Construct 5.5)

The variable region of heavy and light chain DNA sequences encoding a binder specific for CEA, clone T84.66-LCHA, were subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1. The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831. Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-CEA-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-CEA light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a CD19-binding Fab ( FIG. 40E , Construct 5.5).

›Example 11 · 3 of 4

Table 86 shows the cDNA and amino acid sequences of the monovalent CEA(T84.66-LCHA) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule containing crossed CH-CL cross without charged residues (construct 5.5).

11.2.6 Preparation of Bivalent CEA(T84.66-LCHA) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding (Construct 5.6)

A polypeptide containing two ectodomains of 4-1BB ligand (71-248), separated by (G 4 S) 2 (SEQ ID NO:13) linkers was fused to the C-terminus of human IgG1 Fc hole chain, as depicted in FIG. 29C : human IgG1 Fc hole, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand. A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the C-terminus of human IgG1 Fc knob chain as described in FIG. 29D : human IgG1 Fc knob, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand.

Table 87 shows the cDNA and amino acid sequences of the bivalent CEA(T84.66-LCHA) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule (construct 5.6).

11.2.7 Preparation of Monovalent CEA(T84.66) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains with Charged Residues (Construct 5.7)

Table 88 shows the cDNA and amino acid sequences of the monovalent CEA(T84.66) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule with crossed CH-CL and charged residues (construct 5.7).

11.2.8 Preparation of Bivalent CEA(T84.66) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule (Construct 5.8)

A polypeptide containing two ectodomains of 4-1BB ligand (71-254), separated by (G 4 S) 2 (SEQ ID NO:13) linkers was fused to the C-terminus of human IgG1 Fc hole chain, as depicted in FIG. 29C : human IgG1 Fc hole, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand. A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the C-terminus of human IgG1 Fc knob chain as described in FIG. 29D : human IgG1 Fc knob, (G 4 S) 2 (SEQ ID NO:13) connector, human 4-1BB ligand.

The variable region of heavy and light chain DNA sequences encoding a binder specific for CEA, clone T84.66, were subcloned in frame with either the constant heavy chain of the hole, the knob or the constant light chain of human IgG1. The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831. Combination of the anti-CEA huIgG1 hole dimeric ligand chain containing the Y349C/T366S/L368A/Y407V mutations, the anti-CEA huIgG1 knob monomeric ligand chain containing the S354C/T366W mutations and the anti-CEA light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and two CEA binding Fabs. Construct 5.8 corresponds to Construct 5.3 as shown in FIG. 40C .

Table 89 shows the cDNA and amino acid sequences of the bivalent CEA(T84.66) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule (construct 5.8).

11.3 Preparation of Untargeted Split Trimeric 4-1BB Ligand Fc Fusion Molecules and Human IgG as Control Molecules

11.3.1 Preparation of Untargeted Human 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules (Control Molecules)

These control molecules were prepared as described above for the CEA targeted construct 3.1 (termed control B), 3.3 (termed control C), 3.4 (termed control D) and 3.5 (termed control E) with the only difference that the anti-CD19 binder (VH-VL) was replaced by a germline control, termed DP47, not binding to the antigen (see FIGS. 40A to 40F ). The cDNA and amino acid sequences of control B, the monovalent DP47-untargeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion containing crossed CH-CL with charged residues, are shown in Table 68 above (see Example 7.3.1). Table 69 shows the cDNA and amino acid sequences of the bivalent DP47-untargeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion, control C. Table 70 shows the cDNA and amino acid sequences of the monovalent DP47-untargeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion containing CH-CL cross with charged residues, control D. Table 71 shows the cDNA and amino acid sequences of the monovalent DP47-untargeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion without charged residues in the CH-CL cross, control E.

›Example 11 · 4 of 4

11.3.2 Antibodies as Control Molecules

An additional control used in the assays, termed control F, was an untargeted DP47, germline control, human IgG1, containing the Pro329Gly, Leu234Ala and Leu235Ala mutations, to abrogate binding to Fc gamma receptors. The cDNA and amino acid sequences of control F can be found in Table 73 above.

11.4 Production of CEA-Targeted Split Trimeric 4-1BB Ligand Fc Fusion Antigen Binding Molecules and their Control Molecules

The split trimeric 4-1BB ligand Fc (kih) fusion was produced by co-transfecting HEK293-EBNA cells with the mammalian expression vectors using polyethylenimine. The cells were transfected with the corresponding expression vectors. For variants 1,2,4,5 and it's control B, D and E, at a 1:1:1:1 ratio (“vector dimeric ligand-CL-knob chain”: “vector monomeric ligand fusion-CH1”: “vector anti-CEA Fab-hole chain”: “vector anti-CEA light chain”). For variant 3, 6 and it's control C, at a 1:1:1 ratio (“vector huIgG1 Fc hole dimeric ligand chain”: “vector huIgG1 Fc knob monomeric ligand chain”: “vector anti-CEA light chain”). Human IgGs, used as control in the assay, were produced as for the bispecific construct (for transfection only a vector for light and a vector for heavy chain were used at a 1:1 ratio).

For production in 500 mL shake flasks, 300 million HEK293 EBNA cells were seeded 24 hours before transfection. For transfection cells were centrifuged for 10 minutes at 210×g, and the supernatant was replaced by 20 mL pre-warmed CD CHO medium. Expression vectors (200 μg of total DNA) were mixed in 20 mL CD CHO medium. After addition of 540 μL PEI, the solution was vortexed for 15 seconds and incubated for 10 minutes at room temperature. Afterwards, cells were mixed with the DNA/PEI solution, transferred to a 500 mL shake flask and incubated for 3 hours at 37° C. in an incubator with a 5% CO 2 atmosphere. After the incubation, 160 mL of Excell medium supplemented with 6 mM L-Glutamine, 5 g/L PEPSOY and 1.2 mM valproic acid was added and cells were cultured for 24 hours. One day after transfection 12% Feed (amino acid and glucose) were added. After culturing for 7 days, the supernatant was collected by centrifugation for 30-40 minutes at least 400×g. The solution was sterile filtered (0.22 μm filter), supplemented with sodium azide to a final concentration of 0.01% (w/v), and kept at 4° C.

The split trimeric 4-1BB ligand Fc (kih) fusion, as well as the IgG, was purified from cell culture supernatants by affinity chromatography using Protein A, followed by size exclusion chromatography. For affinity chromatography, the supernatant was loaded on a MABSELECT SURE® column (CV=5-15 mL, resin from GE Healthcare) equilibrated with Sodium Phosphate (20 mM), Sodium Citrate (20 mM) buffer (pH 7.5). Unbound protein was removed by washing with at least 6 column volumes of the same buffer. The bound protein was eluted using either a linear gradient (20 CV) or a step elution (8 CV) with 20 mM sodium citrate, 100 mM Sodium chloride, 100 mM Glycine buffer (pH 3.0). For the linear gradient an additional 4 column volumes step elution was applied.

The pH of collected fractions was adjusted by adding 1/10 (v/v) of 0.5M sodium phosphate, pH8.0. The protein was concentrated prior to loading on a HILOAD® Superdex 200 column (GE Healthcare) equilibrated with 20 mM Histidine, 140 mM sodium chloride, 0.01% (v/v) TWEEN® 20 (polysorbate 20) solution of pH 6.0.

The protein concentration was determined by measuring the optical density (OD) at 280 nm, using a molar extinction coefficient calculated on the basis of the amino acid sequence. Purity and molecular weight of the targeted trimeric 4-1BB ligand Fc (kih) fusion antigen binding molecule was analyzed by SDS-PAGE in the presence and absence of a reducing agent (5 mM 1,4-dithiotreitol) and staining with Coomassie SIMPLYBLUE™ SafeStain (Invitrogen USA) or CE-SDS using Caliper LabChip GXII (Perkin Elmer). The aggregate content of samples was analyzed using a TSKGEL® G3000 SW XL analytical size-exclusion column (Tosoh) equilibrated in 25 mM K 2 HPO 4 , 125 mM NaCl, 200 mM L-Arginine Monohydrocloride, 0.02% (w/v) NaN3, pH 6.7 running buffer at 25° C.

Table 90 summarizes the yield and final monomer content of the CEA targeted split trimeric 4-1BB ligand Fc (kih) fusion antigen binding molecules.

Table 91 summarizes the yield and final monomer content of the DP47 untargeted split trimeric 4-1BB ligand Fc (kih) fusion molecules, both monovalent (control B, D and E) and bivalent (control C), and of the germline DP47 human IgG1 PGLALA (control F).

›Example 12

Functional characterization of the CEA targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules

12.1 Surface Plasmon Resonance (Simultaneous Binding)

Production of hu NA3B3A2 as antigen for CEA targeted trimeric split 4-1BBL constructs

The antigen used to assess binding by SPR to CEA was a hybrid molecule composed of A3 and B3 domains from human CEACAM5 (CEA) and N and A2 domains from human CEACAM1 (BGP1) similarly to what has been described for NABA (Durbin H. et al, Proc Natl Acad Sci USA. 1994 May 10; 91(10):4313-7). The antigen is termed here NA3B3A2 and a schematic description can be found in FIG. 41A .

Table 92 shows the nucleotide and amino acid sequences of hu NA3B3A2-avi-His.

Protein production was performed as described above for the Fc-fusion protein (Example 7.1.1). Secreted proteins were purified from cell culture supernatants by chelating chromatography, followed by size exclusion chromatography. The first chromatographic step was performed on a Ni-NTA SUPERFLOW′ Cartridge (5 ml, Qiagen) equilibrated in 20 mM sodium phosphate, 500 nM sodium chloride, pH7.4. Elution was performed by applying a gradient over 12 column volume from 5% to 45% of elution buffer (20 mM sodium phosphate, 500 nM sodium chloride, 500 mM Imidazole, pH7.4).

The protein was concentrated and filtered prior to loading on a HILOAD® Superdex 75 column (GE Healthcare) equilibrated with 20 mM Histidine, 140 mM NaCl, 0.01% TWEEN® 20 (polysorbate 20) pH 6.0. Table 93 summarizes the yield and final monomer content of human NA3B3A2-avi-His.

The capacity of binding simultaneously human 4-1BB Fc (kih) and human NA3B3A2 was assessed by surface plasmon resonance (SPR). All SPR experiments were performed on a BIACORE® T200 instrument at 25° C. with HBS-EP as running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% Surfactant P20, Biacore, Freiburg/Germany). Biotinylated human 4-1BB Fc (kih) was directly coupled to a flow cell of a streptavidin (SA) sensor chip. Immobilization levels up to 250 resonance units (RU) were used.

The CEA targeted trimeric split 4-1BBL constructs (constructs 5.4, 5.6, 5.7 and 5.8) were passed at a concentration range of 200 nM with a flow of 30 μL/minute through the flow cells over 90 seconds and dissociation was set to zero seconds. Human NA3B3A2 was injected as second analyte with a flow of 30 μL/minute through the flow cells over 90 seconds at a concentration of 500 nM ( FIG. 41B ). The dissociation was monitored for 120 seconds. Bulk refractive index

›Tables in the description — 94

TABLE A CDR Definitions 1 1 Numbering of all CDR definitions in Table A is according to the numbering conventions set forth by Kabat et al. (see below). 2 “AbM” with a lowercase “b” as used in Table A refers to the CDRs as defined by Oxford Molecular's “AbM” antibody modeling software.

CDR	Kabat	Chothia	AbM 2
V H CDR1	31-35	26-32	26-35
V H CDR2	50-65	52-58	50-58
V H CDR3	95-102	95-102	95-102
V L CDR1	24-34	26-32	24-34
V L CDR2	50-56	50-52	50-56
V L CDR3	89-97	91-96	89-97

TABLE B

Original	Exemplary	Preferred
Residue	Substitutions	Substitutions
Ala (A)	Val; Leu; Ile	Val
Arg (R)	Lys; Gln; Asn	Lys
Asn (N)	Gln; His; Asp, Lys; Arg	Gln
Asp (D)	Glu; Asn	Glu
Cys (C)	Ser; Ala	Ser
Gln (Q)	Asn; Glu	Asn
Glu (E)	Asp; Gln	Asp
Gly (G)	Ala	Ala
His (H)	Asn; Gln; Lys; Arg	Arg
Ile (I)	Leu; Val; Met; Ala; Phe;	Leu
	Norleucine
Leu (L)	Norleucine; Ile; Val;	Ile
	Met; Ala; Phe
Lys (K)	Arg; Gln; Asn	Arg
Met (M)	Leu; Phe; Ile	Leu
Phe (F)	Trp; Leu; Val; Ile; Ala;	Tyr
	Tyr
Pro (P)	Ala	Ala
Ser (S)	Thr	Thr
Thr (T)	Val; Ser	Ser
Trp (W)	Tyr; Phe	Tyr
Tyr (Y)	Trp; Phe; Thr; Ser	Phe
Val (V)	Ile; Leu; Met; Phe; Ala;	Leu
	Norleucine

TABLE C — (Sequences): SEQ

ID NO:	Name	Sequence
1	Human (hu) 4-1BBL (71-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP
	254)	LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVY
		YVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA
		ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG
		VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLP
		SPRSE
2	hu 4-1BBL (85-254)	LDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSL
		TGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAG
		EGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEA
		RNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQ
		LTQGATVLGLFRVTPEIPAGLPSPRSE
3	hu 4-1BBL (80-254)	DPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGL
		AGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRR
		VVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPP
		ASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARAR
		HAWQLTQGATVLGLFRVTPEIPAGLPSPRSE
4	hu 4-1BBL (52-254)	PWAVSGARASPGSAASPRLREGPELSPDDPAGLLDLR
		QGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGL
		SYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSG
		SVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSA
		FGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQG
		ATVLGLFRVTPEIPAGLPSPRSE
5	dimeric hu 4-1BBL (71-254)	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP
	connected by (G4S) 2 linker	LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVY
		YVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA
		ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG
		VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLP
		SPRSEGGGGSGGGGSREGPELSPDDPAGLLDLRQGM
		FAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYK
		EDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSL
		ALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGF
		QGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATV
		LGLFRVTPEIPAGLPSPRSE
6	monomeric hu 4-1B BL (71-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP
	254) plus (G4S) 2 linker	LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVY
		YVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA
		ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG
		VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLP
		SPRSEGGGGSGGGGS
7	FAP (28H1) CDR-H1	SHAMS
8	FAP (28H1) CDR-H2	AIWASGEQYYADSVKG
9	FAP (28H1) CDR-H3	GWLGNFDY
10	FAP (28H1) CDR-L1	RASQSVSRSYLA
11	FAP (28H1) CDR-L2	GASTRAT
12	FAP (28H1) CDR-L3	QQGQVIPPT
13	(G4S) 2	GGGGSGGGGS
14	dimeric hu 4-1BBL (71-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP
	254)-CH1 Fc knob chain	LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVY
		YVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA
		ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG
		VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLP
		SPRSEGGGGSGGGGSREGPELSPDDPAGLLDLRQGM
		FAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYK
		EDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSL
		ALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGF
		QGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATV
		LGLFRVTPEIPAGLPSPRSEGGGGSGGGGSASTKGPS
		VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG
		ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
		CNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAA
		GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE
		VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
		VLHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQP
		REPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAV
		EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS
		RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
15	monomeric hu 4-1B BL (71-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP
	254)-CL	LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVY
		YVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA
		ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG
		VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLP
		SPRSEGGGGSGGGGSRTVAAPSVFIFPPSDEQLKSGT
		ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT
		EQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQG
		LSSPVTKSFNRGEC
16	FAP (28H1) VH	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSHA
		MSWVRQAPGKGLEWVSAIWASGEQYYADSVK
		GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK
		GWLGNFDYWGQGTLVTVSS
17	FAP (28H1) VL	EIVLTQSPGTLSLSPGERATLSCRASQSVSRSYLA
		WYQQKPGQAPRLLIIGASTRATGIPDRFSGSGSG
		TDFTLTISRLEPEDFAVYYCQQGQVIPPTFGQGT
		KVEIK
18	anti-FAP (28H1) Fc hole	see Table 2
	chain
19	anti-FAP (28H1)	see Table 2
	light chain
20	Human (hu) FAP	UniProt no. Q12884
21	hu FAP ectodomain + poly-	RPSRVHNSEENTMRALTLKDILNGTFSYKTFFPNWIS
	lys-tag + his 6 -tag	GQEYLHQSADNNIVLYNIETGQSYTILSNRTMKSVNA
		SNYGLSPDRQFVYLESDYSKLWRYSYTATYYIYDLS
		NGEFVRGNELPRPIQYLCWSPVGSKLAYVYQNNIYL
		KQRPGDPPFQITFNGRENKIFNGIPDWVYEEEMLATK
		YALWWSPNGKFLAYAEFNDTDIPVIAYSYYGDEQYP
		RTINIPYPKAGAKNPVVRIFIIDTTYPAYVGPQEVPVP
		AMIASSDYYFSWLTWVTDERVCLQWLKRVQNVSVL
		SICDFREDWQTWDCPKTQEHIEESRTGWAGGFFVST
		PVFSYDAISYYKIFSDKDGYKHIHYIKDTVENAIQITS
		GKWEAINIFRVTQDSLFYSSNEFEEYPGRRNIYRISIGS
		YPPSKKCVTCHLRKERCQYYTASFSDYAKYYALVCY
		GPGIPISTLHDGRTDQEIKILEENKELENALKNIQLPKE
		EIKKLEVDEITLWYKMILPPQFDRSKKYPLLIQVYGG
		PCSQSVRSVFAVNWISYLASKEGMVIALVDGRGTAF
		QGDKLLYAVYRKLGVYEVEDQITAVRKFIEMGFIDE
		KRIAIWGWSYGGYVSSLALASGTGLFKCGIAVAPVSS
		WEYYASVYTERFMGLPTKDDNLEHYKNSTVMARAE
		YFRNVDYLLIHGTADDNVHFQNSAQIAKALVNAQV
		DFQAMWYSDQNHGLSGLSTNHLYTHMTHFLKQCFS
		LSDGKKKKKKGHHHHHH
22	nucleotide sequence	CGCCCTTCAAGAGTTCATAACTCTGAAGAAAATAC
	hu FAP ectodomain + poly-	AATGAGAGCACTCACACTGAAGGATATTTTAAATG
	lys-tag + his 6 -tag	GAACATTTTCTTATAAAACATTTTTTCCAAACTGGA
		TTTCAGGACAAGAATATCTTCATCAATCTGCAGAT
		AACAATATAGTACTTTATAATATTGAAACAGGACA
		ATCATATACCATTTTGAGTAATAGAACCATGAAAA
		GTGTGAATGCTTCAAATTACGGCTTATCACCTGAT
		CGGCAATTTGTATATCTAGAAAGTGATTATTCAAA
		GCTTTGGAGATACTCTTACACAGCAACATATTACA
		TCTATGACCTTAGCAATGGAGAATTTGTAAGAGGA
		AATGAGCTTCCTCGTCCAATTCAGTATTTATGCTGG
		TCGCCTGTTGGGAGTAAATTAGCATATGTCTATCA
		AAACAATATCTATTTGAAACAAAGACCAGGAGAT
		CCACCTTTTCAAATAACATTTAATGGAAGAGAAAA
		TAAAATATTTAATGGAATCCCAGACTGGGTTTATG
		AAGAGGAAATGCTTGCTACAAAATATGCTCTCTGG
		TGGTCTCCTAATGGAAAATTTTTGGCATATGCGGA
		ATTTAATGATACGGATATACCAGTTATTGCCTATTC
		CTATTATGGCGATGAACAATATCCTAGAACAATAA
		ATATTCCATACCCAAAGGCTGGAGCTAAGAATCCC
		GTTGTTCGGATATTTATTATCGATACCACTTACCCT
		GCGTATGTAGGTCCCCAGGAAGTGCCTGTTCCAGC
		AATGATAGCCTCAAGTGATTATTATTTCAGTTGGC
		TCACGTGGGTTACTGATGAACGAGTATGTTTGCAG
		TGGCTAAAAAGAGTCCAGAATGTTTCGGTCCTGTC
		TATATGTGACTTCAGGGAAGACTGGCAGACATGGG
		ATTGTCCAAAGACCCAGGAGCATATAGAAGAAAG
		CAGAACTGGATGGGCTGGTGGATTCTTTGTTTCAA
		CACCAGTTTTCAGCTATGATGCCATTTCGTACTACA
		AAATATTTAGTGACAAGGATGGCTACAAACATATT
		CACTATATCAAAGACACTGTGGAAAATGCTATTCA
		AATTACAAGTGGCAAGTGGGAGGCCATAAATATA
		TTCAGAGTAACACAGGATTCACTGTTTTATTCTAG
		CAATGAATTTGAAGAATACCCTGGAAGAAGAAAC
		ATCTACAGAATTAGCATTGGAAGCTATCCTCCAAG
		CAAGAAGTGTGTTACTTGCCATCTAAGGAAAGAAA
		GGTGCCAATATTACACAGCAAGTTTCAGCGACTAC
		GCCAAGTACTATGCACTTGTCTGCTACGGCCCAGG
		CATCCCCATTTCCACCCTTCATGATGGACGCACTG
		ATCAAGAAATTAAAATCCTGGAAGAAAACAAGGA
		ATTGGAAAATGCTTTGAAAAATATCCAGCTGCCTA
		AAGAGGAAATTAAGAAACTTGAAGTAGATGAAAT
		TACTTTATGGTACAAGATGATTCTTCCTCCTCAATT
		TGACAGATCAAAGAAGTATCCCTTGCTAATTCAAG
		TGTATGGTGGTCCCTGCAGTCAGAGTGTAAGGTCT
		GTATTTGCTGTTAATTGGATATCTTATCTTGCAAGT
		AAGGAAGGGATGGTCATTGCCTTGGTGGATGGTCG
		AGGAACAGCTTTCCAAGGTGACAAACTCCTCTATG
		CAGTGTATCGAAAGCTGGGTGTTTATGAAGTTGAA
		GACCAGATTACAGCTGTCAGAAAATTCATAGAAAT
		GGGTTTCATTGATGAAAAAAGAATAGCCATATGGG
		GCTGGTCCTATGGAGGATACGTTTCATCACTGGCC
		CTTGCATCTGGAACTGGTCTTTTCAAATGTGGTATA
		GCAGTGGCTCCAGTCTCCAGCTGGGAATATTACGC
		GTCTGTCTACACAGAGAGATTCATGGGTCTCCCAA
		CAAAGGATGATAATCTTGAGCACTATAAGAATTCA
		ACTGTGATGGCAAGAGCAGAATATTTCAGAAATGT
		AGACTATCTTCTCATCCACGGAACAGCAGATGATA
		ATGTGCACTTTCAAAACTCAGCACAGATTGCTAAA
		GCTCTGGTTAATGCACAAGTGGATTTCCAGGCAAT
		GTGGTACTCTGACCAGAACCACGGCTTATCCGGCC
		TGTCCACGAACCACTTATACACCCACATGACCCAC
		TTCCTAAAGCAGTGTTTCTCTTTGTCAGACGGCAA
		AAAGAAAAAGAAAAAGGGCCACCACCATCACCAT
		CAC
23	mouse FAP	UniProt no. P97321
24	Murine FAP	RPSRVYKPEGNTKRALTLKDILNGTFSYKTYFPNWIS
	ectodomain + poly-lys-	EQEYLHQSEDDNIVFYNIETRESYIILSNSTMKSVNAT
	tag + his 6 -tag	DYGLSPDRQFVYLESDYSKLWRYSYTATYY1YDLQN
		GEFVRGYELPRPIQYLCWSPVGSKLAYVYQNNIYLK
		QRPGDPPFQITYTGRENRIFNGIPDWVYEEEMLATKY
		ALWWSPDGKFLAYVEFNDSDIPIIAYSYYGDGQYPR
		TINIPYPKAGAKNPVVRVFIVDTTYPHHVGPMEVPVP
		EMIASSDYYFSWLTWVSSERVCLQWLKRVQNVSVL
		SICDFREDWHAWECPKNQEHVEESRTGWAGGFFVST
		PAFSQDATSYYKIFSDKDGYKHIHYIKDTVENAIQITS
		GKWEAIYIFRVTQDSLFYSSNEFEGYPGRRNIYRISIG
		NSPPSKKCVTCHLRKERCQYYTASFSYKAKYYALVC
		YGPGLPISTLHDGRTDQEIQVLEENKELENSLRNIQLP
		KVEIKKLKDGGLTFWYKMILPPQFDRSKKYPLLIQVY
		GGPCSQSVKSVFAVNWITYLASKEGIVIALVDGRGTA
		FQGDKFLHAVYRKLGVYEVEDQLTAVRKFIEMGFID
		EERIAIWGWSYGGYVSSLALASGTGLFKCGIAVAPVS
		SWEYYASIYSERFMGLPTKDDNLEHYKNSTVMARA
		EYFRNVDYLLIHGTADDNVHFQNSAQIAKALVNAQV
		DFQAMWYSDQNHGILSGRSQNHLYTHMTHFLKQCF
		SLSDGKKKKKKGHHHHHH
25	nucleotide sequence	CGTCCCTCAAGAGTTTACAAACCTGAAGGAAACAC
	Murine FAP	AAAGAGAGCTCTTACCTTGAAGGATATTTTAAATG
	ectodomain + poly-lys-	GAACATTCTCATATAAAACATATTTTCCCAACTGG
	tag + his 6 -tag	ATTTCAGAACAAGAATATCTTCATCAATCTGAGGA
		TGATAACATAGTATTTTATAATATTGAAACAAGAG
		AATCATATATCATTTTGAGTAATAGCACCATGAAA
		AGTGTGAATGCTACAGATTATGGTTTGTCACCTGA
		TCGGCAATTTGTGTATCTAGAAAGTGATTATTCAA
		AGCTCTGGCGATATTCATACACAGCGACATACTAC
		ATCTACGACCTTCAGAATGGGGAATTTGTAAGAGG
		ATACGAGCTCCCTCGTCCAATTCAGTATCTATGCT
		GGTCGCCTGTTGGGAGTAAATTAGCATATGTATAT
		CAAAACAATATTTATTTGAAACAAAGACCAGGAG
		ATCCACCTTTTCAAATAACTTATACTGGAAGAGAA
		AATAGAATATTTAATGGAATACCAGACTGGGTTTA
		TGAAGAGGAAATGCTTGCCACAAAATATGCTCTTT
		GGTGGTCTCCAGATGGAAAATTTTTGGCATATGTA
		GAATTTAATGATTCAGATATACCAATTATTGCCTA
		TTCTTATTATGGTGATGGACAGTATCCTAGAACTA
		TAAATATTCCATATCCAAAGGCTGGGGCTAAGAAT
		CCGGTTGTTCGTGTTTTTATTGTTGACACCACCTAC
		CCTCACCACGTGGGCCCAATGGAAGTGCCAGTTCC
		AGAAATGATAGCCTCAAGTGACTATTATTTCAGCT
		GGCTCACATGGGTGTCCAGTGAACGAGTATGCTTG
		CAGTGGCTAAAAAGAGTGCAGAATGTCTCAGTCCT
		GTCTATATGTGATTTCAGGGAAGACTGGCATGCAT
		GGGAATGTCCAAAGAACCAGGAGCATGTAGAAGA
		AAGCAGAACAGGATGGGCTGGTGGATTCTTTGTTT
		CGACACCAGCTTTTAGCCAGGATGCCACTTCTTAC
		TACAAAATATTTAGCGACAAGGATGGTTACAAACA
		TATTCACTACATCAAAGACACTGTGGAAAATGCTA
		TTCAAATTACAAGTGGCAAGTGGGAGGCCATATAT
		ATATTCCGCGTAACACAGGATTCACTGTTTTATTCT
		AGCAATGAATTTGAAGGTTACCCTGGAAGAAGAA
		ACATCTACAGAATTAGCATTGGAAACTCTCCTCCG
		AGCAAGAAGTGTGTTACTTGCCATCTAAGGAAAGA
		AAGGTGCCAATATTACACAGCAAGTTTCAGCTACA
		AAGCCAAGTACTATGCACTCGTCTGCTATGGCCCT
		GGCCTCCCCATTTCCACCCTCCATGATGGCCGCAC
		AGACCAAGAAATACAAGTATTAGAAGAAAACAAA
		GAACTGGAAAATTCTCTGAGAAATATCCAGCTGCC
		TAAAGTGGAGATTAAGAAGCTCAAAGACGGGGGA
		CTGACTTTCTGGTACAAGATGATTCTGCCTCCTCAG
		TTTGACAGATCAAAGAAGTACCCTTTGCTAATTCA
		AGTGTATGGTGGTCCTTGTAGCCAGAGTGTTAAGT
		CTGTGTTTGCTGTTAATTGGATAACTTATCTCGCAA
		GTAAGGAGGGGATAGTCATTGCCCTGGTAGATGGT
		CGGGGCACTGCTTTCCAAGGTGACAAATTCCTGCA
		TGCCGTGTATCGAAAACTGGGTGTATATGAAGTTG
		AGGACCAGCTCACAGCTGTCAGAAAATTCATAGA
		AATGGGTTTCATTGATGAAGAAAGAATAGCCATAT
		GGGGCTGGTCCTACGGAGGTTATGTTTCATCCCTG
		GCCCTTGCATCTGGAACTGGTCTTTTCAAATGTGG
		CATAGCAGTGGCTCCAGTCTCCAGCTGGGAATATT
		ACGCATCTATCTACTCAGAGAGATTCATGGGCCTC
		CCAACAAAGGACGACAATCTCGAACACTATAAAA
		ATTCAACTGTGATGGCAAGAGCAGAATATTTCAGA
		AATGTAGACTATCTTCTCATCCACGGAACAGCAGA
		TGATAATGTGCACTTTCAGAACTCAGCACAGATTG
		CTAAAGCTTTGGTTAATGCACAAGTGGATTTCCAG
		GCGATGTGGTACTCTGACCAGAACCATGGTATATT
		ATCTGGGCGCTCCCAGAATCATTTATATACCCACA
		TGACGCACTTCCTCAAGCAATGCTTTTCTTTATCAG
		ACGGCAAAAAGAAAAAGAAAAAGGGCCACCACCA
		TCACCATCAC
26	Cynomolgus FAP	RPPRVHNSEENTMRALTLKDILNGTFSYKTFFPNWIS
	ectodomain + poly-lys-	GQEYLHQSADNNIVLYNIETGQSYTILSNRTMKSVNA
	tag + his 6 -tag	SNYGLSPDRQFVYLESDYSKLWRYSYTATYYWDLS
		NGEFVRGNELPRPIQYLCWSPVGSKLAYVYQNNIYL
		KQRPGDPPFQITFNGRENKIFNGIPDWVYEEEMLATK
		YALWWSPNGKFLAYAEFNDTDIPVIAYSYYGDEQYP
		RTINIPYPKAGAKNPFVRIFIIDTTYPAYVGPQEVPVP
		AMIASSDYYFSWLTWVTDERVCLQWLKRVQNVSVL
		SICDFREDWQTWDCPKTQEHIEESRTGWAGGFFVST
		PVFSYDAISYYKIFSDKDGYKHIHYIKDTVENAIQITS
		GKWEAINIFRVTQDSLFYSSNEFEDYPGRRNIYRISIG
		SYPPSKKCVTCHLRKERCQYYTASFSDYAKYYALVC
		YGPGIPISTLHDGRTDQEIKILEENKELENALKNIQLP
		KEEIKKLEVDEITLWYKMILPPQFDRSKKYPLLIQVY
		GGPCSQSVRSVFAVNWISYLASKEGMVIALVDGRGT
		AFQGDKLLYAVYRKLGVYEVEDQITAVRKFIEMGFI
		DEKRIAIWGWSYGGYVSSLALASGTGLFKCGIAVAP
		VSSWEYYASVYTERFMGLPTKDDNLEHYKNSTVMA
		RAEYFRNVDYLLIHGTADDNVHFQNSAQIAKALVNA
		QVDFQAMWYSDQNHGLSGLSTNHLYTHMTHFLKQ
		CFSLSDGKKKKKKGHHHHHH
27	nucleotide sequence	CGCCCTCCAAGAGTTCATAACTCTGAAGAAAATAC
	Cynomolgus FAP	AATGAGAGCACTCACACTGAAGGATATTTTAAATG
	ectodomain + poly-lys-	GGACATTTTCTTATAAAACATTTTTTCCAAACTGGA
	tag + his 6 -tag	TTTCAGGACAAGAATATCTTCATCAATCTGCAGAT
		AACAATATAGTACTTTATAATATTGAAACAGGACA
		ATCATATACCATTTTGAGTAACAGAACCATGAAAA
		GTGTGAATGCTTCAAATTATGGCTTATCACCTGAT
		CGGCAATTTGTATATCTAGAAAGTGATTATTCAAA
		GCTTTGGAGATACTCTTACACAGCAACATATTACA
		TCTATGACCTTAGCAATGGAGAATTTGTAAGAGGA
		AATGAGCTTCCTCGTCCAATTCAGTATTTATGCTGG
		TCGCCTGTTGGGAGTAAATTAGCATATGTCTATCA
		AAACAATATCTATTTGAAACAAAGACCAGGAGAT
		CCACCTTTTCAAATAACATTTAATGGAAGAGAAAA
		TAAAATATTTAATGGAATCCCAGACTGGGTTTATG
		AAGAGGAAATGCTTGCTACAAAATATGCTCTCTGG
		TGGTCTCCTAATGGAAAATTTTTGGCATATGCGGA
		ATTTAATGATACAGATATACCAGTTATTGCCTATTC
		CTATTATGGCGATGAACAATATCCCAGAACAATAA
		ATATTCCATACCCAAAGGCCGGAGCTAAGAATCCT
		TTTGTTCGGATATTTATTATCGATACCACTTACCCT
		GCGTATGTAGGTCCCCAGGAAGTGCCTGTTCCAGC
		AATGATAGCCTCAAGTGATTATTATTTCAGTTGGC
		TCACGTGGGTTACTGATGAACGAGTATGTTTGCAG
		TGGCTAAAAAGAGTCCAGAATGTTTCGGTCTTGTC
		TATATGTGATTTCAGGGAAGACTGGCAGACATGGG
		ATTGTCCAAAGACCCAGGAGCATATAGAAGAAAG
		CAGAACTGGATGGGCTGGTGGATTCTTTGTTTCAA
		CACCAGTTTTCAGCTATGATGCCATTTCATACTACA
		AAATATTTAGTGACAAGGATGGCTACAAACATATT
		CACTATATCAAAGACACTGTGGAAAATGCTATTCA
		AATTACAAGTGGCAAGTGGGAGGCCATAAATATA
		TTCAGAGTAACACAGGATTCACTGTTTTATTCTAG
		CAATGAATTTGAAGATTACCCTGGAAGAAGAAAC
		ATCTACAGAATTAGCATTGGAAGCTATCCTCCAAG
		CAAGAAGTGTGTTACTTGCCATCTAAGGAAAGAAA
		GGTGCCAATATTACACAGCAAGTTTCAGCGACTAC
		GCCAAGTACTATGCACTTGTCTGCTATGGCCCAGG
		CATCCCCATTTCCACCCTTCATGACGGACGCACTG
		ATCAAGAAATTAAAATCCTGGAAGAAAACAAGGA
		ATTGGAAAATGCTTTGAAAAATATCCAGCTGCCTA
		AAGAGGAAATTAAGAAACTTGAAGTAGATGAAAT
		TACTTTATGGTACAAGATGATTCTTCCTCCTCAATT
		TGACAGATCAAAGAAGTATCCCTTGCTAATTCAAG
		TGTATGGTGGTCCCTGCAGTCAGAGTGTAAGGTCT
		GTATTTGCTGTTAATTGGATATCTTATCTTGCAAGT
		AAGGAAGGGATGGTCATTGCCTTGGTGGATGGTCG
		GGGAACAGCTTTCCAAGGTGACAAACTCCTGTATG
		CAGTGTATCGAAAGCTGGGTGTTTATGAAGTTGAA
		GACCAGATTACAGCTGTCAGAAAATTCATAGAAAT
		GGGTTTCATTGATGAAAAAAGAATAGCCATATGGG
		GCTGGTCCTATGGAGGATATGTTTCATCACTGGCC
		CTTGCATCTGGAACTGGTCTTTTCAAATGTGGGAT
		AGCAGTGGCTCCAGTCTCCAGCTGGGAATATTACG
		CGTCTGTCTACACAGAGAGATTCATGGGTCTCCCA
		ACAAAGGATGATAATCTTGAGCACTATAAGAATTC
		AACTGTGATGGCAAGAGCAGAATATTTCAGAAAT
		GTAGACTATCTTCTCATCCACGGAACAGCAGATGA
		TAATGTGCACTTTCAAAACTCAGCACAGATTGCTA
		AAGCTCTGGTTAATGCACAAGTGGATTTCCAGGCA
		ATGTGGTACTCTGACCAGAACCACGGCTTATCCGG
		CCTGTCCACGAACCACTTATACACCCACATGACCC
		ACTTCCTAAAGCAGTGTTTCTCTTTGTCAGACGGC
		AAAAAGAAAAAGAAAAAGGGCCACCACCATCACC
		ATCAC
28	human CEA	UniProt no. P06731
29	human MCSP	UniProt no. Q6UVK1
30	human EGFR	UniProt no. P00533
31	human CD19	UniProt no. P15391
32	human CD20	Uniprot no. P11836
33	human CD33	UniProt no. P20138
34	human Lymphotoxin α	UniProt no. P01374
35	human TNF	UniProt no. P01375
36	human Lymphotoxin β	UniProt no. Q06643
37	human OX40L	UniProt no. P23510
38	human CD40L	UniProt no. P29965
39	human FasL	UniProt no. P48023
40	human CD27L	UniProt no. P32970
41	human CD30L	UniProt no. P32971
42	human 4-1BBL	UniProt no. P41273
43	human TRAIL	UniProt no. P50591
44	human RANKL	UniProt no. O14788
45	human TWEAK	UniProt no. O43508
46	human APRIL	UniProt no. O75888
47	human BAFF	UniProt no. Q9Y275
48	human LIGHT	UniProt no. O43557
49	human TL1A	UniProt no. O95150
50	human GITRL	UniProt no. Q9UNG2
51	human ectodysplasin A	UniProt no. Q92838
52	hu 4-1BBL (50-254)	ACPWAVSGARASPGSAASPRLREGPELSPDDPAGLL
		DLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLT
		GGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGE
		GSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEAR
		NSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQL
		TQGATVLGLFRVTPEIPAGLPSPRSE
53	hu OX40L (51-183)	QVSHRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMK
		VQNNSVIINCDGFYLISLKGYFSQEVNISLHYQKDEEP
		LFQLKKVRSVNSLMVASLTYKDKVYLNVTTDNTSL
		DDFHVNGGELILIHQNPGEFCVL
54	hu OX40L (52-183)	VSHRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMKV
		QNNSVIINCDGFYLISLKGYFSQEVNISLHYQKDEEPL
		FQLKKVRSVNSLMVASLTYKDKVYLNVTTDNTSLD
		DFHVNGGELILIHQNPGEFCVL
55	Peptide linker (SG4) 2	SGGGGSGGGG
56	Peptide linker G4(SG4) 2	GGGGSGGGGSGGGG
57	Peptide linker	GSPGSSSSGS
58	Peptide linker (G4S) 4	GGGGSGGGGSGGGGSGGGGS
59	Peptide linker	GSGSGNGS
60	Peptide linker	GGSGSGSG
61	Peptide linker	GGSGSG
62	Peptide linker	GGSG
63	Peptide linker	GGSGNGSG
64	Peptide linker	GGNGSGSG
65	Peptide linker	GGNGSG
66	nucleotide sequence	See Table 2
	dimeric hu 4-1BBL (71-
	254)-CH1 Fc knob chain
67	nucleotide sequence	See Table 2
	monomeric hu 4-1BBL (71-
	254)-CL1
68	nucleotide sequence	See Table 2
	anti-FAP (28H1) Fc hole
	chain
69	nucleotide sequence	See Table 2
	anti-FAP (28H1) light
	chain
70	Murine (mu) 4-1BBL	UniProt no. Q3U1Z9-1
71	nucleotide sequence	See Table 13
	dimeric mu 4-1BBL (104-
	309, C137, 160, 246S)-CH1
	Fc knob chain
72	nucleotide sequence	See Table 13
	monomeric mu 4-1BBL
	(104-309, C137, 160, 246S)-
	CL
73	nucleotide sequence	See Table 13
	anti-FAP Fc KK chain
74	nucleotide sequence	See Table 13
	anti-FAP light chain
75	dimeric mu 4-1BBL (104-	See Table 13
	309, C137, 160, 246S)-CL
	Fc DD chain
76	monomeric mu 4-1BBL	See Table 13
	(104-309, C137, 160, 246S)-
	CL1
77	anti-FAP Fc KK chain	See Table 13
78	anti-FAP light chain	See Table 13
79	nucleotide sequence DP47	See Table 18
	Fc-hole chain
80	nucleotide sequence DP47	See Table 18
	light chain
81	DP47 Fc-hole chain	See Table 18
82	DP47 light chain	See Table 18
83	Human 4-1BB Fc(kih)	See Table 31
84	Cynomolgus 4-1BB Fc (kih)	See Table 31
85	Murine 4-1BB Fc (kih)	See Table 31
86	nucleotide sequence	See Table 32
	Fc hole chain
87	nucleotide sequence	See Table 32
	Human 4-1BB Fc (kih)
88	nucleotide sequence	See Table 32
	Cynomolgus 4-1BB Fc (kih)
89	nucleotide sequence	See Table 32
	Murine 4-1BB Fc (kih)
90	Fc hole chain	See Table 32
91	Human 4-1BB Fc (kih)	See Table 32
92	Cynomolgus 4-1BB Fc (kih)	See Table 32
93	Murine 4-1BB Fc (kih)	See Table 32
94	nucleotide sequence	See Table 33
	Human 4-1BB His
95	Human 4-1BB His	See Table 33
96	Human (hu) 4-1BBL (71-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP
	248)	LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVY
		YVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA
		ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG
		VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGL
97	dimeric hu 4-1BBL (71-248)	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP
	connected by (G4S) 2 linker	LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVY
		YVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA
		ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG
		VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLG
		GGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQLVA
		QNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKEL
		VVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQP
		LRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLH
		LSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRV
		TPEIPAGL
98	dimeric hu 4-1BBL (80-254)	DPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGL
	connected by (G4S) 2 linker	AGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRR
		VVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPP
		ASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARAR
		HAWQLTQGATVLGLFRVTPEIPAGLPSPRSEGGGGSG
		GGGSDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY
		SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQ
		LELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALT
		VDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHT
		EARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSE
99	dimeric hu 4-1BBL (52-254)	PWAVSGARASPGSAASPRLREGPELSPDDPAGLLDLR
	connected by (G4S) 2 linker	QGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGL
		SYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSG
		SVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSA
		FGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQG
		ATVLGLFRVTPEIPAGLPSPRSEGGGGSGGGGSPWAV
		SGARASPGSAASPRLREGPELSPDDPAGLLDLRQGMF
		AQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKE
		DTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSL
		ALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGF
		QGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATV
		LGLFRVTPEIPAGLPSPRSE
100	FAP (4B9) CDR-H1	SYAMS
101	FAP (4B9) CDR-H2	AIIGSGASTYYADSVKG
102	FAP (4B9) CDR-H3	GWFGGFNY
103	FAP (4B9) CDR-L1	RASQSVTSSYLA
104	FAP (4B9) CDR-L2	VGSRRAT
105	FAP (4B9) CDR-L3	QQGIMLPPT
106	FAP (4B9) VH	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA
		MSWVRQAPGKGLEWVSAIIGSGASTYYADSVK
		GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK
		GWFGGFNYWGQGTLVTVSS
107	FAP (4B9) VL	EIVLTQSPGTLSLSPGERATLSCRASQSVTSSYLA
		WYQQKPGQAPRLLINVGSRRATGIPDRFSGSGSG
		TDFTLTISRLEPEDFAVYYCQQGIMLPPTFGQGT
		KVEIK
108	dimeric hu 4-1BBL (71-	see Table 4
	254)-CH1* Fc knob chain
109	monomeric hu 4-1BBL (71-	see Table 4
	254)-CL*
110	monomeric hu 4-1BBL (71-	see Table 7
	254)-(G4S)1-CL*
111	dimeric hu 4-1BBL (52-	see Table 10
	254)-CH1* Fc knob chain
112	monomeric hu 4-1BBL (52-	see Table 10
	254)-CL*
113	dimeric hu 4-1BBL (80-	see Table 11
	254)-CH1* Fc knob chain
114	monomeric hu 4-1BBL (80-	see Table 11
	254)-CL*
115	dimeric hu 4-1BBL (71-	see Table 3
	254)-CL* Fc knob chain
116	monomeric hu 4-1BBL (71-	see Table 3
	254)-CH1*
117	dimeric hu 4-1BBL (71-	see Table 22
	254)-CL Fc knob chain
118	monomeric hu 4-1BBL (71-	see Table 22
	254)-CH1
119	dimeric hu 4-1BBL (71-	see Table 24
	248)-CL* Fc knob chain
120	monomeric hu 4-1BBL (71-	see Table 24
	248)-CH1*
121	anti-FAP (28H1) Fc hole	see Table 6
	chain fused to dimeric 4-
	1BBL (71-254)
122	anti-FAP (28H1) Fc knob	see Table 6
	chain fused to monomeric 4-
	1BBL (71-254)
123	anti-FAP (4B9) Fc hole	see Table 23
	chain fused to dimeric 4-
	1BBL (71-254)
124	anti-FAP (4B9) Fc knob	see Table 23
	chain fused to monomeric 4-
	1BBL (71-254)
125	anti-FAP (4B9) light chain	see Table 21
126	anti-FAP (4B9) Fc hole	see Table 26
	chain fused to dimeric 4-
	1BBL (71-248)
127	anti-FAP (4B9) Fc knob	see Table 26
	chain fused to monomeric 4-
	1BBL (71-248)
128	Peptide linker	GGGGS
129	nucleotide sequence dimeric	see Table 3
	hu 4-1BBL (71-254)-CL*
	Fc knob chain
130	nucleotide sequence	see Table 3
	monomeric hu 4-1BBL (71-
	254)-CH1*
131	nucleotide sequence dimeric	see Table 4
	hu 4-1BBL (71-254)-
	CH1* Fc knob chain
132	nucleotide sequence	see Table 4
	monomeric hu 4-1BBL (71-
	254)-CL*
133	nucleotide sequence anti-	see Table 4
	FAP (28H1) (VHCL) Fc
	hole chain
134	nucleotide sequence anti-	see Table 4
	FAP (28H1) (VLCH1) light
	chain
135	anti-FAP (VHCL) (28H1)	see Table 4
	Fc hole chain
136	anti-FAP (VLCH1) (28H1)	see Table 4
	light chain
137	nucleotide sequence	see Table 5
	monomeric hu 4-1BBL (71-
	254)-CH1* Fc knob chain
138	nucleotide sequence dimeric	see Table 5
	hu 4-1BBL (71-254)-CL*
139	monomeric hu 4-1BBL (71-	see Table 5
	254)-CL* Fc knob chain
140	dimeric hu 4-1BBL (71-254)-	see Table 5
	CL*
141	nucleotide sequence anti-	see Table 6
	FAP (28H1) Fc hole chain
	fused to dimeric hu 4-1BBL
	(71-254)
142	nucleotide sequence anti-	see Table 6
	FAP (28H1) Fc knob chain
	fused to monomeric hu 4-
	1BBL (71-254)
143	nucleotide sequence	see Table 7
	monomeric hu 4-1BBL (71-
	254)-(G4S) 1 - CL*
144	nucleotide sequence [anti-	see Table 8
	FAP (28H1)] 2 Fc hole chain
145	[anti-FAP (28H1)] 2 Fc hole	see Table 8
	chain
146	nucleotide sequence dimeric	see Table 9
	hu 4-1BBL (71-254)-FAP
	(VHCL*) Fc knob chain
147	nucleotide sequence	see Table 9
	monomeric hu 4-1BBL (71-
	254)-FAP (VLCH1*)
148	dimeric hu 4-1BBL (71-254)-	see Table 9
	FAP (VHCL*) Fc knob
	chain
149	monomeric hu 4-1BBL (71-	see Table 9
	254)-FAP (VLCH1*)
150	nucleotide sequence dimeric	see Table 10
	hu 4-1BBL (52-254)-
	CH1* Fc knob chain
151	nucleotide sequence	see Table 10
	Monomeric hu 4-1BBL (52-
	254)-CL*
152	nucleotide sequence dimeric	see Table 11
	hu 4-1BBL (80-254)-
	CH1* Fc knob chain
153	nucleotide sequence	see Table 11
	Monomeric hu 4-1BBL (80-
	254)-CL*
154	nucleotide sequence DP47	see Table 14
	FC KK chain
155	nucleotide sequence DP47	see Table 14
	light chain
156	DP47 FC KK chain	see Table 14
157	DP47 light chain	see Table 14
158	nucleotide sequence dimeric	see Table 15
	mu 4-1BBL (104-309,
	C160S)-CL Fc DD chain
159	nucleotide sequence	see Table 15
	monomeric murine 4-1BBL
	(104-309, C160S)-CH1
160	dimeric mu 4-1BBL (104-	see Table 15
	309, C160S)-CL Fc DD
	chain
161	monomeric murine 4-1BBL	see Table 15
	(104-309, C160S)-CH1
162	nucleotide sequence	see Table 21
	anti-FAP (4B9) Fc hole
	chain
163	nucleotide sequence	see Table 21
	anti-FAP (4B9) light chain
164	anti-FAP (4B9) Fc hole	see Table 21
	chain
165	nucleotide sequence dimeric	see Table 22
	hu 4-1BBL (71-254)-CL
	Fc knob chain
166	nucleotide sequence	see Table 22
	monomeric hu 4-1BBL (71-
	254)-CH1
167	nucleotide sequence anti-	see Table 23
	FAP (4B9) Fc hole chain
	fused to dimeric hu 4-1BBL
	(71-254)
168	nucleotide sequence anti-	see Table 23
	FAP (4B9) Fc knob chain
	fused to monomeric hu 4-
	1BBL (71-254)
169	nucleotide sequence dimeric	see Table 24
	hu 4-1BBL (71-248)-CL*
	Fc knob chain
170	nucleotide sequence	see Table 24
	monomeric hu
	4-1BBL (71-248)-CH1*
171	nucleotide sequence dimeric	see Table 25
	hu 4-1BBL (71-248)-CL
	Fc knob chain
172	nucleotide sequence	see Table 25
	monomeric hu
	4-1BBL (71-248)-CH1
173	Dimeric hu 4-1BBL (71-	see Table 25
	248)-CL Fc knob chain
174	Monomeric hu	see Table 25
	4-1BBL (71-248)-CH1
175	nucleotide sequence anti-	see Table 26
	FAP (4B9) Fc hole chain
	fused to dimeric hu 4-1BBL
	(71-248)
176	nucleotide sequence anti-	see Table 26
	FAP (4B9) Fc knob chain
	fused to monomeric hu 4-
	1BBL (71-248)
177	nucleotide sequence DP47	see Table 27
	Fc hole chain fused to
	dimeric hu 4-1BBL (71-254)
178	nucleotide sequence DP47	see Table 27
	Fc knob chain fused to
	monomeric hu 4-1BBL (71-
	254)
179	DP47 Fc hole chain fused to	see Table 27
	dimeric hu 4-1BBL (71-254)
180	DP47 Fc knob chain fused	see Table 27
	to monomeric hu 4-1BBL
	(71-254)
181	nucleotide sequence DP47	see Table 29
	heavy chain (hu IgG1
	PGLALA)
182	DP47 heavy chain (hu IgG1	see Table 29
	PGLALA)
183	monomeric hu 4-1BBL (71-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP
	254) plus (G4S) 1 linker	LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVY
		YVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA
		ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG
		VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLP
		SPRSEGGGGS
184	monomeric hu 4-1BBL (71-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP
	248) plus (G4S) 2 linker	LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVY
		YVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA
		ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG
		VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLG
		GGGSGGGGS
185	monomeric hu 4-1BBL (71-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP
	248) plus (G4S) 1 linker	LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVY
		YVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA
		ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG
		VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLG
		GGGS
186	Nucleotide sequence	see Table 43
	human CD19 antigen Fc
	knob chain avi tag
187	Polypeptide sequence	see Table 43
	human CD19 antigen Fc
	knob chain avi tag
188	Nucleotide sequence	see Table 43
	cynomolgus CD19 antigen
	Fc knob chain avi tag
189	Polypeptide sequence	see Table 43
	cynomolgus CD19 antigen
	Fc knob chain avi tag
190	humanized CD19 (8B8)	NSNGNT
	HVR-L1
191	humanized CD19 (8B8)	KFNG
	HVR-H2
192	humanized CD19 (8B8)	TEKFQGRVTM
	var.1 to 9 HVR-H2
193	humanized CD19 (8B8)	LENPNGNT
	var.5 HVR-L1
194	humanized CD19 (8B8)	LENPSGNT
	var.9 HVR-L1
195	CD19 (8B8-018) CDR-H1	DYIMH
196	CD19 (8B8-018) CDR-H2	YINPYNDGSKYTEKFQG
197	CD19 (8B8-018) CDR-H3	GTYYYGSALFDY
198	CD19 (8B8-018) CDR-L1	KSSQSLENPNGNTYLN
199	CD19 (8B8-018) CDR-L2	RVSKRFS
200	CD19 (8B8-018) CDR-L3	LQLTHVPYT
201	CD19 (8B8-018) VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMH
		WVRQAPGQGLEWMGYINPYNDGSKYTEKFQGRVT
		MTSDTSISTAYMELSRLRSDDTAVYYCARGTYYYGS
		ALFDYWGQGTTVTVSS
202	CD19 (8B8-018) VL	DIVMTQTPLSLSVTPGQPASISCKSSQSLENPNGNTYL
		NWYLQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTD
		FTLKISRVEAEDVGVYYCLQLTHVPYTFGQGTKLEIK
203	Nucleotide sequence anti-	see Table 47
	CD19 (8B8-018)
	Fc hole chain
204	Nucleotide sequence anti-	see Table 47
	CD19 (8B8-018) light chain
205	anti-CD19 (8B8-018) Fc hole	see Table 47
	chain
206	anti-CD19 (8B8-018) light	see Table 47
	chain
207	Nucleotide sequence anti-	see Table 49
	CD19 (8B8-018) Fc hole
	dimeric ligand chain
208	Nucleotide sequence anti-	see Table 49
	CD19 (8B8-018) Fc knob
	monomeric ligand
209	anti-CD19 (8B8-018) Fc hole	see Table 49
	dimeric ligand chain
210	anti-CD19 (8B8-018) Fc	see Table 49
	knob monomeric ligand
211	Nucleotide sequence anti-	see Table 52
	CD19 (8B8-018) Fc hole
	dimeric ligand (71-248)
	chain
212	Nucleotide sequence anti-	see Table 52
	CD19 (8B8-018) Fc knob
	monomeric (71-248) ligand
213	anti-CD19 (8B8-018) Fc hole	see Table 52
	dimeric ligand (71-248)
	chain
214	anti-CD19 (8B8-018) Fc	see Table 52
	knob monomeric (71-248)
	ligand
215	Nucleotide sequence CD19	GAGGTCCAGCTGCAGCAGTCTGGACCTGAGCTGGT
	(8B8) VH Parental clone	AAAGCCTGGGGCTTCAGTGAAGATGGCCTGCAAG
		GCTTCTGGATACACATTCACTGACTATATTATGCA
		CTGGGTGAAGCAGAAGACTGGGCAGGGCCTTGAG
		TGGATTGGATATATTAATCCTTACAATGATGGTTCT
		AAGTACACTGAGAAGTTCAACGGCAAGGCCACAC
		TGACTTCAGACAAATCTTCCATCACAGCCTACATG
		GAGCTCAGCAGCCTGACCTCTGAGGACTCTGCGGT
		CTATTACTGTGCAAGAGGGACCTATTATTATGGTA
		GCGCCCTCTTTGACTACTGGGGCCAAGGCACCACT
		CTCACAGTCTCCTCG
216	Nucleotide sequence CD19	GATGCTGTGATGACCCAAACTCCACTCTCCCTGCC
	(8B8) VL Parental clone	TGTCAGTCTTGGAGATCAAGCCTCCATCTCTTGCA
		GGTCTAGTCAGAGCCTTGAAAACAGTAATGGAAA
		CACCTATTTGAACTGGTACCTCCAGAAACCAGGCC
		AGTCTCCACAACTCCTGATCTACAGGGTTTCCAAA
		CGATTTTCTGGGGTCCTAGACAGGTTCAGTGGTAG
		TGGATCAGGGACAGATTTCACACTGAAAATCAGCA
		GAGTGGAGGCTGAGGATTTGGGAGTTTATTTCTGC
		CTACAACTTACACATGTCCCGTACACGTTCGGAGG
		GGGGACCAAGCTGGAAATAAAA
217	CD19 L1 reverse random	see Table 53
218	CD19 L2 forward random	see Table 53
219	CD19 H1 reverse random	see Table 53
220	CD19 H2 forward random	see Table 53
221	CD19 H3 reverse constant	see Table 53
222	LMB3	see Table 53
223	D19 L1 forward constant	see Table 54
224	CD19 L3 reverse random	see Table 54
225	CD19 L3 forward constant	see Table 54
226	CD19 H3 reverse random	see Table 54
227	Nucleotide sequence SNAP	GGCCGCCGCTAGCGGCATCGACTACAAGGACGAC
	tag human CD19 ECD-	GATGACAAGGCCGGCATCGATGCCATCATGGACA
	PDGFR	AAGACTGCGAAATGAAGCGCACCACCCTGGATAG
		CCCTCTGGGCAAGCTGGAACTGTCTGGGTGCGAAC
		AGGGCCTGCACGAGATCAAGCTGCTGGGCAAAGG
		AACATCTGCCGCCGACGCCGTGGAAGTGCCTGCCC
		CAGCCGCCGTGCTGGGCGGACCAGAGCCACTGAT
		GCAGGCCACCGCCTGGCTCAACGCCTACTTTCACC
		AGCCTGAGGCCATCGAGGAGTTCCCTGTGCCAGCC
		CTGCACCACCCAGTGTTCCAGCAGGAGAGCTTTAC
		CCGCCAGGTGCTGTGGAAACTGCTGAAAGTGGTGA
		AGTTCGGAGAGGTCATCAGCTACCAGCAGCTGGCC
		GCCCTGGCCGGCAATCCCGCCGCCACCGCCGCCGT
		GAAAACCGCCCTGAGCGGAAATCCCGTGCCCATTC
		TGATCCCCTGCCACCGGGTGGTGTCTAGCTCTGGC
		GCCGTGGGGGGCTACGAGGGCGGGCTCGCCGTGA
		AAGAGTGGCTGCTGGCCCACGAGGGCCACAGACT
		GGGCAAGCCTGGGCTGGGTGATATCCCCGAGGAA
		CCCCTGGTCGTGAAGGTGGAAGAGGGCGACAATG
		CCGTGCTGCAGTGCCTGAAGGGCACCTCCGATGGC
		CCTACCCAGCAGCTGACCTGGTCCAGAGAGAGCCC
		CCTGAAGCCCTTCCTGAAGCTGTCTCTGGGCCTGC
		CTGGCCTGGGCATCCATATGAGGCCTCTGGCCATC
		TGGCTGTTCATCTTCAACGTGTCCCAGCAGATGGG
		CGGCTTCTACCTGTGTCAGCCTGGCCCCCCATCTG
		AGAAGGCTTGGCAGCCTGGCTGGACCGTGAACGT
		GGAAGGATCCGGCGAGCTGTTCCGGTGGAACGTGT
		CCGATCTGGGCGGCCTGGGATGCGGCCTGAAGAA
		CAGATCTAGCGAGGGCCCCAGCAGCCCCAGCGGC
		AAACTGATGAGCCCCAAGCTGTACGTGTGGGCCAA
		GGACAGACCCGAGATCTGGGAGGGCGAGCCTCCT
		TGCCTGCCCCCTAGAGACAGCCTGAACCAGAGCCT
		GAGCCAGGACCTGACAATGGCCCCTGGCAGCACA
		CTGTGGCTGAGCTGTGGCGTGCCACCCGACTCTGT
		GTCTAGAGGCCCTCTGAGCTGGACCCACGTGCACC
		CTAAGGGCCCTAAGAGCCTGCTGAGCCTGGAACTG
		AAGGACGACAGGCCCGCCAGAGATATGTGGGTCA
		TGGAAACCGGCCTGCTGCTGCCTAGAGCCACAGCC
		CAGGATGCCGGCAAGTACTACTGCCACAGAGGCA
		ACCTGACCATGAGCTTCCACCTGGAAATCACCGCC
		AGACCCGTGCTGTGGCACTGGCTGCTGAGAACAGG
		CGGCTGGAAGGTCGACGAACAAAAACTCATCTCA
		GAAGAGGATCTGAATGCTGTGGGCCAGGACACGC
		AGGAGGTCATCGTGGTGCCACACTCCTTGCCCTTT
		AAGGTGGTGGTGATCTCAGCCATCCTGGCCCTGGT
		GGTGCTCACCATCATCTCCCTTATCATCCTCATCAT
		GCTTTGGCAGAAGAAGCCACGT
228	Nucleotide sequence SNAP	CCGGCCGCCGCTAGCGGCATCGACTACAAGGACG
	tag cynomolgus CD19	ACGATGACAAGGCCGGCATCGATGCCATCATGGA
	ECD-PDGFR	CAAAGACTGCGAAATGAAGCGCACCACCCTGGAT
		AGCCCTCTGGGCAAGCTGGAACTGTCTGGGTGCGA
		ACAGGGCCTGCACGAGATCAAGCTGCTGGGCAAA
		GGAACATCTGCCGCCGACGCCGTGGAAGTGCCTGC
		CCCAGCCGCCGTGCTGGGCGGACCAGAGCCACTG
		ATGCAGGCCACCGCCTGGCTCAACGCCTACTTTCA
		CCAGCCTGAGGCCATCGAGGAGTTCCCTGTGCCAG
		CCCTGCACCACCCAGTGTTCCAGCAGGAGAGCTTT
		ACCCGCCAGGTGCTGTGGAAACTGCTGAAAGTGGT
		GAAGTTCGGAGAGGTCATCAGCTACCAGCAGCTG
		GCCGCCCTGGCCGGCAATCCCGCCGCCACCGCCGC
		CGTGAAAACCGCCCTGAGCGGAAATCCCGTGCCCA
		TTCTGATCCCCTGCCACCGGGTGGTGTCTAGCTCTG
		GCGCCGTGGGGGGCTACGAGGGCGGGCTCGCCGT
		GAAAGAGTGGCTGCTGGCCCACGAGGGCCACAGA
		CTGGGCAAGCCTGGGCTGGGTGATATCCCCCAGGA
		ACCCCTGGTCGTGAAGGTGGAAGAGGGCGACAAT
		GCCGTGCTCCAGTGTCTCGAGGGCACCTCCGATGG
		CCCTACACAGCAGCTCGTGTGGTGCAGAGACAGCC
		CCTTCGAGCCCTTCCTGAACCTGTCTCTGGGCCTGC
		CTGGCATGGGCATCAGAATGGGCCCTCTGGGCATC
		TGGCTGCTGATCTTCAACGTGTCCAACCAGACCGG
		CGGCTTCTACCTGTGTCAGCCTGGCCTGCCAAGCG
		AGAAGGCTTGGCAGCCTGGATGGACCGTGTCCGTG
		GAAGGATCTGGCGAGCTGTTCCGGTGGAACGTGTC
		CGATCTGGGCGGCCTGGGATGCGGCCTGAAGAAC
		AGAAGCAGCGAGGGCCCTAGCAGCCCCAGCGGCA
		AGCTGAATAGCAGCCAGCTGTACGTGTGGGCCAA
		GGACAGACCCGAGATGTGGGAGGGCGAGCCTGTG
		TGTGGCCCCCCTAGAGATAGCCTGAACCAGAGCCT
		GAGCCAGGACCTGACAATGGCCCCTGGCAGCACA
		CTGTGGCTGAGCTGTGGCGTGCCACCCGACTCTGT
		GTCCAGAGGCCCTCTGAGCTGGACACACGTGCGGC
		CTAAGGGCCCTAAGAGCAGCCTGCTGAGCCTGGA
		ACTGAAGGACGACCGGCCCGACCGGGATATGTGG
		GTGGTGGATACAGGCCTGCTGCTGACCAGAGCCAC
		AGCCCAGGATGCCGGCAAGTACTACTGCCACAGA
		GGCAACTGGACCAAGAGCTTTTACCTGGAAATCAC
		CGCCAGACCCGCCCTGTGGCACTGGCTGCTGAGAA
		TCGGAGGCTGGAAGGTCGACGAGCAGAAGCTGAT
		CTCCGAAGAGGACCTGAACGCCGTGGGCCAGGAT
		ACCCAGGAAGTGATCGTGGTGCCCCACAGCCTGCC
		CTTCAAGGTGGTCGTGATCAGCGCCATTCTGGCCC
		TGGTGGTGCTGACCATCATCAGCCTGATCATCCTG
		ATTATGCTGTGGCAGAAAAAGCCCCGC
229	Polypeptide sequence SNAP	PAAASGIDYKDDDDKAGIDAIMDKDCEMKRTTLDSP
	tag human CD19 ECD-	LGKLELSGCEQGLHEIKLLGKGTSAADAVEVPAPAA
	PDGFR	VLGGPEPLMQATAWLNAYFHQPEAIEEFPVPALHHP
		VFQQESFTRQVLWKLLKVVKFGEVISYQQLAALAGN
		PAATAAVKTALSGNPVPILIPCHRVVSSSGAVGGYEG
		GLAVKEWLLAHEGHRLGKPGLGDIPEEPLVVKVEEG
		DNAVLQCLKGTSDGPTQQLTWSRESPLKPFLKLSLG
		LPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSE
		KAWQPGWTVNVEGSGELFRWNVSDLGGLGCGLKN
		RSSEGPSSPSGKLMSPKLYVWAKDRPEIWEGEPPCLP
		PRDSLNQSLSQDLTMAPGSTLWLSCGVPPDSVSRGPL
		SWTHVHPKGPKSLLSLELKDDRPARDMWVMETGLL
		LPRATAQDAGKYYCHRGNLTMSFHLEITARPVLWH
		WLLRTGGWKVDEQKLISEEDLNAVGQDTQEVIVVP
		HSLPFKVVVISAILALVVLTIISLIILIMLWQKKPR
230	Polypeptide sequence SNAP	PAAASGIDYKDDDDKAGIDAIMDKDCEMKRTTLDSP
	tag cynomolgus CD19	LGKLELSGCEQGLHEIKLLGKGTSAADAVEVPAPAA
	ECD-PDGFR	VLGGPEPLMQATAWLNAYFHQPEAIEEFPVPALHHP
		VFQQESFTRQVLWKLLKVVKFGEVISYQQLAALAGN
		PAATAAVKTALSGNPVPILIPCHRVVSSSGAVGGYEG
		GLAVKEWLLAHEGHRLGKPGLGDIPQEPLVVKVEEG
		DNAVLQCLEGTSDGPTQQLVWCRDSPFEPFLNLSLG
		LPGMGIRMGPLGIWLLIFNVSNQTGGFYLCQPGLPSE
		KAWQPGWTVSVEGSGELFRWNVSDLGGLGCGLKN
		RSSEGPSSPSGKLNSSQLYVWAKDRPEMWEGEPVCG
		PPRDSLNQSLSQDLTMAPGSTLWLSCGVPPDSVSRGP
		LSWTHVRPKGPKSSLLSLELKDDRPDRDMWVVDTG
		LLLTRATAQDAGKYYCHRGNWTKSFYLEITARPAL
		WHWLLRIGGWKVDEQKLISEEDLNAVGQDTQEVIV
		VPHSLPFKVVVISAILALVVLTIISLIILIMLWQKKPR
231	CD19 (8B8-5H09) CDR-L1	see Table 56
232	CD19 (8B8-5H09) CDR-L2	see Table 56
233	CD19 (8B8-5H09) CDR-L3	see Table 56
234	CD19 (8B8-5H09) CDR-H1	see Table 57
235	CD19 (8B8-5H09) CDR-H2	see Table 57
236	CD19 (8B8-5H09) CDR-H3	see Table 57
237	CD19 (8B8-7H07) CDR-L1	see Table 56
238	CD19 (8B8-7H07) CDR-L2	see Table 56
239	CD19 (8B8-7H07) CDR-L3	see Table 56
240	CD19 (8B8-7H07) CDR-H1	see Table 57
241	CD19 (8B8-7H07) CDR-H2	see Table 57
242	CD19 (8B8-7H07) CDR-H3	see Table 57
243	CD19 (8B8-2B03) CDR-L1	see Table 56
244	CD19 (8B8-2B03) CDR-L2	see Table 56
245	CD19 (8B8-2B03) CDR-L3	see Table 56
246	CD19 (8B8-2B03) CDR-H1	see Table 57
247	CD19 (8B8-2B03) CDR-H2	see Table 57
248	CD19 (8B8-2B03) CDR-H3	see Table 57
249	CD19 (8B8-2B11) CDR-L1	see Table 56
250	CD19 (8B8-2B11) CDR-L2	see Table 56
251	CD19 (8B8-2B11) CDR-L3	see Table 56
252	CD19 (8B8-2B11) CDR-H1	see Table 57
253	CD19 (8B8-2B11) CDR-H2	see Table 57
254	CD19 (8B8-2B11) CDR-H3	see Table 57
255	CD19 (8B8-5A07) CDR-L1	see Table 56
256	CD19 (8B8-5A07) CDR-L2	see Table 56
257	CD19 (8B8-5A07) CDR-L3	see Table 56
258	CD19 (8B8-5A07) CDR-H1	see Table 57
259	CD19 (8B8-5A07) CDR-H2	see Table 57
260	CD19 (8B8-5A07) CDR-H3	see Table 57
261	CD19 (8B8-5B08) CDR-L1	see Table 56
262	CD19 (8B8-5B08) CDR-L2	see Table 56
263	CD19 (8B8-5B08) CDR-L3	see Table 56
264	CD19 (8B8-5B08) CDR-H1	see Table 57
265	CD19 (8B8-5B08) CDR-H2	see Table 57
266	CD19 (8B8-5B08) CDR-H3	see Table 57
267	CD19 (8B8-5D08) CDR-L1	see Table 56
268	CD19 (8B8-5D08) CDR-L2	see Table 56
269	CD19 (8B8-5D08) CDR-L3	see Table 56
270	CD19 (8B8-5D08) CDR-H1	see Table 57
271	CD19 (8B8-5D08) CDR-H2	see Table 57
272	CD19 (8B8-5D08) CDR-H3	see Table 57
273	nucleotide sequence CD19	see Table 58
	(8B8) parental light chain
274	nucleotide sequence CD19	see Table 58
	(8B8) parental heavy chain
275	CD19 (8B8) parental light	see Table 58
	chain
276	CD19 (8B8) parental heavy	see Table 58
	chain
277	nucleotide sequence CD19	see Table 59
	(8B8-2B11) light chain
278	nucleotide sequence CD19	see Table 59
	(8B8-2B11) heavy chain
279	CD19 (8B8-2B11) light	see Table 59
	chain
280	CD19 (8B8-2B11) heavy	see Table 59
	chain
281	nucleotide sequence CD19	see Table 59
	(8B8-7H07) light chain
282	nucleotide sequence CD19	see Table 59
	(8B8-7H07) heavy chain
283	CD19 (8B8-7H07) light	see Table 59
	chain
284	CD19 (8B8-7H07) heavy	see Table 59
	chain
285	nucleotide sequence CD19	see Table 59
	(8B8-2B03) light chain
286	nucleotide sequence CD19	see Table 59
	(8B8-2B03) heavy chain
287	CD19 (8B8-2B03) light	see Table 59
	chain
288	CD19 (8B8-2B03) heavy	see Table 59
	chain
289	nucleotide sequence CD19	see Table 59
	(8B8-5A07) light chain
290	nucleotide sequence CD19	see Table 59
	(8B8-5A07) heavy chain
291	CD19 (8B8-5A07) light	see Table 59
	chain
292	CD19 (8B8-5A07) heavy	see Table 59
	chain
293	nucleotide sequence CD19	see Table 59
	(8B8-5D08) light chain
294	nucleotide sequence CD19	see Table 59
	(8B8-5D08) heavy chain
295	CD19 (8B8-5D08) light	see Table 59
	chain
296	CD19 (8B8-5D08) heavy	see Table 59
	chain
297	nucleotide sequence CD19	see Table 59
	(8B8-5B08) light chain
298	nucleotide sequence CD19	see Table 59
	(8B8-5B08) heavy chain
299	CD19 (8B8-5B08) light	see Table 59
	chain
300	CD19 (8B8-5B08) heavy	see Table 59
	chain
301	nucleotide sequence CD19	see Table 59
	(8B8-5H09) light chain
302	nucleotide sequence CD19	see Table 59
	(8B8-5H09) heavy chain
303	CD19 (8B8-5H09) light	see Table 59
	chain
304	CD19 (8B8-5H09) heavy	see Table 59
	chain
305	Nucleotide sequence anti-	see Table 62
	CD19 (8B8-2B11)
	Fc hole chain
306	anti-CD19 (8B8-2B11) Fc	see Table 62
	hole chain
307	Nucleotide sequence anti-	see Table 64
	CD19 (8B8-2B11) Fc hole
	dimeric ligand chain
308	Nucleotide sequence anti-	see Table 64
	CD19 (8B8-2B11) Fc knob
	monomeric ligand
309	anti-CD19 (8B8-2B11) Fc	see Table 64
	hole dimeric ligand chain
310	anti-CD19 (8B8-2B11) Fc	see Table 64
	knob monomeric ligand
311	Nucleotide sequence anti-	see Table 67
	CD19 (8B8-2B11) Fc hole
	dimeric ligand (71-248)
	chain
312	Nucleotide sequence anti-	see Table 67
	CD19 (8B8-2B11) Fc knob
	monomeric (71-248) ligand
313	anti-CD19 (8B8-2B11) Fc	see Table 67
	hole dimeric ligand (71-
	248)chain
314	anti-CD19 (8B8-2B11) Fc	see Table 67
	knob monomeric (71-248)
	ligand
315	nucleotide sequence	see Table 72
	CD19 (8B8-018) heavy chain
	(huIgG1 PGLALA)
316	CD19 (8B8-018) heavy chain	see Table 72
	(huIgG1 PGLALA)
317	anti-mu CEA T84.66	MKCSWVIFFL MAVVTGVNSE VQLQQSGAEL
	VH	VEPGASVKLS CTASGFNIKD TYMHWVKQRP
		EQGLEWIGRI DPANGNSKYV PKFQGKATIT
		ADTSSNTAYL QLTSLTSEDT AVYYCAPFGY
		YVSDYAMAYW GQGTSVTVSS
318	anti-mu CEA T84.66	METDTLLLWV LLLWVPGSTG DIVLTQSPAS
	VL	LAVSLGQRAT MSCRAGESVD IFGVGFLHWY
		QQKPGQPPKL LIYRASNLES GIPVRFSGTG
		SRTDFTLIID PVEADDVATY YCQQTNEDPY
		TFGGGTKLEI K
319	IGHV1-69*08	TAAGGGGCTT CCTAGTCCTA AGGCTGAGGA
	IMGT Acc No. Z14309	AGGGATCCTG GTTTAGTTAA AGAGGATTTT
		ATTCACCCCT GTGTCCTCTC CACAGGTGTC
		CAGTCCCAGG TCCAGCTGGT GCAATCTGGG
		GCTGAGGTGA AGAAGCCTGG GTCCTCGGTG
		AAGGTCTCCT GCAAGGCTTC TGGAGGCACC
		TTCAGCAGCT ATACTATCAG CTGGGTGCGA
		CAGGCCCCTG GACAAGGGCT TGAGTGGATG
		GGAAGGATCA TCCCTATCCT TGGTACAGCA
		AACTACGCAC AGAAGTTCCA GGGCAGAGTC
		ACGATTACCG CGGACAAATC CACGAGCACA
		GCCTACATGG AGCTGAGCAG CCTGAGATCT
		GAGGACACGG CCGTGTATTA CTGTGCGAGA GA
320	IGKV3-11*01	CTGCAGCTGG AAGCTCAGCT CCCACCCAGC
	IMGT Acc No.	TGCTTTGCAT GTCCCTCCCA GCTGCCCTAC
		CTTCCAGAGC CCATATCAAT GCCTGTGTCA
		GAGCCCTGGG GAGGAACTGC TCAGTTAGGA
		CCCAGAGGGA ACCATGGAAG CCCCAGCTCA
		GCTTCTCTTC CTCCTGCTAC TCTGGCTCCC
		AGGTGAGGGG AACATGAGGT GGTTTTGCAC
		ATTAGTGAAA ACTCTTGCCA CCTCTGCTCA
		GCAAGAAATA TAATTAAAAT TCAAAGTATA
		TCAACAATTT TGGCTCTACT CAAAGACAGT
		TGGTTTGATC TTGATTACAT GAGTGCATTT
		CTGTTTTATT TCCAATTTCA GATACCACCG
		GAGAAATTGT GTTGACACAG TCTCCAGCCA
		CCCTGTCTTT GTCTCCAGGG GAAAGAGCCA
		CCCTCTCCTG CAGGGCCAGT CAGAGTGTTA
		GCAGCTACTT AGCCTGGTAC CAACAGAAAC
		CTGGCCAGGC TCCCAGGCTC CTCATCTATG
		ATGCATCCAA CAGGGCCACT GGCATCCCAG
		CCAGGTTCAG TGGCAGTGGG TCTGGGACAG
		ACTTCACTCT CACCATCAGC AGCCTAGAGC
		CTGAAGATTT TGCAGTTTAT TACTGTCAGC
		AGCGTAGCAA CTGGCCTCCC ACAGTGATTC
		CACATGAAAC AAAAACCCCA ACAAGACCAT
		CAGTGTTTAC TAGATTATTA TACCAGCTGC
		TTCCTTTACA GACAGCTAGT GGGGTGGCCA
		CTCAGTGTTA GCATCTCAGC TCTATTTGGC
		CATTTTGGAG TTCAAGT
321	CEA CDR-H1	see Table 81
322	CEA CDR-H2	see Table 81
323	CEA CDR-H3	see Table 81
324	CEA CDR-L1	see Table 81
325	CEA CDR-L2	see Table 81
326	CEA CDR-L3	see Table 81
327	Parental CEA binder VH	see Table 81
328	Parental CEA binder VL	see Table 81
329	Humanized CEA binder VH	see Table 81
330	Humanized CEA binder VL	see Table 81
331	Nucleotide sequence anti-	see Table 82
	CEA (T84.66-LCHA) Fc
	hole chain
332	Nucleotide sequence anti-	see Table 82
	CEA (T84.66-LCHA) light
	chain
333	anti-CEA (T84.66-LCHA)	see Table 82
	Fc hole chain
334	anti-CEA (T84.66-LCHA)	see Table 82
	light chain
335	Nucleotide sequence anti-	see Table 84
	CEA (T84.66-LCHA) Fc
	hole dimeric ligand chain
336	Nucleotide sequence anti-	see Table 84
	CEA (T84.66-LCHA) Fc
	knob monomeric ligand
337	anti-CEA (T84.66-LCHA)	see Table 84
	Fc hole dimeric ligand
	chain
338	anti-CEA (T84.66-LCHA)	see Table 84
	Fc knob monomeric ligand
339	Nucleotide sequence anti-	see Table 87
	CEA (T84.66-LCHA) Fc
	hole dimeric ligand (71-
	248) chain
340	Nucleotide sequence anti-	see Table 87
	CEA (T84.66-LCHA) Fc
	knob monomeric (71-248)
	ligand
341	anti-CEA (T84.66-LCHA)	see Table 87
	Fc hole dimeric ligand
	(71-248) chain
342	anti-CEA (T84.66-LCHA)	see Table 87
	Fc knob monomeric (71-
	248) ligand
343	Nucleotide sequence anti-	see Table 88
	CEA (T84.66) Fc hole chain
344	Nucleotide sequence anti-	see Table 88
	CEA (T84.66) light chain
345	anti-CEA (T84.66) Fc hole	see Table 88
	chain
346	anti-CEA (T84.66) light	see Table 88
	chain
347	Nucleotide sequence anti-	see Table 89
	CEA (T84.66) Fc hole
	dimeric ligand chain
348	Nucleotide sequence anti-	see Table 89
	CEA (T84.66) Fc knob
	monomeric ligand
349	anti-CEA (T84.66) Fc hole	see Table 89
	dimeric ligand chain
350	anti-CEA (T84.66) Fc knob	see Table 89
	monomeric ligand
351	nucleotide sequence hu	see Table 92
	NA3B3A2-avi His
352	human NA3B3A2-avi-His	see Table 92
353	Nucleotide sequence	see Table 97
	Dimeric hu OX40L (51-183)-
	CL* Fc knob chain
354	Nucleotide sequence	see Table 97
	Monomeric hu
	OX40L (51-183)-CH1*
355	Dimeric hu OX40L (51-183)-	see Table 97
	CL* Fc knob chain
356	Monomeric hu	see Table 97
	OX40L (51-183)-CH1*
357	CD19 (8B8-2B11) VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMH
		WVRQAPGQGLEWMGYINPYNDGSKYTEKFQGRVT
		MTSDTSISTAYMELSRLRSDDTAVYYCARGTYYYGP
		QLFDYWGQGTTVTVSS
358	CD19 (8B8-2B11) VL	DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGTTYL
		NWYLQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTD
		FTLKISRVEAEDVGVYYCLQLLEDPYTFGQGTKLEIK
359	CD19 (8B8-7H07) VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMH
		WVRQAPGQGLEWMGYINPYNDGSKYTEKFQGRVT
		MTSDTSISTAYMELSRLRSDDTAVYYCARGTYYYGS
		ELFDYWGQGTTVTVSS
360	CD19 (8B8-7H07) VL	DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGNTYL
		NWYLQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTD
		FTLKISRVEAEDVGVYYCLQATHIPYTFGQGTKLEIK
361	CD19 (8B8-2B03) VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYITH
		WVRQAPGQGLEWMGYINPYNDGSKYTEKFQGRVT
		MTSDTSISTAYMELSRLRSDDTAVYYCARGTYYYGP
		DLFDYWGQGTTVTVSS
362	CD19 (8B8-2B03) VL	DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGNTYL
		NWYLQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTD
		FTLKISRVEAEDVGVYYCLQLTHVPYTFGQGXKLEIK
363	CD19 (8B8-5A07) VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMH
		WVRQAPGQGLEWMGYINPYNDGSKYTEKFQGRVT
		MTSDTSISTAYMELSRLRSDDTAVYYCARGTYYYGS
		ALFDYWGQGTTVTVSS
364	CD19 (8B8-5A07) VL	DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGNTYL
		NWYLQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTD
		FTLKISRVEAEDVGVYYCLQPGHYPGTFGQGTKLEIK
365	CD19 (8B8-5D08) VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMH
		WVRQAPGQGLEWMGYINPYNDGSKYTEKFQGRVT
		MTSDTSISTAYMELSRLRSDDTAVYYCARGTYYYGS
		ELFDYWGQGTTVTVSS
366	CD19 (8B8-5D08) VL	DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGNTYL
		NWYLQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTD
		FTLKISRVEAEDVGVYYCLQLTHEPYTFGQGTKLEIK
367	CD19 (8B8-5B08) VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMH
		WVRQAPGQGLEWMGYINPYNDGSKYTEKFQGRVT
		MTSDTSISTAYMELSRLRSDDTAVYYCARGTYYYGP
		QLFDYWGQGTTVTVSS
368	CD19 (8B8-5B08) VL	DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGNTYL
		NWYLQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTD
		FTLKISRVEAEDVGVYYCLQLDSYPNTFGQGTKLEIK
369	CD19 (8B8-5H09) VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMH
		WVRQAPGQGLEWMGYINPYNDGSKYTEKFQGRVT
		MTSDTSISTAYMELSRLRSDDTAVYYCARGTYYYGS
		ALFDYWGQGTTVTVSS
370	CD19 (8B8-5H09) VL	DIVMTQTPLSLSVTPGQPASISCKSSQSLESSTGNTYL
		NWYLQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTD
		FTLKISRVEAEDVGVYYCLQLIDYPVTFGQGTKLEIK
371	dimeric huOX40L (51-183)	QVSHRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMK
	connected by (G4S) 2 linker	VQNNSVIINCDGFYLISLKGYFSQEVNISLHYQKDEEP
		LFQLKKVRSVNSLMVASLTYKDKVYLNVTTDNTSL
		DDFHVNGGELILIHQNPGEFCVLGGGGSGGGGSQVS
		HRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMKVQN
		NSVIINCDGFYLISLKGYFSQEVNISLHYQKDEEPLFQ
		LKKVRSVNSLMVASLTYKDKVYLNVTTDNTSLDDF
		HVNGGELILIHQNPGEFCVL
372	dimeric huOX40L (52-183)	VSHRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMKV
	connected by (G4S) 2 linker	QNNSVIINCDGFYLISLKGYFSQEVNISLHYQKDEEPL
		FQLKKVRSVNSLMVASLTYKDKVYLNVTTDNTSLD
		DFHVNGGELILIHQNPGEFCVLGGGGSGGGGSVSHR
		YPRIQSIKVQFTEYKKEKGFILTSQKEDEIMKVQNNS
		VIINCDGFYLISLKGYFSQEVNISLHYQKDEEPLFQLK
		KVRSVNSLMVASLTYKDKVYLNVTTDNTSLDDFHV
		NGGELILIHQNPGEFCVL
373	hu 4-1BBL (85-248)	LDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSL
		TGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAG
		EGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEA
		RNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQ
		LTQGATVLGLFRVTPEIPAGL
374	hu 4-1BBL (80-248)	DPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGL
		AGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRR
		VVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPP
		ASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARAR
		HAWQLTQGATVLGLFRVTPEIPAGL
375	hu 4-1BBL (52-248)	PWAVSGARASPGSAASPRLREGPELSPDDPAGLLDLR
		QGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGL
		SYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSG
		SVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSA
		FGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQG
		ATVLGLFRVTPEIPAGL

TABLE 1 — Characteristics of produced TNF ligand trimer-containing antigen binding molecules (FAP split 4-1BBL trimers)

	Valency for	FAP	4-1BBL	Crossed CH1-CL	Charged	Linker to 4-1BBL in
Construct	FAP	binder	ectodomain	domains	residues	light chain
1.1	monovalent	28H1	71-254	no	no	(G4S)2
1.2	monovalent	28H1	71-254	yes (Ligand)	yes	(G4S)2
					(Ligand)
1.3	monovalent	28H1	71-254	yes (FAP	yes	(G4S)2
				Fab)	(Ligand)
1.4	monovalent	28H1	71-254	no	yes	(G4S)2
					(Ligand)
1.5	bivalent	28H1	71-254	no	no	(G4S)2
1.6	monovalent	28H1	71-254	no	yes	(G4S)1
					(Ligand)
1.7	bivalent	28H1	71-254	yes (Ligand)	yes	(G4S)2
					(Ligand)
1.8	bivalent	28H1	71-254	yes (FAP	yes	(G4S)2
				Fab fused to	(Ligand)
				Ligand)
1.9	monovalent	28H1	52-254	no	yes	(G4S)2
					(Ligand)
1.10	monovalent	28H1	80-254	no	yes	(G4S)2
					(Ligand)

TABLE 2 — Sequences of FAP-targeted human 4-1BB ligand trimer containing Fc (kih) fusion molecule Construct 1.1 SEQ ID

NO:	Description	Sequence
66	Dimeric hu 4-	AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG
	1BBL (71-254)-	ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT
	CH1 Fc knob	GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG
	chain	GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG
		CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG
		TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG
		AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT
		GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCGCT
		GCTGGCGCTGCAGCTCTGGCACTGACAGTGGATCTGCCT
		CCTGCCAGCTCCGAGGCCCGGAATAGCGCATTTGGGTTT
		CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT
		GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG
		CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG
		TTCAGAGTGACCCCCGAGATTCCAGCCGGCCTGCCTTCT
		CCAAGAAGCGAAGGCGGAGGCGGATCTGGCGGCGGAG
		GATCTAGAGAGGGACCCGAACTGTCCCCTGACGATCCA
		GCCGGGCTGCTGGATCTGAGACAGGGAATGTTCGCCCA
		GCTGGTGGCTCAGAATGTGCTGCTGATTGACGGACCTCT
		GAGCTGGTACTCCGACCCAGGGCTGGCAGGGGTGTCCC
		TGACTGGGGGACTGTCCTACAAAGAAGATACAAAAGAA
		CTGGTGGTGGCTAAAGCTGGGGTGTACTATGTGTTTTTT
		CAGCTGGAACTGAGGCGGGTGGTGGCTGGGGAGGGCTC
		AGGATCTGTGTCCCTGGCTCTGCATCTGCAGCCACTGCG
		CTCTGCTGCTGGCGCAGCTGCACTGGCTCTGACTGTGGA
		CCTGCCACCAGCCTCTAGCGAGGCCAGAAACAGCGCCT
		TCGGGTTCCAAGGACGCCTGCTGCATCTGAGCGCCGGAC
		AGCGCCTGGGAGTGCATCTGCATACTGAAGCCAGAGCC
		CGGCATGCTTGGCAGCTGACTCAGGGGGCAACTGTGCTG
		GGACTGTTTCGCGTGACACCTGAGATCCCTGCCGGACTG
		CCAAGCCCTAGATCAGAAGGGGGCGGAGGAAGCGGAG
		GGGGAGGAAGTGCTAGCACCAAGGGCCCTAGCGTGTTC
		CCTCTGGCCCCTAGCAGCAAGAGCACAAGTGGAGGAAC
		AGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGA
		GCCCGTGACCGTGTCCTGGAATTCTGGCGCCCTGACAAG
		CGGCGTGCACACATTTCCAGCCGTGCTGCAGAGCAGCG
		GCCTGTACTCTCTGAGCAGCGTCGTGACCGTGCCCTCTA
		GCTCTCTGGGCACCCAGACCTACATCTGCAACGTGAACC
		ACAAGCCCAGCAACACCAAAGTGGACAAGAAGGTGGA
		ACCCAAGAGCTGCGACAAGACCCACACCTGTCCCCCTTG
		CCCTGCCCCTGAAGCTGCTGGTGGCCCTTCCGTGTTCCT
		GTTCCCCCCAAAGCCCAAGGACACCCTGATGATCAGCC
		GGACCCCCGAAGTGACCTGCGTGGTGGTCGATGTGTCCC
		ACGAGGACCCTGAAGTGAAGTTCAATTGGTACGTGGAC
		GGCGTGGAAGTGCACAATGCCAAGACCAAGCCGCGGGA
		GGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCC
		TCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG
		TACAAGTGCAAGGTCTCCAACAAAGCCCTCGGCGCCCC
		CATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCC
		GAGAACCACAGGTGTACACCCTGCCCCCATGCCGGGAT
		GAGCTGACCAAGAACCAGGTCAGCCTGTGGTGCCTGGT
		CAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGG
		AGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACG
		CCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACA
		GCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGG
		AACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCAC
		AACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT
		AAA
67	Monomeric hu 4-	AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG
	1BBL (71-254)-	ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT
	CL	GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG
		GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG
		CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG
		TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG
		AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT
		GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCGCT
		GCTGGCGCTGCAGCTCTGGCACTGACAGTGGATCTGCCT
		CCTGCCAGCTCCGAGGCCCGGAATAGCGCATTTGGGTTT
		CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT
		GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG
		CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG
		TTCAGAGTGACCCCCGAGATTCCAGCCGGCCTGCCTTCT
		CCAAGAAGCGAAGGCGGAGGCGGATCTGGCGGCGGAG
		GATCTCGTACGGTGGCTGCACCATCTGTCTTCATCTTCCC
		GCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGT
		TGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAA
		AGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTA
		ACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC
		AGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAA
		AGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAG
		TCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCT
		TCAACAGGGGAGAGTGT
68	anti-FAP Fc hole	GAAGTGCAGCTGCTGGAATCCGGCGGAGGCCTGGTGCA
	chain	GCCTGGCGGATCTCTGAGACTGTCCTGCGCCGCCTCCGG
		CTTCACCTTCTCCTCCCACGCCATGTCCTGGGTCCGACA
		GGCTCCTGGCAAAGGCCTGGAATGGGTGTCCGCCATCTG
		GGCCTCCGGCGAGCAGTACTACGCCGACTCTGTGAAGG
		GCCGGTTCACCATCTCCCGGGACAACTCCAAGAACACCC
		TGTACCTGCAGATGAACTCCCTGCGGGCCGAGGACACC
		GCCGTGTACTACTGTGCCAAGGGCTGGCTGGGCAACTTC
		GACTACTGGGGACAGGGCACCCTGGTCACCGTGTCCAG
		CGCTAGCACCAAGGGCCCCTCCGTGTTCCCCCTGGCCCC
		CAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCTCTGG
		GCTGCCTGGTCAAGGACTACTTCCCCGAGCCCGTGACCG
		TGTCCTGGAACAGCGGAGCCCTGACCTCCGGCGTGCAC
		ACCTTCCCCGCCGTGCTGCAGAGTTCTGGCCTGTATAGC
		CTGAGCAGCGTGGTCACCGTGCCTTCTAGCAGCCTGGGC
		ACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAG
		CAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCT
		GCGACAAAACTCACACATGCCCACCGTGCCCAGCACCT
		GAAGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCA
		AAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGA
		GGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACC
		CTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAG
		GTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA
		CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCT
		GCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCA
		AGGTCTCCAACAAAGCCCTCGGCGCCCCCATCGAGAAA
		ACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACA
		GGTGTGCACCCTGCCCCCATCCCGGGATGAGCTGACCAA
		GAACCAGGTCAGCCTCTCGTGCGCAGTCAAAGGCTTCTA
		TCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGC
		AGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTG
		GACTCCGACGGCTCCTTCTTCCTCGTGAGCAAGCTCACC
		GTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTC
		ATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACAC
		GCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
69	anti-FAP light	GAGATCGTGCTGACCCAGTCCCCCGGCACCCTGTCTCTG
	chain	AGCCCTGGCGAGAGAGCCACCCTGTCCTGCAGAGCCTC
		CCAGTCCGTGTCCCGGTCCTACCTCGCCTGGTATCAGCA
		GAAGCCCGGCCAGGCCCCTCGGCTGCTGATCATCGGCG
		CCTCTACCAGAGCCACCGGCATCCCTGACCGGTTCTCCG
		GCTCTGGCTCCGGCACCGACTTCACCCTGACCATCTCCC
		GGCTGGAACCCGAGGACTTCGCCGTGTACTACTGCCAGC
		AGGGCCAGGTCATCCCTCCCACCTTTGGCCAGGGCACCA
		AGGTGGAAATCAAGCGTACGGTGGCTGCACCATCTGTCT
		TCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAA
		CTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAG
		AGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCC
		AATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGAC
		AGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGAC
		GCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACG
		CCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCA
		CAAAGAGCTTCAACAGGGGAGAGTGT
14	Dimeric hu 4-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY
	1BBL (71-254)-	SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR
	CH1 Fc knob	RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASS
	chain	EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT
		QGATVLGLFRVTPEIPAGLPSPRSEGGGGSGGGGSREGPEL
		SPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLA
		GVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAG
		EGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNS
		AFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATV
		LGLFRVTPEIPAGLPSPRSEGGGGSGGGGSASTKGPSVFPLA
		PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHT
		FPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK
		VDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTL
		MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
		PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALG
		APIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVK
		GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT
		VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
		REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY
15	Monomeric hu 4-	SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR
	1BBL (71-254)-	RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASS
	CL1	EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT
		QGATVLGLFRVTPEIPAGLPSPRSEGGGGSGGGGSRTVAAP
		SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNA
		LQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA
		CEVTHQGLSSPVTKSFNRGEC
18	anti-FAP (28H1)	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSHAMSWVRQA
	FC hole chain	PGKGLEWVSAIWASGEQYYADSVKGRFTISRDNSKNTLYL
		QMNSLRAEDTAVYYCAKGWLGNFDYWGQGTLVTVSSAS
		TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
		GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVF
		LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG
		VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
		CKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRDELTKN
		QVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
		GSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS
		LSLSPGK
19	anti-FAP (28H1)	EIVLTQSPGTLSLSPGERATLSCRASQSVSRSYLAWYQQKP
	light chain	GQAPRLLIIGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDF
		AVYYCQQGQVIPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQ
		LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESV
		TEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSS
		PVTKSFNRGEC

TABLE 3 — Sequences of FAP-targeted human 4-1BB ligand trimer containing Fc (kih) fusion molecule Construct 1.2 SEQ ID

NO:	Description	Sequence
129	Dimeric hu 4-	AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG
	1BBL (71-254)-	ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT
	CL* Fc knob	GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG
	chain	GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG
		CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG
		TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG
		AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT
		GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCGCT
		GCTGGCGCTGCAGCTCTGGCACTGACAGTGGATCTGCCT
		CCTGCCAGCTCCGAGGCCCGGAATAGCGCATTTGGGTTT
		CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT
		GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG
		CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG
		TTCAGAGTGACCCCCGAGATTCCAGCCGGCCTGCCTTCT
		CCAAGAAGCGAAGGCGGAGGCGGATCTGGCGGCGGAG
		GATCTAGAGAGGGACCCGAACTGTCCCCTGACGATCCA
		GCCGGGCTGCTGGATCTGAGACAGGGAATGTTCGCCCA
		GCTGGTGGCTCAGAATGTGCTGCTGATTGACGGACCTCT
		GAGCTGGTACTCCGACCCAGGGCTGGCAGGGGTGTCCC
		TGACTGGGGGACTGTCCTACAAAGAAGATACAAAAGAA
		CTGGTGGTGGCTAAAGCTGGGGTGTACTATGTGTTTTTT
		CAGCTGGAACTGAGGCGGGTGGTGGCTGGGGAGGGCTC
		AGGATCTGTGTCCCTGGCTCTGCATCTGCAGCCACTGCG
		CTCTGCTGCTGGCGCAGCTGCACTGGCTCTGACTGTGGA
		CCTGCCACCAGCCTCTAGCGAGGCCAGAAACAGCGCCT
		TCGGGTTCCAAGGACGCCTGCTGCATCTGAGCGCCGGAC
		AGCGCCTGGGAGTGCATCTGCATACTGAAGCCAGAGCC
		CGGCATGCTTGGCAGCTGACTCAGGGGGCAACTGTGCTG
		GGACTGTTTCGCGTGACACCTGAGATCCCTGCCGGACTG
		CCAAGCCCTAGATCAGAAGGGGGCGGAGGTTCCGGAGG
		GGGAGGATCTCGTACGGTGGCTGCACCATCTGTCTTTAT
		CTTCCCACCCAGCGACCGGAAGCTGAAGTCTGGCACAG
		CCAGCGTCGTGTGCCTGCTGAATAACTTCTACCCCCGCG
		AGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAG
		AGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACA
		GCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACC
		CTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGC
		CTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGAC
		CAAGAGCTTCAACCGGGGCGAGTGCGACAAGACCCACA
		CCTGTCCTCCATGCCCTGCCCCTGAAGCTGCTGGCGGCC
		CTAGCGTGTTCCTGTTCCCCCCAAAGCCCAAGGACACCC
		TGATGATCAGCCGGACCCCTGAAGTGACCTGCGTGGTGG
		TGGATGTGTCCCACGAGGACCCTGAAGTGAAGTTCAATT
		GGTACGTGGACGGCGTGGAAGTGCACAATGCCAAGACC
		AAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGT
		GGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAA
		TGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCC
		TCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAA
		GGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCC
		ATGCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGT
		GGTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCG
		TGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTAC
		AAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTC
		TTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTG
		GCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGA
		GGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCT
		GTCTCCGGGTAAA
130	Monomeric hu 4-	AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG
	1BBL (71-254-	ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT
	CH1*	GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG
		GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG
		CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG
		TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG
		AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT
		GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCGCT
		GCTGGCGCTGCAGCTCTGGCTCTGACAGTGGATCTGCCT
		CCTGCCAGCTCCGAGGCCCGGAATAGCGCATTTGGGTTT
		CAAGGCCGGCTGCTGCACCTGTCTGCCGGCCAGAGACT
		GGGAGTGCATCTGCACACAGAGGCCAGAGCCAGGCACG
		CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG
		TTCAGAGTGACCCCCGAGATTCCTGCCGGCCTGCCTAGC
		CCTAGATCTGAAGGCGGCGGAGGTTCCGGAGGCGGAGG
		ATCTGCTAGCACAAAGGGCCCCAGCGTGTTCCCTCTGGC
		CCCTAGCAGCAAGAGCACATCTGGCGGAACAGCCGCCC
		TGGGCTGCCTGGTGGAAGATTACTTCCCCGAGCCCGTGA
		CCGTGTCCTGGAATTCTGGCGCCCTGACAAGCGGCGTGC
		ACACCTTTCCAGCCGTGCTGCAGAGCAGCGGCCTGTACT
		CTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCTCTCTGG
		GCACCCAGACCTACATCTGCAACGTGAACCACAAGCCC
		AGCAACACCAAGGTGGACGAGAAGGTGGAACCCAAGTC
		CTGC
68	anti-FAP Fc hole	See Table 2
	chain
69	anti-FAP light	See Table 2
	chain
115	Dimeric hu 4-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY
	1BBL (71-254)-	SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR
	CL* Fc knob	RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASS
	chain	EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT
		QGATVLGLFRVTPEIPAGLPSPRSEGGGGSGGGGSREGPEL
		SPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLA
		GVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAG
		EGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNS
		AFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATV
		LGLFRVTPEIPAGLPSPRSEGGGGSGGGGSRTVAAPSVFIFP
		PSDRKLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
		SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
		QGLSSPVTKSFNRGECDKTHTCPPCPAPEAAGGPSVFLFPP
		KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV
		HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV
		SNKALGAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVS
		LWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF
		FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
		SPGK
116	Monomeric hu 4-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY
	1BBL (71-254)-	SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR
	CH1*	RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASS
		EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT
		QGATVLGLFRVTPEIPAGLPSPRSEGGGGSGGGGSASTKGP
		SVFPLAPSSKSTSGGTAALGCLVEDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK
		PSNTKVDEKVEPKSC
18	anti-FAP (28H1)	See Table 2
	Fc hole chain
19	anti-FAP (28H1)	See Table 2
	light chain

TABLE 4 — Sequences of FAP-targeted human 4-1BB ligand trimer containing Fc (kih) fusion molecule Construct 1.3 SEQ ID

NO:	Description	Sequence
131	Dimeric hu 4-	AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG
	1BBL (71-254)-	ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT
	CH1* Fc knob	GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG
	chain	GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG
		CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG
		TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG
		AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT
		GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCGCT
		GCTGGCGCTGCAGCTCTGGCACTGACAGTGGATCTGCCT
		CCTGCCAGCTCCGAGGCCCGGAATAGCGCATTTGGGTTT
		CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT
		GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG
		CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG
		TTCAGAGTGACCCCCGAGATTCCAGCCGGCCTGCCTTCT
		CCAAGAAGCGAAGGCGGAGGCGGATCTGGCGGCGGAG
		GATCTAGAGAGGGACCCGAACTGTCCCCTGACGATCCA
		GCCGGGCTGCTGGATCTGAGACAGGGAATGTTCGCCCA
		GCTGGTGGCTCAGAATGTGCTGCTGATTGACGGACCTCT
		GAGCTGGTACTCCGACCCAGGGCTGGCAGGGGTGTCCC
		TGACTGGGGGACTGTCCTACAAAGAAGATACAAAAGAA
		CTGGTGGTGGCTAAAGCTGGGGTGTACTATGTGTTTTTT
		CAGCTGGAACTGAGGCGGGTGGTGGCTGGGGAGGGCTC
		AGGATCTGTGTCCCTGGCTCTGCATCTGCAGCCACTGCG
		CTCTGCTGCTGGCGCAGCTGCACTGGCTCTGACTGTGGA
		CCTGCCACCAGCCTCTAGCGAGGCCAGAAACAGCGCCT
		TCGGGTTCCAAGGACGCCTGCTGCATCTGAGCGCCGGAC
		AGCGCCTGGGAGTGCATCTGCATACTGAAGCCAGAGCC
		CGGCATGCTTGGCAGCTGACTCAGGGGGCAACTGTGCTG
		GGACTGTTTCGCGTGACACCTGAGATCCCTGCCGGACTG
		CCAAGCCCTAGATCAGAAGGGGGCGGAGGAAGCGGAG
		GGGGAGGAAGTGCTAGCACCAAGGGCCCCTCCGTGTTC
		CCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCAC
		AGCCGCTCTGGGCTGCCTGGTCGAGGACTACTTCCCCGA
		GCCCGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCTC
		CGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGTTCTGG
		CCTGTATAGCCTGAGCAGCGTGGTCACCGTGCCTTCTAG
		CAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACC
		ACAAGCCCAGCAACACCAAGGTGGACGAGAAGGTGGA
		GCCCAAGAGCTGCGACAAAACTCACACATGCCCACCGT
		GCCCAGCACCTGAAGCTGCAGGGGGACCGTCAGTCTTC
		CTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
		CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAG
		CCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
		ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGG
		GAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGT
		CCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGG
		AGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGCGCC
		CCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCC
		CCGAGAACCACAGGTGTACACCCTGCCCCCATGCCGGG
		ATGAGCTGACCAAGAACCAGGTCAGCCTGTGGTGCCTG
		GTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGG
		GAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCAC
		GCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTAC
		AGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGG
		GAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCA
		CAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGG
		TAAA
132	Monomeric hu 4-	AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG
	1BBL (71-254)-	ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT
	CL*	GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG
		GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG
		CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG
		TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG
		AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT
		GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCGCT
		GCTGGCGCTGCAGCTCTGGCACTGACAGTGGATCTGCCT
		CCTGCCAGCTCCGAGGCCCGGAATAGCGCATTTGGGTTT
		CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT
		GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG
		CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG
		TTCAGAGTGACCCCCGAGATTCCAGCCGGCCTGCCTTCT
		CCAAGAAGCGAAGGCGGAGGCGGATCTGGCGGCGGAG
		GATCTCGTACGGTGGCTGCACCATCTGTCTTCATCTTCCC
		GCCATCTGATCGGAAGTTGAAATCTGGAACTGCCTCTGT
		TGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAA
		AGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTA
		ACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC
		AGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAA
		AGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAG
		TCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCT
		TCAACAGGGGAGAGTGT
133	anti-FAP (VHCL)	GAAGTGCAGCTGCTGGAATCCGGCGGAGGCCTGGTGCA
	(28H1) Fc hole	GCCTGGCGGATCTCTGAGACTGTCCTGCGCCGCCTCCGG
	chain	CTTCACCTTCTCCTCCCACGCCATGTCCTGGGTCCGACA
		GGCTCCTGGCAAAGGCCTGGAATGGGTGTCCGCCATCTG
		GGCCTCCGGCGAGCAGTACTACGCCGACTCTGTGAAGG
		GCCGGTTCACCATCTCCCGGGACAACTCCAAGAACACCC
		TGTACCTGCAGATGAACTCCCTGCGGGCCGAGGACACC
		GCCGTGTACTACTGTGCCAAGGGCTGGCTGGGCAACTTC
		GACTACTGGGGACAGGGCACCCTGGTCACCGTGTCCAG
		CGCTAGCGTGGCCGCTCCCAGCGTGTTCATCTTCCCACC
		CAGCGACGAGCAGCTGAAGTCCGGCACAGCCAGCGTGG
		TGTGCCTGCTGAACAACTTCTACCCCCGCGAGGCCAAGG
		TGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAAC
		AGCCAGGAATCCGTGACCGAGCAGGACAGCAAGGACTC
		CACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGG
		CCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTG
		ACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTC
		AACCGGGGCGAGTGCGACAAGACCCACACCTGTCCCCC
		TTGCCCTGCCCCTGAAGCTGCTGGTGGCCCTTCCGTGTT
		CCTGTTCCCCCCAAAGCCCAAGGACACCCTGATGATCAG
		CCGGACCCCCGAAGTGACCTGCGTGGTGGTCGATGTGTC
		CCACGAGGACCCTGAAGTGAAGTTCAATTGGTACGTGG
		ACGGCGTGGAAGTGCACAATGCCAAGACCAAGCCGCGG
		GAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGT
		CCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGG
		AGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGCGCC
		CCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCC
		CCGAGAACCACAGGTGTGCACCCTGCCCCCATCCCGGG
		ATGAGCTGACCAAGAACCAGGTCAGCCTCTCGTGCGCA
		GTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGG
		GAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCAC
		GCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCGT
		GAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGG
		GGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGC
		ACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG
		GTAAA
134	anti-FAP	GAGATCGTGCTGACCCAGTCTCCCGGCACCCTGAGCCTG
	(VLCH1) (28H1)	AGCCCTGGCGAGAGAGCCACCCTGAGCTGCAGAGCCAG
	light chain	CCAGAGCGTGAGCCGGAGCTACCTGGCCTGGTATCAGC
		AGAAGCCCGGCCAGGCCCCCAGACTGCTGATCATCGGC
		GCCAGCACCCGGGCCACCGGCATCCCCGATAGATTCAG
		CGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAG
		CCGGCTGGAACCCGAGGACTTCGCCGTGTACTACTGCCA
		GCAGGGCCAGGTGATCCCCCCCACCTTCGGCCAGGGCA
		CCAAGGTGGAAATCAAGAGCAGCGCTTCCACCAAAGGC
		CCTTCCGTGTTTCCTCTGGCTCCTAGCTCCAAGTCCACCT
		CTGGAGGCACCGCTGCTCTCGGATGCCTCGTGAAGGATT
		ATTTTCCTGAGCCTGTGACAGTGTCCTGGAATAGCGGAG
		CACTGACCTCTGGAGTGCATACTTTCCCCGCTGTGCTGC
		AGTCCTCTGGACTGTACAGCCTGAGCAGCGTGGTGACAG
		TGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGC
		AACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAA
		GAAGGTGGAACCCAAGTCTTGT
108	Dimeric hu 4-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY
	1BBL (71-254)-	SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR
	CH1* Fc knob	RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASS
	chain	EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT
		QGATVLGLFRVTPEIPAGLPSPRSEGGGGSGGGGSREGPEL
		SPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLA
		GVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAG
		EGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNS
		AFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATV
		LGLFRVTPEIPAGLPSPRSEGGGGSGGGGSASTKGPSVFPLA
		PSSKSTSGGTAALGCLVEDYFPEPVTVSWNSGALTSGVHTF
		PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV
		DEKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLM
		ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP
		REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGA
		PIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKG
		FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
		DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
109	Monomeric hu 4-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY
	1BBL (71-254)-	SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR
	CL*	RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASS
		EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT
		QGATVLGLFRVTPEIPAGLPSPRSEGGGGSGGGGSRTVAAP
		SVFIFPPSDRKLKSGTASVVCLLNNFYPREAKVQWKVDNA
		LQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA
		CEVTHQGLSSPVTKSFNRGEC
135	anti-FAP (VHCL)	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSHAMSWVRQA
	(28H1) Fc hole	PGKGLEWVSAIWASGEQYYADSVKGRFTISRDNSKNTLYL
	chain	QMNSLRAEDTAVYYCAKGWLGNFDYWGQGTLVTVSSAS
		VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWK
		VDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKH
		KVYACEVTHQGLSSPVTKSFNRGECDKTHTCPPCPAPEAA
		GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN
		WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL
		NGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSR
		DELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTP
		PVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHN
		HYTQKSLSLSPGK
136	anti-FAP	EIVLTQSPGTLSLSPGERATLSCRASQSVSRSYLAWYQQKP
	(VLCH1) (28H1)	GQAPRLLIIGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDF
	light chain	AVYYCQQGQVIPPTFGQGTKVEIKSSASTKGPSVFPLAPSS
		KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA
		VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK
		KVEPKSC

TABLE 5 — Sequences of FAP-targeted human 4-1BB ligand trimer containing Fc (kih) fusion molecule Construct 1.4 SEQ ID

NO:	Description	Sequence
137	Monomeric hu4-	AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGGACT
	1BBL (71-254)-	GCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT
	CH1* Fc knob	GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG
	chain	GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG
		CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG
		TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG
		AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT
		GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCGCT
		GCTGGCGCTGCAGCTCTGGCTCTGACAGTGGATCTGCCT
		CCTGCCAGCTCCGAGGCCCGGAATAGCGCATTTGGGTTT
		CAAGGCCGGCTGCTGCACCTGTCTGCCGGCCAGAGACT
		GGGAGTGCATCTGCACACAGAGGCCAGAGCCAGGCACG
		CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG
		TTCAGAGTGACCCCCGAGATTCCTGCCGGCCTGCCTAGC
		CCTAGATCTGAAGGCGGCGGAGGTTCCGGAGGCGGAGG
		ATCTGCTAGCACCAAGGGCCCCTCCGTGTTCCCCCTGGC
		CCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCTC
		TGGGCTGCCTGGTCGAGGACTACTTCCCCGAGCCCGTGA
		CCGTGTCCTGGAACAGCGGAGCCCTGACCTCCGGCGTGC
		ACACCTTCCCCGCCGTGCTGCAGAGTTCTGGCCTGTATA
		GCCTGAGCAGCGTGGTCACCGTGCCTTCTAGCAGCCTGG
		GCACCCAGACCTACATCTGCAACGTGAACCACAAGCCC
		AGCAACACCAAGGTGGACGAGAAGGTGGAGCCCAAGA
		GCTGCGACAAAACTCACACATGCCCACCGTGCCCAGCA
		CCTGAAGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCC
		CCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCT
		GAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGA
		CCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGG
		AGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAG
		TACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTC
		CTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTG
		CAAGGTCTCCAACAAAGCCCTCGGCGCCCCCATCGAGA
		AAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCA
		CAGGTGTACACCCTGCCCCCATGCCGGGATGAGCTGACC
		AAGAACCAGGTCAGCCTGTGGTGCCTGGTCAAAGGCTTC
		TATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGG
		GCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGC
		TGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCA
		CCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTC
		TCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTAC
		ACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
138	Dimeric hu4-	AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG
	1BBL (71-254)-	ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT
	CL*	GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG
		GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG
		CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG
		TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG
		AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT
		GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCGCT
		GCTGGCGCTGCAGCTCTGGCACTGACAGTGGATCTGCCT
		CCTGCCAGCTCCGAGGCCCGGAATAGCGCATTTGGGTTT
		CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT
		GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG
		CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG
		TTCAGAGTGACCCCCGAGATTCCAGCCGGCCTGCCTTCT
		CCAAGAAGCGAAGGCGGAGGCGGATCTGGCGGCGGAG
		GATCTAGAGAGGGACCCGAACTGTCCCCTGACGATCCA
		GCCGGGCTGCTGGATCTGAGACAGGGAATGTTCGCCCA
		GCTGGTGGCTCAGAATGTGCTGCTGATTGACGGACCTCT
		GAGCTGGTACTCCGACCCAGGGCTGGCAGGGGTGTCCC
		TGACTGGGGGACTGTCCTACAAAGAAGATACAAAAGAA
		CTGGTGGTGGCTAAAGCTGGGGTGTACTATGTGTTTTTT
		CAGCTGGAACTGAGGCGGGTGGTGGCTGGGGAGGGCTC
		AGGATCTGTGTCCCTGGCTCTGCATCTGCAGCCACTGCG
		CTCTGCTGCTGGCGCAGCTGCACTGGCTCTGACTGTGGA
		CCTGCCACCAGCCTCTAGCGAGGCCAGAAACAGCGCCT
		TCGGGTTCCAAGGACGCCTGCTGCATCTGAGCGCCGGAC
		AGCGCCTGGGAGTGCATCTGCATACTGAAGCCAGAGCC
		CGGCATGCTTGGCAGCTGACTCAGGGGGCAACTGTGCTG
		GGACTGTTTCGCGTGACACCTGAGATCCCTGCCGGACTG
		CCAAGCCCTAGATCAGAAGGGGGCGGAGGTTCCGGAGG
		GGGAGGATCTCGTACGGTGGCTGCACCATCTGTCTTCAT
		CTTCCCGCCATCTGATCGGAAGTTGAAATCTGGAACTGC
		CTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGA
		GGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAAT
		CGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGC
		AAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCT
		GAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCT
		GCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACA
		AAGAGCTTCAACAGGGGAGAGTGT
68	anti-FAP (28H1)	see Table 2
	Fc hole chain
69	anti-FAP (28H1)	See Table 2
	light chain
139	Monomeric hu4-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY
	1BBL (71-254)-	SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR
	CL* Fc knob	RVVAGEGSGSVSLALHOPLRSAAGAAALALTVDLPPASS
	chain	EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT
		QGATVLGLFRVTPEIPAGLPSPRSEGGGGSGGGGSREGPEL
		SPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLA
		GVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAG
		EGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNS
		AFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATV
		LGLFRVTPEIPAGLPSPRSEGGGGSGGGGSASTKGPSVFPLA
		PSSKSTSGGTAALGCLVEDYFPEPVTVSWNSGALTSGVHTF
		PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV
		DEKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLM
		ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP
		REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGA
		PIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKG
		FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
		DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
140	Dimeric hu4-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY
	1BBL (71-254)-	SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR
	CL*	RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASS
		EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT
		QGATVLGLFRVTPEIPAGLPSPRSEGGGGSGGGGSREGPEL
		SPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLA
		GVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAG
		EGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNS
		AFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATV
		LGLFRVTPEIPAGLPSPRSEGGGGSGGGGSRTVAAPSVFIFP
		PSDRKLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
		SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
		QGLSSPVTKSFNRGEC
18	anti-FAP (28H1)	see Table 2
	Fc hole chain
19	anti-FAP (28H1)	see Table 2
	light chain

TABLE 6 — Sequences of FAP-targeted human 4-1BB ligand trimer containing Fc (kih) fusion molecule Construct 1.5 SEQ ID

NO:	Description	Sequence
141	anti-FAP (28H1)	GAAGTGCAGCTGCTGGAATCCGGCGGAGGCCTGGTGCA
	Fc hole chain	GCCTGGCGGATCTCTGAGACTGTCCTGCGCCGCCTCCGG
	fused to dimeric	CTTCACCTTCTCCTCCCACGCCATGTCCTGGGTCCGACA
	hu 4-1BBL (71-	GGCTCCTGGCAAAGGCCTGGAATGGGTGTCCGCCATCTG
	254)	GGCCTCCGGCGAGCAGTACTACGCCGACTCTGTGAAGG
		GCCGGTTCACCATCTCCCGGGACAACTCCAAGAACACCC
		TGTACCTGCAGATGAACTCCCTGCGGGCCGAGGACACC
		GCCGTGTACTACTGTGCCAAGGGCTGGCTGGGCAACTTC
		GACTACTGGGGACAGGGCACCCTGGTCACCGTGTCCAG
		CGCTAGCACCAAGGGCCCCTCCGTGTTCCCCCTGGCCCC
		CAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCTCTGG
		GCTGCCTGGTCAAGGACTACTTCCCCGAGCCCGTGACCG
		TGTCCTGGAACAGCGGAGCCCTGACCTCCGGCGTGCAC
		ACCTTCCCCGCCGTGCTGCAGAGTTCTGGCCTGTATAGC
		CTGAGCAGCGTGGTCACCGTGCCTTCTAGCAGCCTGGGC
		ACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAG
		CAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCT
		GCGACAAAACTCACACATGCCCACCGTGCCCAGCACCT
		GAAGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCA
		AAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGA
		GGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACC
		CTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAG
		GTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA
		CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCT
		GCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCA
		AGGTCTCCAACAAAGCCCTCGGCGCCCCCATCGAGAAA
		ACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACA
		GGTGTGCACCCTGCCCCCATCCCGGGATGAGCTGACCAA
		GAACCAGGTCAGCCTCTCGTGCGCAGTCAAAGGCTTCTA
		TCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGC
		AGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTG
		GACTCCGACGGCTCCTTCTTCCTCGTGAGCAAGCTCACC
		GTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTC
		ATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACAC
		GCAGAAGAGCCTCTCCCTGTCTCCGGGTGGAGGCGGCG
		GAAGCGGAGGAGGAGGATCCAGAGAGGGCCCTGAGCTG
		AGCCCCGATGATCCTGCTGGACTGCTGGACCTGCGGCAG
		GGCATGTTTGCTCAGCTGGTGGCCCAGAACGTGCTGCTG
		ATCGATGGCCCCCTGTCCTGGTACAGCGATCCTGGACTG
		GCTGGCGTGTCACTGACAGGCGGCCTGAGCTACAAAGA
		GGACACCAAAGAACTGGTGGTGGCCAAGGCCGGCGTGT
		ACTACGTGTTCTTTCAGCTGGAACTGCGGAGAGTGGTGG
		CCGGCGAAGGATCTGGCTCTGTGTCTCTGGCCCTGCATC
		TGCAGCCTCTGAGAAGCGCTGCTGGCGCTGCAGCTCTGG
		CACTGACAGTGGATCTGCCTCCTGCCAGCTCCGAGGCCC
		GGAATAGCGCATTTGGGTTTCAAGGCAGGCTGCTGCACC
		TGTCTGCCGGCCAGAGGCTGGGAGTGCATCTGCACACA
		GAGGCCAGGGCTAGACACGCCTGGCAGCTGACACAGGG
		CGCTACAGTGCTGGGCCTGTTCAGAGTGACCCCCGAGAT
		TCCAGCCGGCCTGCCTTCTCCAAGAAGCGAAGGCGGAG
		GCGGATCTGGCGGCGGAGGATCTAGAGAGGGACCCGAA
		CTGTCCCCTGACGATCCAGCCGGGCTGCTGGATCTGAGA
		CAGGGAATGTTCGCCCAGCTGGTGGCTCAGAATGTGCTG
		CTGATTGACGGACCTCTGAGCTGGTACTCCGACCCAGGG
		CTGGCAGGGGTGTCCCTGACTGGGGGACTGTCCTACAAA
		GAAGATACAAAAGAACTGGTGGTGGCTAAAGCTGGGGT
		GTACTATGTGTTTTTTCAGCTGGAACTGAGGCGGGTGGT
		GGCTGGGGAGGGCTCAGGATCTGTGTCCCTGGCTCTGCA
		TCTGCAGCCACTGCGCTCTGCTGCTGGCGCAGCTGCACT
		GGCTCTGACTGTGGACCTGCCACCAGCCTCTAGCGAGGC
		CAGAAACAGCGCCTTCGGGTTCCAAGGACGCCTGCTGC
		ATCTGAGCGCCGGACAGCGCCTGGGAGTGCATCTGCAT
		ACTGAAGCCAGAGCCCGGCATGCTTGGCAGCTGACTCA
		GGGGGCAACTGTGCTGGGACTGTTTCGCGTGACACCTGA
		GATCCCTGCCGGACTGCCAAGCCCTAGATCAGAA
		GAAGTGCAGCTGCTGGAATCCGGCGGAGGCCTGGTGCA
142	anti-FAP (28H1)	GCCTGGCGGATCTCTGAGACTGTCCTGCGCCGCCTCCGG
	Fc knob chain	CTTCACCTTCTCCTCCCACGCCATGTCCTGGGTCCGACA
	fused to	GGCTCCTGGCAAAGGCCTGGAATGGGTGTCCGCCATCTG
	monomeric hu 4-	GGCCTCCGGCGAGCAGTACTACGCCGACTCTGTGAAGG
	1BBL (71-254)	GCCGGTTCACCATCTCCCGGGACAACTCCAAGAACACCC
		TGTACCTGCAGATGAACTCCCTGCGGGCCGAGGACACC
		GCCGTGTACTACTGTGCCAAGGGCTGGCTGGGCAACTTC
		GACTACTGGGGACAGGGCACCCTGGTCACCGTGTCCAG
		CGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACC
		CTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGG
		GCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGG
		TGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCAC
		ACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCC
		CTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGC
		ACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAG
		CAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTT
		GTGACAAAACTCACACATGCCCACCGTGCCCAGCACCT
		GAAGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCA
		AAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGA
		GGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACC
		CTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAG
		GTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA
		CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCT
		GCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCA
		AGGTCTCCAACAAAGCCCTCGGCGCCCCCATCGAGAAA
		ACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACA
		GGTGTACACCCTGCCCCCCTGCAGAGATGAGCTGACCA
		AGAACCAGGTGTCCCTGTGGTGTCTGGTCAAGGGCTTCT
		ACCCCAGCGATATCGCCGTGGAGTGGGAGAGCAACGGC
		CAGCCTGAGAACAACTACAAGACCACCCCCCCTGTGCT
		GGACAGCGACGGCAGCTTCTTCCTGTACTCCAAACTGAC
		CGTGGACAAGAGCCGGTGGCAGCAGGGCAACGTGTTCA
		GCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTAC
		ACCCAGAAGTCCCTGAGCCTGAGCCCCGGCGGAGGCGG
		CGGAAGCGGAGGAGGAGGATCCAGAGAGGGCCCTGAG
		CTGAGCCCCGATGATCCTGCTGGACTGCTGGACCTGCGG
		CAGGGCATGTTTGCTCAGCTGGTGGCCCAGAACGTGCTG
		CTGATCGATGGCCCCCTGTCCTGGTACAGCGATCCTGGA
		CTGGCTGGCGTGTCACTGACAGGCGGCCTGAGCTACAA
		AGAGGACACCAAAGAACTGGTGGTGGCCAAGGCCGGCG
		TGTACTACGTGTTCTTTCAGCTGGAACTGCGGAGAGTGG
		TGGCCGGCGAAGGATCTGGCTCTGTGTCTCTGGCCCTGC
		ATCTGCAGCCTCTGAGAAGCGCTGCTGGCGCTGCAGCTC
		TGGCACTGACAGTGGATCTGCCTCCTGCCAGCTCCGAGG
		CCCGGAATAGCGCATTTGGGTTTCAAGGCAGGCTGCTGC
		ACCTGTCTGCCGGCCAGAGGCTGGGAGTGCATCTGCAC
		ACAGAGGCCAGGGCTAGACACGCCTGGCAGCTGACACA
		GGGCGCTACAGTGCTGGGCCTGTTCAGAGTGACCCCCG
		AGATTCCAGCCGGCCTGCCTTCTCCAAGAAGCGAA
69	anti-FAP (28H1)	see Table 2
	light chain
121	anti-FAP (28H1)	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSHAMSWVRQA
	Fc hole chain	PGKGLEWVSAIWASGEQYYADSVKGRFTISRDNSKNTLYL
	fused to dimeric	QMNSLRAEDTAVYYCAKGWLGNFDYWGQGTLVTVSSAS
	hu 4-1BBL (71-	TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
	254)	GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVF
		LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG
		VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
		CKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRDELTKN
		QVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
		GSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS
		LSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQ
		LVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELV
		VAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAA
		GAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGV
		HLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSEG
		GGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQLVAQNV
		LLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGV
		YYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALA
		LTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEA
		RARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSE
122	anti-FAP(28H1)	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSHAMSWVRQA
	Fc knob chain	PGKGLEWVSAIWASGEQYYADSVKGRFTISRDNSKNTLYL
	fused to	QMNSLRAEDTAVYYCAKGWLGNFDYWGQGTLVTVSSAS
	monomeric hu4-	TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
	1BBL (71-254)	GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVF
		LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG
		VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
		CKVSNKALGAPIEKTISKAKGQPREPQVYTLPPCRDELTKN
		QVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
		GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS
		LSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQ
		LVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELV
		VAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAA
		GAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGV
		HLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSE
19	anti-FAP (28H1)	see Table 2
	light chain

TABLE 7 — Sequences of FAP-targeted human 4-1BB ligand trimer containing Fc (kih) fusion molecule Construct 1.6 SEQ ID

NO:	Description	Sequence
131	Dimeric hu 4-	see Table 4
	1BBL (71-
	254)-CH1* Fc
	knob chain
143	Monomeric hu	AGAGAGGGCCCTGAGCTGAGCCCCGAT
	4-1BBL (71-	GATCCTGCTGGACTGCTGGACCTGCGG
	254)-(G4S) 1 -	CAGGGCATGTTTGCTCAGCTGGTGGCC
	CL*	CAGAACGTGCTGCTGATCGATGGCCCC
		CTGTCCTGGTACAGCGATCCTGGACTG
		GCTGGCGTGTCACTGACAGGCGGCCTG
		AGCTACAAAGAGGACACCAAAGAACTG
		GTGGTGGCCAAGGCCGGCGTGTACTAC
		GTGTTCTTTCAGCTGGAACTGCGGAGA
		GTGGTGGCCGGCGAAGGATCTGGCTCT
		GTGTCTCTGGCCCTGCATCTGCAGCCT
		CTGAGAAGCGCTGCTGGCGCTGCAGCT
		CTGGCACTGACAGTGGATCTGCCTCCT
		GCCAGCTCCGAGGCCCGGAATAGCGCA
		TTTGGGTTTCAAGGCAGGCTGCTGCAC
		CTGTCTGCCGGCCAGAGGCTGGGAGTG
		CATCTGCACACAGAGGCCAGGGCTAGA
		CACGCCTGGCAGCTGACACAGGGCGCT
		ACAGTGCTGGGCCTGTTCAGAGTGACC
		CCCGAGATTCCAGCCGGCCTGCCTTCT
		CCAAGAAGCGAAGGCGGAGGCGGATCT
		CGTACGGTGGCTGCACCATCTGTCTTC
		ATCTTCCCGCCATCTGATCGGAAGTTG
		AAATCTGGAACTGCCTCTGTTGTGTGC
		CTGCTGAATAACTTCTATCCCAGAGAG
		GCCAAAGTACAGTGGAAGGTGGATAAC
		GCCCTCCAATCGGGTAACTCCCAGGAG
		AGTGTCACAGAGCAGGACAGCAAGGAC
		AGCACCTACAGCCTCAGCAGCACCCTG
		ACGCTGAGCAAAGCAGACTACGAGAAA
		CACAAAGTCTACGCCTGCGAAGTCACC
		CATCAGGGCCTGAGCTCGCCCGTCACA
		AAGAGCTTCAACAGGGGAGAGTGT
68	anti-FAP	see Table 2
	(28H1)
	Fc hole chain
69	anti-FAP	see Table 2
	(28H1)
	light chain
108	Dimeric hu 4-	see Table 4
	1BBL (71-254)-
	CH1* Fc knob
	chain
110	Monomeric hu	REGPELSPDDPAGLLDLRQGMFAQLVA
	4-1BBL (71-	QNVLLIDGPLSWYSDPGLAGVSLTGGL
	254)-(G4S) 1 -	SYKEDTKELVVAKAGVYYVFFQLELRR
	CL*	VVAGEGSGSVSLALHOPLRSAAGAAAL
		ALTVDLPPASSEARNSAFGFQGRLLHL
		SAGQRLGVHLHTEARARHAWQLTQGAT
		VLGLFRVTPEIPAGLPSPRSEGGGGSR
		TVAAPSVFIFPPSDRKLKSGTASVVCL
		LNNFYPREAKVQWKVDNALQSGNSQES
		VTEQDSKDSTYSLSSTLTLSKADYEKH
		KVYACEVTHQGLSSPVTKSFNRGEC
18	anti-FAP	see Table 2
	(28H1)
	Fc hole chain
19	anti-FAP	see Table 2
	(28H1)
	light chain

TABLE 8 — Sequences of FAP-targeted human 4-1BB ligand trimer containing Fc (kih) fusion molecule Construct 1.7 SEQ ID

NO:	Description	Sequence
129	Dimeric hu4-	see Table 3
	1BBL (71-254)-
	CL* Fc knob
	chain
130	Monomeric hu4-	see Table 3
	1BBL (71-254)-
	CH1*
144	[anti-FAP	GAAGTGCAGCTGCTGGAATCCGGCGGAGGCCTGGTGCAGCCTGGCG
	(28H1)] 2 Fc hole	GATCTCTGAGACTGTCCTGCGCCGCCTCCGGCTT
	chain	CACCTTCTCCTCCCACGCCATGTCCTGGGTCCGACA
		GGCTCCTGGCAAAGGCCTGGAATGGGTGTCCGCCATCTG
		GGCCTCCGGCGAGCAGTACTACGCCGACTCTGTGAAGG
		GCCGGTTCACCATCTCCCGGGACAACTCCAAGAACACCC
		TGTACCTGCAGATGAACTCCCTGCGGGCCGAGGACACC
		GCCGTGTACTACTGTGCCAAGGGCTGGCTGGGCAACTTC
		GACTACTGGGGACAGGGCACCCTGGTCACCGTGTCCAG
		CGCTAGCACAAAGGGACCTAGCGTGTTCCCCCTGGCCCC
		CAGCAGCAAGTCTACATCTGGCGGAACAGCCGCCCTGG
		GCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACCG
		TGTCCTGGAACTCTGGCGCTCTGACAAGCGGCGTGCACA
		CCTTTCCAGCCGTGCTGCAGAGCAGCGGCCTGTACTCTC
		TGAGCAGCGTCGTGACAGTGCCCAGCAGCTCTCTGGGC
		ACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAG
		CAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCT
		GCGACGGCGGAGGGGGATCTGGCGGCGGAGGATCCGAA
		GTGCAGCTGCTGGAATCCGGCGGAGGCCTGGTGCAGCC
		TGGCGGATCTCTGAGACTGTCCTGCGCCGCCTCCGGCTT
		CACCTTCTCCTCCCACGCCATGTCCTGGGTCCGACAGGC
		TCCTGGCAAAGGCCTGGAATGGGTGTCCGCCATCTGGGC
		CTCCGGCGAGCAGTACTACGCCGACTCTGTGAAGGGCC
		GGTTCACCATCTCCCGGGACAACTCCAAGAACACCCTGT
		ACCTGCAGATGAACTCCCTGCGGGCCGAGGACACCGCC
		GTGTACTACTGTGCCAAGGGCTGGCTGGGCAACTTCGAC
		TACTGGGGACAGGGCACCCTGGTCACCGTGTCCAGCGCT
		AGCACCAAGGGCCCCTCCGTGTTCCCCCTGGCCCCCAGC
		AGCAAGAGCACCAGCGGCGGCACAGCCGCTCTGGGCTG
		CCTGGTCAAGGACTACTTCCCCGAGCCCGTGACCGTGTC
		CTGGAACAGCGGAGCCCTGACCTCCGGCGTGCACACCTT
		CCCCGCCGTGCTGCAGAGTTCTGGCCTGTATAGCCTGAG
		CAGCGTGGTCACCGTGCCTTCTAGCAGCCTGGGCACCCA
		GACCTACATCTGCAACGTGAACCACAAGCCCAGCAACA
		CCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGCGAC
		AAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGC
		TGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACC
		CAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCAC
		ATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGG
		TCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCAT
		AATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
		GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACC
		AGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTC
		TCCAACAAAGCCCTCGGCGCCCCCATCGAGAAAACCAT
		CTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGT
		GCACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAAC
		CAGGTCAGCCTCTCGTGCGCAGTCAAAGGCTTCTATCCC
		AGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCC
		GGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACT
		CCGACGGCTCCTTCTTCCTCGTGAGCAAGCTCACCGTGG
		ACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGC
		TCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAG
		AAGAGCCTCTCCCTGTCTCCGGGTAAA
69	anti-FAP (28H1)	see Table 2
	light chain
115	Dimeric hu4-	see Table 3
	1BBL(71-254)-
	CL* Fc knob
	chain
116	Monomeric hu4-	see Table 3
	1BBL(71-254)-
	CH1*
145	[anti-FAP	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSHAMSWVRQA
	(28H1)] 2 Fc hole	PGKGLEWVSAIWASGEQYYADSVKGRFTISRDNSKNTLYL
	chain	QMNSLRAEDTAVYYCAKGWLGNFDYWGQGTLVTVSSAS
		TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
		GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDGGGGSGGGGSEVQLLESGG
		GLVQPGGSLRLSCAASGFTFSSHAMSWVRQAPGKGLEWV
		SAIWASGEQYYADSVKGRFTISRDNSKNTLYLQMNSLRAE
		DTAVYYCAKGWLGNFDYWGQGTLVTVSSASTKGPSVFPL
		APSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH
		TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
		KVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDT
		LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
		KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL
		GAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKL
		TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
19	anti-FAP (28H1)	see Table 2
	light chain

TABLE 9 — Sequences of FAP-targeted human 4-1BB ligand trimer containing Fc (kih) fusion molecule Construct 1.8 SEQ ID

NO:	Description	Sequence
146	Dimeric hu 4-	AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG
	1BBL (71-254)-	ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT
	FAP (VHCL*) Fc	GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG
	knob chain	GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG
		CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG
		TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG
		AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT
		GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCGCT
		GCTGGCGCTGCAGCTCTGGCACTGACAGTGGATCTGCCT
		CCTGCCAGCTCCGAGGCCCGGAATAGCGCATTTGGGTTT
		CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT
		GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG
		CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG
		TTCAGAGTGACCCCCGAGATTCCAGCCGGCCTGCCTTCT
		CCAAGAAGCGAAGGCGGAGGCGGATCTGGCGGCGGAG
		GATCTAGAGAGGGACCCGAACTGTCCCCTGACGATCCA
		GCCGGGCTGCTGGATCTGAGACAGGGAATGTTCGCCCA
		GCTGGTGGCTCAGAATGTGCTGCTGATTGACGGACCTCT
		GAGCTGGTACTCCGACCCAGGGCTGGCAGGGGTGTCCC
		TGACTGGGGGACTGTCCTACAAAGAAGATACAAAAGAA
		CTGGTGGTGGCTAAAGCTGGGGTGTACTATGTGTTTTTT
		CAGCTGGAACTGAGGCGGGTGGTGGCTGGGGAGGGCTC
		AGGATCTGTGTCCCTGGCTCTGCATCTGCAGCCACTGCG
		CTCTGCTGCTGGCGCAGCTGCACTGGCTCTGACTGTGGA
		CCTGCCACCAGCCTCTAGCGAGGCCAGAAACAGCGCCT
		TCGGGTTCCAAGGACGCCTGCTGCATCTGAGCGCCGGAC
		AGCGCCTGGGAGTGCATCTGCATACTGAAGCCAGAGCC
		CGGCATGCTTGGCAGCTGACTCAGGGGGCAACTGTGCTG
		GGACTGTTTCGCGTGACACCTGAGATCCCTGCCGGACTG
		CCAAGCCCTAGATCAGAAGGGGGCGGAGGTTCCGGAGG
		CGGAGGATCTGAGGTGCAGCTGCTGGAATCCGGCGGAG
		GCCTGGTGCAGCCTGGCGGATCTCTGAGACTGTCCTGCG
		CCGCCTCCGGCTTCACCTTCTCCTCCCACGCCATGTCCTG
		GGTCCGACAGGCTCCTGGCAAAGGCCTGGAATGGGTGT
		CCGCCATCTGGGCCTCCGGCGAGCAGTACTACGCCGACT
		CTGTGAAGGGCCGGTTCACCATCTCCCGGGACAACTCCA
		AGAACACCCTGTACCTGCAGATGAACTCCCTGCGGGCC
		GAGGACACCGCCGTGTACTACTGTGCCAAGGGCTGGCT
		GGGCAACTTCGACTACTGGGGCCAGGGCACCCTGGTCA
		CCGTGTCCAGCGCTAGCGTGGCTGCACCATCTGTCTTTA
		TCTTCCCACCCAGCGACCGGAAGCTGAAGTCTGGCACA
		GCCAGCGTCGTGTGCCTGCTGAATAACTTCTACCCCCGC
		GAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCA
		GAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGAC
		AGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGAC
		CCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACG
		CCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGA
		CCAAGAGCTTCAACCGGGGCGAGTGCGACAAGACCCAC
		ACCTGTCCTCCATGCCCTGCCCCTGAAGCTGCTGGCGGC
		CCTAGCGTGTTCCTGTTCCCCCCAAAGCCCAAGGACACC
		CTGATGATCAGCCGGACCCCTGAAGTGACCTGCGTGGTG
		GTGGATGTGTCCCACGAGGACCCTGAAGTGAAGTTCAAT
		TGGTACGTGGACGGCGTGGAAGTGCACAATGCCAAGAC
		CAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTG
		TGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGA
		ATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCC
		CTCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAA
		AGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCC
		CATGCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTG
		TGGTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCC
		GTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTA
		CAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTT
		CTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGT
		GGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATG
		AGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCC
		CTGTCTCCGGGTAAA
147	Monomeric hu 4-	AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG
	1BBL (71-254)-	ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT
	FAP (VLCH1*)	GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG
		GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG
		CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG
		TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG
		AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT
		GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCGCT
		GCTGGCGCTGCAGCTCTGGCTCTGACAGTGGATCTGCCT
		CCTGCCAGCTCCGAGGCCCGGAATAGCGCATTTGGGTTT
		CAAGGCCGGCTGCTGCACCTGTCTGCCGGCCAGAGACT
		GGGAGTGCATCTGCACACAGAGGCCAGAGCCAGGCACG
		CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG
		TTCAGAGTGACCCCCGAGATTCCTGCCGGCCTGCCTAGC
		CCTAGATCTGAAGGCGGCGGAGGTTCCGGAGGCGGAGG
		ATCTGAGATCGTGCTGACCCAGTCTCCCGGCACCCTGAG
		CCTGAGCCCTGGCGAGAGAGCCACCCTGAGCTGCAGAG
		CCAGCCAGAGCGTGAGCCGGAGCTACCTGGCCTGGTAT
		CAGCAGAAGCCCGGCCAGGCCCCCAGACTGCTGATCAT
		CGGCGCCAGCACCCGGGCCACCGGCATCCCCGATAGAT
		TCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCA
		TCAGCCGGCTGGAACCCGAGGACTTCGCCGTGTACTACT
		GCCAGCAGGGCCAGGTGATCCCCCCCACCTTCGGCCAG
		GGCACCAAGGTGGAAATCAAGTCCTCTGCTAGCACAAA
		GGGCCCCAGCGTGTTCCCTCTGGCCCCTAGCAGCAAGAG
		CACATCTGGCGGAACAGCCGCCCTGGGCTGCCTGGTGG
		AAGATTACTTCCCCGAGCCCGTGACCGTGTCCTGGAATT
		CTGGCGCCCTGACAAGCGGCGTGCACACCTTTCCAGCCG
		TGCTGCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCG
		TGACAGTGCCCAGCAGCTCTCTGGGCACCCAGACCTACA
		TCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTG
		GACGAGAAGGTGGAACCCAAGTCCTGC
68	anti-FAP (28H1)	see Table 2
	Fc hole chain
69	anti-FAP (28H1)	see Table 2
	light chain
148	Dimeric hu 4-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY
	1BBL (71-254)-	SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR
	FAP (VHCL*) Fc	RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASS
	knob chain	EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT
		QGATVLGLFRVTPEIPAGLPSPRSEGGGGSGGGGSREGPEL
		SPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLA
		GVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAG
		EGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNS
		AFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATV
		LGLFRVTPEIPAGLPSPRSEGGGGSGGGGSEVQLLESGGGL
		VQPGGSLRLSCAASGFTFSSHAMSWVRQAPGKGLEWVSAI
		WASGEQYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDT
		AVYYCAKGWLGNFDYWGQGTLVTVSSASVAAPSVFIFPPS
		DRKLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
		ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQG
		LSSPVTKSFNRGECDKTHTCPPCPAPEAAGGPSVFLFPPKPK
		DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA
		KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK
		ALGAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWC
		LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS
		KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
149	Monomeric hu 4-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY
	1BBL (71-254)-	SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR
	FAP (VLCH1*)	RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASS
		EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT
		QGATVLGLFRVTPEIPAGLPSPRSEGGGGSGGGGSEIVLTQS
		PGTLSLSPGERATLSCRASQSVSRSYLAWYQQKPGQAPRL
		LIIGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQ
		QGQVIPPTFGQGTKVEIKSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVEDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL
		YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDEKVEPKSC
18	anti-FAP (28H1)	see Table 2
	Fc hole chain
19	anti-FAP (28H1)	see Table 2
	light chain

TABLE 10 — Sequences of FAP-targeted human 4-1BB ligand trimer containing Fc (kih) fusion molecule Construct 1.9 SEQ ID

NO:	Description	Sequence
150	Dimeric hu 4-	CCTTGGGCTGTGTCTGGCGCTAGAGCCTCTCCTGGATCT
	1BBL (52-254)	GCCGCCAGCCCCAGACTGAGAGAGGGACCTGAGCTGAG
	CH1* Fc knob	CCCCGATGATCCTGCCGGACTGCTGGATCTGAGACAGG
	chain	GCATGTTCGCCCAGCTGGTGGCCCAGAACGTGCTGCTGA
		TCGATGGCCCCCTGTCCTGGTACAGCGATCCTGGACTGG
		CTGGCGTGTCACTGACAGGCGGCCTGAGCTACAAAGAG
		GACACCAAAGAACTGGTGGTGGCCAAGGCCGGCGTGTA
		CTACGTGTTCTTTCAGCTGGAACTGCGGAGAGTGGTGGC
		CGGCGAGGGATCTGGATCTGTGTCTCTGGCCCTGCATCT
		GCAGCCCCTGAGAAGCGCTGCTGGCGCTGCAGCTCTGG
		CACTGACAGTGGATCTGCCTCCTGCCAGCTCCGAGGCCC
		GGAATAGCGCATTTGGGTTTCAAGGCAGACTGCTGCACC
		TGTCTGCCGGCCAGAGGCTGGGAGTGCATCTGCACACA
		GAGGCCAGGGCTAGACACGCCTGGCAGCTGACACAGGG
		CGCTACAGTGCTGGGCCTGTTCAGAGTGACCCCCGAGAT
		TCCAGCCGGACTGCCCAGCCCTAGATCTGAAGGCGGCG
		GAGGAAGCGGAGGCGGAGGATCCCCTTGGGCTGTGTCT
		GGCGCTAGAGCCTCTCCTGGATCTGCCGCCAGCCCCAGA
		CTGAGAGAGGGACCTGAGCTGAGCCCCGATGATCCTGC
		CGGACTGCTGGACCTGCGGCAGGGAATGTTCGCTCAGCT
		GGTGGCTCAGAATGTGCTGCTGATTGACGGACCTCTGTC
		CTGGTACTCCGACCCTGGCCTGGCAGGGGTGTCCCTGAC
		TGGGGGACTGTCCTACAAAGAAGATACAAAAGAACTGG
		TGGTGGCTAAAGCTGGGGTGTACTATGTGTTTTTTCAGC
		TGGAACTGAGGCGGGTGGTGGCTGGGGAGGGCTCAGGA
		TCTGTGTCCCTGGCTCTGCATCTGCAGCCTCTGCGCTCTG
		CTGCTGGCGCAGCTGCACTGGCTCTGACTGTGGACCTGC
		CACCAGCCTCTAGCGAGGCCAGAAACAGCGCCTTCGGG
		TTCCAAGGACGGCTGCTGCATCTGAGCGCCGGACAGCG
		CCTGGGAGTGCATCTGCATACTGAAGCCAGAGCCCGGC
		ATGCTTGGCAGCTGACCCAGGGGGCAACTGTGCTGGGA
		CTGTTTCGCGTGACACCTGAGATCCCCGCTGGCCTGCCT
		AGCCCAAGAAGTGAAGGGGGAGGCGGATCTGGCGGAG
		GGGGATCTGCTAGCACCAAGGGCCCCTCCGTGTTCCCCC
		TGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCC
		GCTCTGGGCTGCCTGGTCGAGGACTACTTCCCCGAGCCC
		GTGACCGTGTCCTGGAACAGCGGAGCCCTGACCTCCGG
		CGTGCACACCTTCCCCGCCGTGCTGCAGAGTTCTGGCCT
		GTATAGCCTGAGCAGCGTGGTCACCGTGCCTTCTAGCAG
		CCTGGGCACCCAGACCTACATCTGCAACGTGAACCACA
		AGCCCAGCAACACCAAGGTGGACGAGAAGGTGGAGCCC
		AAGAGCTGCGACAAAACTCACACATGCCCACCGTGCCC
		AGCACCTGAAGCTGCAGGGGGACCGTCAGTCTTCCTCTT
		CCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGAC
		CCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACG
		AAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGC
		GTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGA
		GCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCAC
		CGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACA
		AGTGCAAGGTCTCCAACAAAGCCCTCGGCGCCCCCATC
		GAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGA
		ACCACAGGTGTACACCCTGCCCCCATGCCGGGATGAGCT
		GACCAAGAACCAGGTCAGCCTGTGGTGCCTGGTCAAAG
		GCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGC
		AATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCC
		CGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAA
		GCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACG
		TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACC
		ACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
		CCTTGGGCTGTGTCTGGCGCTAGAGCCTCTCCTGGATCT
151	Monomeric hu 4-	GCCGCCAGCCCCAGACTGAGAGAGGGACCTGAGCTGAG
	1BBL (52-254)-	CCCCGATGATCCTGCCGGACTGCTGGATCTGAGACAGG
	CL*	GCATGTTCGCCCAGCTGGTGGCCCAGAACGTGCTGCTGA
		TCGATGGCCCCCTGTCCTGGTACAGCGATCCTGGACTGG
		CTGGCGTGTCACTGACAGGCGGCCTGAGCTACAAAGAG
		GACACCAAAGAACTGGTGGTGGCCAAGGCCGGCGTGTA
		CTACGTGTTCTTTCAGCTGGAACTGCGGAGAGTGGTGGC
		CGGCGAGGGATCTGGATCTGTGTCTCTGGCCCTGCATCT
		GCAGCCCCTGAGAAGCGCTGCTGGCGCTGCAGCTCTGG
		CACTGACAGTGGATCTGCCTCCTGCCAGCTCCGAGGCCC
		GGAATAGCGCATTTGGGTTTCAAGGCAGGCTGCTGCACC
		TGTCTGCCGGCCAGAGGCTGGGAGTGCATCTGCACACA
		GAGGCCAGGGCTAGACACGCCTGGCAGCTGACACAGGG
		CGCTACAGTGCTGGGCCTGTTCAGAGTGACCCCCGAGAT
		TCCAGCCGGCCTGCCTTCTCCAAGAAGCGAAGGCGGAG
		GCGGATCTGGCGGCGGAGGATCTCGTACGGTGGCTGCA
		CCATCTGTCTTCATCTTCCCGCCATCTGATCGGAAGTTGA
		AATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACT
		TCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGAT
		AACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCAC
		AGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCA
		GCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACAC
		AAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAG
		CTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
68	anti-FAP (28H1)	see Table 2
	Fc hole chain
69	anti-FAP (28H1)	see Table 2
	light chain
111	Dimeric hu 4-	PWAVSGARASPGSAASPRLREGPELSPDDPAGLLDLRQGM
	1BBL (52-254)-	FAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTK
	CH1* Fc knob	ELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLR
	chain	SAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQR
		LGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPSP
		RSEGGGGSGGGGSPWAVSGARASPGSAASPRLREGPELSP
		DDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAG
		VSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGE
		GSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAF
		GFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLG
		LFRVTPEIPAGLPSPRSEGGGGSGGGGSASTKGPSVFPLAPS
		SKSTSGGTAALGCLVEDYFPEPVTVSWNSGALTSGVHTFP
		AVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVD
		EKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMI
		SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAP
		IEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD
		KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
112	Monomeric hu 4-	PWAVSGARASPGSAASPRLREGPELSPDDPAGLLDLRQGM
	1BBL (52-254)-	FAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTK
	CL*	ELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLR
		SAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQR
		LGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPSP
		RSEGGGGSGGGGSRTVAAPSVFIFPPSDRKLKSGTASVVCL
		LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS
		LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
18	anti-FAP (28H1)	see Table 2
	Fc hole chain
19	anti-FAP (28H1)	see Table 2
	light chain

TABLE 11 — Sequences of FAP-targeted human 4-1BB ligand trimer containing Fc (kih) fusion molecule Construct 10 SEQ ID

NO:	Description	Sequence
152	Dimeric hu 4-	GATCCTGCCGGCCTGCTGGATCTGCGGCAGGGAATGTTTGC
	1BBL (80-254)-	CCAGCTGGTGGCCCAGAACGTGCTGCTGATCGATGG
	CH1* Fc knob	CCCCCTGAGCTGGTACAGCGATCCTGGACTGGCTGGCGT
	chain	GTCACTGACAGGCGGCCTGAGCTACAAAGAGGACACCA
		AAGAACTGGTGGTGGCCAAGGCCGGCGTGTACTACGTG
		TTCTTTCAGCTGGAACTGCGGAGAGTGGTGGCCGGCGAA
		GGATCTGGCTCTGTGTCTCTGGCCCTGCATCTGCAGCCC
		CTGAGAAGCGCTGCTGGCGCTGCAGCTCTGGCACTGAC
		AGTGGATCTGCCTCCTGCCAGCTCCGAGGCCCGGAATAG
		CGCATTTGGGTTTCAAGGCAGACTGCTGCACCTGTCTGC
		CGGCCAGAGGCTGGGAGTGCATCTGCACACAGAGGCCA
		GGGCTAGACACGCCTGGCAGCTGACACAGGGCGCTACA
		GTGCTGGGCCTGTTCAGAGTGACCCCCGAGATTCCAGCC
		GGACTGCCCAGCCCTAGATCTGAAGGCGGCGGAGGAAG
		CGGAGGCGGAGGATCCGACCCAGCTGGACTGCTGGACC
		TGCGGCAGGGAATGTTCGCTCAGCTGGTGGCTCAGAATG
		TGCTGCTGATTGACGGACCTCTGTCCTGGTACTCCGACC
		CTGGCCTGGCAGGGGTGTCCCTGACTGGGGGACTGTCCT
		ACAAAGAAGATACAAAAGAACTGGTGGTGGCTAAAGCT
		GGGGTGTACTATGTGTTTTTTCAGCTGGAACTGAGGCGG
		GTGGTGGCTGGGGAGGGCTCAGGATCTGTGTCCCTGGCT
		CTGCATCTGCAGCCTCTGCGCTCTGCTGCTGGCGCAGCT
		GCACTGGCTCTGACTGTGGACCTGCCACCAGCCTCTAGC
		GAGGCCAGAAACAGCGCCTTCGGGTTCCAAGGACGGCT
		GCTGCATCTGAGCGCCGGACAGCGCCTGGGAGTGCATC
		TGCATACTGAAGCCAGAGCCCGGCATGCTTGGCAGCTG
		ACCCAGGGGGCAACTGTGCTGGGACTGTTTCGCGTGACA
		CCTGAGATCCCCGCTGGCCTGCCTAGCCCAAGAAGTGA
		AGGGGGAGGCGGATCTGGCGGAGGGGGATCTGCTAGCA
		CCAAGGGCCCCTCCGTGTTCCCCCTGGCCCCCAGCAGCA
		AGAGCACCAGCGGCGGCACAGCCGCTCTGGGCTGCCTG
		GTCGAGGACTACTTCCCCGAGCCCGTGACCGTGTCCTGG
		AACAGCGGAGCCCTGACCTCCGGCGTGCACACCTTCCCC
		GCCGTGCTGCAGAGTTCTGGCCTGTATAGCCTGAGCAGC
		GTGGTCACCGTGCCTTCTAGCAGCCTGGGCACCCAGACC
		TACATCTGCAACGTGAACCACAAGCCCAGCAACACCAA
		GGTGGACGAGAAGGTGGAGCCCAAGAGCTGCGACAAAA
		CTCACACATGCCCACCGTGCCCAGCACCTGAAGCTGCAG
		GGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGG
		ACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCG
		TGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAG
		TTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCC
		AAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGT
		ACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT
		GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAAC
		AAAGCCCTCGGCGCCCCCATCGAGAAAACCATCTCCAA
		AGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCC
		TGCCCCCATGCCGGGATGAGCTGACCAAGAACCAGGTC
		AGCCTGTGGTGCCTGGTCAAAGGCTTCTATCCCAGCGAC
		ATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAA
		CAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACG
		GCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGA
		GCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
		TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGC
		CTCTCCCTGTCTCCGGGTAAA
153	Monomeric hu4-	GATCCTGCCGGCCTGCTGGATCTGCGGCAGGGAATGTTT
	1BBL (80-254)-	GCCCAGCTGGTGGCCCAGAACGTGCTGCTGATCGATGG
	CL*	CCCCCTGAGCTGGTACAGCGATCCTGGACTGGCTGGCGT
		GTCACTGACAGGCGGCCTGAGCTACAAAGAGGACACCA
		AAGAACTGGTGGTGGCCAAGGCCGGCGTGTACTACGTG
		TTCTTTCAGCTGGAACTGCGGAGAGTGGTGGCCGGCGAA
		GGATCTGGCTCTGTGTCTCTGGCCCTGCATCTGCAGCCC
		CTGAGAAGCGCTGCTGGCGCTGCAGCTCTGGCACTGAC
		AGTGGATCTGCCTCCTGCCAGCTCCGAGGCCCGGAATAG
		CGCATTTGGGTTTCAAGGCAGGCTGCTGCACCTGTCTGC
		CGGCCAGAGGCTGGGAGTGCATCTGCACACAGAGGCCA
		GGGCTAGACACGCCTGGCAGCTGACACAGGGCGCTACA
		GTGCTGGGCCTGTTCAGAGTGACCCCCGAGATTCCAGCC
		GGCCTGCCTTCTCCAAGAAGCGAAGGCGGAGGCGGATC
		TGGCGGCGGAGGATCTCGTACGGTGGCTGCACCATCTGT
		CTTCATCTTCCCGCCATCTGATCGGAAGTTGAAATCTGG
		AACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCC
		AGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCT
		CCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGG
		ACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTG
		ACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTA
		CGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGT
		CACAAAGAGCTTCAACAGGGGAGAGTGT
68	anti-FAP (28H1)	see Table 2
	Fc hole chain
69	anti-FAP (28H1)	see Table 2
	light chain
113	Dimeric hu4-	DPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGV
	1BBL (80-254)-	SLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGS
	CH1* Fc knob	GSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGF
	chain	QGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLF
		RVTPEIPAGLPSPRSEGGGGSGGGGSDPAGLLDLRQGMFA
		QLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKEL
		VVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSA
		AGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG
		VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSE
		GGGGSGGGGSASTKGPSVFPLAPSSKSTSGGTAALGCLVE
		DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV
		PSSSLGTQTYICNVNHKPSNTKVDEKVEPKSCDKTHTCPPC
		PAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED
		PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL
		HQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVY
		TLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPEN
		NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
		EALHNHYTQKSLSLSPGK
114	Monomeric hu4-	DPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGV
	1BBL (80-254)-	SLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGS
	CL*	GSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGF
		QGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLF
		RVTPEIPAGLPSPRSEGGGGSGGGGSRTVAAPSVFIFPPSDR
		KLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES
		VTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLS
		SPVTKSFNRGEC
18	anti-FAP (28H1)	see Table 2
	Fc hole chain
19	anti-FAP (28H1)	see Table 2
	light chain

TABLE 12 — Biochemical Analysis of the FAP (28H1)-targeted 4-1BBL trimer- containing Fc (kih) fusion antigen binding molecules Monomer

	Yield	[%]
Construct	[mg/l]	(SEC)
Construct 1.1	12.7	95
Construct 1.2	25.2	97
Construct 1.3	22	92
Construct 1.4	14.2	99
Construct 1.5	14	99
Construct 1.6	12	98
Construct 1.7	3.4	99
Construct 1.8	5.4	98
Construct 1.9	11.2	98
Construct 1.10	19.8	99

TABLE 13 — Sequences of FAP-targeted murine Construct M.1 SEQ ID

NO:	Description	Sequence
71	Dimeric murine	AGAACCGAGCCCAGACCCGCCCTGACCATCACCACCAG
	4-1BBL (104-	CCCTAACCTGGGCACCAGAGAGAACAACGCCGACCAAG
	309,	TGACCCCCGTGTCCCACATCGGCAGCCCCAATACCACAC
	C137,160,246S)-	AGCAGGGCAGCCCTGTGTTCGCCAAGCTGCTGGCCAAG
	CL Fc DD chain	AACCAGGCCAGCCTGAGCAACACCACCCTGAACTGGCA
		CAGCCAGGATGGCGCCGGAAGCAGCTATCTGAGCCAGG
		GCCTGAGATACGAAGAGGACAAGAAAGAACTGGTGGTG
		GACAGCCCTGGCCTGTACTACGTGTTCCTGGAACTGAAG
		CTGAGCCCCACCTTCACCAACACCGGCCACAAGGTGCA
		GGGCTGGGTGTCACTGGTGCTGCAGGCCAAACCCCAGG
		TGGACGACTTCGACAACCTGGCCCTGACCGTGGAACTGT
		TCCCCAGCAGCATGGAAAACAAGCTGGTGGATCGGAGC
		TGGTCCCAGCTTCTGCTGCTGAAGGCCGGACACAGACTG
		AGCGTGGGCCTGAGGGCTTATCTGCACGGCGCCCAGGA
		CGCCTACAGAGACTGGGAGCTGAGCTACCCCAACACAA
		CCAGCTTCGGCCTGTTCCTCGTGAAGCCCGACAACCCTT
		GGGAAGGCGGCGGAGGATCTGGCGGAGGCGGATCTAGA
		ACAGAGCCTCGGCCTGCCCTGACAATTACCACATCCCCC
		AATCTGGGCACCCGGGAAAACAATGCAGATCAAGTGAC
		ACCTGTGTCTCATATTGGCTCCCCAAACACTACCCAGCA
		GGGCTCCCCCGTGTTTGCTAAACTGCTGGCTAAAAATCA
		GGCCTCCCTGTCTAACACAACACTGAACTGGCACTCCCA
		GGACGGCGCTGGCAGCTCTTACCTGAGTCAGGGACTGC
		GCTATGAGGAAGATAAGAAAGAACTGGTGGTGGATTCC
		CCCGGACTGTACTATGTGTTTCTGGAACTGAAACTGTCC
		CCTACCTTTACAAATACCGGGCACAAAGTGCAGGGATG
		GGTGTCCCTGGTGCTGCAGGCTAAGCCTCAGGTGGACGA
		TTTTGATAATCTGGCTCTGACAGTGGAACTGTTTCCTAG
		CAGCATGGAAAACAAGCTGGTGGACAGAAGCTGGTCCC
		AGCTCCTGCTGCTGAAGGCCGGACACAGACTGAGCGTG
		GGCCTGAGAGCCTATCTGCACGGCGCCCAGGACGCCTA
		CAGAGACTGGGAGCTGAGCTACCCCAACACAACCAGCT
		TCGGCCTGTTCCTCGTGAAGCCCGACAACCCTTGGGAAG
		GCGGCGGAGGATCTGGCGGAGGCGGATCCAGAGCTGAT
		GCTGCCCCTACCGTGTCCATCTTCCCACCCAGCAGCGAG
		CAGCTGACATCTGGGGGAGCTAGCGTCGTGTGCTTCCTG
		AACAACTTCTACCCCAAGGACATCAACGTGAAGTGGAA
		GATCGACGGCAGCGAGCGGCAGAACGGCGTGCTGAATA
		GCTGGACCGACCAGGACAGCAAGGACTCCACCTACAGC
		ATGAGCAGCACCCTGACCCTGACCAAGGACGAGTACGA
		GCGGCACAACAGCTACACATGCGAGGCCACCCACAAGA
		CCAGCACCAGCCCCATCGTGAAGTCCTTCAACCGGAAC
		GAGTGCGTGCCCAGAGACTGCGGCTGCAAGCCTTGCAT
		CTGCACCGTGCCTGAGGTGTCCAGCGTGTTCATCTTCCC
		ACCCAAGCCCAAGGACGTGCTGACCATCACCCTGACAC
		CCAAAGTGACCTGCGTGGTGGTGGCCATCAGCAAGGAT
		GACCCCGAGGTGCAGTTCAGTTGGTTCGTGGACGACGTG
		GAAGTGCACACCGCTCAGACCAAGCCCAGAGAGGAACA
		GATCAACAGCACCTTCAGAAGCGTGTCCGAGCTGCCCAT
		CATGCACCAGGACTGGCTGAACGGCAAAGAATTCAAGT
		GCAGAGTGAACAGCGCCGCCTTTGGCGCCCCTATCGAG
		AAAACCATCTCCAAGACCAAGGGCAGACCCAAGGCCCC
		CCAGGTGTACACAATCCCCCCACCCAAAGAACAGATGG
		CCAAGGACAAGGTGTCCCTGACCTGCATGATCACCAATT
		TCTTCCCAGAGGATATCACCGTGGAATGGCAGTGGAAC
		GGCCAGCCCGCCGAGAACTACGACAACACCCAGCCTAT
		CATGGACACCGACGGCTCCTACTTCGTGTACAGCGACCT
		GAACGTGCAGAAGTCCAACTGGGAGGCCGGCAACACCT
		TCACCTGTAGCGTGCTGCACGAGGGCCTGCACAACCACC
		ACACCGAGAAGTCCCTGTCCCACAGCCCTGGCAAG
72	Monomeric	AGAACCGAGCCCAGACCCGCCCTGACCATCACCACCAG
	murine 4-1BBL	CCCTAACCTGGGCACCAGAGAGAACAACGCCGACCAAG
	(104-309,	TGACCCCCGTGTCCCACATCGGCAGCCCCAATACCACAC
	C137,160,246S)-	AGCAGGGCAGCCCTGTGTTCGCCAAGCTGCTGGCCAAG
	CL	AACCAGGCCAGCCTGAGCAACACCACCCTGAACTGGCA
		CAGCCAGGATGGCGCCGGAAGCAGCTATCTGAGCCAGG
		GCCTGAGATACGAAGAGGACAAGAAAGAACTGGTGGTG
		GACAGCCCTGGCCTGTACTACGTGTTCCTGGAACTGAAG
		CTGAGCCCCACCTTCACCAACACCGGCCACAAGGTGCA
		GGGCTGGGTGTCACTGGTGCTGCAGGCCAAACCCCAGG
		TGGACGACTTCGACAACCTGGCCCTGACCGTGGAACTGT
		TCCCCAGCAGCATGGAAAACAAGCTGGTGGATCGGAGC
		TGGTCCCAGCTTCTGCTGCTGAAGGCCGGACACAGACTG
		AGCGTGGGCCTGAGGGCCTATCTGCATGGCGCCCAGGA
		CGCCTACAGAGACTGGGAGCTGAGCTACCCCAACACAA
		CCAGCTTCGGCCTGTTCCTCGTGAAGCCCGACAACCCTT
		GGGAAGGCGGCGGAGGCTCCGGAGGAGGCGGAAGCGC
		TAAGACCACCCCCCCCAGCGTGTACCCTCTGGCCCCTGG
		ATCTGCCGCCCAGACCAACAGCATGGTGACCCTGGGCT
		GCCTGGTGAAGGGCTACTTCCCCGAGCCTGTGACCGTGA
		CCTGGAACAGCGGCAGCCTGAGCAGCGGCGTGCACACC
		TTTCCAGCCGTGCTGCAGAGCGACCTGTACACCCTGAGC
		AGCTCCGTGACCGTGCCTAGCAGCACCTGGCCCAGCCA
		GACAGTGACCTGCAACGTGGCCCACCCTGCCAGCAGCA
		CCAAGGTGGACAAGAAAATCGTGCCCCGGGACTGC
73	anti-FAP (28H1)	GAAGTGCAGCTGCTGGAATCCGGCGGAGGCCTGGTGCA
	Fc KK heavy	GCCTGGCGGATCTCTGAGACTGTCCTGCGCCGCCTCCGG
	chain	CTTCACCTTCTCCTCCCACGCCATGTCCTGGGTCCGACA
		GGCTCCTGGCAAAGGCCTGGAATGGGTGTCCGCCATCTG
		GGCCTCCGGCGAGCAGTACTACGCCGACTCTGTGAAGG
		GCCGGTTCACCATCTCCCGGGACAACTCCAAGAACACCC
		TGTACCTGCAGATGAACTCCCTGCGGGCCGAGGACACC
		GCCGTGTACTACTGTGCCAAGGGCTGGCTGGGCAACTTC
		GACTACTGGGGACAGGGCACCCTGGTCACCGTGTCCAG
		CGCTAAGACCACCCCCCCTAGCGTGTACCCTCTGGCCCC
		TGGATCTGCCGCCCAGACCAACAGCATGGTGACCCTGG
		GCTGCCTGGTGAAGGGCTACTTCCCCGAGCCTGTGACCG
		TGACCTGGAACAGCGGCAGCCTGAGCAGCGGCGTGCAC
		ACCTTTCCAGCCGTGCTGCAGAGCGACCTGTACACCCTG
		AGCAGCTCCGTGACCGTGCCTAGCAGCACCTGGCCCAG
		CCAGACAGTGACCTGCAACGTGGCCCACCCTGCCAGCA
		GCACCAAGGTGGACAAGAAAATCGTGCCCCGGGACTGC
		GGCTGCAAGCCCTGCATCTGCACCGTGCCCGAGGTGTCC
		AGCGTGTTCATCTTCCCACCCAAGCCCAAGGACGTGCTG
		ACCATCACCCTGACCCCCAAAGTGACCTGCGTGGTGGTG
		GCCATCAGCAAGGACGACCCCGAGGTGCAGTTCTCTTG
		GTTTGTGGACGACGTGGAGGTGCACACAGCCCAGACAA
		AGCCCCGGGAGGAACAGATCAACAGCACCTTCAGAAGC
		GTGTCCGAGCTGCCCATCATGCACCAGGACTGGCTGAAC
		GGCAAAGAATTCAAGTGCAGAGTGAACAGCGCCGCCTT
		CGGCGCCCCCATCGAGAAAACCATCAGCAAGACCAAGG
		GCAGACCCAAGGCCCCCCAGGTGTACACCATCCCCCCA
		CCCAAAAAACAGATGGCCAAGGACAAGGTGTCCCTGAC
		CTGCATGATCACCAACTTTTTCCCCGAGGACATCACCGT
		GGAGTGGCAGTGGAATGGCCAGCCCGCCGAGAACTACA
		AGAACACCCAGCCCATCATGAAGACCGACGGCAGCTAC
		TTCGTGTACAGCAAGCTGAACGTGCAGAAGTCCAACTG
		GGAGGCCGGCAACACCTTCACCTGTAGCGTGCTGCACG
		AGGGCCTGCACAACCACCACACCGAGAAGTCCCTGAGC
		CACTCCCCCGGCAAG
74	anti-FAP (28H1)	GAGATCGTGCTGACCCAGTCCCCCGGCACCCTGTCTCTG
	light chain	AGCCCTGGCGAGAGAGCCACCCTGTCCTGCAGAGCCTC
		CCAGTCCGTGTCCCGGTCCTACCTCGCCTGGTATCAGCA
		GAAGCCCGGCCAGGCCCCTCGGCTGCTGATCATCGGCG
		CCTCTACCAGAGCCACCGGCATCCCTGACCGGTTCTCCG
		GCTCTGGCTCCGGCACCGACTTCACCCTGACCATCTCCC
		GGCTGGAACCCGAGGACTTCGCCGTGTACTACTGCCAGC
		AGGGCCAGGTCATCCCTCCCACCTTTGGCCAGGGCACCA
		AGGTGGAAATCAAGCGTGCCGATGCTGCACCAACTGTA
		TCGATTTTCCCACCATCCAGTGAGCAGTTAACATCTGGA
		GGTGCCTCAGTCGTGTGCTTCTTGAACAACTTCTACCCC
		AAAGACATCAATGTCAAGTGGAAGATTGATGGCAGTGA
		ACGACAAAATGGCGTCCTGAACAGTTGGACTGATCAGG
		ACAGCAAAGACAGCACCTACAGCATGAGCAGCACCCTC
		ACGTTGACCAAGGACGAGTATGAACGACATAACAGCTA
		TACCTGTGAGGCCACTCACAAGACATCAACTTCACCCAT
		TGTCAAGAGCTTCAACAGGAATGAGTGT
75	Dimeric murine	RTEPRPALTITTSPNLGTRENNADQVTPVSHIGSPNTTQQGS
	4-1BBL (104-	PVFAKLLAKNQASLSNTTLNWHSQDGAGSSYLSQGLRYEE
	309,	DKKELVVDSPGLYYVFLELKLSPTFTNTGHKVQGWVSLVL
	C137,160,246S)-	QAKPQVDDFDNLALTVELFPSSMENKLVDRSWSQLLLLKA
	CL Fc DD chain	GHRLSVGLRAYLHGAQDAYRDWELSYPNTTSFGLFLVKP
		DNPWEGGGGSGGGGSRTEPRPALTITTSPNLGTRENNADQ
		VTPVSHIGSPNTTQQGSPVFAKLLAKNQASLSNTTLNWHS
		QDGAGSSYLSQGLRYEEDKKELVVDSPGLYYVFLELKLSP
		TFTNTGHKVQGWVSLVLQAKPQVDDFDNLALTVELFPSS
		MENKLVDRSWSQLLLLKAGHRLSVGLRAYLHGAQDAYR
		DWELSYPNTTSFGLFLVKPDNPWEGGGGSGGGGSRADAA
		PTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSE
		RQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYT
		CEATHKTSTSPIVKSFNRNECVPRDCGCKPCICTVPEVSSVF
		IFPPKPKDVLTITLTPKVTCVVVAISKDDPEVQFSWFVDDV
		EVHTAQTKPREEQINSTFRSVSELPIMHQDWLNGKEFKCR
		VNSAAFGAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKV
		SLTCMITNFFPEDITVEWQWNGQPAENYDNTQPIMDTDGS
		YFVYSDLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLS
		HSPGK
76	Monomeric	RTEPRPALTITTSPNLGTRENNADQVTPVSHIGSPNTTQQGS
	murine 4-1BBL	PVFAKLLAKNQASLSNTTLNWHSQDGAGSSYLSQGLRYEE
	(104-309,	DKKELVVDSPGLYYVFLELKLSPTFTNTGHKVQGWVSLVL
	C137,160,246S)-	QAKPQVDDFDNLALTVELFPSSMENKLVDRSWSQLLLLKA
	CL	GHRLSVGLRAYLHGAQDAYRDWELSYPNTTSFGLFLVKP
		DNPWEGGGGSGGGGSAKTTPPSVYPLAPGSAAQTNSMVT
		LGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTL
		SSSVTVPSSTWPSQTVTCNVAHPASSTKVDKKIVPRDC
77	anti-FAP (28H1)	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSHAMSWVRQA
	Fc KK chain	PGKGLEWVSAIWASGEQYYADSVKGRFTISRDNSKNTLYL
		QMNSLRAEDTAVYYCAKGWLGNFDYWGQGTLVTVSSAK
		TTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWN
		SGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSQTVTCN
		VAHPASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPKPK
		DVLTITLTPKVTCVVVAISKDDPEVQFSWFVDDVEVHTAQ
		TKPREEQINSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFG
		APIEKTISKTKGRPKAPQVYTIPPPKKQMAKDKVSLTCMIT
		NFFPEDITVEWQWNGQPAENYKNTQPIMKTDGSYFVYSKL
		NVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK
78	anti-FAP (28H1)	EIVLTQSPGTLSLSPGERATLSCRASQSVSRSYLAWYQQKP
	light chain	GQAPRLLIIGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDF
		AVYYCQQGQVIPPTFGQGTKVEIKRADAAPTVSIFPPSSEQ
		LTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWT
		DQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPI
		VKSFNRNEC

TABLE 14 — Sequences of untargeted murine Control M.1 SEQ ID

NO:	Description	Sequence
71	Dimeric murine	See Table 13
	4-1BBL (104-
	309, C137,
	160, 246S)-
	CL Fc DD chain
72	Monomeric	See Table 13
	murine 4-1BBL
	(104-309,
	C137, 160,
	246S)-CH1
154	DP47 Fc KK	GAGGTGCAATTGTTGGAGTCTGGGGGAGGCTTGGTACA
	chain	GCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCCGG
		ATTCACCTTTAGCAGTTATGCCATGAGCTGGGTCCGCCA
		GGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTA
		GTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGA
		AGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAAC
		ACGCTGTATCTGCAGATGAACAGCCTGAGAGCCGAGGA
		CACGGCCGTATATTACTGTGCGAAAGGCAGCGGATTTGA
		CTACTGGGGCCAAGGAACCCTGGTCACCGTCTCGAGCG
		CTAAGACCACCCCCCCTAGCGTGTACCCTCTGGCCCCTG
		GATCTGCCGCCCAGACCAACAGCATGGTGACCCTGGGC
		TGCCTGGTGAAGGGCTACTTCCCCGAGCCTGTGACCGTG
		ACCTGGAACAGCGGCAGCCTGAGCAGCGGCGTGCACAC
		CTTTCCAGCCGTGCTGCAGAGCGACCTGTACACCCTGAG
		CAGCTCCGTGACCGTGCCTAGCAGCACCTGGCCCAGCCA
		GACAGTGACCTGCAACGTGGCCCACCCTGCCAGCAGCA
		CCAAGGTGGACAAGAAAATCGTGCCCCGGGACTGCGGC
		TGCAAGCCCTGCATCTGCACCGTGCCCGAGGTGTCCAGC
		GTGTTCATCTTCCCACCCAAGCCCAAGGACGTGCTGACC
		ATCACCCTGACCCCCAAAGTGACCTGCGTGGTGGTGGCC
		ATCAGCAAGGACGACCCCGAGGTGCAGTTCTCTTGGTTT
		GTGGACGACGTGGAGGTGCACACAGCCCAGACAAAGCC
		CCGGGAGGAACAGATCAACAGCACCTTCAGAAGCGTGT
		CCGAGCTGCCCATCATGCACCAGGACTGGCTGAACGGC
		AAAGAATTCAAGTGCAGAGTGAACAGCGCCGCCTTCGG
		CGCCCCCATCGAGAAAACCATCAGCAAGACCAAGGGCA
		GACCCAAGGCCCCCCAGGTGTACACCATCCCCCCACCCA
		AAAAACAGATGGCCAAGGACAAGGTGTCCCTGACCTGC
		ATGATCACCAACTTTTTCCCCGAGGACATCACCGTGGAG
		TGGCAGTGGAATGGCCAGCCCGCCGAGAACTACAAGAA
		CACCCAGCCCATCATGAAGACCGACGGCAGCTACTTCGT
		GTACAGCAAGCTGAACGTGCAGAAGTCCAACTGGGAGG
		CCGGCAACACCTTCACCTGTAGCGTGCTGCACGAGGGCC
		TGCACAACCACCACACCGAGAAGTCCCTGAGCCACTCC
		CCCGGCAAG
155	DP47 light	GAAATCGTGTTAACGCAGTCTCCAGGCACCCTGTCTTTG
	chain	TCTCCAGGGGAAAGAGCCACCCTCTCTTGCAGGGCCAGT
		CAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAG
		AAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGAGCA
		TCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGG
		CAGTGGATCCGGGACAGACTTCACTCTCACCATCAGCAG
		ACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCA
		GTATGGTAGCTCACCGCTGACGTTCGGCCAGGGGACCA
		AAGTGGAAATCAAACGTGCCGATGCTGCACCAACTGTA
		TCGATTTTCCCACCATCCAGTGAGCAGTTAACATCTGGA
		GGTGCCTCAGTCGTGTGCTTCTTGAACAACTTCTACCCC
		AAAGACATCAATGTCAAGTGGAAGATTGATGGCAGTGA
		ACGACAAAATGGCGTCCTGAACAGTTGGACTGATCAGG
		ACAGCAAAGACAGCACCTACAGCATGAGCAGCACCCTC
		ACGTTGACCAAGGACGAGTATGAACGACATAACAGCTA
		TACCTGTGAGGCCACTCACAAGACATCAACTTCACCCAT
		TGTCAAGAGCTTCAACAGGAATGAGTGT
75	Dimeric murine	see Table 13
	4-1BBL (104-
	309, C137,
	160, 246S)-
	CL Fc DD chain
76	Monomeric	See Table 13
	murine 4-1BBL
	(104-309,
	C137, 160,
	246S)-CH1
156	DP47 Fc KK	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQA
	chain	PGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYL
		QMNSLRAEDTAVYYCAKGSGFDYWGQGTLVTVSSAKTTP
		PSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGS
		LSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSQTVTCNVAH
		PASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPKPKDVL
		TITLTPKVTCVVVAISKDDPEVQFSWFVDDVEVHTAQTKP
		REEQINSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFGAPI
		EKTISKTKGRPKAPQVYTIPPPKKQMAKDKVSLTCMITNFF
		PEDITVEWQWNGQPAENYKNTQPIMKTDGSYFVYSKLNV
		QKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK
157	DP47 light	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKP
	chain	GQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDF
		AVYYCQQYGSSPLTFGQGTKVEIKRADAAPTVSIFPPSSEQ
		LTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWT
		DQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPI
		VKSFNRNEC

TABLE 15 — Sequences of FAP-targeted murine Construct M.2 SEQ ID

NO:	Description	Sequence
158	Dimeric murine	AGAACCGAGCCCAGACCCGCCCTGACCATCACCACCAG
	4-1BBL (104-	CCCTAACCTGGGCACCAGAGAGAACAACGCCGACCAAG
	309, C160S)-CL	TGACCCCCGTGTCCCACATCGGCTGCCCCAATACCACAC
	Fc DD chain	AGCAGGGCAGCCCTGTGTTCGCCAAGCTGCTGGCCAAG
		AACCAGGCCAGCCTGAGCAACACCACCCTGAACTGGCA
		CAGCCAGGATGGCGCCGGAAGCAGCTATCTGAGCCAGG
		GCCTGAGATACGAAGAGGACAAGAAAGAACTGGTGGTG
		GACAGCCCTGGCCTGTACTACGTGTTCCTGGAACTGAAG
		CTGAGCCCCACCTTCACCAACACCGGCCACAAGGTGCA
		GGGCTGGGTGTCACTGGTGCTGCAGGCCAAACCCCAGG
		TGGACGACTTCGACAACCTGGCCCTGACCGTGGAACTGT
		TCCCCTGCAGCATGGAAAACAAGCTGGTGGATCGGAGC
		TGGTCCCAGCTTCTGCTGCTGAAGGCCGGACACAGACTG
		AGCGTGGGCCTGAGGGCTTATCTGCACGGCGCCCAGGA
		CGCCTACAGAGACTGGGAGCTGAGCTACCCCAACACAA
		CCAGCTTCGGCCTGTTCCTCGTGAAGCCCGACAACCCTT
		GGGAAGGCGGCGGAGGCTCCGGAGGAGGCGGATCTAGA
		ACAGAGCCTCGGCCTGCCCTGACAATTACCACATCCCCC
		AATCTGGGCACCCGGGAAAACAATGCAGATCAAGTGAC
		ACCTGTGTCTCATATTGGGTGCCCCAACACTACCCAGCA
		GGGGTCCCCAGTGTTTGCTAAACTGCTGGCTAAAAATCA
		GGCCTCCCTGTCTAACACAACACTGAATTGGCATAGTCA
		GGACGGGGCTGGCAGCAGCTACCTGTCTCAGGGACTGC
		GCTATGAGGAAGATAAGAAAGAACTGGTGGTGGATTCC
		CCCGGACTGTACTATGTGTTTCTGGAACTGAAACTGTCC
		CCTACCTTTACAAATACCGGGCACAAAGTGCAGGGATG
		GGTGTCCCTGGTGCTGCAGGCTAAGCCTCAGGTGGACGA
		TTTTGATAATCTGGCTCTGACAGTGGAACTGTTTCCTTGC
		TCTATGGAAAACAAACTGGTGGACCGCTCTTGGAGCCA
		GTTGCTGCTGCTGAAAGCTGGCCACCGGCTGTCTGTGGG
		ACTGAGAGCATACCTGCATGGGGCACAGGATGCCTACC
		GGGATTGGGAACTGTCCTACCCTAACACTACTTCCTTCG
		GACTGTTCCTCGTGAAACCTGATAATCCCTGGGAGGGCG
		GAGGCGGAAGTGGCGGAGGGGGATCCAGAGCTGATGCT
		GCCCCTACCGTGTCCATCTTCCCACCCAGCAGCGAGCAG
		CTGACATCTGGGGGAGCTAGCGTCGTGTGCTTCCTGAAC
		AACTTCTACCCCAAGGACATCAACGTGAAGTGGAAGAT
		CGACGGCAGCGAGCGGCAGAACGGCGTGCTGAATAGCT
		GGACCGACCAGGACAGCAAGGACTCCACCTACAGCATG
		AGCAGCACCCTGACCCTGACCAAGGACGAGTACGAGCG
		GCACAACAGCTACACATGCGAGGCCACCCACAAGACCA
		GCACCAGCCCCATCGTGAAGTCCTTCAACCGGAACGAG
		TGCGTGCCCAGAGACTGCGGCTGCAAGCCTTGCATCTGC
		ACCGTGCCTGAGGTGTCCAGCGTGTTCATCTTCCCACCC
		AAGCCCAAGGACGTGCTGACCATCACCCTGACACCCAA
		AGTGACCTGCGTGGTGGTGGCCATCAGCAAGGATGACC
		CCGAGGTGCAGTTCAGTTGGTTCGTGGACGACGTGGAA
		GTGCACACCGCTCAGACCAAGCCCAGAGAGGAACAGAT
		CAACAGCACCTTCAGAAGCGTGTCCGAGCTGCCCATCAT
		GCACCAGGACTGGCTGAACGGCAAAGAATTCAAGTGCA
		GAGTGAACAGCGCCGCCTTTGGCGCCCCTATCGAGAAA
		ACCATCTCCAAGACCAAGGGCAGACCCAAGGCCCCCCA
		GGTGTACACAATCCCCCCACCCAAAGAACAGATGGCCA
		AGGACAAGGTGTCCCTGACCTGCATGATCACCAATTTCT
		TCCCAGAGGATATCACCGTGGAATGGCAGTGGAACGGC
		CAGCCCGCCGAGAACTACGACAACACCCAGCCTATCAT
		GGACACCGACGGCTCCTACTTCGTGTACAGCGACCTGAA
		CGTGCAGAAGTCCAACTGGGAGGCCGGCAACACCTTCA
		CCTGTAGCGTGCTGCACGAGGGCCTGCACAACCACCAC
		ACCGAGAAGTCCCTGTCCCACAGCCCTGGCAAG
159	Monomeric	AGAACCGAGCCCAGACCCGCCCTGACCATCACCACCAG
	murine 4-1BBL	CCCTAACCTGGGCACCAGAGAGAACAACGCCGACCAAG
	(104-309, C160S)-	TGACCCCCGTGTCCCACATCGGCTGCCCCAATACCACAC
	CH1	AGCAGGGCAGCCCTGTGTTCGCCAAGCTGCTGGCCAAG
		AACCAGGCCAGCCTGAGCAACACCACCCTGAACTGGCA
		CAGCCAGGATGGCGCCGGAAGCAGCTATCTGAGCCAGG
		GCCTGAGATACGAAGAGGACAAGAAAGAACTGGTGGTG
		GACAGCCCTGGCCTGTACTACGTGTTCCTGGAACTGAAG
		CTGAGCCCCACCTTCACCAACACCGGCCACAAGGTGCA
		GGGCTGGGTGTCACTGGTGCTGCAGGCCAAACCCCAGG
		TGGACGACTTCGACAACCTGGCCCTGACCGTGGAACTGT
		TCCCCTGCAGCATGGAAAACAAGCTGGTGGATCGGAGC
		TGGTCCCAGCTTCTGCTGCTGAAGGCCGGACACAGACTG
		AGCGTGGGCCTGAGGGCTTATCTGCACGGCGCCCAGGA
		CGCCTACAGAGACTGGGAGCTGAGCTACCCCAACACAA
		CCAGCTTCGGCCTGTTCCTCGTGAAGCCCGACAACCCTT
		GGGAAGGCGGCGGAGGCTCCGGAGGAGGCGGAAGCGC
		TAAGACCACCCCCCCCAGCGTGTACCCTCTGGCCCCTGG
		ATCTGCCGCCCAGACCAACAGCATGGTGACCCTGGGCT
		GCCTGGTGAAGGGCTACTTCCCCGAGCCTGTGACCGTGA
		CCTGGAACAGCGGCAGCCTGAGCAGCGGCGTGCACACC
		TTTCCAGCCGTGCTGCAGAGCGACCTGTACACCCTGAGC
		AGCTCCGTGACCGTGCCTAGCAGCACCTGGCCCAGCCA
		GACAGTGACCTGCAACGTGGCCCACCCTGCCAGCAGCA
		CCAAGGTGGACAAGAAAATCGTGCCCCGGGACTGC
73	anti-FAP (28H1)	see Table 13
	Fc KK chain
74	anti-FAP (28H1)	see Table 13
	light chain
160	Dimeric murine	RTEPRPALTITTSPNLGTRENNADQVTPVSHIGCPNTTQQGS
	4-1BBL (104-	PVFAKLLAKNQASLSNTTLNWHSQDGAGSSYLSQGLRYEE
	309, C160S)-CL	DKKELVVDSPGLYYVFLELKLSPTFTNTGHKVQGWVSLVL
	Fc DD chain	QAKPQVDDFDNLALTVELFPCSMENKLVDRSWSQLLLLK
		AGHRLSVGLRAYLHGAQDAYRDWELSYPNTTSFGLFLVK
		PDNPWEGGGGSGGGGSRTEPRPALTITTSPNLGTRENNAD
		QVTPVSHIGCPNTTQQGSPVFAKLLAKNQASLSNTTLNWH
		SQDGAGSSYLSQGLRYEEDKKELVVDSPGLYYVFLELKLS
		PTFTNTGHKVQGWVSLVLQAKPQVDDFDNLALTVELFPCS
		MENKLVDRSWSQLLLLKAGHRLSVGLRAYLHGAQDAYR
		DWELSYPNTTSFGLFLVKPDNPWEGGGGSGGGGSRADAA
		PTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSE
		RQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYT
		CEATHKTSTSPIVKSFNRNECVPRDCGCKPCICTVPEVSSVF
		IFPPKPKDVLTITLTPKVTCVVVAISKDDPEVQFSWFVDDV
		EVHTAQTKPREEQINSTFRSVSELPIMHQDWLNGKEFKCR
		VNSAAFGAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKV
		SLTCMITNFFPEDITVEWQWNGQPAENYDNTQPIMDTDGS
		YFVYSDLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLS
		HSPGK
161	Monomeric	RTEPRPALTITTSPNLGTRENNADQVTPVSHIGCPNTTQQGS
	murine 4-1BBL	PVFAKLLAKNQASLSNTTLNWHSQDGAGSSYLSQGLRYEE
	(104-309, C160S)-	DKKELVVDSPGLYYVFLELKLSPTFTNTGHKVQGWVSLVL
	CH1	QAKPQVDDFDNLALTVELFPCSMENKLVDRSWSQLLLLK
		AGHRLSVGLRAYLHGAQDAYRDWELSYPNTTSFGLFLVK
		PDNPWEGGGGSGGGGSAKTTPPSVYPLAPGSAAQTNSMV
		TLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYT
		LSSSVTVPSSTWPSQTVTCNVAHPASSTKVDKKIVPRDC
77	anti-FAP (28H1)	see Table 13
	Fc KK chain
78	anti-FAP (28H1)	see Table 13
	light chain

TABLE 16 — Sequences of FAP-targeted murine Control M.2 SEQ ID

NO:	Description	Sequence
158	Dimeric mu 4-1BBL	see Table 15
	(104-309, C160S) - CL
	Fc DD chain
159	Monomeric mu 4-1BBL	see Table 15
	(104-309, C160S) - CH1
154	DP47 Fc KK chain	see Table 14
155	DP47 light chain	see Table 14
160	Dimeric mu 4-1BBL	see Table 15
	(104-309, C160S) - CL
	Fc DD chain
161	Monomeric mu 4-1BBL	see Table 15
	(104-309, C160S) - CH1
156	DP47 Fc KK chain	see Table 14
157	DP47 light chain	see Table 14

TABLE 17 — Summary of the production of the FAP-targeted and untargeted murine 4-1BBL trimer-containing Fc fusion antigen binding molecules Monomer

	Yield	[%]
Construct	[mg/l]	(SEC)
Construct M.1	2.6	95
Control M.2	2.3	96
Construct M.2	8.5	98
Control M.2	8.1	97

TABLE 18 — Sequences of DP47 untargeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecule (DP47 split 4-1BBL trimer) Control A SEQ ID

NO:	Description	Sequence
66	Dimeric hu 4-	See Table 2
	1BBL (71-254)-
	CH1 Fc knob
	chain
67	Monomeric hu	see Table 2
	4-1BBL (71-254)-
	CL
79	DP47 Fc hole	GAGGTGCAATTGTTGGAGTCTGGGGGAGGCTTGGTACA
	chain	GCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCCGG
		ATTCACCTTTAGCAGTTATGCCATGAGCTGGGTCCGCCA
		GGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTA
		GTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGA
		AGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAAC
		ACGCTGTATCTGCAGATGAACAGCCTGAGAGCCGAGGA
		CACGGCCGTATATTACTGTGCGAAAGGCAGCGGATTTGA
		CTACTGGGGCCAAGGAACCCTGGTCACCGTCTCGAGTGC
		TAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTC
		CTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCT
		GCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGT
		CGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACC
		TTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTC
		AGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCAC
		CCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCA
		ACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGT
		GACAAAACTCACACATGCCCACCGTGCCCAGCACCTGA
		AGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAA
		ACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGT
		CACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTG
		AGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTG
		CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAA
		CAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCA
		CCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGG
		TCTCCAACAAAGCCCTCGGCGCCCCCATCGAGAAAACC
		ATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGT
		GTGCACCCTGCCCCCATCCCGGGATGAGCTGACCAAGA
		ACCAGGTCAGCCTCTCGTGCGCAGTCAAAGGCTTCTATC
		CCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAG
		CCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGA
		CTCCGACGGCTCCTTCTTCCTCGTGAGCAAGCTCACCGT
		GGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCAT
		GCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGC
		AGAAGAGCCTCTCCCTGTCTCCGGGTAAA
80	DP47 light	GAAATCGTGTTAACGCAGTCTCCAGGCACCCTGTCTTTG
	chain	TCTCCAGGGGAAAGAGCCACCCTCTCTTGCAGGGCCAGT
		CAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAG
		AAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGAGCA
		TCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGG
		CAGTGGATCCGGGACAGACTTCACTCTCACCATCAGCAG
		ACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCA
		GTATGGTAGCTCACCGCTGACGTTCGGCCAGGGGACCA
		AAGTGGAAATCAAACGTACGGTGGCTGCACCATCTGTCT
		TCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAA
		CTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAG
		AGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCC
		AATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGAC
		AGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGAC
		GCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACG
		CCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCA
		CAAAGAGCTTCAACAGGGGAGAGTGT
14	Dimeric hu 4-	See Table 2
	1BBL (71-254)-
	CH1 Fc knob
	chain
15	Monomeric hu 4-	See Table 2
	1BBL (71-254)-
	CL
81	DP47 Fc hole	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQA
	chain	PGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYL
		QMNSLRAEDTAVYYCAKGSGFDYWGQGTLVTVSSASTKG
		PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL
		TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
		KPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPP
		KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV
		HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV
		SNKALGAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVS
		LSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
		LVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS
		PGK
82	DP47 light	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKP
	chain	GQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDF
		AVYYCQQYGSSPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQ
		LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESV
		TEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSS
		PVTKSFNRGEC

TABLE 19 — Sequences of DP47 untargeted 4-1BB ligand trimer- containing Fc (kih) fusion antigen binding molecule (DP47 split 4-1BBL trimer) Control B SEQ ID

NO:	Description	Sequence
96	Dimeric hu 4-1BBL	see Table 3
	(71-254) - CL* Fc
	knob chain
97	Monomeric hu 4-1BBL	see Table 3
	(71-254) - CH1*
79	DP47 Fc hole chain	see Table 18
80	DP47 light chain	see Table 18
98	Dimeric hu 4-1BBL	see Table 3
	(71-254) - CL* Fc
	knob chain
99	Monomeric hu 4-1BBL	see Table 3
	(71-254) - CH1*
81	DP47 Fc hole chain	see Table 18
82	DP47 light chain	see Table 18

TABLE 20 — Production Characteristics of DP47 untargeted 4-1BBL trimer-containing Fc (kih) fusion antigen binding molecules (Control molecules) Monomer

	[%]	Yield	LC/MS
Construct	(SEC)	[mg/l]	(non red)
Control A	97	3.7	Theoretical*:
			179069.7 Da
			Experimental:
			179116.2 Da
			* without
			terminal lysines
Control B	99	15.4

TABLE 21 — Sequences of monovalent FAP (4B9)-targeted human 4-1BB ligand (71-254) containing Fc (kih) fusion molecule Construct 2.1 SEQ ID

NO:	Description	Sequence
129	Dimeric hu 4-	see Table 3
	1BBL (71-254)-
	CL* Fc knob
	chain
130	Monomeric hu	see Table 3
	4-1BBL (71-254)-
	CH1*
162	anti-FAP (4B9)	GAGGTGCAGCTGCTCGAAAGCGGCGGAGGACTGGTGCA
	Fc hole chain	GCCTGGCGGCAGCCTGAGACTGTCTTGCGCCGCCAGCG
		GCTTCACCTTCAGCAGCTACGCCATGAGCTGGGTCCGCC
		AGGCCCCTGGCAAGGGACTGGAATGGGTGTCCGCCATC
		ATCGGCTCTGGCGCCAGCACCTACTACGCCGACAGCGTG
		AAGGGCCGGTTCACCATCAGCCGGGACAACAGCAAGAA
		CACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGG
		ACACCGCCGTGTACTACTGCGCCAAGGGATGGTTCGGC
		GGCTTCAACTACTGGGGACAGGGCACCCTGGTCACAGT
		GTCCAGCGCTAGCACCAAGGGCCCCTCCGTGTTCCCCCT
		GGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCG
		CTCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAGCCCG
		TGACCGTGTCCTGGAACAGCGGAGCCCTGACCTCCGGC
		GTGCACACCTTCCCCGCCGTGCTGCAGAGTTCTGGCCTG
		TATAGCCTGAGCAGCGTGGTCACCGTGCCTTCTAGCAGC
		CTGGGCACCCAGACCTACATCTGCAACGTGAACCACAA
		GCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCA
		AGAGCTGCGACAAAACTCACACATGCCCACCGTGCCCA
		GCACCTGAAGCTGCAGGGGGACCGTCAGTCTTCCTCTTC
		CCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACC
		CCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGA
		AGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCG
		TGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG
		CAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACC
		GTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAA
		GTGCAAGGTCTCCAACAAAGCCCTCGGCGCCCCCATCG
		AGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAA
		CCACAGGTGTGCACCCTGCCCCCATCCCGGGATGAGCTG
		ACCAAGAACCAGGTCAGCCTCTCGTGCGCAGTCAAAGG
		CTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCA
		ATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCC
		GTGCTGGACTCCGACGGCTCCTTCTTCCTCGTGAGCAAG
		CTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGT
		CTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCA
		CTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
163	anti-FAP (4B9)	GAGATCGTGCTGACCCAGTCCCCCGGCACCCTGTCTCTG
	light chain	AGCCCTGGCGAGAGAGCCACCCTGTCCTGCAGAGCCTC
		CCAGTCCGTGACCTCCTCCTACCTCGCCTGGTATCAGCA
		GAAGCCCGGCCAGGCCCCTCGGCTGCTGATCAACGTGG
		GCAGTCGGAGAGCCACCGGCATCCCTGACCGGTTCTCCG
		GCTCTGGCTCCGGCACCGACTTCACCCTGACCATCTCCC
		GGCTGGAACCCGAGGACTTCGCCGTGTACTACTGCCAGC
		AGGGCATCATGCTGCCCCCCACCTTTGGCCAGGGCACCA
		AGGTGGAAATCAAGCGTACGGTGGCTGCACCATCTGTCT
		TCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAA
		CTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAG
		AGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCC
		AATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGAC
		AGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGAC
		GCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACG
		CCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCA
		CAAAGAGCTTCAACAGGGGAGAGTGT
115	Dimeric hu 4-	see Table 3
	1BBL (71-254)-
	CL* Fc knob
	chain
116	Monomeric hu	see Table 3
	4-1BBL (71-254)-
	CH1*
164	anti-FAP (4B9)	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQA
	Fc hole chain	PGKGLEWVSAIIGSGASTYYADSVKGRFTISRDNSKNTLYL
		QMNSLRAEDTAVYYCAKGWFGGFNYWGQGTLVTVSSAS
		TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
		GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVF
		LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG
		VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
		CKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRDELTKN
		QVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
		GSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS
		LSLSPGK
125	anti-FAP (4B9)	EIVLTQSPGTLSLSPGERATLSCRASQSVTSSYLAWYQQKP
	light chain	GQAPRLLINVGSRRATGIPDRFSGSGSGTDFTLTISRLEPEDF
		AVYYCQQGIMLPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQ
		LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESV
		TEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSS
		PVTKSFNRGEC

TABLE 22 — Sequences of monovalent FAP (4B9)-targeted human 4-1BB ligand (71-254) containing Fc (kih) fusion molecule Construct 2.2 SEQ ID

NO:	Description	Sequence
165	Dimeric hu 4-	AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG
	1BBL (71-254)-	ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT
	CL Fc knob chain	GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG
		GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG
		CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG
		TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG
		AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT
		GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCGCT
		GCTGGCGCTGCAGCTCTGGCACTGACAGTGGATCTGCCT
		CCTGCCAGCTCCGAGGCCCGGAATAGCGCATTTGGGTTT
		CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT
		GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG
		CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG
		TTCAGAGTGACCCCCGAGATTCCAGCCGGCCTGCCTTCT
		CCAAGAAGCGAAGGCGGAGGCGGATCTGGCGGCGGAG
		GATCTAGAGAGGGACCCGAACTGTCCCCTGACGATCCA
		GCCGGGCTGCTGGATCTGAGACAGGGAATGTTCGCCCA
		GCTGGTGGCTCAGAATGTGCTGCTGATTGACGGACCTCT
		GAGCTGGTACTCCGACCCAGGGCTGGCAGGGGTGTCCC
		TGACTGGGGGACTGTCCTACAAAGAAGATACAAAAGAA
		CTGGTGGTGGCTAAAGCTGGGGTGTACTATGTGTTTTTT
		CAGCTGGAACTGAGGCGGGTGGTGGCTGGGGAGGGCTC
		AGGATCTGTGTCCCTGGCTCTGCATCTGCAGCCACTGCG
		CTCTGCTGCTGGCGCAGCTGCACTGGCTCTGACTGTGGA
		CCTGCCACCAGCCTCTAGCGAGGCCAGAAACAGCGCCT
		TCGGGTTCCAAGGACGCCTGCTGCATCTGAGCGCCGGAC
		AGCGCCTGGGAGTGCATCTGCATACTGAAGCCAGAGCC
		CGGCATGCTTGGCAGCTGACTCAGGGGGCAACTGTGCTG
		GGACTGTTTCGCGTGACACCTGAGATCCCTGCCGGACTG
		CCAAGCCCTAGATCAGAAGGGGGCGGAGGTTCCGGAGG
		GGGAGGATCTCGTACGGTGGCCGCTCCCTCCGTGTTTAT
		CTTTCCCCCATCCGATGAACAGCTGAAAAGCGGCACCGC
		CTCCGTCGTGTGTCTGCTGAACAATTTTTACCCTAGGGA
		AGCTAAAGTGCAGTGGAAAGTGGATAACGCACTGCAGT
		CCGGCAACTCCCAGGAATCTGTGACAGAACAGGACTCC
		AAGGACAGCACCTACTCCCTGTCCTCCACCCTGACACTG
		TCTAAGGCTGATTATGAGAAACACAAAGTCTACGCCTGC
		GAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAA
		GAGCTTCAACAGGGGAGAGTGTGACAAGACCCACACCT
		GTCCCCCTTGTCCTGCCCCTGAAGCTGCTGGCGGCCCTT
		CTGTGTTCCTGTTCCCCCCAAAGCCCAAGGACACCCTGA
		TGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTG
		GATGTGTCCCACGAGGACCCTGAAGTGAAGTTCAATTGG
		TACGTGGACGGCGTGGAAGTGCACAATGCCAAGACCAA
		GCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGG
		TCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATG
		GCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTC
		GGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
		GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCAT
		GCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGTGG
		TGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTG
		GAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAA
		GACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTT
		CCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGC
		AGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGG
		CTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGT
		CTCCGGGTAAA
166	Monomeric hu 4-	AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG
	1BBL (71-254)-	ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT
	CH1	GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG
		GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG
		CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG
		TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG
		AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT
		GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCGCT
		GCTGGCGCTGCAGCTCTGGCTCTGACAGTGGATCTGCCT
		CCTGCCAGCTCCGAGGCCCGGAATAGCGCATTTGGGTTT
		CAAGGCCGGCTGCTGCACCTGTCTGCCGGCCAGAGACT
		GGGAGTGCATCTGCACACAGAGGCCAGAGCCAGGCACG
		CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG
		TTCAGAGTGACCCCCGAGATTCCTGCCGGCCTGCCTAGC
		CCTAGATCTGAAGGCGGCGGAGGTTCCGGAGGCGGAGG
		ATCTGCTAGCACCAAAGGCCCTTCCGTGTTTCCTCTGGC
		TCCTAGCTCCAAGTCCACCTCTGGAGGCACCGCTGCTCT
		CGGATGCCTCGTGAAGGATTATTTTCCTGAGCCTGTGAC
		AGTGTCCTGGAATAGCGGAGCACTGACCTCTGGAGTGC
		ATACTTTCCCCGCTGTGCTGCAGTCCTCTGGACTGTACA
		GCCTGAGCAGCGTGGTGACAGTGCCCAGCAGCAGCCTG
		GGCACCCAGACCTACATCTGCAACGTGAACCACAAGCC
		CAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGT
		CTTGT
162	anti-FAP (4B9)	see Table 21
	Fc hole chain
163	anti-FAP (4B9)	see Table 21
	light chain
117	Dimeric hu 4-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY
	1BBL (71-254)-	SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR
	CL Fc knob chain	RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASS
		EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT
		QGATVLGLFRVTPEIPAGLPSPRSEGGGGSGGGGSREGPEL
		SPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLA
		GVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAG
		EGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNS
		AFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATV
		LGLFRVTPEIPAGLPSPRSEGGGGSGGGGSRTVAAPSVFIFP
		PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
		SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
		QGLSSPVTKSFNRGECDKTHTCPPCPAPEAAGGPSVFLFPP
		KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV
		HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV
		SNKALGAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVS
		LWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF
		FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
		SPGK
118	Monomeric hu 4-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY
	1BBL (71-254)-	SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR
	CH1	RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASS
		EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT
		QGATVLGLFRVTPEIPAGLPSPRSEGGGGSGGGGSASTKGP
		SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK
		PSNTKVDKKVEPKSC
164	anti-FAP (4B9)	see Table 21
	Fc hole chain
125	anti-FAP (4B9)	see Table 21
	light chain

TABLE 23 — Sequences of bivalent FAP (4B9)-targeted human 4-1BB ligand (71-254) containing Fc (kih) fusion molecule Construct 2.3 SEQ ID

NO:	Description	Sequence
167	anti-FAP (4B9)	GAGGTGCAGCTGCTCGAAAGCGGCGGAGGACTGGTGCA
	Fc hole chain	GCCTGGCGGCAGCCTGAGACTGTCTTGCGCCGCCAGCG
	fused to dimeric	GCTTCACCTTCAGCAGCTACGCCATGAGCTGGGTCCGCC
	hu 4-1BBL (71-	AGGCCCCTGGCAAGGGACTGGAATGGGTGTCCGCCATC
	254)	ATCGGCTCTGGCGCCAGCACCTACTACGCCGACAGCGTG
		AAGGGCCGGTTCACCATCAGCCGGGACAACAGCAAGAA
		CACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGG
		ACACCGCCGTGTACTACTGCGCCAAGGGATGGTTCGGC
		GGCTTCAACTACTGGGGACAGGGCACCCTGGTCACAGT
		GTCCAGCGCTAGCACCAAGGGCCCCTCCGTGTTCCCCCT
		GGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCG
		CTCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAGCCCG
		TGACCGTGTCCTGGAACAGCGGAGCCCTGACCTCCGGC
		GTGCACACCTTCCCCGCCGTGCTGCAGAGTTCTGGCCTG
		TATAGCCTGAGCAGCGTGGTCACCGTGCCTTCTAGCAGC
		CTGGGCACCCAGACCTACATCTGCAACGTGAACCACAA
		GCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCA
		AGAGCTGCGACAAAACTCACACATGCCCACCGTGCCCA
		GCACCTGAAGCTGCAGGGGGACCGTCAGTCTTCCTCTTC
		CCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACC
		CCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGA
		AGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCG
		TGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG
		CAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACC
		GTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAA
		GTGCAAGGTCTCCAACAAAGCCCTCGGCGCCCCCATCG
		AGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAA
		CCACAGGTGTGCACCCTGCCCCCATCCCGGGATGAGCTG
		ACCAAGAACCAGGTCAGCCTCTCGTGCGCAGTCAAAGG
		CTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCA
		ATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCC
		GTGCTGGACTCCGACGGCTCCTTCTTCCTCGTGAGCAAG
		CTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGT
		CTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCA
		CTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTGGAGG
		CGGCGGAAGCGGAGGAGGAGGATCCAGAGAGGGCCCT
		GAGCTGAGCCCCGATGATCCTGCTGGACTGCTGGACCTG
		CGGCAGGGCATGTTTGCTCAGCTGGTGGCCCAGAACGTG
		CTGCTGATCGATGGCCCCCTGTCCTGGTACAGCGATCCT
		GGACTGGCTGGCGTGTCACTGACAGGCGGCCTGAGCTA
		CAAAGAGGACACCAAAGAACTGGTGGTGGCCAAGGCCG
		GCGTGTACTACGTGTTCTTTCAGCTGGAACTGCGGAGAG
		TGGTGGCCGGCGAAGGATCTGGCTCTGTGTCTCTGGCCC
		TGCATCTGCAGCCTCTGAGAAGCGCTGCTGGCGCTGCAG
		CTCTGGCACTGACAGTGGATCTGCCTCCTGCCAGCTCCG
		AGGCCCGGAATAGCGCATTTGGGTTTCAAGGCAGGCTG
		CTGCACCTGTCTGCCGGCCAGAGGCTGGGAGTGCATCTG
		CACACAGAGGCCAGGGCTAGACACGCCTGGCAGCTGAC
		ACAGGGCGCTACAGTGCTGGGCCTGTTCAGAGTGACCC
		CCGAGATTCCAGCCGGCCTGCCTTCTCCAAGAAGCGAA
		GGCGGAGGCGGATCTGGCGGCGGAGGATCTAGAGAGGG
		ACCCGAACTGTCCCCTGACGATCCAGCCGGGCTGCTGGA
		TCTGAGACAGGGAATGTTCGCCCAGCTGGTGGCTCAGA
		ATGTGCTGCTGATTGACGGACCTCTGAGCTGGTACTCCG
		ACCCAGGGCTGGCAGGGGTGTCCCTGACTGGGGGACTG
		TCCTACAAAGAAGATACAAAAGAACTGGTGGTGGCTAA
		AGCTGGGGTGTACTATGTGTTTTTTCAGCTGGAACTGAG
		GCGGGTGGTGGCTGGGGAGGGCTCAGGATCTGTGTCCCT
		GGCTCTGCATCTGCAGCCACTGCGCTCTGCTGCTGGCGC
		AGCTGCACTGGCTCTGACTGTGGACCTGCCACCAGCCTC
		TAGCGAGGCCAGAAACAGCGCCTTCGGGTTCCAAGGAC
		GCCTGCTGCATCTGAGCGCCGGACAGCGCCTGGGAGTG
		CATCTGCATACTGAAGCCAGAGCCCGGCATGCTTGGCA
		GCTGACTCAGGGGGCAACTGTGCTGGGACTGTTTCGCGT
		GACACCTGAGATCCCTGCCGGACTGCCAAGCCCTAGATC
		AGAA
168	anti-FAP (4B9)	GAGGTGCAGCTGCTCGAAAGCGGCGGAGGACTGGTGCA
	Fc knob chain	GCCTGGCGGCAGCCTGAGACTGTCTTGCGCCGCCAGCG
	fused to	GCTTCACCTTCAGCAGCTACGCCATGAGCTGGGTCCGCC
	monomeric hu 4-	AGGCCCCTGGCAAGGGACTGGAATGGGTGTCCGCCATC
	1BBL (71-254)	ATCGGCTCTGGCGCCAGCACCTACTACGCCGACAGCGTG
		AAGGGCCGGTTCACCATCAGCCGGGACAACAGCAAGAA
		CACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGG
		ACACCGCCGTGTACTACTGCGCCAAGGGATGGTTCGGC
		GGCTTCAACTACTGGGGACAGGGCACCCTGGTCACAGT
		GTCCAGCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCT
		GGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGG
		CCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGG
		TGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGC
		GTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTC
		TACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
		TTGGGCACCCAGACCTACATCTGCAACGTGAATCACAA
		GCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCA
		AATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAG
		CACCTGAAGCTGCAGGGGGACCGTCAGTCTTCCTCTTCC
		CCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCC
		CTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAA
		GACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGT
		GGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGC
		AGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCG
		TCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAG
		TGCAAGGTCTCCAACAAAGCCCTCGGCGCCCCCATCGA
		GAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC
		CACAGGTGTACACCCTGCCCCCCTGCAGAGATGAGCTG
		ACCAAGAACCAGGTGTCCCTGTGGTGTCTGGTCAAGGGC
		TTCTACCCCAGCGATATCGCCGTGGAGTGGGAGAGCAA
		CGGCCAGCCTGAGAACAACTACAAGACCACCCCCCCTG
		TGCTGGACAGCGACGGCAGCTTCTTCCTGTACTCCAAAC
		TGACCGTGGACAAGAGCCGGTGGCAGCAGGGCAACGTG
		TTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCA
		CTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGCGGAG
		GCGGCGGAAGCGGAGGAGGAGGATCCAGAGAGGGCCC
		TGAGCTGAGCCCCGATGATCCTGCTGGACTGCTGGACCT
		GCGGCAGGGCATGTTTGCTCAGCTGGTGGCCCAGAACGT
		GCTGCTGATCGATGGCCCCCTGTCCTGGTACAGCGATCC
		TGGACTGGCTGGCGTGTCACTGACAGGCGGCCTGAGCTA
		CAAAGAGGACACCAAAGAACTGGTGGTGGCCAAGGCCG
		GCGTGTACTACGTGTTCTTTCAGCTGGAACTGCGGAGAG
		TGGTGGCCGGCGAAGGATCTGGCTCTGTGTCTCTGGCCC
		TGCATCTGCAGCCTCTGAGAAGCGCTGCTGGCGCTGCAG
		CTCTGGCACTGACAGTGGATCTGCCTCCTGCCAGCTCCG
		AGGCCCGGAATAGCGCATTTGGGTTTCAAGGCAGGCTG
		CTGCACCTGTCTGCCGGCCAGAGGCTGGGAGTGCATCTG
		CACACAGAGGCCAGGGCTAGACACGCCTGGCAGCTGAC
		ACAGGGCGCTACAGTGCTGGGCCTGTTCAGAGTGACCC
		CCGAGATTCCAGCCGGCCTGCCTTCTCCAAGAAGCGAA
163	anti-FAP (4B9)	see Table 21
	light chain
123	anti-FAP (4B9)	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQA
	Fc hole chain	PGKGLEWVSAIIGSGASTYYADSVKGRFTISRDNSKNTLYL
	fused to dimeric	QMNSLRAEDTAVYYCAKGWFGGFNYWGQGTLVTVSSAS
	hu 4-1BBL (71-	TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
	254)	GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVF
		LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG
		VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
		CKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRDELTKN
		QVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
		GSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS
		LSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQ
		LVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELV
		VAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAA
		GAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGV
		HLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSEG
		GGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQLVAQNV
		LLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGV
		YYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALA
		LTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEA
		RARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSE
124	anti-FAP (4B9)	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQA
	Fc knob chain	PGKGLEWVSAIIGSGASTYYADSVKGRFTISRDNSKNTLYL
	fused to	QMNSLRAEDTAVYYCAKGWFGGFNYWGQGTLVTVSSAS
	monomeric hu 4-	TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
	1BBL (71-254)	GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVF
		LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG
		VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
		CKVSNKALGAPIEKTISKAKGQPREPQVYTLPPCRDELTKN
		QVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
		GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS
		LSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQ
		LVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELV
		VAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAA
		GAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGV
		HLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSE
125	anti-FAP (4B9)	see Table 21
	light chain

TABLE 24 — Sequences of monovalent FAP (4B9)-targeted human 4-1BB ligand (71-248) containing Fc (kih) fusion molecule Construct 2.4 SEQ ID

NO:	Description	Sequence
169	Dimeric hu 4-	AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG
	1BBL (71-248)-	ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT
	CL* Fc knob	GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG
	chain	GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG
		CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG
		TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG
		AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT
		GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGATCTGCT
		GCTGGCGCCGCTGCTCTGGCACTGACAGTGGATCTGCCT
		CCTGCCAGCAGCGAGGCCCGGAATAGCGCATTTGGGTTT
		CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT
		GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG
		CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG
		TTCAGAGTGACCCCCGAGATTCCAGCCGGACTGGGAGG
		CGGCGGATCTGGCGGCGGAGGATCTAGAGAAGGACCCG
		AGCTGTCCCCTGACGATCCAGCCGGGCTGCTGGATCTGA
		GACAGGGAATGTTCGCCCAGCTGGTGGCTCAGAATGTG
		CTGCTGATTGACGGACCTCTGAGCTGGTACTCCGACCCA
		GGGCTGGCAGGGGTGTCCCTGACTGGGGGACTGTCCTAC
		AAAGAAGATACAAAAGAACTGGTGGTGGCTAAAGCTGG
		GGTGTACTATGTGTTTTTTCAGCTGGAACTGAGGCGGGT
		GGTGGCTGGGGAGGGCTCAGGATCTGTGTCCCTGGCTCT
		GCATCTGCAGCCACTGCGCTCTGCAGCAGGGGCTGCAG
		CACTGGCCCTGACTGTGGACCTGCCCCCAGCTTCTTCCG
		AGGCCAGAAACAGCGCCTTCGGGTTCCAAGGACGCCTG
		CTGCATCTGAGCGCCGGACAGCGCCTGGGAGTGCATCT
		GCATACTGAAGCCAGAGCCCGGCATGCTTGGCAGCTGA
		CTCAGGGGGCAACTGTGCTGGGACTGTTTCGCGTGACAC
		CTGAGATCCCCGCTGGACTGGGCGGAGGCGGTTCCGGA
		GGGGGAGGATCTCGTACGGTGGCTGCACCATCTGTCTTT
		ATCTTCCCACCCAGCGACCGGAAGCTGAAGTCTGGCAC
		AGCCAGCGTCGTGTGCCTGCTGAATAACTTCTACCCCCG
		CGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGC
		AGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGA
		CAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGA
		CCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTAC
		GCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTG
		ACCAAGAGCTTCAACCGGGGCGAGTGCGACAAGACCCA
		CACCTGTCCTCCATGCCCTGCCCCTGAAGCTGCTGGCGG
		CCCTAGCGTGTTCCTGTTCCCCCCAAAGCCCAAGGACAC
		CCTGATGATCAGCCGGACCCCTGAAGTGACCTGCGTGGT
		GGTGGATGTGTCCCACGAGGACCCTGAAGTGAAGTTCA
		ATTGGTACGTGGACGGCGTGGAAGTGCACAATGCCAAG
		ACCAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCG
		TGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCT
		GAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAG
		CCCTCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCC
		AAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCC
		CCCATGCCGGGATGAGCTGACCAAGAACCAGGTCAGCC
		TGTGGTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCG
		CCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAAC
		TACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCC
		TTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGG
		TGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCAT
		GAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTC
		CCTGTCTCCGGGTAAA
170	Monomeric hu 4-	AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG
	1BBL (71-248)-	ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT
	CH1*	GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG
		GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG
		CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG
		TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG
		AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT
		GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGATCTGCT
		GCTGGCGCCGCTGCTCTGGCACTGACAGTGGATCTGCCT
		CCTGCCAGCAGCGAGGCCCGGAATAGCGCATTTGGGTTT
		CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT
		GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG
		CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG
		TTCAGAGTGACCCCCGAGATTCCAGCCGGACTGGGAGG
		CGGAGGTTCCGGAGGCGGAGGATCTGCTAGCACAAAGG
		GCCCCAGCGTGTTCCCTCTGGCCCCTAGCAGCAAGAGCA
		CATCTGGCGGAACAGCCGCCCTGGGCTGCCTGGTGGAA
		GATTACTTCCCCGAGCCCGTGACCGTGTCCTGGAATTCT
		GGCGCCCTGACAAGCGGCGTGCACACCTTTCCAGCCGTG
		CTGCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTG
		ACAGTGCCCAGCAGCTCTCTGGGCACCCAGACCTACATC
		TGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGA
		CGAGAAGGTGGAACCCAAGTCCTGC
162	anti-FAP (4B9)	see Table 21
	Fc hole chain
163	anti-FAP (4B9)	see Table 21
	light chain
119	Dimeric hu 4-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY
	1BBL (71-248)-	SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR
	CL* Fc knob	RVVAGEGSGSVSLALHILQPLRSAAGAAALALTVDLPPASS
	chain	EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT
		QGATVLGLFRVTPEIPAGLGGGGSGGGGSREGPELSPDDPA
		GLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTG
		GLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSV
		SLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQG
		RLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRV
		TPEIPAGLGGGGSGGGGSRTVAAPSVFIFPPSDRKLKSGTAS
		VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
		GECDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE
		VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
		NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTI
		SKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSD
		IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR
		WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
120	Monomeric hu 4-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY
	1BBL (71-248)-	SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR
	CH1*	RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASS
		EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT
		QGATVLGLFRVTPEIPAGLGGGGSGGGGSASTKGPSVFPLA
		PSSKSTSGGTAALGCLVEDYFPEPVTVSWNSGALTSGVHTF
		PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV
		DEKVEPKSC
164	anti-FAP (4B9)	see Table 21
	Fc hole chain
125	anti-FAP (4B9)	see Table 21
	light chain

TABLE 25 — Sequences of monovalent FAP (4B9)-targeted human 4-1BB ligand (71-248) containing Fc (kih) fusion molecule Construct 2.5 SEQ ID

NO:	Description	Sequence
171	nucleotide	AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG
	sequence dimeric	ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT
	hu 4-1BBL (71-	GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG
	248)-CL Fc	GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG
	knob chain	CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG
		TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG
		AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT
		GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGATCTGCT
		GCTGGCGCCGCTGCTCTGGCACTGACAGTGGATCTGCCT
		CCTGCCAGCAGCGAGGCCCGGAATAGCGCATTTGGGTTT
		CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT
		GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG
		CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG
		TTCAGAGTGACCCCCGAGATTCCAGCCGGACTGGGAGG
		CGGCGGATCTGGCGGCGGAGGATCTAGAGAAGGACCCG
		AGCTGTCCCCTGACGATCCAGCCGGGCTGCTGGATCTGA
		GACAGGGAATGTTCGCCCAGCTGGTGGCTCAGAATGTG
		CTGCTGATTGACGGACCTCTGAGCTGGTACTCCGACCCA
		GGGCTGGCAGGGGTGTCCCTGACTGGGGGACTGTCCTAC
		AAAGAAGATACAAAAGAACTGGTGGTGGCTAAAGCTGG
		GGTGTACTATGTGTTTTTTCAGCTGGAACTGAGGCGGGT
		GGTGGCTGGGGAGGGCTCAGGATCTGTGTCCCTGGCTCT
		GCATCTGCAGCCACTGCGCTCTGCAGCAGGGGCTGCAG
		CACTGGCCCTGACTGTGGACCTGCCCCCAGCTTCTTCCG
		AGGCCAGAAACAGCGCCTTCGGGTTCCAAGGACGCCTG
		CTGCATCTGAGCGCCGGACAGCGCCTGGGAGTGCATCT
		GCATACTGAAGCCAGAGCCCGGCATGCTTGGCAGCTGA
		CTCAGGGGGCAACTGTGCTGGGACTGTTTCGCGTGACAC
		CTGAGATCCCCGCTGGACTGGGCGGAGGCGGTTCCGGA
		GGGGGAGGATCTCGTACGGTGGCCGCTCCCTCCGTGTTT
		ATCTTTCCCCCATCCGATGAACAGCTGAAAAGCGGCACC
		GCCTCCGTCGTGTGTCTGCTGAACAATTTTTACCCTAGG
		GAAGCTAAAGTGCAGTGGAAAGTGGATAACGCACTGCA
		GTCCGGCAACTCCCAGGAATCTGTGACAGAACAGGACT
		CCAAGGACAGCACCTACTCCCTGTCCTCCACCCTGACAC
		TGTCTAAGGCTGATTATGAGAAACACAAAGTCTACGCCT
		GCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACA
		AAGAGCTTCAACAGGGGAGAGTGTGACAAGACCCACAC
		CTGTCCCCCTTGTCCTGCCCCTGAAGCTGCTGGCGGCCC
		TTCTGTGTTCCTGTTCCCCCCAAAGCCCAAGGACACCCT
		GATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGG
		TGGATGTGTCCCACGAGGACCCTGAAGTGAAGTTCAATT
		GGTACGTGGACGGCGTGGAAGTGCACAATGCCAAGACC
		AAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGT
		GGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAA
		TGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCC
		TCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAA
		GGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCC
		ATGCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGT
		GGTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCG
		TGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTAC
		AAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTC
		TTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTG
		GCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGA
		GGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCT
		GTCTCCGGGTAAA
172	Monomeric hu 4-	AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG
	1BBL (71-248)-	ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT
	CH1	GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG
		GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG
		CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG
		TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG
		AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT
		GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGATCTGCT
		GCTGGCGCCGCTGCTCTGGCACTGACAGTGGATCTGCCT
		CCTGCCAGCAGCGAGGCCCGGAATAGCGCATTTGGGTTT
		CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT
		GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG
		CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG
		TTCAGAGTGACCCCCGAGATTCCAGCCGGACTGGGAGG
		CGGAGGTTCCGGAGGCGGAGGATCTGCTAGCACCAAAG
		GCCCTTCCGTGTTTCCTCTGGCTCCTAGCTCCAAGTCCAC
		CTCTGGAGGCACCGCTGCTCTCGGATGCCTCGTGAAGGA
		TTATTTTCCTGAGCCTGTGACAGTGTCCTGGAATAGCGG
		AGCACTGACCTCTGGAGTGCATACTTTCCCCGCTGTGCT
		GCAGTCCTCTGGACTGTACAGCCTGAGCAGCGTGGTGAC
		AGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCT
		GCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGAC
		AAGAAGGTGGAACCCAAGTCTTGT
162	anti-FAP (4B9)	see Table 21
	Fc hole chain
163	anti-FAP (4B9)	see Table 21
	light chain
173	Dimeric hu 4-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY
	1BBL (71-248)-	SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR
	CL Fc knob chain	RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASS
		EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT
		QGATVLGLFRVTPEIPAGLGGGGSGGGGSREGPELSPDDPA
		GLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTG
		GLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSV
		SLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQG
		RLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRV
		TPEIPAGLGGGGSGGGGSRTVAAPSVFIFPPSDEQLKSGTAS
		VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
		GECDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE
		VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
		NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTI
		SKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSD
		IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR
		WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
174	Monomeric hu 4-	REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY
	1BBL (71-248)-	SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR
	CH1	RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASS
		EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT
		QGATVLGLFRVTPEIPAGLGGGGSGGGGSASTKGPSVFPLA
		PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHT
		FPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK
		VDKKVEPKSC
164	anti-FAP (4B9)	see Table 21
	Fc hole chain
125	anti-FAP (4B9)	see Table 21
	light chain

TABLE 26 — Sequences of bivalent FAP (4B9)-targeted human 4-1BB ligand (71-248) containing Fc (kih) fusion molecule Construct 2.6 SEQ ID

NO:	Description	Sequence
175	nucleotide	GAGGTGCAGCTGCTCGAAAGCGGCGGAGGACTGGTGCA
	sequence of anti-	GCCTGGCGGCAGCCTGAGACTGTCTTGCGCCGCCAGCG
	FAP (4B9) Fc	GCTTCACCTTCAGCAGCTACGCCATGAGCTGGGTCCGCC
	hole chain fused	AGGCCCCTGGCAAGGGACTGGAATGGGTGTCCGCCATC
	to dimeric hu 4-	ATCGGCTCTGGCGCCAGCACCTACTACGCCGACAGCGTG
	1BBL (71-248)	AAGGGCCGGTTCACCATCAGCCGGGACAACAGCAAGAA
		CACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGG
		ACACCGCCGTGTACTACTGCGCCAAGGGATGGTTCGGC
		GGCTTCAACTACTGGGGACAGGGCACCCTGGTCACAGT
		GTCCAGCGCTAGCACCAAGGGCCCCTCCGTGTTCCCCCT
		GGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCG
		CTCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAGCCCG
		TGACCGTGTCCTGGAACAGCGGAGCCCTGACCTCCGGC
		GTGCACACCTTCCCCGCCGTGCTGCAGAGTTCTGGCCTG
		TATAGCCTGAGCAGCGTGGTCACCGTGCCTTCTAGCAGC
		CTGGGCACCCAGACCTACATCTGCAACGTGAACCACAA
		GCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCA
		AGAGCTGCGACAAAACTCACACATGCCCACCGTGCCCA
		GCACCTGAAGCTGCAGGGGGACCGTCAGTCTTCCTCTTC
		CCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACC
		CCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGA
		AGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCG
		TGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG
		CAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACC
		GTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAA
		GTGCAAGGTCTCCAACAAAGCCCTCGGCGCCCCCATCG
		AGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAA
		CCACAGGTGTGCACCCTGCCCCCATCCCGGGATGAGCTG
		ACCAAGAACCAGGTCAGCCTCTCGTGCGCAGTCAAAGG
		CTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCA
		ATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCC
		GTGCTGGACTCCGACGGCTCCTTCTTCCTCGTGAGCAAG
		CTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGT
		CTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCA
		CTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTGGAGG
		CGGCGGAAGCGGAGGAGGAGGATCCAGAGAGGGCCCT
		GAGCTGAGCCCCGATGATCCTGCTGGACTGCTGGACCTG
		CGGCAGGGCATGTTTGCTCAGCTGGTGGCCCAGAACGTG
		CTGCTGATCGATGGCCCCCTGTCCTGGTACAGCGATCCT
		GGACTGGCTGGCGTGTCACTGACAGGCGGCCTGAGCTA
		CAAAGAGGACACCAAAGAACTGGTGGTGGCCAAGGCCG
		GCGTGTACTACGTGTTCTTTCAGCTGGAACTGCGGAGAG
		TGGTGGCCGGCGAAGGATCTGGCTCTGTGTCTCTGGCCC
		TGCATCTGCAGCCTCTGAGAAGCGCTGCTGGCGCTGCAG
		CTCTGGCACTGACAGTGGATCTGCCTCCTGCCAGCTCCG
		AGGCCCGGAATAGCGCATTTGGGTTTCAAGGCAGGCTG
		CTGCACCTGTCTGCCGGCCAGAGGCTGGGAGTGCATCTG
		CACACAGAGGCCAGGGCTAGACACGCCTGGCAGCTGAC
		ACAGGGCGCTACAGTGCTGGGCCTGTTCAGAGTGACCC
		CCGAGATTCCAGCCGGCCTGGGCGGAGGCGGATCTGGC
		GGCGGAGGATCTAGAGAGGGACCCGAACTGTCCCCTGA
		CGATCCAGCCGGGCTGCTGGATCTGAGACAGGGAATGT
		TCGCCCAGCTGGTGGCTCAGAATGTGCTGCTGATTGACG
		GACCTCTGAGCTGGTACTCCGACCCAGGGCTGGCAGGG
		GTGTCCCTGACTGGGGGACTGTCCTACAAAGAAGATAC
		AAAAGAACTGGTGGTGGCTAAAGCTGGGGTGTACTATG
		TGTTTTTTCAGCTGGAACTGAGGCGGGTGGTGGCTGGGG
		AGGGCTCAGGATCTGTGTCCCTGGCTCTGCATCTGCAGC
		CACTGCGCTCTGCTGCTGGCGCAGCTGCACTGGCTCTGA
		CTGTGGACCTGCCACCAGCCTCTAGCGAGGCCAGAAAC
		AGCGCCTTCGGGTTCCAAGGACGCCTGCTGCATCTGAGC
		GCCGGACAGCGCCTGGGAGTGCATCTGCATACTGAAGC
		CAGAGCCCGGCATGCTTGGCAGCTGACTCAGGGGGCAA
		CTGTGCTGGGACTGTTTCGCGTGACACCTGAGATCCCTG
		CCGGACTG
176	nucleotide	GAGGTGCAGCTGCTCGAAAGCGGCGGAGGACTGGTGCA
	sequence anti-	GCCTGGCGGCAGCCTGAGACTGTCTTGCGCCGCCAGCG
	FAP (4B9) Fc	GCTTCACCTTCAGCAGCTACGCCATGAGCTGGGTCCGCC
	knob chain fused	AGGCCCCTGGCAAGGGACTGGAATGGGTGTCCGCCATC
	to monomeric hu	ATCGGCTCTGGCGCCAGCACCTACTACGCCGACAGCGTG
	4-1BBL (71-248)	AAGGGCCGGTTCACCATCAGCCGGGACAACAGCAAGAA
		CACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGG
		ACACCGCCGTGTACTACTGCGCCAAGGGATGGTTCGGC
		GGCTTCAACTACTGGGGACAGGGCACCCTGGTCACAGT
		GTCCAGCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCT
		GGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGG
		CCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGG
		TGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGC
		GTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTC
		TACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
		TTGGGCACCCAGACCTACATCTGCAACGTGAATCACAA
		GCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCA
		AATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAG
		CACCTGAAGCTGCAGGGGGACCGTCAGTCTTCCTCTTCC
		CCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCC
		CTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAA
		GACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGT
		GGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGC
		AGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCG
		TCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAG
		TGCAAGGTCTCCAACAAAGCCCTCGGCGCCCCCATCGA
		GAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC
		CACAGGTGTACACCCTGCCCCCCTGCAGAGATGAGCTG
		ACCAAGAACCAGGTGTCCCTGTGGTGTCTGGTCAAGGGC
		TTCTACCCCAGCGATATCGCCGTGGAGTGGGAGAGCAA
		CGGCCAGCCTGAGAACAACTACAAGACCACCCCCCCTG
		TGCTGGACAGCGACGGCAGCTTCTTCCTGTACTCCAAAC
		TGACCGTGGACAAGAGCCGGTGGCAGCAGGGCAACGTG
		TTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCA
		CTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGCGGAG
		GCGGCGGAAGCGGAGGAGGAGGATCCAGAGAGGGCCC
		TGAGCTGAGCCCCGATGATCCTGCTGGACTGCTGGACCT
		GCGGCAGGGCATGTTTGCTCAGCTGGTGGCCCAGAACGT
		GCTGCTGATCGATGGCCCCCTGTCCTGGTACAGCGATCC
		TGGACTGGCTGGCGTGTCACTGACAGGCGGCCTGAGCTA
		CAAAGAGGACACCAAAGAACTGGTGGTGGCCAAGGCCG
		GCGTGTACTACGTGTTCTTTCAGCTGGAACTGCGGAGAG
		TGGTGGCCGGCGAAGGATCTGGCTCTGTGTCTCTGGCCC
		TGCATCTGCAGCCTCTGAGAAGCGCTGCTGGCGCTGCAG
		CTCTGGCACTGACAGTGGATCTGCCTCCTGCCAGCTCCG
		AGGCCCGGAATAGCGCATTTGGGTTTCAAGGCAGGCTG
		CTGCACCTGTCTGCCGGCCAGAGGCTGGGAGTGCATCTG
		CACACAGAGGCCAGGGCTAGACACGCCTGGCAGCTGAC
		ACAGGGCGCTACAGTGCTGGGCCTGTTCAGAGTGACCC
		CCGAGATTCCAGCCGGCCTG
163	anti-FAP (4B9)	see Table 21
	light chain
126	anti-FAP (4B9)	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQA
	Fc hole chain	PGKGLEWVSAIIGSGASTYYADSVKGRFTISRDNSKNTLYL
	fused to dimeric	QMNSLRAEDTAVYYCAKGWFGGFNYWGQGTLVTVSSAS
	hu 4-1BBL (71-	TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
	248)	GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVF
		LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG
		VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
		CKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRDELTKN
		QVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
		GSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS
		LSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQ
		LVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELV
		VAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAA
		GAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGV
		HLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLGGGGSG
		GGGSREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP
		LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFF
		QLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDL
		PPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHA
		WQLTQGATVLGLFRVTPEIPAGL
127	anti-FAP (4B9)	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQA
	Fc knob chain	PGKGLEWVSAIIGSGASTYYADSVKGRFTISRDNSKNTLYL
	fused to	QMNSLRAEDTAVYYCAKGWFGGFNYWGQGTLVTVSSAS
	monomeric hu 4-	TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
	1BBL (71-248)	GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVF
		LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG
		VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
		CKVSNKALGAPIEKTISKAKGQPREPQVYTLPPCRDELTKN
		QVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
		GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS
		LSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQ
		LVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELV
		VAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAA
		GAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGV
		HLHTEARARHAWQLTQGATVLGLFRVTPEIPAGL
125	anti-FAP (4B9)	see Table 21
	light chain

TABLE 27 — Sequences of bivalent DP47-untargeted human 4-1BB ligand (71-254) containing Fc (kih) fusion molecule Control C SEQ ID

NO:	Description	Sequence
177	nucleotide	GAGGTGCAATTGTTGGAGTCTGGGGGAGGCTTGGTACA
	sequence DP47	GCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCCGG
	Fc hole chain	ATTCACCTTTAGCAGTTATGCCATGAGCTGGGTCCGCCA
	fused to dimeric	GGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTA
	hu 4-1BBL (71-	GTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGA
	254)	AGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAAC
		ACGCTGTATCTGCAGATGAACAGCCTGAGAGCCGAGGA
		CACGGCCGTATATTACTGTGCGAAAGGCAGCGGATTTGA
		CTACTGGGGCCAAGGAACCCTGGTCACCGTCTCGAGTGC
		TAGCACCAAGGGCCCCTCCGTGTTCCCCCTGGCCCCCAG
		CAGCAAGAGCACCAGCGGCGGCACAGCCGCTCTGGGCT
		GCCTGGTCAAGGACTACTTCCCCGAGCCCGTGACCGTGT
		CCTGGAACAGCGGAGCCCTGACCTCCGGCGTGCACACC
		TTCCCCGCCGTGCTGCAGAGTTCTGGCCTGTATAGCCTG
		AGCAGCGTGGTCACCGTGCCTTCTAGCAGCCTGGGCACC
		CAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAA
		CACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGCG
		ACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAA
		GCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAA
		CCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTC
		ACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGA
		GGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGC
		ATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAAC
		AGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCAC
		CAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGT
		CTCCAACAAAGCCCTCGGCGCCCCCATCGAGAAAACCA
		TCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTG
		TGCACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAA
		CCAGGTCAGCCTCTCGTGCGCAGTCAAAGGCTTCTATCC
		CAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGC
		CGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGAC
		TCCGACGGCTCCTTCTTCCTCGTGAGCAAGCTCACCGTG
		GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATG
		CTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCA
		GAAGAGCCTCTCCCTGTCTCCGGGTGGAGGCGGCGGAA
		GCGGAGGAGGAGGATCCAGAGAGGGCCCTGAGCTGAGC
		CCCGATGATCCTGCTGGACTGCTGGACCTGCGGCAGGGC
		ATGTTTGCTCAGCTGGTGGCCCAGAACGTGCTGCTGATC
		GATGGCCCCCTGTCCTGGTACAGCGATCCTGGACTGGCT
		GGCGTGTCACTGACAGGCGGCCTGAGCTACAAAGAGGA
		CACCAAAGAACTGGTGGTGGCCAAGGCCGGCGTGTACT
		ACGTGTTCTTTCAGCTGGAACTGCGGAGAGTGGTGGCCG
		GCGAAGGATCTGGCTCTGTGTCTCTGGCCCTGCATCTGC
		AGCCTCTGAGAAGCGCTGCTGGCGCTGCAGCTCTGGCAC
		TGACAGTGGATCTGCCTCCTGCCAGCTCCGAGGCCCGGA
		ATAGCGCATTTGGGTTTCAAGGCAGGCTGCTGCACCTGT
		CTGCCGGCCAGAGGCTGGGAGTGCATCTGCACACAGAG
		GCCAGGGCTAGACACGCCTGGCAGCTGACACAGGGCGC
		TACAGTGCTGGGCCTGTTCAGAGTGACCCCCGAGATTCC
		AGCCGGCCTGCCTTCTCCAAGAAGCGAAGGCGGAGGCG
		GATCTGGCGGCGGAGGATCTAGAGAGGGACCCGAACTG
		TCCCCTGACGATCCAGCCGGGCTGCTGGATCTGAGACAG
		GGAATGTTCGCCCAGCTGGTGGCTCAGAATGTGCTGCTG
		ATTGACGGACCTCTGAGCTGGTACTCCGACCCAGGGCTG
		GCAGGGGTGTCCCTGACTGGGGGACTGTCCTACAAAGA
		AGATACAAAAGAACTGGTGGTGGCTAAAGCTGGGGTGT
		ACTATGTGTTTTTTCAGCTGGAACTGAGGCGGGTGGTGG
		CTGGGGAGGGCTCAGGATCTGTGTCCCTGGCTCTGCATC
		TGCAGCCACTGCGCTCTGCTGCTGGCGCAGCTGCACTGG
		CTCTGACTGTGGACCTGCCACCAGCCTCTAGCGAGGCCA
		GAAACAGCGCCTTCGGGTTCCAAGGACGCCTGCTGCATC
		TGAGCGCCGGACAGCGCCTGGGAGTGCATCTGCATACT
		GAAGCCAGAGCCCGGCATGCTTGGCAGCTGACTCAGGG
		GGCAACTGTGCTGGGACTGTTTCGCGTGACACCTGAGAT
		CCCTGCCGGACTGCCAAGCCCTAGATCAGAA
178	nucleotide	GAGGTGCAATTGTTGGAGTCTGGGGGAGGCTTGGTACA
	sequence DP47	GCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCCGG
	Fc knob chain	ATTCACCTTTAGCAGTTATGCCATGAGCTGGGTCCGCCA
	fused to	GGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTA
	monomeric hu 4-	GTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGA
	1BBL (71-254)	AGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAAC
		ACGCTGTATCTGCAGATGAACAGCCTGAGAGCCGAGGA
		CACGGCCGTATATTACTGTGCGAAAGGCAGCGGATTTGA
		CTACTGGGGCCAAGGAACCCTGGTCACCGTCTCGAGTGC
		TAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTC
		CTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCT
		GCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGT
		CGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACC
		TTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTC
		AGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCAC
		CCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCA
		ACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGT
		GACAAAACTCACACATGCCCACCGTGCCCAGCACCTGA
		AGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAA
		ACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGT
		CACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTG
		AGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTG
		CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAA
		CAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCA
		CCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGG
		TCTCCAACAAAGCCCTCGGCGCCCCCATCGAGAAAACC
		ATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGT
		GTACACCCTGCCCCCCTGCAGAGATGAGCTGACCAAGA
		ACCAGGTGTCCCTGTGGTGTCTGGTCAAGGGCTTCTACC
		CCAGCGATATCGCCGTGGAGTGGGAGAGCAACGGCCAG
		CCTGAGAACAACTACAAGACCACCCCCCCTGTGCTGGA
		CAGCGACGGCAGCTTCTTCCTGTACTCCAAACTGACCGT
		GGACAAGAGCCGGTGGCAGCAGGGCAACGTGTTCAGCT
		GCAGCGTGATGCACGAGGCCCTGCACAACCACTACACC
		CAGAAGTCCCTGAGCCTGAGCCCCGGCGGAGGCGGCGG
		AAGCGGAGGAGGAGGATCCAGAGAGGGCCCTGAGCTGA
		GCCCCGATGATCCTGCTGGACTGCTGGACCTGCGGCAGG
		GCATGTTTGCTCAGCTGGTGGCCCAGAACGTGCTGCTGA
		TCGATGGCCCCCTGTCCTGGTACAGCGATCCTGGACTGG
		CTGGCGTGTCACTGACAGGCGGCCTGAGCTACAAAGAG
		GACACCAAAGAACTGGTGGTGGCCAAGGCCGGCGTGTA
		CTACGTGTTCTTTCAGCTGGAACTGCGGAGAGTGGTGGC
		CGGCGAAGGATCTGGCTCTGTGTCTCTGGCCCTGCATCT
		GCAGCCTCTGAGAAGCGCTGCTGGCGCTGCAGCTCTGGC
		ACTGACAGTGGATCTGCCTCCTGCCAGCTCCGAGGCCCG
		GAATAGCGCATTTGGGTTTCAAGGCAGGCTGCTGCACCT
		GTCTGCCGGCCAGAGGCTGGGAGTGCATCTGCACACAG
		AGGCCAGGGCTAGACACGCCTGGCAGCTGACACAGGGC
		GCTACAGTGCTGGGCCTGTTCAGAGTGACCCCCGAGATT
		CCAGCCGGCCTGCCTTCTCCAAGAAGCGAA
80	nucleotide	see Table 18
	sequence DP47
	light chain
179	DP47 Fc hole	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQA
	chain fused to	PGKGLEWVSAIIGSGASTYYADSVKGRFTISRDNSKNTLYL
	dimeric hu 4-	QMNSLRAEDTAVYYCAKGWFGGFNYWGQGTLVTVSSAS
	1BBL (71-254)	TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
		GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVF
		LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG
		VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
		CKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRDELTKN
		QVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
		GSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS
		LSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQ
		LVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELV
		VAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAA
		GAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGV
		HLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSEG
		GGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQLVAQNV
		LLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGV
		YYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALA
		LTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEA
		RARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSE
180	DP47 Fc knob	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQA
	chain fused to	PGKGLEWVSAIIGSGASTYYADSVKGRFTISRDNSKNTLYL
	monomeric hu 4-	QMNSLRAEDTAVYYCAKGWFGGFNYWGQGTLVTVSSAS
	1BBL (71-254)	TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
		GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVF
		LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG
		VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
		CKVSNKALGAPIEKTISKAKGQPREPQVYTLPPCRDELTKN
		QVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
		GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS
		LSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQ
		LVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELV
		VAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAA
		GAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGV
		FILHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSE
82	DP47 light chain	see Table 18

TABLE 28 — Sequences of monovalent untargeted human 4-1BB ligand (71-248) containing Fc (kih) fusion molecule Control E

SEQ ID NO:	Description	Sequence
171	Dimeric hu	see Table 25
	4-1BBL
	(71-248) - CL
	Fc knob chain
172	Monomeric hu	see Table 25
	4-1BBL
	(71-248) - CH1
79	DP47 Fc hole	see Table 18
	chain
80	DP47 light chain	see Table 18
173	Dimeric hu	see Table 25
	4-1BBL
	(71-248) - CL
	Fc knob chain
174	Monomeric hu	see Table 25
	4-1BBL
	(71-248) - CH1
81	DP47 Fc hole	see Table 18
	chain
82	DP47 light chain	see Table 18

TABLE 29 — Sequences of untargeted DP47 huIgG1 (Control F) SEQ ID

NO:	Description	Sequence
181	nucleotide	GAGGTGCAATTGTTGGAGTCTGGGGGAGGCTTGGTACA
	sequence DP47	GCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCCGG
	heavy chain (hu	ATTCACCTTTAGCAGTTATGCCATGAGCTGGGTCCGCCA
	IgG1 PGLALA)	GGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTA
		GTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGA
		AGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAAC
		ACGCTGTATCTGCAGATGAACAGCCTGAGAGCCGAGGA
		CACGGCCGTATATTACTGTGCGAAAGGCAGCGGATTTGA
		CTACTGGGGCCAAGGAACCCTGGTCACCGTCTCGAGTGC
		TAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTC
		CTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCT
		GCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGT
		CGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACC
		TTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTC
		AGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCAC
		CCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCA
		ACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGT
		GACAAAACTCACACATGCCCACCGTGCCCAGCACCTGA
		AGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAA
		ACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGT
		CACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTG
		AGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTG
		CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAA
		CAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCA
		CCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGG
		TCTCCAACAAAGCCCTCGGCGCCCCCATCGAGAAAACC
		ATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGT
		GTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGA
		ACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATC
		CCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAG
		CCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGA
		CTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGT
		GGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCAT
		GCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGC
		AGAAGAGCCTCTCCCTGTCTCCGGGTAAA
80	DP47 light chain	see Table 18
182	DP47 heavy chain	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQA
	(hu IgG1	PGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYL
	PGLALA)	QMNSLRAEDTAVYYCAKGSGFDYWGQGTLVTVSSASTKG
		PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL
		TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
		KPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPP
		KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV
		HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV
		SNKALGAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVS
		LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
		LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS
		PGK
82	DP47 light chain	see Table 18

TABLE 30 — Biochemical analysis of FAP (4B9) targeted and untargeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules and control molecules

	Monomer [%]	Yield
Construct	(SEC)	[mg/l]
Construct 2.1	95	15.8
Construct 2.3	97	11.5
Construct 2.4	97	14.1
Construct 2.5	100	16.5
Control C (bivalent)	98	12.6
Control E (monovalent)	93	4.1
Control F (germline DP47	100	50
human IgG1 PGLALA

TABLE 31 — Amino acid numbering of antigen ectodomains (ECD) and their origin

SEQ ID NO:	Construct	Origin	ECD
83	human 4-1BB ECD	Synthetized	aa 24-186
		according
		to Q07011
84	cynomolgus 4-1BB ECD	isolated from	aa 24-186
		cynomolgus blood
85	murine 4-1BB ECD	Synthetized	aa 24-187
		according
		to P20334

TABLE 32 — cDNA and Amino acid sequences of monomeric antigen Fc(kih) fusion molecules SEQ ID

NO:	Antigen	Sequence
86	Nucleotide	GACAAAACTCACACATGCCCACCGTGCCCAGCACCTGA
	sequence	ACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAA
	Fc hole chain	ACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGT
		CACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTG
		AGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTG
		CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAA
		CAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCA
		CCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGG
		TCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACC
		ATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGT
		GTGCACCCTGCCCCCATCCCGGGATGAGCTGACCAAGA
		ACCAGGTCAGCCTCTCGTGCGCAGTCAAAGGCTTCTATC
		CCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAG
		CCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGA
		CTCCGACGGCTCCTTCTTCCTCGTGAGCAAGCTCACCGT
		GGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCAT
		GCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGC
		AGAAGAGCCTCTCCCTGTCTCCGGGTAAA
87	Nucleotide	CTGCAGGACCCCTGCAGCAACTGCCCTGCCGGCACCTTC
	sequence	TGCGACAACAACCGGAACCAGATCTGCAGCCCCTGCCC
	human 4-1BB	CCCCAACAGCTTCAGCTCTGCCGGCGGACAGCGGACCT
	antigen Fc knob	GCGACATCTGCAGACAGTGCAAGGGCGTGTTCAGAACC
	chain	CGGAAAGAGTGCAGCAGCACCAGCAACGCCGAGTGCGA
		CTGCACCCCCGGCTTCCATTGTCTGGGAGCCGGCTGCAG
		CATGTGCGAGCAGGACTGCAAGCAGGGCCAGGAACTGA
		CCAAGAAGGGCTGCAAGGACTGCTGCTTCGGCACCTTC
		AACGACCAGAAGCGGGGCATCTGCCGGCCCTGGACCAA
		CTGTAGCCTGGACGGCAAGAGCGTGCTGGTCAACGGCA
		CCAAAGAACGGGACGTCGTGTGCGGCCCCAGCCCTGCT
		GATCTGTCTCCTGGGGCCAGCAGCGTGACCCCTCCTGCC
		CCTGCCAGAGAGCCTGGCCACTCTCCTCAGGTCGACGAA
		CAGTTATATTTTCAGGGCGGCTCACCCAAATCTGCAGAC
		AAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTC
		CTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCC
		AAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACA
		TGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGT
		CAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATA
		ATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGC
		ACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG
		GACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTC
		CAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCT
		CCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATGCCGGGATGAGCTGACCAAGAACCA
		GGTCAGCCTGTGGTGCCTGGTCAAAGGCTTCTATCCCAG
		CGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGG
		AGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCC
		GACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGAC
		AAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTC
		CGTGATGCATGAGGCTCTGCACAACCACTACACGCAGA
		AGAGCCTCTCCCTGTCTCCGGGTAAATCCGGAGGCCTGA
		ACGACATCTTCGAGGCCCAGAAGATTGAATGGCACGAG
88	Nucleotide	TTGCAGGATCTGTGTAGTAACTGCCCAGCTGGTACATTC
	sequence	TGTGATAATAACAGGAGTCAGATTTGCAGTCCCTGTCCT
	cynomolgus 4-	CCAAATAGTTTCTCCAGCGCAGGTGGACAAAGGACCTGT
	1BB antigen	GACATATGCAGGCAGTGTAAAGGTGTTTTCAAGACCAG
	Fc knob chain	GAAGGAGTGTTCCTCCACCAGCAATGCAGAGTGTGACT
		GCATTTCAGGGTATCACTGCCTGGGGGCAGAGTGCAGC
		ATGTGTGAACAGGATTGTAAACAAGGTCAAGAATTGAC
		AAAAAAAGGTTGTAAAGACTGTTGCTTTGGGACATTTAA
		TGACCAGAAACGTGGCATCTGTCGCCCCTGGACAAACT
		GTTCTTTGGATGGAAAGTCTGTGCTTGTGAATGGGACGA
		AGGAGAGGGACGTGGTCTGCGGACCATCTCCAGCCGAC
		CTCTCTCCAGGAGCATCCTCTGCGACCCCGCCTGCCCCT
		GCGAGAGAGCCAGGACACTCTCCGCAGGTCGACGAACA
		GTTATATTTTCAGGGCGGCTCACCCAAATCTGCAGACAA
		AACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCT
		GGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAA
		GGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATG
		CGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCA
		AGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAAT
		GCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCA
		CGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGG
		ACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCC
		AACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTC
		CAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACA
		CCCTGCCCCCATGCCGGGATGAGCTGACCAAGAACCAG
		GTCAGCCTGTGGTGCCTGGTCAAAGGCTTCTATCCCAGC
		GACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGA
		GAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCG
		ACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACA
		AGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCC
		GTGATGCATGAGGCTCTGCACAACCACTACACGCAGAA
		GAGCCTCTCCCTGTCTCCGGGTAAATCCGGAGGCCTGAA
		CGACATCTTCGAGGCCCAGAAGATTGAATGGCACGAG
89	murine 4-1BB	GTGCAGAACAGCTGCGACAACTGCCAGCCCGGCACCTT
	antigen Fc knob	CTGCCGGAAGTACAACCCCGTGTGCAAGAGCTGCCCCC
	chain	CCAGCACCTTCAGCAGCATCGGCGGCCAGCCCAACTGC
		AACATCTGCAGAGTGTGCGCCGGCTACTTCCGGTTCAAG
		AAGTTCTGCAGCAGCACCCACAACGCCGAGTGCGAGTG
		CATCGAGGGCTTCCACTGCCTGGGCCCCCAGTGCACCAG
		ATGCGAGAAGGACTGCAGACCCGGCCAGGAACTGACCA
		AGCAGGGCTGTAAGACCTGCAGCCTGGGCACCTTCAAC
		GACCAGAACGGGACCGGCGTGTGCCGGCCTTGGACCAA
		TTGCAGCCTGGACGGGAGAAGCGTGCTGAAAACCGGCA
		CCACCGAGAAGGACGTCGTGTGCGGCCCTCCCGTGGTGT
		CCTTCAGCCCTAGCACCACCATCAGCGTGACCCCTGAAG
		GCGGCCCTGGCGGACACTCTCTGCAGGTCCTGGTCGACG
		AACAGTTATATTTTCAGGGCGGCTCACCCAAATCTGCAG
		ACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAA
		CTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAA
		CCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTC
		ACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGA
		GGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGC
		ATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAAC
		AGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCAC
		CAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGT
		CTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCA
		TCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTG
		TACACCCTGCCCCCATGCCGGGATGAGCTGACCAAGAA
		CCAGGTCAGCCTGTGGTGCCTGGTCAAAGGCTTCTATCC
		CAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGC
		CGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGAC
		TCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTG
		GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATG
		CTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCA
		GAAGAGCCTCTCCCTGTCTCCGGGTAAATCCGGAGGCCT
		GAACGACATCTTCGAGGCCCAGAAGATTGAATGGCACG
		AG
90	Fc hole chain	DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV
		VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
		VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG
		QPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWE
		SNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNV
		FSCSVMHEALHNHYTQKSLSLSPGK
91	human 4-1BB	LQDPCSNCPAGTFCDNNRNQICSPCPPNSFSSAGGQRTCDI
	antigen Fc knob	CRQCKGVFRTRKECSSTSNAECDCTPGFHCLGAGCSMCEQ
	chain	DCKQGQELTKKGCKDCCFGTFNDQKRGICRPWTNCSLDG
		KSVLVNGTKERDVVCGPSPADLSPGASSVTPPAPAREPGHS
		PQVDEQLYFQGGSPKSADKTHTCPPCPAPELLGGPSVFLFP
		PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE
		VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK
		VSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQV
		SLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS
		FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS
		LSPGKSGGLNDIFEAQKIEWHE
92	cynomolgus 4-	LQDLCSNCPAGTFCDNNRSQICSPCPPNSFSSAGGQRTCDIC
	1BB antigen	RQCKGVFKTRKECSSTSNAECDCISGYHCLGAECSMCEQD
	Fc knob chain	CKQGQELTKKGCKDCCFGTFNDQKRGICRPWTNCSLDGK
		SVLVNGTKERDVVCGPSPADLSPGASSATPPAPAREPGHSP
		QVDEQLYFQGGSPKSADKTHTCPPCPAPELLGGPSVFLFPP
		KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV
		HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV
		SNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVS
		LWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF
		FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
		SPGKSGGLNDIFEAQKIEWHE
93	murine 4-1BB	VQNSCDNCQPGTFCRKYNPVCKSCPPSTFSSIGGQPNCNIC
	antigen Fc knob	RVCAGYFRFKKFCSSTHNAECECIEGFHCLGPQCTRCEKDC
	chain	RPGQELTKQGCKTCSLGTFNDQNGTGVCRPWTNCSLDGR
		SVLKTGTTEKDVVCGPPVVSFSPSTTISVTPEGGPGGHSLQ
		VLVDEQLYFQGGSPKSADKTHTCPPCPAPELLGGPSVFLFP
		PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE
		VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK
		VSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQV
		SLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS
		FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS
		LSPGKSGGLNDIFEAQKIEWHE

TABLE 33 — Sequences of monomeric human 4-1BB His molecule SEQ ID

NO:	antigen	Sequence
94	nucleotide	CTGCAGGACCCCTGCAGCAACTGCCCTGCCGGCACCTTCTG
	sequence	CGACAACAACCGGAACCAGATCTGCAGCCCCTGCCCCCCC
	human	AACAGCTTCAGCTCTGCCGGCGGACAGCGGACCTGCGACA
	4-1BB His	TCTGCAGACAGTGCAAGGGCGTGTTCAGAACCCGGAAAGA
		GTGCAGCAGCACCAGCAACGCCGAGTGCGACTGCACCCCC
		GGCTTCCATTGTCTGGGAGCCGGCTGCAGCATGTGCGAGC
		AGGACTGCAAGCAGGGCCAGGAACTGACCAAGAAGGGCT
		GCAAGGACTGCTGCTTCGGCACCTTCAACGACCAGAAGCG
		GGGCATCTGCCGGCCCTGGACCAACTGTAGCCTGGACGGC
		AAGAGCGTGCTGGTCAACGGCACCAAAGAACGGGACGTCG
		TGTGCGGCCCCAGCCCTGCTGATCTGTCTCCTGGGGCCAGC
		AGCGTGACCCCTCCTGCCCCTGCCAGAGAGCCTGGCCACTC
		TCCTCAGGTCGACGAACAGTTATATTTTCAGGGCGGCTCAG
		GCCTGAACGACATCTTCGAGGCCCAGAAGATCGAGTGGCA
		CGAGGCTCGAGCTCACCACCATCACCATCAC
95	human	LQDPCSNCPAGTFCDNNRNQICSPCPPNSFSSAGGQRTCDICR
	4-1BB His	QCKGVFRTRKECSSTSNAECDCTPGFHCLGAGCSMCEQDCK
		QGQELTKKGCKDCCFGTFNDQKRGICRPWTNCSLDGKSVLV
		NGTKERDVVCGPSPADLSPGASSVTPPAPAREPGHSPQVDEQL
		YFQGGSGLNDIFEAQKIEWHEARAHHHHHH

TABLE 34 — Fittings to 1:1 Langmuir binding and Affinity constants

Ligand	Analyte	ka (1/Ms)	kd (1/s)	KD (M)
FAP split 4-1BBL	hu4-1BB	4.8E+04	2.6E−02	5.5E−07
trimer
(Construct 1.1)
DP47 split 4-1BBL	hu4-1BB	6.2E+04	3.3E−02	5.2E−07
trimer (Control A)

TABLE 35 — Binding on activated human CD3+ CD8+ T cells and CD3+ CD4+ T cells

	EC 50 [nM]	EC 50 [nM]
Construct	4-1BB + CD8 +	4-1BB + CD4 +
Control B	0.11	16.21
1.1	0.43	4.99
1.2	0.18	20.79
1.3	0.07	2.82
1.4	0.19	0.34
1.5	0.17	2.67
1.6	0.19	0.95
1.7	0.26	16.47
1.8	0.14	2.77
1.9	0.18	12.92
1.10	0.12	0.3

TABLE 36 — Binding on activated 4-1BB-expressing CD4+ T cells and CD8+ T cells

	EC 50 [nM]	EC 50 [nM]
Construct	4-1BB + CD8 +	4-1BB + CD4 +
Control B	0.36	0.42
Control C	0.39	0.41
Control E	0.57	0.76
2.1	0.21	0.24
2.3	0.44	0.3
2.4	0.3	0.38
2.5	0.35	0.68
2.6	0.33	0.24

TABLE 37 — Binding to human FAP-expressing tumor cells

	EC 50 [nM]	EC 50 [nM]
Construct	FAP + MV-3	NIH/3T3-hu FAP
1.1	4.14	12.2
1.2	5.36	9.35
1.3	—	14.97
1.4	5.13	—
1.5	0.53	10.06
1.6	8.16	—
1.7	4.09	—
1.8	2.79	—
1.9	4.22	—
1.10	4.31	—

TABLE 38 — Binding to human FAP-expressing tumor cells

	EC 50 [nM]	EC 50 [nM]
Construct	FAP + MV-3	FAP + WM-266-4
2.1	1.66	0.99
2.3	0.53	0.42
2.4	0.83	0.59
2.5	1.66	1.2

TABLE 39 — Binding on activated 4-1BB-expressing CD4+ T cells and CD8+ T cells

	EC 50 [nM]	EC 50 [nM]
Construct	4-1BB + CD8 +	4-1BB + CD4 +
Control M.1	0.95	0.74
M.1	0.87	0.52
Control M.2	0.78	0.6
M.2	0.54	0.42

TABLE 40 — Binding to human FAP-expressing tumor cells

	EC 50 [nM]	EC 50 [nM]
Construct	FAP + MV-3	FAP + WM-266-4
M.1	7.26	5.14
M.2	6.9	5.63

TABLE 41 — Incidence of Histopathogical Findings (n = 4/group)

		Lob 12.3	Construct
Treatment	Vehicle	muIgG1 Wt	M.2
Foci of hepatocellular degeneration	—	4	—
with macrophages and inflammatory
cells
Perivascular inflammatory cells	—	4	—
infiltrates
Single cell necrosis	—	4	—

TABLE 42 — FAP prevalence in human tumors % cases with moderate

	to high grade of FAP +	No. of samples
Tumor Type	infiltrate	investigated
HNSCC	90	10
Breast Cancer	77	105
triple negative BC	80	7
CRC	77	90
PAC	74	19
Gastric Cancer	68	28
NSCLC	66	90
Mesothelioma	60	10

TABLE 43 — cDNA and Amino acid sequences of monomeric human and cynomolgus CD19 antigen Fc (kih) fusion molecule SEQ ID

NO:	Antigen	Sequence
86	Nucleotide	see Table 32
	sequence
	Fc hole chain
186	Nucleotide	CCCGAGGAACCCCTGGTCGTGAAGGTGGAAGAGGGCGACAAT
	sequence	GCCGTGCTGCAGTGCCTGAAGGGCACCTCCGATGGCCCTACC
	human CD19	CAGCAGCTGACCTGGTCCAGAGAGAGCCCCCTGAAGCCCTTC
	antigen Fc	CTGAAGCTGTCTCTGGGCCTGCCTGGCCTGGGCATCCATATG
	knob chain	AGGCCTCTGGCCATCTGGCTGTTCATCTTCAACGTGTCCCAG
	avi tag	CAGATGGGCGGCTTCTACCTGTGTCAGCCTGGCCCCCCATCT
		GAGAAGGCTTGGCAGCCTGGCTGGACCGTGAACGTGGAAGGA
		TCCGGCGAGCTGTTCCGGTGGAACGTGTCCGATCTGGGCGGC
		CTGGGATGCGGCCTGAAGAACAGATCTAGCGAGGGCCCCAGC
		AGCCCCAGCGGCAAACTGATGAGCCCCAAGCTGTACGTGTGG
		GCCAAGGACAGACCCGAGATCTGGGAGGGCGAGCCTCCTTGC
		CTGCCCCCTAGAGACAGCCTGAACCAGAGCCTGAGCCAGGAC
		CTGACAATGGCCCCTGGCAGCACACTGTGGCTGAGCTGTGGC
		GTGCCACCCGACTCTGTGTCTAGAGGCCCTCTGAGCTGGACC
		CACGTGCACCCTAAGGGCCCTAAGAGCCTGCTGAGCCTGGAA
		CTGAAGGACGACAGGCCCGCCAGAGATATGTGGGTCATGGAA
		ACCGGCCTGCTGCTGCCTAGAGCCACAGCCCAGGATGCCGGC
		AAGTACTACTGCCACAGAGGCAACCTGACCATGAGCTTCCAC
		CTGGAAATCACCGCCAGACCCGTGCTGTGGCACTGGCTGCTG
		AGAACAGGCGGCTGGAAGGTCGACGCTAGCGGTGGTAGTCCG
		ACACCTCCGACACCCGGGGGTGGTTCTGCAGACAAAACTCAC
		ACATGCCCACCGTGCCCAGCACCTGAAGCCGCAGGGGGACCG
		TCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATG
		ATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTG
		AGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGAC
		GGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG
		CAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTC
		CTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAG
		GTCTCCAACAAAGCCCTCGGAGCCCCCATCGAGAAAACCATC
		TCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACC
		CTGCCCCCATGCCGGGATGAGCTGACCAAGAACCAGGTCAGC
		CTGTGGTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCC
		GTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAG
		ACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTC
		TACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGG
		AACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAAC
		CACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATCC
		GGAGGCCTGAACGACATCTTCGAGGCCCAGAAGATTGAATGG
		CACGAG
90	Polypeptide	see Table 32
	sequence Fc
	hole chain
187	Polypeptide	PEEPLVVKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKPF
	sequence	LKLSLGLPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPS
	human CD19	EKAWQPGWTVNVEGSGELFRWNVSDLGGLGCGLKNRSSEGPS
	antigen Fc	SPSGKLMSPKLYVWAKDRPEIWEGEPPCLPPRDSLNQSLSQD
	knob chain	LTMAPGSTLWLSCGVPPDSVSRGPLSWTHVHPKGPKSLLSLE
	avi tag	LKDDRPARDMWVMETGLLLPRATAQDAGKYYCHRGNLTMSFH
		LEITARPVLWHWLLRTGGWKVDASGGSPTPPTPGGGSADKTH
		TCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV
		SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV
		LHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYT
		LPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYK
		TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN
		HYTQKSLSLSPGKSGGLNDIFEAQKIEWHE
188	Nucleotide	CCCCAGGAACCCCTGGTCGTGAAGGTGGAAGAGGGCGACAAT
	sequence	GCCGTGCTCCAGTGCCTGGAAGGCACCTCCGATGGCCCTACA
	cynomolgus	CAGCAGCTCGTGTGGTGCAGAGACAGCCCCTTCGAGCCCTTC
	CD19 antigen	CTGAACCTGTCTCTGGGCCTGCCTGGCATGGGCATCAGAATG
	Fc knob	GGCCCTCTGGGCATCTGGCTGCTGATCTTCAACGTGTCCAAC
	chain avi tag	CAGACCGGCGGCTTCTACCTGTGTCAGCCTGGCCTGCCAAGC
		GAGAAGGCTTGGCAGCCTGGATGGACCGTGTCCGTGGAAGGA
		TCTGGCGAGCTGTTCCGGTGGAACGTGTCCGATCTGGGCGGC
		CTGGGATGCGGCCTGAAGAACAGAAGCAGCGAGGGCCCTAGC
		AGCCCCAGCGGCAAGCTGAATAGCAGCCAGCTGTACGTGTGG
		GCCAAGGACAGACCCGAGATGTGGGAGGGCGAGCCTGTGTGT
		GGCCCCCCTAGAGATAGCCTGAACCAGAGCCTGAGCCAGGAC
		CTGACAATGGCCCCTGGCAGCACACTGTGGCTGAGCTGTGGC
		GTGCCACCCGACTCTGTGTCCAGAGGCCCTCTGAGCTGGACA
		CACGTGCGGCCAAAGGGCCCTAAGAGCAGCCTGCTGAGCCTG
		GAACTGAAGGACGACCGGCCCGACCGGGATATGTGGGTGGTG
		GATACAGGCCTGCTGCTGACCAGAGCCACAGCCCAGGATGCC
		GGCAAGTACTACTGCCACAGAGGCAACTGGACCAAGAGCTTT
		TACCTGGAAATCACCGCCAGACCCGCCCTGTGGCACTGGCTG
		CTGAGAATCGGAGGCTGGAAGGTCGACGCTAGCGGTGGTAGT
		CCGACACCTCCGACACCCGGGGGTGGTTCTGCAGACAAAACT
		CACACATGCCCACCGTGCCCAGCACCTGAAGCCGCAGGGGGA
		CCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTC
		ATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGAC
		GTGAGCCACGAAGACCCTGAGGTCAAGTTCACTGGTACGTG
		GACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAG
		GAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACC
		GTCCTGCACCAGGACTGGCTGATGGCAAGGAGTACAAGTGC
		AAGGTCTCCAACAAAGCCCTCGGAGCCCCCATCGAGAAAACC
		ATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATGCCGGGATGAGCTGACCAAGAACCAGGTC
		AGCCTGTGGTGCCTGGTCAAAGGCTICTATCCCAGCGACATC
		GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTAC
		AAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTIC
		CTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAG
		GGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCAC
		AACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
		TCCGGAGGCCTGAACGACATCTTCGAGGCCCAGAAGATTGA
		TGGCACGAG
189	Polypeptide	PQEPLVVKVEEGDNAVLQCLEGTSDGPTQQLVWCRDSPFEPF
	sequence	LNLSLGLPGMGIRMGPLGIWLLIFNVSNQTGGFYLCQPGLPS
	cynomolgus	EKAWQPGWTVSVEGSGELFRWNVSDLGGLGCGLKNRSSEGPS
	CD19 antigen	SPSGKLNSSQLYVWAKDRPEMWEGEPVCGPPRDSLNQSLSQD
	Fc knob	LTMAPGSTLWLSCGVPPDSVSRGPLSWTHVRPKGPKSSLLSL
	chain avi tag	ELKDDRPDRDMWVVDTGLLLTRATAQDAGKYYCHRGNWTKSF
		YLEITARPALWHWLLRIGGWKVDASGGSPTPPTPGGGSADKT
		HTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVD
		VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
		VLHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVY
		TLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNY
		KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
		NHYTQKSLSLSPGKSGGLNDIFEAQKIEWHE

TABLE 44 — Biochemical analysis of monomeric human and cynomolgus CD19 antigen Fc(kih) fusion protein

	Monomer [%]	Yield
Construct	(SEC)	[mg/l]
monomeric human CD19 Fc(kih) fusion protein	91	0.2
monomeric cynomolgus CD19 Fc(kih) fusion	95	3.56
protein

TABLE 45A — Variants of humanized wild-type CD19 antibody

	Kabat		Kabat
Variant	position	LC:	position: 6, 4	HC:
var.0:	wt	SEQ ID	QSLENSNGNTYLNW	wt	SEQ ID	TEKFNGKATM
		NO: 379			NO: 389
var.1:	N27dH	SEQ ID	QSLEHSNGNTYLNW		SEQ ID	TEKFQGRVTM
		NO: 380			NO: 192
var.2:	N27dQ	SEQ ID	QSLEQSNGNTYLNW		SEQ ID	TEKFQGRVTM
		NO: 381			NO: 192
var.3:	S27eA	SEQ ID	QSLENANGNTYLNW		SEQ ID	TEKFQGRVTM
		NO: 382			NO: 192
var.4:	S27eV	SEQ ID	QSLENVNGNTYLNW		SEQ ID	TEKFQGRVTM
		NO: 383			NO: 192
var.5:	S27eP	SEQ ID	QSLENPNGNTYLNW		SEQ ID	TEKFQGRVTM
		NO: 384			NO: 192
var.6:	N28Q	SEQ ID	QSLENSQGNTYLNW		SEQ ID	TEKFQGRVTM
		NO: 385			NO: 192
var.7:	G29A	SEQ ID	QSLENSNANTYLNW		SEQ ID	TEKFQGRVTM
		NO: 386			NO: 192
var.8:	G29V	SEQ ID	QSLENSNVNTYLNW		SEQ ID	TEKFQGRVTM
		NO: 387			NO: 192
var.9:	S27eP/N28S	SEQ ID	QSLENPSGNTYLNW		SEQ ID	TEKFQGRVTM
		NO: 388			NO: 192

TABLE 45B — variant

parameter	0	1	2	3	4	5	6	7	8	9
K D	5	250	136	2	1	6	54	4	16	45
(BIACORE ®)
[nM]
t 1/2	—	0.1	1.1	105.2	191.5	43.6	4.4	51.5	17.6	4
[min]
human CD19	46	0	75	84	85	95	91	72	83	83
binding after pH
7.4 incubation
[%]
human CD19	90	0	95	95	97	99	97	86	91	87
binding after pH
6.0 incubation
[%]
SEC main peak	>95	>95	>95	>95	>95	>95	>95	>95	>95	—
after incubation
[%]

EC50 [μg/ml]	var.0	var.5	var.9
huCD19 ECD	0.087	0.084	0.089
cyCD19 ECD	0.313	0.255	0.435

TABLE 47 — cDNA and amino acid sequences of monovalent CD19 (8B8-018) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion containing CH-CL cross with charged residues (construct 3.1). *for charged residues SEQ ID

NO:	Description	Sequence
129	Nucleotide	see Table 3
	sequence Dimeric
	hu 4-1BBL (71-
	254)-CL* Fc
	knob chain
130	Nucleotide	see Table 3
	sequence
	Monomeric hu
	4-1BBL (71-254)-
	CH1*
203	Nucleotide	CAGGTCCAGCTGGTGCAGTCCGGCGCCGAGGTCAAGAA
	sequence anti-	ACCCGGGGCTTCTGTGAAGGTTTCATGCAAGGCAAGCG
	CD19 (8B8-018)	GATACACCTTCACCGACTATATCATGCATTGGGTCAGGC
	Fc hole chain	AGGCCCCTGGCCAAGGTCTCGAATGGATGGGCTACATTA
		ACCCATATAATGATGGCTCCAAATACACCGAGAAGTTTC
		AGGGAAGAGTCACTATGACATCTGACACCAGTATCAGC
		ACTGCTTACATGGAGCTGTCCCGCCTTCGGTCTGATGAC
		ACCGCAGTGTATTACTGTGCCAGGGGCACATATTACTAC
		GGCTCAGCTCTGTTCGACTATTGGGGGCAGGGAACCACA
		GTAACCGTGAGCTCCGCTAGCACCAAGGGCCCCTCCGTG
		TTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGG
		CACAGCCGCTCTGGGCTGCCTGGTCAAGGACTACTTCCC
		CGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCCCTGA
		CCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGTT
		CTGGCCTGTATAGCCTGAGCAGCGTGGTCACCGTGCCTT
		CTAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTG
		AACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGT
		GGAGCCCAAGAGCTGCGACAAAACTCACACATGCCCAC
		CGTGCCCAGCACCTGAAGCTGCAGGGGGACCGTCAGTC
		TTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATC
		TCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTG
		AGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGT
		GGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGC
		GGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGC
		GTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAG
		GAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGCGC
		CCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGC
		CCCGAGAACCACAGGTGTGCACCCTGCCCCCATCCCGG
		GATGAGCTGACCAAGAACCAGGTCAGCCTCTCGTGCGC
		AGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTG
		GGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACC
		ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTC
		GTGAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCA
		GGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCT
		GCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCC
		GGGTAAA
204	Nucleotide	GACATCGTCATGACCCAGACACCCCTGTCCCTCTCTGTG
	sequence anti-	ACCCCTGGCCAGCCAGCCTCAATTAGCTGCAAGTCCTCT
	CD19 (8B8-018)	CAAAGTCTGGAGAACCCCAATGGGAACACTTACCTTAAT
	light chain	TGGTATCTGCAGAAACCCGGACAATCCCCTCAACTCCTG
		ATCTACAGGGTCTCTAAGAGATTCTCAGGCGTGCCAGAT
		CGCTTTAGCGGTTCCGGGTCTGGCACAGACTTCACCTTG
		AAGATTAGTCGGGTTGAAGCTGAGGATGTGGGAGTCTA
		TTACTGTCTGCAGCTCACTCATGTGCCCTACACCTTTGGT
		CAGGGCACAAAACTGGAGATCAAGCGGACCGTGGCCGC
		TCCCTCCGTGTTCATCTTCCCACCCTCCGACGAGCAGCT
		GAAGTCCGGCACCGCCAGCGTGGTGTGCCTGCTGAACA
		ACTTCTACCCCCGCGAGGCCAAGGTGCAGTGGAAGGTG
		GACAACGCCCTGCAGTCCGGCAACTCCCAGGAATCCGT
		GACCGAGCAGGACTCCAAGGACAGCACCTACTCCCTGT
		CCTCCACCCTGACCCTGTCCAAGGCCGACTACGAGAAGC
		ACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTG
		TCCAGCCCCGTGACCAAGTCCTTCAACCGGGGCGAGTGC
115	Dimeric hu 4-	see Table 3
	1BBL (71-254)-
	CL* Fc knob
	chain
116	Monomeric hu	see Table 3
	4-1BBL (71-254)-
	CH1*
205	anti-CD19 (8B8-	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQ
	018) Fc hole	APGQGLEWMGYINPYNDGSKYTEKFQGRVTMTSDTSISTA
	chain	YMELSRLRSDDTAVYYCARGTYYYGSALFDYWGQGTTVT
		VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT
		VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
		TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG
		GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
		YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN
		GKEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRD
		ELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPP
		VLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNH
		YTQKSLSLSPGK
206	anti-CD19 (8B8-	DIVMTQTPLSLSVTPGQPASISCKSSQSLENPNGNTYLNWY
	018) light chain	LQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTDFTLKISRV
		EAEDVGVYYCLQLTHVPYTFGQGTKLEIKRTVAAPSVFIFP
		PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
		SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
		QGLSSPVTKSFNRGEC

TABLE 48 — cDNA and amino acid sequences of monovalent CD19(8B8-018) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion containing CH-CL cross without charged residues (construct 3.2).

SEQ ID NO:	Description	Sequence
165	Nucleotide	see Table 22
	sequence dimeric
	ligand
	(71-254)- CL
	Fc knob chain
166	Nucleotide	see Table 22
	sequence
	monomeric hu
	4-1BBL
	(71-254) - CH1
203	Nucleotide	see Table 47
	sequence anti-
	CD19(8B8-018)
	Fc hole chain
204	Nucleotide	see Table 47
	sequence anti-
	CD19(8B8-018)
	light chain
117	Dimeric ligand	see Table 22
	(71-254) - CL
	Fc knob chain
118	Monomeric	see Table 22
	ligand
	(71-254) - CH1
205	anti-	see Table 47
	CD19(8B8-018)
	Fc hole chain
206	anti-	see Table 47
	CD19(8B8-018)
	light chain

TABLE 49 — Base pair sequences of bivalent CD19 (8B8-018) targeted split trimeric 4-1BB ligand Fc (kih) PGLALA fusion (construct 3.3) SEQ ID

NO:	Description	Sequence
207	Nucleotide	CAGGTCCAGCTGGTGCAGTCCGGCGCCGAGGTCAAGAA
	sequence anti-	ACCCGGGGCTTCTGTGAAGGTTTCATGCAAGGCAAGCG
	CD19 (8B8-018)	GATACACCTTCACCGACTATATCATGCATTGGGTCAGGC
	Fc hole dimeric	AGGCCCCTGGCCAAGGTCTCGAATGGATGGGCTACATTA
	ligand chain	ACCCATATAATGATGGCTCCAAATACACCGAGAAGTTTC
		AGGGAAGAGTCACTATGACATCTGACACCAGTATCAGC
		ACTGCTTACATGGAGCTGTCCCGCCTTCGGTCTGATGAC
		ACCGCAGTGTATTACTGTGCCAGGGGCACATATTACTAC
		GGCTCAGCTCTGTTCGACTATTGGGGGCAGGGAACCACA
		GTAACCGTGAGCTCCGCTAGCACCAAGGGCCCCTCCGTG
		TTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGG
		CACAGCCGCTCTGGGCTGCCTGGTCAAGGACTACTTCCC
		CGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCCCTGA
		CCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGTT
		CTGGCCTGTATAGCCTGAGCAGCGTGGTCACCGTGCCTT
		CTAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTG
		AACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGT
		GGAGCCCAAGAGCTGCGACAAAACTCACACATGCCCAC
		CGTGCCCAGCACCTGAAGCTGCAGGGGGACCGTCAGTC
		TTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATC
		TCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTG
		AGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGT
		GGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGC
		GGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGC
		GTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAG
		GAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGCGC
		CCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGC
		CCCGAGAACCACAGGTGTGCACCCTGCCCCCATCCCGG
		GATGAGCTGACCAAGAACCAGGTCAGCCTCTCGTGCGC
		AGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTG
		GGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACC
		ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTC
		GTGAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCA
		GGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCT
		GCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCC
		GGGTGGAGGCGGCGGAAGCGGAGGAGGAGGATCCAGA
		GAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGGACT
		GCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGTGGC
		CCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTGGTA
		CAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGGCG
		GCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGGTG
		GCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGGAA
		CTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCTGT
		GTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCGCTGC
		TGGCGCTGCAGCTCTGGCACTGACAGTGGATCTGCCTCC
		TGCCAGCTCCGAGGCCCGGAATAGCGCATTTGGGTTTCA
		AGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCTGG
		GAGTGCATCTGCACACAGAGGCCAGGGCTAGACACGCC
		TGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTGTTC
		AGAGTGACCCCCGAGATTCCAGCCGGCCTGCCTTCTCCA
		AGAAGCGAAGGCGGAGGCGGATCTGGCGGCGGAGGATC
		TAGAGAGGGACCCGAACTGTCCCCTGACGATCCAGCCG
		GGCTGCTGGATCTGAGACAGGGAATGTTCGCCCAGCTG
		GTGGCTCAGAATGTGCTGCTGATTGACGGACCTCTGAGC
		TGGTACTCCGACCCAGGGCTGGCAGGGGTGTCCCTGACT
		GGGGGACTGTCCTACAAAGAAGATACAAAAGAACTGGT
		GGTGGCTAAAGCTGGGGTGTACTATGTGTTTTTTCAGCT
		GGAACTGAGGCGGGTGGTGGCTGGGGAGGGCTCAGGAT
		CTGTGTCCCTGGCTCTGCATCTGCAGCCACTGCGCTCTG
		CTGCTGGCGCAGCTGCACTGGCTCTGACTGTGGACCTGC
		CACCAGCCTCTAGCGAGGCCAGAAACAGCGCCTTCGGG
		TTCCAAGGACGCCTGCTGCATCTGAGCGCCGGACAGCG
		CCTGGGAGTGCATCTGCATACTGAAGCCAGAGCCCGGC
		ATGCTTGGCAGCTGACTCAGGGGGCAACTGTGCTGGGA
		CTGTTTCGCGTGACACCTGAGATCCCTGCCGGACTGCCA
		AGCCCTAGATCAGAA
208	Nucleotide	CAGGTCCAGCTGGTGCAGTCCGGCGCCGAGGTCAAGAA
	sequence anti-	ACCCGGGGCTTCTGTGAAGGTTTCATGCAAGGCAAGCG
	CD19 (8B8-018)	GATACACCTTCACCGACTATATCATGCATTGGGTCAGGC
	Fc knob	AGGCCCCTGGCCAAGGTCTCGAATGGATGGGCTACATTA
	monomeric ligand	ACCCATATAATGATGGCTCCAAATACACCGAGAAGTTTC
		AGGGAAGAGTCACTATGACATCTGACACCAGTATCAGC
		ACTGCTTACATGGAGCTGTCCCGCCTTCGGTCTGATGAC
		ACCGCAGTGTATTACTGTGCCAGGGGCACATATTACTAC
		GGCTCAGCTCTGTTCGACTATTGGGGGCAGGGAACCACA
		GTAACCGTGAGCTCCGCTAGCACCAAGGGCCCATCGGT
		CTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGG
		CACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCC
		CGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGA
		CCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCT
		CAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCT
		CCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTG
		AATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGT
		TGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACC
		GTGCCCAGCACCTGAAGCTGCAGGGGGACCGTCAGTCT
		TCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCT
		CCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTG
		AGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGT
		GGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGC
		GGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGC
		GTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAG
		GAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGCGC
		CCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGC
		CCCGAGAACCACAGGTGTACACCCTGCCCCCCTGCAGA
		GATGAGCTGACCAAGAACCAGGTGTCCCTGTGGTGTCTG
		GTCAAGGGCTTCTACCCCAGCGATATCGCCGTGGAGTGG
		GAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCAC
		CCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCTGTA
		CTCCAAACTGACCGTGGACAAGAGCCGGTGGCAGCAGG
		GCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTG
		CACAACCACTACACCCAGAAGTCCCTGAGCCTGAGCCC
		CGGCGGAGGCGGCGGAAGCGGAGGAGGAGGATCCAGA
		GAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGGACT
		GCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGTGGC
		CCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTGGTA
		CAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGGCG
		GCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGGTG
		GCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGGAA
		CTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCTGT
		GTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCGCTGC
		TGGCGCTGCAGCTCTGGCACTGACAGTGGATCTGCCTCC
		TGCCAGCTCCGAGGCCCGGAATAGCGCATTTGGGTTTCA
		AGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCTGG
		GAGTGCATCTGCACACAGAGGCCAGGGCTAGACACGCC
		TGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTGTTC
		AGAGTGACCCCCGAGATTCCAGCCGGCCTGCCTTCTCCA
		AGAAGCGAA
204	Nucleotide	see Table 47
	sequence anti-
	CD19 (8B8-018)
	light chain
209	anti-CD19 (8B8-	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQ
	018) Fc hole	APGQGLEWMGYINPYNDGSKYTEKFQGRVTMTSDTSISTA
	dimeric ligand	YMELSRLRSDDTAVYYCARGTYYYGSALFDYWGQGTTVT
	chain	VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT
		VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
		TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG
		GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
		YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN
		GKEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRD
		ELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPP
		VLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNH
		YTQKSLSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLRQ
		GMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKED
		TKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQP
		LRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAG
		QRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLP
		SPRSEGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQL
		VAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVV
		AKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAG
		AAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVH
		LHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSE
210	anti-CD19 (8B8-	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQ
	018) Fc knob	APGQGLEWMGYINPYNDGSKYTEKFQGRVTMTSDTSISTA
	monomeric ligand	YMELSRLRSDDTAVYYCARGTYYYGSALFDYWGQGTTVT
		VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT
		VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
		TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG
		GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
		YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN
		GKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPCRD
		ELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPP
		VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH
		YTQKSLSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLRQ
		GMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKED
		TKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQP
		LRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAG
		QRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLP
		SPRSE
206	anti-CD19 (8B8-	see Table 47
	018) light chain

TABLE 50 — cDNA and amino acid sequences of monovalent CD19(8B8-018) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion containing CH-CL cross with charged residues (construct 3.4). SEQ ID

NO:	Description	Sequence
169	Nucleotide	see Table 24
	sequence dimeric
	ligand (71-248) -
	CL* Fc knob
	chain
170	Nucleotide	see Table 24
	sequence
	monomeric hu
	4-1BBL (71-248) -
	CH1*
203	Nucleotide	see Table 47
	sequence anti-
	CD19(8B8-018)
	Fc hole chain
204	Nucleotide	see Table 47
	sequence anti-
	CD19(8B8-018)
	light chain
119	Dimeric ligand	see Table 24
	(71-248) - CL*
	Fc knob chain
120	Monomeric	see Table 24
	ligand (71-248)-
	CH1*
205	anti-CD19(8B8-	see Table 47
	018) Fc hole
	chain
206	anti-CD19(8B8-	see Table 47
	018) light chain
*charged residues

TABLE 51 — cDNA and amino acid sequences of monovalent CD19(8B8-018) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion containing CH-CL cross without charged residues (construct 3.5). SEQ ID

NO:	Description	Sequence
171	Nucleotide	see Table 25
	sequence dimeric
	ligand (71-248) -
	CL Fc knob chain
172	Nucleotide	see Table 25
	sequence
	monomeric ligand
	(71-248)-CH1
203	Nucleotide	see Table 47
	sequence anti-
	CD19(8B8-018)
	Fc hole chain
204	Nucleotide	see Table 47
	sequence anti-
	CD19(8B8-018)
	light chain
173	Dimeric ligand	see Table 25
	(71-248) - CL Fc
	knob chain
174	Monomeric	see Table 25
	ligand (71-248)-
	CH1
205	anti-CD19(8B8-	see Table 47
	018) Fc hole
	chain
206	anti-CD19(8B8-	see Table 47
	018) light chain

TABLE 52 — cDNA and amino acid sequences of bivalent CD19(8B8-018) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion (construct 3.6) SEQ

ID NO:	Description	Sequence
211	Nucleotide	CAGGTCCAGCTGGTGCAGTCCGGCGCCGAGGTCAAGAA
	sequence anti-	ACCCGGGGCTTCTGTGAAGGTTTCATGCAAGGCAAGCG
	CD19(8B8-018)	GATACACCTTCACCGACTATATCATGCATTGGGTCAGGC
	Fc hole dimeric	AGGCCCCTGGCCAAGGTCTCGAATGGATGGGCTACATTA
	ligand (71-248)	ACCCATATAATGATGGCTCCAAATACACCGAGAAGTTTC
	chain	AGGGAAGAGTCACTATGACATCTGACACCAGTATCAGC
		ACTGCTTACATGGAGCTGTCCCGCCTTCGGTCTGATGAC
		ACCGCAGTGTATTACTGTGCCAGGGGCACATATTACTAC
		GGCTCAGCTCTGTTCGACTATTGGGGGCAGGGAACCACA
		GTAACCGTGAGCTCCGCTAGCACCAAGGGCCCCTCCGTG
		TTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGG
		CACAGCCGCTCTGGGCTGCCTGGTCAAGGACTACTTCCC
		CGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCCCTGA
		CCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGTT
		CTGGCCTGTATAGCCTGAGCAGCGTGGTCACCGTGCCTT
		CTAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTG
		AACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGT
		GGAGCCCAAGAGCTGCGACAAAACTCACACATGCCCAC
		CGTGCCCAGCACCTGAAGCTGCAGGGGGACCGTCAGTC
		TTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATC
		TCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTG
		AGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGT
		GGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGC
		GGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGC
		GTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAG
		GAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGCGC
		CCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGC
		CCCGAGAACCACAGGTGTGCACCCTGCCCCCATCCCGG
		GATGAGCTGACCAAGAACCAGGTCAGCCTCTCGTGCGC
		AGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTG
		GGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACC
		ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTC
		GTGAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCA
		GGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCT
		GCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCC
		GGGTGGAGGCGGCGGAAGCGGAGGAGGAGGATCCAGA
		GAGGGCCCTGAGCTGAGCCCTGATGATCCTGCCGGACT
		GCTGGACCTGCGGCAGGGAATGTTTGCCCAGCTGGTGGC
		CCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTGGTA
		CAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGGCG
		GCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGGTG
		GCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGGAA
		CTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCTGT
		GTCTCTGGCCCTGCATCTGCAGCCTCTGAGATCTGCTGC
		TGGCGCCGCTGCTCTGGCACTGACAGTGGATCTGCCTCC
		TGCCAGCAGCGAGGCCCGGAATAGCGCATTTGGGTTTCA
		AGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCTGG
		GAGTGCATCTGCACACAGAGGCCAGGGCTAGACACGCC
		TGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTGTTC
		AGAGTGACCCCCGAGATTCCAGCAGGCCTGGGAGGCGG
		CGGATCTGGCGGCGGAGGATCTAGAGAAGGACCCGAGC
		TGTCCCCCGACGATCCCGCTGGGCTGCTGGATCTGAGAC
		AGGGCATGTTCGCTCAGCTGGTGGCTCAGAATGTGCTGC
		TGATTGACGGACCTCTGAGCTGGTACTCCGACCCAGGGC
		TGGCAGGGGTGTCCCTGACTGGGGGACTGTCCTACAAA
		GAAGATACAAAAGAACTGGTGGTGGCTAAAGCTGGGGT
		GTACTATGTGTTTTTTCAGCTGGAACTGAGGCGGGTGGT
		GGCTGGGGAGGGCTCAGGATCTGTGTCCCTGGCTCTGCA
		TCTGCAGCCACTGCGCTCTGCAGCAGGGGCTGCAGCACT
		GGCCCTGACTGTGGACCTGCCCCCAGCTTCTTCCGAGGC
		CAGAAACAGCGCCTTCGGGTTCCAAGGACGCCTGCTGC
		ATCTGAGCGCCGGACAGCGCCTGGGAGTGCATCTGCAT
		ACTGAAGCCAGAGCCCGGCATGCTTGGCAGCTGACTCA
		GGGGGCAACTGTGCTGGGACTGTTTCGCGTGACACCTGA
		GATCCCAGCCGGGCTC
212	Nucleotide	CAGGTCCAGCTGGTGCAGTCCGGCGCCGAGGTCAAGAA
	sequence anti-	ACCCGGGGCTTCTGTGAAGGTTTCATGCAAGGCAAGCG
	CD19(8B8-018)	GATACACCTTCACCGACTATATCATGCATTGGGTCAGGC
	Fc knob	AGGCCCCTGGCCAAGGTCTCGAATGGATGGGCTACATTA
	monomeric (71-	ACCCATATAATGATGGCTCCAAATACACCGAGAAGTTTC
	248) ligand	AGGGAAGAGTCACTATGACATCTGACACCAGTATCAGC
		ACTGCTTACATGGAGCTGTCCCGCCTTCGGTCTGATGAC
		ACCGCAGTGTATTACTGTGCCAGGGGCACATATTACTAC
		GGCTCAGCTCTGTTCGACTATTGGGGGCAGGGAACCACA
		GTAACCGTGAGCTCCGCTAGCACCAAGGGCCCATCGGT
		CTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGG
		CACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCC
		CGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGA
		CCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCT
		CAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCT
		CCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTG
		AATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGT
		TGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACC
		GTGCCCAGCACCTGAAGCTGCAGGGGGACCGTCAGTCT
		TCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCT
		CCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTG
		AGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGT
		GGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGC
		GGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGC
		GTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAG
		GAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGCGC
		CCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGC
		CCCGAGAACCACAGGTGTACACCCTGCCCCCCTGCAGA
		GATGAGCTGACCAAGAACCAGGTGTCCCTGTGGTGTCTG
		GTCAAGGGCTTCTACCCCAGCGATATCGCCGTGGAGTGG
		GAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCAC
		CCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCTGTA
		CTCCAAACTGACCGTGGACAAGAGCCGGTGGCAGCAGG
		GCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTG
		CACAACCACTACACCCAGAAGTCCCTGAGCCTGAGCCC
		CGGCGGAGGCGGCGGAAGCGGAGGAGGAGGATCCAGA
		GAGGGCCCTGAGCTGAGCCCTGATGATCCTGCCGGACT
		GCTGGACCTGCGGCAGGGAATGTTTGCCCAGCTGGTGGC
		CCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTGGTA
		CAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGGCG
		GCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGGTG
		GCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGGAA
		CTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCTGT
		GTCTCTGGCCCTGCATCTGCAGCCTCTGAGATCTGCTGC
		TGGCGCCGCTGCTCTGGCACTGACAGTGGATCTGCCTCC
		TGCCAGCAGCGAGGCCCGGAATAGCGCATTTGGGTTTCA
		AGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCTGG
		GAGTGCATCTGCACACAGAGGCCAGGGCTAGACACGCC
		TGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTGTTC
		AGAGTGACCCCCGAGATTCCTGCCGGGCTC
204	Nucleotide	see Table 47
	sequence anti-
	CD19(8B8-018)
	light chain
213	anti-CD19 (8B8-	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQ
	018) Fc hole	APGQGLEWMGYINPYNDGSKYTEKFQGRVTMTSDTSISTA
	dimeric ligand	YMELSRLRSDDTAVYYCARGTYYYGSALFDYWGQGTTVT
	(71-248) chain	VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT
		VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
		TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG
		GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
		YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN
		GKEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRD
		ELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPP
		VLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNH
		YTQKSLSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLRQ
		GMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKED
		TKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQP
		LRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAG
		QRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLG
		GGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQLVAQNV
		LLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGV
		YYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALA
		LTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEA
		RARHAWQLTQGATVLGLFRVTPEIPAGL
214	anti-CD19(8B8-	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQ
	018) Fc knob	APGQGLEWMGYINPYNDGSKYTEKFQGRVTMTSDTSISTA
	monomeric (71-	YMELSRLRSDDTAVYYCARGTYYYGSALFDYWGQGTTVT
	248) ligand	VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT
		VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
		TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG
		GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
		YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN
		GKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPCRD
		ELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPP
		VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH
		YTQKSLSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLRQ
		GMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKED
		TKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQP
		LRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAG
		QRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGL
206	anti-CD19(8B8-	see Table 47
	018) light chain

TABLE 53 — Primers for 8B8 affinity maturation and hotspot removal library L1_L2/H1_H2

SEQ ID	Name	Sequence
217	CD19 L1	CAG CTG CGG GCT CTG ACC CGG TTT CTG GAG ATA
	reverse	CCA GTT CAG 1 CGT 2 GCC 3 GGA 4 TTC CAG AGA TTG
	random	GCT GGA TTT GCA AGA AAT G
		1: 40% Y, 6% A/S/T/G/P/D/N/E/Q/V, 2: 40% N, 6%
		A/S/T/Y/G/P/D/E/Q/V, 3: 25% S/T/Q/E, 4: 25% S/T/Q/E
218	CD19 L2	CTC CAG AAA CCG GGT CAG AGC CCG CAG CTG CTG
	forward	ATC TAC 5 GTA TCT 6 CGC 7 8 GGC GTT 9 GAT CGT TTC
	random	AGC GGT TCT GGA TCC GGC ACC
		5: 30% R, 20% E, 5% A/S/T/Y/G/P/D/N/Q/V. 6: 30% K, 20%
		S, 5% A/N/T/Y/G/P/D/E/Q/V, 7: 40% F, 5%
		A/S/T/Y/G/P/D/E/Q/V/I/L, 8: 40% S, 6.6%
		A/T/Y/G/P/D/E/Q/V, 9: 50% P, 50% L
219	CD19 H1	CAT CCA CTC CAG ACC CTG GCC CGG GGC CTG ACG
	reverse	AAC CCA 10 CAT 11 12 13 14 GAA 15 GTA ACC AGA TGC
	random	TTT GCA GCT CAC TTT AAC GGA AGC
		10: 52% H, 4% G/A/S/P/T/N/Y/D/E/Q/V/I, 11: 30% I,
		15% Y, 5% G/A/S/T/P/N/H/D/E/Q/V, 12: 52% Y, 4%
		G/A/S/P/T/N/H/D/E/Q/V/I, 13: 30% D, 15% G, 5%
		A/S/P/Y/N/H/D/E/Q/V/I, 14: 52% T, 4%
		G/A/S/P/Y/N/H/D/E/Q/V/I, 15: 52% T, 4%
		G/A/S/P/Y/N/H/D/E/Q/V/I
220	CD19 H2	CAG GCC CCG GGC CAG GGT CTG GAG TGG ATG GGC
	forward	16 ATT 17 CCA 18 19 20 21 TCC 22 TAT ACC 23 AAA TTC
	random	CAG GGC CGC GTC ACG ATG ACC
		16: 45% Y, 5% A/S/P/T/N/H/D/E/Q/V/I, 17: 52% N, 4%
		G/A/S/P/Y/T/H/D/E/Q/V/I, 18: 40% Y, 5%
		G/A/S/P/T/N/H/D/E/Q/V/I, 19: 30% N, 15% S, 5%
		G/A/T/P/Y/H/D/E/Q/V/I, 20: 30% D, 15% G, 5%
		A/S/T/P/Y/N/H/E/Q/V/I, 21: 52% G, 4%
		N/A/S/P/Y/T/H/D/E/Q/V/I, 22: 30% K, 15% N, 4%
		G/A/S/P/Y/T/H/D/E/Q/V/I, 23: 30% E, 15% Q, 5%
		G/A/S/T/P/Y/N/H/D/V/I
221	CD19 H3	CGTCACCGGTTCGGGGAAGTAGTCCTTGACCAG
	reverse
	constant
222	LMB3	CAGGAAACAGCTATGACCATGATTAC

TABLE 54 — Primers for 8B8 affinity maturation and hotspot removal library L1_L3/H3

SEQ ID	Name	Sequence
223	CD19 L1	TGGTATCTCCAGAAACCGGGTCAGAGCCCGCAG
	forward
	constant
217	CD19 L1	See Table 53
	reverse
	random
224	CD19 L3	TTT AAT TTC CAG TTT AGT TCC TTG
	reverse	ACC GAA GGT 24 25 26 27 28 29 CTG
	random	CAG ACA ATA GTA GAC GCC AAC GTC
		TTC AGC
		24: 52% Y, 4% G/A/S/T/N/P/D/E/Q/
		V/L/I, 25: 52% P, 4% G/A/S/T/Y/N/
		H/D/E/Q/V/I, 26: 42% V, 10% L,
		4% G/A/S/T/Y/N/P/D/E/Q/V/I,
		27: 52% H, 4% G/A/S/T/Y/N/P/D/E/
		Q/V/I, 28: 42% T, 10% I, 4% G/A/
		S/T/Y/N/P/D/E/Q/V/L, 29: 45% L,
		11% G, 4% A/S/T/Y/N/P/D/E/Q/V/I
225	CD19 L3	ACCTTCGGTCAAGGAACTAAACTGGAAATTAAA
	forward	CG
	constant
226	CD19 H3	TT GGT GCT AGC AGA GCT TAC GGT CAC
	reverse	CGT GGT ACC TTG GCC CCA GTA ATC AAA
	random	30 31 32 33 34 35 36 37 38 GCG TGC
		ACA ATA GTA AAC AGC GGT GTC
		30: 50% L, 3.8% G/A/S/T/P/H/Y/N/D/
		E/Q/V/I, 31: 50% A, 4.2% G/S/T/P/
		H/Y/N/D/E/Q/V/I, 32: 50% S, 4.2%
		G/A/T/P/H/Y/N/D/E/Q/V/I, 33: 50%
		G, 4.2% S/A/T/P/H/Y/N/D/E/Q/V/I,
		34: 50% Y, 4.2% G/A/T/P/H/S/N/D/E/
		Q/V/I, 35: 50% Y, 4.2% G/A/T/P/H/S/
		N/D/E/Q/V/I, 36: 50% Y, 4.2% G/A/T/
		P/H/S/N/D/E/Q/V/I, 37: 50% T,
		4.2% G/A/Y/P/H/S/N/D/E/Q/V/I,
		38: 50% G, 4.2% Y/A/T/P/H/S/N/D/
		E/Q/V/I
222	LMB3	See Table 53

TABLE 55 — Dissociation constants of selected clones obtained in screening analysis with bacterial supernatant

clone	Dissociation constant kd (1/s)
Parental 8B8	3.01E−4
5H09	2.58E−4
7H07	5.75E−5
2B03	3.24E−5
2B11	4.37E−6
5A07	n.d.
5B08	n.d.
5D08	1.95E−4

TABLE 56 — CDR sequences of the selected 8B8 light chains

	SEQ		SEQ		SEQ
	ID		ID		ID
clone	NO	CDR-L1	NO	CDR-L2	NO	CDR-L3
5H09	231	KSSQSLES	232	RVSKRFS	233	LQLIDYPVT
		STGNTYLN
7H07	237	KSSQSLET	238	RVSKRFS	239	LQATHIPYT
		STGNTYLN
2B03	243	KSSQSLET	244	RVSKRFS	245	LQLTHVPYT
		STGNTYLN
2B11	249	KSSQSLET	250	RVSKRFS	251	LQLLEDPYT
		STGTTYLN
5A07	255	KSSQSLET	256	RVSKRFS	257	LQPGHYPGT
		STGNTYLN
5B08	261	KSSQSLET	262	RVSKRFS	263	LQLDSYPNT
		STGNTYLN
5D08	267	KSSQSLET	268	RVSKRFS	269	LQLTHEPYT
		STGNTYLN

TABLE 57 — CDR sequences of the selected 8B8 heavy chains

	SEQ		SEQ		SEQ
	ID		ID		ID
clone	NO	CDR-H1	NO	CDR-H2	NO	CDR-H3
5H09	234	DYIMH	235	YINPYNDGS	236	GTYYYG
				KYTEKFQG		SALFDY
7H07	240	DYIMH	241	YINPYNDGS	242	GTYYYG
				KYTEKFQG		SELFDY
2B03	246	DYITH	247	YINPYNDGS	248	GTYYYG
				KYTEKFQG		PDLFDY
2B11	252	DYIMH	253	YINPYNDGS	254	GTYYYG
				KYTEKFQG		PQLFDY
5A07	258	DYIMH	259	YINPYNDGS	260	GTYYYG
				KYTEKFQG		SALFDY
5B08	264	DYIMH	265	YINPYNDGS	266	GTYYYG
				KYTEKFQG		PQLFDY
5D08	270	DYIMH	271	YINPYNDGS	272	GTYYYG
				KYTEKFQG		SELFDY

TABLE 59 — cDNA and amino acid sequences of affinity matured anti-CD19 clones in P329GLALA human IgG1 format

SEQ	Clone
ID	and
NO:	Chain	Sequence
277	2B11	GATATTGTCATGACTCAAACTCCACTGTCTCTGTCCGTGACCCCGGGT
	light	CAGCCAGCGAGCATTTCTTGCAAATCCAGCCAATCTCTGGAAACCTCC
	chain	ACCGGCACCACGTACCTGAACTGGTATCTCCAGAAACCGGGTCAGAG
		CCCGCAGCTGCTGATCTACCGTGTATCTAAGCGCTTCTCCGGCGTTCC
		TGATCGTTTCAGCGGTTCTGGATCCGGCACCGACTTTACTCTGAAAAT
		CAGCCGTGTGGAAGCTGAAGACGTTGGCGTCTACTATTGTCTGCAGCT
		GCTGGAAGATCCATACACCTTCGGTCAAGGAACGAAACTGGAAATTA
		AACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATG
		AGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACT
		TCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTC
		CAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGG
		ACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGAC
		TACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCT
		GAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
278	2B11	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCGC
	heavy	TTCCGTTAAAGTGAGCTGCAAAGCATCTGGTTACACCTTCACTGACTA
	chain	TATCATGCACTGGGTTCGTCAGGCCCCGGGCCAGGGTCTGGAGTGGA
		TGGGCTACATTAACCCATACAACGACGGTTCCAAATATACCGAGAAA
		TTCCAGGGCCGCGTCACGATGACCAGCGACACTTCTATCTCCACCGCG
		TACATGGAACTGTCTAGACTGCGTTCTGACGACACCGCTGTTTACTAT
		TGTGCACGCGGTACCTACTACTACGGTCCACAGCTGTTTGATTACTGG
		GGCCAAGGTACCACGGTGACCGTAAGCTCTGCTAGCACCAAGGGCCC
		ATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCAC
		AGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGA
		CGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTC
		CCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTG
		ACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGT
		GAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC
		AAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGA
		AGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGG
		ACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTG
		GACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGA
		CGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAG
		TACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCA
		GGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAA
		GCCCTCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA
		GCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGC
		TGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTAT
		CCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGA
		ACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCT
		TCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGG
		AACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTAC
		ACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
279	2B11	DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGTTYLNWYLQKPGQSPQL
	light	LIYRVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQLLEDPY
	chain	TFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV
		QWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC
		EVTHQGLSSPVTKSFNRGEC
280	2B11	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQAPGQGLEW
	heavy	MGYINPYNDGSKYTEKFQGRVTMTSDTSISTAYMELSRLRSDDTAVYYC
	chain	ARGTYYYGPQLFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAA
		LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
		SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVF
		LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
		KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISK
		AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
		NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY
		TQKSLSLSPGK
281	7H07	GATATTGTTATGACTCAAACTCCACTGTCTCTGTCCGTGACCCCGGGT
	light	CAGCCAGCGAGCATTTCTTGCAAATCCAGCCAATCTCTGGAAACCTCC
	chain	ACCGGCAACACGTACCTGAACTGGTATCTCCAGAAACCGGGTCAGAG
		CCCGCAGCTGCTGATCTACCGTGTATCTAAGCGCTTCTCCGGCGTTCC
		TGATCGTTTCAGCGGTTCTGGATCCGGCACCGACTTTACTCTGAAAAT
		CAGCCGTGTGGAAGCTGAAGACGTTGGCGTCTACTATTGTCTGCAGG
		CAACCCATATCCCATACACCTTCGGTCAAGGAACTAAACTGGAAATT
		AAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGAT
		GAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAAC
		TTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCT
		CCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAG
		GACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGA
		CTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC
		TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
282	7H07	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCGC
	heavy	TTCCGTTAAAGTGAGCTGCAAAGCATCTGGTTACACCTTCACTGACTA
	chain	TATCATGCACTGGGTTCGTCAGGCCCCGGGCCAGGGTCTGGAGTGGA
		TGGGCTACATTAACCCATACAACGACGGTTCCAAATATACCGAGAAA
		TTCCAGGGCCGCGTCACGATGACCAGCGACACTTCTATCTCCACCGCG
		TACATGGAACTGTCTAGACTGCGTTCTGACGACACCGCTGTTTACTAT
		TGTGCACGCGGTACCTACTACTACGGTTCTGAACTGTTTGATTACTGG
		GGCCAAGGTACCACGGTGACCGTAAGCTCTGCTAGCACCAAGGGCCC
		ATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCAC
		AGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGA
		CGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTC
		CCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTG
		ACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGT
		GAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC
		AAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGA
		AGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGG
		ACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTG
		GACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGA
		CGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAG
		TACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCA
		GGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAA
		GCCCTCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA
		GCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGC
		TGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTAT
		CCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGA
		ACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCT
		TCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGG
		AACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTAC
		ACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
283	7H07	DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGNTYLNWYLQKPGQSPQL
	light	LIYRVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQATHIPYT
	chain	FGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
		WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE
		VTHQGLSSPVTKSFNRGEC
284	7H07	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQAPGQGLEW
	heavy	MGYINPYNDGSKYTEKFQGRVTMTSDTSISTAYMELSRLRSDDTAVYYC
	chain	ARGTYYYGSELFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAA
		LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
		SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVF
		LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
		KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISK
		AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
		NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY
		TQKSLSLSPGK
285	2B03	GATATTGTTATGACTCAAACTCCACTGTCTCTGTCCGTGACCCCGGGT
	light	CAGCCAGCGAGCATTTCTTGCAAATCCAGCCAATCTCTGGAAACCTC
	chain	CACCGGCAACACGTACCTGAACTGGTATCTCCAGAAACCGGGTCAGA
		GCCCGCAGCTGCTGATCTACCGTGTATCTAAGCGCTTCTCCGGCGTTC
		CTGATCGTTTCAGCGGTTCTGGATCCGGCACCGACTTTACTCTGAAAA
		TCAGCCGTGTGGAAGCTGAAGACGTTGGCGTCTACTATTGTCTGCAG
		TTGACCCACGTTCCGTACACCTTCGGTCAAGGAANNAAACTGGAAAT
		TAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGA
		TGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAA
		CTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCC
		TCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAA
		GGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCA
		GACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGG
		CCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
286	2B03	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCGC
	heavy	TTCCGTTAAAGTGAGCTGCAAAGCATCTGGTTACACCTTCACTGACTA
	chain	TATCACGCACTGGGTTCGTCAGGCCCCGGGCCAGGGTCTGGAGTGGA
		TGGGCTACATTAACCCATACAACGACGGTTCCAAATATACCGAGAAA
		TTCCAGGGCCGCGTCACGATGACCAGCGACACTTCTATCTCCACCGC
		GTACATGGAACTGTCTAGACTGCGTTCTGACGACACCGCTGTTTACTA
		TTGTGCACGCGGTACCTACTACTACGGTCCAGATCTGTTTGATTACTG
		GGGCCAAGGTACCACGGTGACCGTAAGCTCTGCTAGCACCAAGGGCC
		CATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCA
		CAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTG
		ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTT
		CCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGT
		GACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACG
		TGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCC
		CAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
		AAGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG
		GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGT
		GGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
		ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCA
		GTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACC
		AGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA
		AGCCCTCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC
		AGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAG
		CTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTA
		TCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG
		AACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTT
		CTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGG
		GGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACT
		ACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
287	2B03	DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGNTYLNWYLQKPGQSPQ
	light	LLIYRVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQLTHVP
	chain	YTFGQGXKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK
		VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA
		CEVTHQGLSSPVTKSFNRGEC
288	2B03	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYITHWVRQAPGQGLEW
	heavy	MGYINPYNDGSKYTEKFQGRVTMTSDTSISTAYMELSRLRSDDTAVYYC
	chain	ARGTYYYGPDLFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAA
		LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
		SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSV
		FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
		KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISK
		AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP
		ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH
		YTQKSLSLSPGK
289	5A07	GATATTGTTATGACTCAAACTCCACTGTCTCTGTCCGTGACCCCGGGT
	light	CAGCCAGCGAGCATTTCTTGCAAATCCAGCCAATCTCTGGAAACCTC
	chain	CACCGGCAACACGTACCTGAACTGGTATCTCCAGAAACCGGGTCAGA
		GCCCGCAGCTGCTGATCTACCGTGTATCTAAGCGCTTCTCCGGCGTTC
		CTGATCGTTTCAGCGGTTCTGGATCCGGCACCGACTTTACTCTGAAAA
		TCAGCCGTGTGGAAGCTGAAGACGTTGGCGTCTACTATTGTCTGCAG
		CCAGGTCATTACCCAGGTACCTTCGGTCAAGGAACTAAACTGGAAAT
		TAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGA
		TGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAA
		CTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCC
		TCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAA
		GGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCA
		GACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGG
		CCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
290	5A07	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCGC
	heavy	TTCCGTTAAAGTGAGCTGCAAAGCATCTGGTTACACCTTCACTGACTA
	chain	TATCATGCACTGGGTTCGTCAGGCCCCGGGCCAGGGTCTGGAGTGGA
		TGGGCTACATTAACCCATACAACGACGGTTCCAAATATACCGAGAAA
		TTCCAGGGCCGCGTCACGATGACCAGCGACACTTCTATCTCCACCGC
		GTACATGGAACTGTCTAGACTGCGTTCTGACGACACCGCTGTTTACTA
		TTGTGCACGCGGTACTTACTACTACGGTTCCGCCCTCTTTGATTACTG
		GGGCCAAGGTACCACGGTGACCGTAAGCTCTGCTAGCACCAAGGGCC
		CATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCA
		CAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTG
		ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTT
		CCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGT
		GACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACG
		TGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCC
		CAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
		AAGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG
		GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGT
		GGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
		ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCA
		GTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACC
		AGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA
		AGCCCTCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC
		AGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAG
		CTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTA
		TCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG
		AACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTT
		CTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGG
		GGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACT
		ACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
291	5A07	DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGNTYLNWYLQKPGQSPQ
	light	LLIYRVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQPGHYP
	chain	GTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK
		VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA
		CEVTHQGLSSPVTKSFNRGEC
292	5A07	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQAPGQGLEW
	heavy	MGYINPYNDGSKYTEKFQGRVTMTSDTSISTAYMELSRLRSDDTAVYYC
	chain	ARGTYYYGSALFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAA
		LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
		SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSV
		FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
		KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISK
		AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP
		ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH
		YTQKSLSLSPGK
293	5D08	GATATTGTTATGACTCAAACTCCACTGTCTCTGTCCGTGACCCCGGGT
	light	CAGCCAGCGAGCATTTCTTGCAAATCCAGCCAATCTCTGGAAACCTC
	chain	CACCGGCAACACGTACCTGAACTGGTATCTCCAGAAACCGGGTCAGA
		GCCCGCAGCTGCTGATCTACCGTGTATCTAAGCGCTTCTCCGGCGTTC
		CTGATCGTTTCAGCGGTTCTGGATCCGGCACCGACTTTACTCTGAAAA
		TCAGCCGTGTGGAAGCTGAAGACGTTGGCGTCTACTATTGTCTGCAG
		CTGACCCATGAACCATACACCTTCGGTCAAGGAACTAAACTGGAAAT
		TAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGA
		TGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAA
		CTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCC
		TCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAA
		GGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCA
		GACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGG
		CCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
294	5D08	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCGC
	heavy	TTCCGTTAAAGTGAGCTGCAAAGCATCTGGTTACACCTTCACTGACTA
	chain	TATCATGCACTGGGTTCGTCAGGCCCCGGGCCAGGGTCTGGAGTGGA
		TGGGCTACATTAACCCATACAACGACGGTTCCAAATATACCGAGAAA
		TTCCAGGGCCGCGTCACGATGACCAGCGACACTTCTATCTCCACCGC
		GTACATGGAACTGTCTAGACTGCGTTCTGACGACACCGCTGTTTACTA
		TTGTGCACGCGGTACCTACTACTACGGTTCTGAACTGTTTGATTACTG
		GGGCCAAGGTACCACGGTGACCGTAAGCTCTGCTAGCACCAAGGGCC
		CATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCA
		CAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTG
		ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTT
		CCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGT
		GACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACG
		TGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCC
		CAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
		AAGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG
		GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGT
		GGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
		ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCA
		GTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACC
		AGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA
		AGCCCTCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC
		AGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAG
		CTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTA
		TCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG
		AACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTT
		CTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGG
		GGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACT
		ACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
295	5D08	DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGNTYLNWYLQKPGQSPQ
	light	LLIYRVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQLTHEP
	chain	YTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK
		VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA
		CEVTHQGLSSPVTKSFNRGEC
296	5D08	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQAPGQGLEW
	heavy	MGYINPYNDGSKYTEKFQGRVTMTSDTSISTAYMELSRLRSDDTAVYYC
	chain	ARGTYYYGSELFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAA
		LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
		SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSV
		FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
		KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISK
		AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP
		ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH
		YTQKSLSLSPGK
297	5B08	GATATTGTTATGACTCAAACTCCACTGTCTCTGTCCGTGACCCCGGGT
	light	CAGCCAGCGAGCATTTCTTGCAAATCCAGCCAATCTCTGGAAACCTC
	chain	CACCGGCAACACGTACCTGAACTGGTATCTCCAGAAACCGGGTCAGA
		GCCCGCAGCTGCTGATCTACCGTGTATCTAAGCGCTTCTCCGGCGTTC
		CTGATCGTTTCAGCGGTTCTGGATCCGGCACCGACTTTACTCTGAAAA
		TCAGCCGTGTGGAAGCTGAAGACGTTGGCGTCTACTATTGTCTGCAG
		CTGGATTCTTACCCAAACACCTTCGGTCAAGGAACTAAACTGGAAAT
		TAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGA
		TGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAA
		CTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCC
		TCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAA
		GGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCA
		GACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGG
		CCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
298	5B08	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCGC
	heavy	TTCCGTTAAAGTGAGCTGCAAAGCATCTGGTTACACCTTCACTGACTA
	chain	TATCATGCACTGGGTTCGTCAGGCCCCGGGCCAGGGTCTGGAGTGGA
		TGGGCTACATTAACCCATACAACGACGGTTCCAAATATACCGAGAAA
		TTCCAGGGCCGCGTCACGATGACCAGCGACACTTCTATCTCCACCGC
		GTACATGGAACTGTCTAGACTGCGTTCTGACGACACCGCTGTTTACTA
		TTGTGCACGCGGTACCTACTACTACGGTCCACAGCTGTTTGATTACTG
		GGGCCAAGGTACCACGGTGACCGTAAGCTCTGCTAGCACCAAGGGCC
		CATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCA
		CAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTG
		ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTT
		CCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGT
		GACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACG
		TGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCC
		CAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
		AAGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG
		GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGT
		GGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
		ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCA
		GTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACC
		AGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA
		AGCCCTCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC
		AGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAG
		CTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTA
		TCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG
		AACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTT
		CTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGG
		GGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACT
		ACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
299	5B08	DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGNTYLNWYLQKPGQSPQ
	light	LLIYRVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQLDSYP
	chain	NTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK
		VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA
		CEVTHQGLSSPVTKSFNRGEC
300	5B08	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQAPGQGLEW
	heavy	MGYINPYNDGSKYTEKFQGRVTMTSDTSISTAYMELSRLRSDDTAVYYC
	chain	ARGTYYYGPQLFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAA
		LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
		SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSV
		FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
		KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISK
		AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP
		ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH
		YTQKSLSLSPGK
301	5H09	GATATTGTTATGACTCAAACTCCACTGTCTCTGTCCGTGACCCCGGGT
	light	CAGCCAGCGAGCATTTCTTGCAAATCCAGCCAATCTCTGGAATCTTCC
	chain	ACCGGCAACACGTACCTGAACTGGTATCTCCAGAAACCGGGTCAGAG
		CCCGCAGCTGCTGATCTACCGTGTATCTAAGCGCTTCTCCGGCGTTCC
		TGATCGTTTCAGCGGTTCTGGATCCGGCACCGACTTTACTCTGAAAAT
		CAGCCGTGTGGAAGCTGAAGACGTTGGCGTCTACTATTGTCTGCAGC
		TGATCGATTACCCAGTTACCTTCGGTCAAGGAACTAAACTGGAAATT
		AAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGAT
		GAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAA
		CTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCC
		TCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAA
		GGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCA
		GACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGG
		CCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
302	5H09	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCGC
	heavy	TTCCGTTAAAGTGAGCTGCAAAGCATCTGGTTACACCTTCACTGACTA
	chain	TATCATGCACTGGGTTCGTCAGGCCCCGGGCCAGGGTCTGGAGTGGA
		TGGGCTACATTAACCCATACAACGACGGTTCCAAATATACCGAGAAA
		TTCCAGGGCCGCGTCACGATGACCAGCGACACTTCTATCTCCACCGC
		GTACATGGAACTGTCTAGACTGCGTTCTGACGACACCGCTGTTTACTA
		TTGTGCACGCGGTACCTACTACTACGGTTCTGCACTGTTTGATTACTG
		GGGCCAAGGTACCACGGTGACCGTAAGCTCTGCTAGCACCAAGGGCC
		CATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCA
		CAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTG
		ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTT
		CCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGT
		GACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACG
		TGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCC
		CAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
		AAGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG
		GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGT
		GGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
		ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCA
		GTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACC
		AGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA
		AGCCCTCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC
		AGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAG
		CTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTA
		TCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG
		AACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTT
		CTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGG
		GGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACT
		ACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
303	5H09	DIVMTQTPLSLSVTPGQPASISCKSSQSLESSTGNTYLNWYLQKPGQSPQ
	light	LLIYRVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQLIDYP
	chain	VTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK
		VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA
		CEVTHQGLSSPVTKSFNRGEC
304	5H09	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQAPGQGLEW
	heavy	MGYINPYNDGSKYTEKFQGRVTMTSDTSISTAYMELSRLRSDDTAVYYC
	chain	ARGTYYYGSALFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAA
		LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
		SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSV
		FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
		KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISK
		AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP
		ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH
		YTQKSLSLSPGK

TABLE 60 — Summary of the kinetic and thermodynamic data for the interaction between anti-CD19 huIgG1 and human CD19

clone	ka (1/Ms)	kd (1/s)	KD (M)
Parental 8B8	5.66E+4	1.34E−4	2.36E−9
5H09	7.91E+4	1.50E−5	1.89E−10
7H07	7.45E+4	5.57E−5	7.47E−10
2B03	6.02E+4	5.00E−5	8.31E−10
2B11	6.34E+4	3.14E−5	4.95E−10
5A07	6.98E+4	3.07E−5	4.40E−10
5B08	6.81E+4	5.26E−5	7.72E−10
5D08	8.88E+4	8.44E−5	9.51E−10

TABLE 61 — Biochemical analysis of anti-CD19 P329G LALA IgG1 clones

	Yield	Monomer	CE-SDS
Clone	[mg/l]	[%]	(non red)
Parental 8B8	25.3	100	99.1
2B11	35.4	100	98.4
7H07	89.8	100	99.4
2B03	182	100	100
5A07	90.2	100	99.4
5D08	90.2	100	99.3
5B08	24.1	99.6	100
5H09	29.9	100	98.1

TABLE 62 — cDNA and amino acid sequences of monovalent CD19(8B8-2B11) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion containing CH-CL cross with charged residues (construct 4.1). *for charged residues SEQ ID

NO:	Description	Sequence
129	Nucleotide	see Table 3
	sequence Dimeric
	hu 4-1BBL (71-
	254)-CL* Fc
	knob chain
130	Nucleotide	see Table 3
	sequence
	Monomeric hu
	4-1BBL (71-254)-
	CH1*
305	Nucleotide	CAGGTGCAATTGGTTCAATCT
	sequence anti-	GGTGCTGAAGTAAAAAAACCG
	CD19(8B8-2B11)	GGCGCTTCCGTTAAAGTGAGC
	Fc hole chain	TGCAAAGCATCTGGTTACACC
		TTCACTGACTATATCATGCAC
		TGGGTTCGTCAGGCCCCGGGC
		CAGGGTCTGGAGTGGATGGGC
		TACATTAACCCATACAACGAC
		GGTTCCAAATATACCGAGAAA
		TTCCAGGGCCGCGTCACGATG
		ACCAGCGACACTTCTATCTCC
		ACCGCGTACATGGAACTGTCT
		AGACTGCGTTCTGACGACACC
		GCTGTTTACTATTGTGCACGC
		GGTACCTACTACTACGGTCCA
		CAGCTGTTTGATTACTGGGGC
		CAAGGTACCACGGTGACCGTA
		AGCTCTGCTAGCACCAAGGGC
		CCCTCCGTGTTCCCCCTGGCC
		CCCAGCAGCAAGAGCACCAGC
		GGCGGCACAGCCGCTCTGGGC
		TGCCTGGTCAAGGACTACTTC
		CCCGAGCCCGTGACCGTGTCC
		TGGAACAGCGGAGCCCTGACC
		TCCGGCGTGCACACCTTCCCC
		GCCGTGCTGCAGAGTTCTGGC
		CTGTATAGCCTGAGCAGCGTG
		GTCACCGTGCCTTCTAGCAGC
		CTGGGCACCCAGACCTACATC
		TGCAACGTGAACCACAAGCCC
		AGCAACACCAAGGTGGACAAG
		AAGGTGGAGCCCAAGAGCTGC
		GACAAAACTCACACATGCCCA
		CCGTGCCCAGCACCTGAAGCT
		GCAGGGGGACCGTCAGTCTTC
		CTCTTCCCCCCAAAACCCAAG
		GACACCCTCATGATCTCCCGG
		ACCCCTGAGGTCACATGCGTG
		GTGGTGGACGTGAGCCACGAA
		GACCCTGAGGTCAAGTTCAAC
		TGGTACGTGGACGGCGTGGAG
		GTGCATAATGCCAAGACAAAG
		CCGCGGGAGGAGCAGTACAAC
		AGCACGTACCGTGTGGTCAGC
		GTCCTCACCGTCCTGCACCAG
		GACTGGCTGAATGGCAAGGAG
		TACAAGTGCAAGGTCTCCAAC
		AAAGCCCTCGGCGCCCCCATC
		GAGAAAACCATCTCCAAAGCC
		AAAGGGCAGCCCCGAGAACCA
		CAGGTGTGCACCCTGCCCCCA
		TCCCGGGATGAGCTGACCAAG
		AACCAGGTCAGCCTCTCGTGC
		GCAGTCAAAGGCTTCTATCCC
		AGCGACATCGCCGTGGAGTGG
		GAGAGCAATGGGCAGCCGGAG
		AACAACTACAAGACCACGCCT
		CCCGTGCTGGACTCCGACGGC
		TCCTTCTTCCTCGTGAGCAAG
		CTCACCGTGGACAAGAGCAGG
		TGGCAGCAGGGGAACGTCTTC
		TCATGCTCCGTGATGCATGAG
		GCTCTGCACAACCACTACACG
		CAGAAGAGCCTCTCCCTGTCT
		CCGGGTAAA
277	Nucleotide	see Table 59
	sequence anti-
	CD19(8B8-2B11)
	light chain
115	Dimeric hu 4-	see Table 3
	1BBL (71-254)-
	CL* Fc knob
	chain
116	Monomeric hu	see Table 3
	4-1BBL (71-254)-
	CH1*
306	anti-CD19(8B8-	QVQLVQSGAEVKKPGASVKVS
	2B11) Fc hole	CKASGYTFTDYIMHWVRQAPG
	chain	QGLEWMGYINPYNDGSKYTEK
		FQGRVTMTSDTSISTAYMELS
		RLRSDDTAVYYCARGTYYYGP
		QLFDYWGQGTTVTVSSASTKG
		PSVFPLAPSSKSTSGGTAALG
		CLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSV
		VTVPSSSLGTQTYICNVNHKP
		SNTKVDKKVEPKSCDKTHTCP
		PCPAPEAAGGPSVFLFPPKPK
		DTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTK
		PREEQYNSTYRVVSVLTVLHQ
		DWLNGKEYKCKVSNKALGAPI
		EKTISKAKGQPREPQVCTLPP
		SRDELTKNQVSLSCAVKGFYP
		SDIAVEWESNGQPENNYKTTP
		PVLDSDGSFFLVSKLTVDKSR
		WQQGNVFSCSVMHEALHNHYT
		QKSLSLSPGK
206	anti-CD19(8B8-	see Table 59
	2b11) light chain

TABLE 63 — cDNA and amino acid sequences of monovalent CD19(8B8- 2B11) targeted split trimeric 4-1BB ligand (71- 254) Fc (kih) fusion containing CH-CL cross without charged residues (construct 4.2). SEQ ID

NO:	Description	Sequence
165	Nucleotide	see Table 22
	sequence dimeric
	ligand (71-254)-
	CL Fc knob chain
166	Nucleotide	see Table 22
	sequence
	monomeric hu
	4-1BBL (71-254) -
	CH1
305	Nucleotide	see Table 62
	sequence anti-
	CD19(8B8-2B11)
	Fc hole chain
277	Nucleotide	see Table 59
	sequence anti-
	CD19(8B8-2B11)
	light chain
117	Dimeric ligand	see Table 22
	(71-254) - CL Fc
	knob chain
118	Monomeric	see Table 22
	ligand (71-254) -
	CH1
306	anti-CD19(8B8-	see Table 62
	2B11) Fc hole
	chain
279	anti-CD19(8B8-	see Table 59
	018) light chain

TABLE 65 — cDNA and amino acid sequences of monovalent CD19(8B8- 2B11) targeted split trimeric 4-1BB ligand (71- 248) Fc (kih) fusion containing CH-CL cross with charged residues (construct 4.4). SEQ ID

NO:	Description	Sequence
169	Nucleotide	see Table 24
	sequence dimeric
	ligand (71-248) -
	CL* Fc knob
	chain
170	Nucleotide	see Table 24
	sequence
	monomeric hu
	4-1BBL (71-248) -
	CH1*
305	Nucleotide	see Table 62
	sequence anti-
	CD19(8B8-2B11)
	Fc hole chain
277	Nucleotide	see Table 59
	sequence anti-
	CD19(8B8-2B11)
	light chain
119	Dimeric ligand	see Table 24
	(71-248) - CL*
	Fc knob chain
120	Monomeric	see Table 24
	ligand (71-248)-
	CH1*
306	anti-CD19(8B8-	see Table 62
	2B11) Fc hole
	chain
279	anti-CD19(8B8-	see Table 59
	2B11) light chain
*charged residues

TABLE 66 — cDNA and amino acid sequences of monovalent CD19(8B8- 2B11) targeted split trimeric 4-1BB ligand (71- 248) Fc (kih) fusion containing CH-CL cross without charged residues (construct 4.5). SEQ ID

NO:	Description	Sequence
171	Nucleotide	see Table 25
	sequence dimeric
	ligand (71-248) -
	CL Fc knob chain
172	Nucleotide	see Table 25
	sequence
	monomeric ligand
	(71-248)-CH1
305	Nucleotide	see Table 62
	sequence anti-
	CD19(8B8-2B11)
	Fc hole chain
277	Nucleotide	see Table 59
	sequence anti-
	CD19(8B8-2B11)
	light chain
173	Dimeric ligand	see Table 25
	(71-248) - CL Fc
	knob chain
174	Monomeric	see Table 25
	ligand (71-248)-
	CH1
306	anti-CD19(8B8-	see Table 62
	2B11) Fc hole
	chain
279	anti-CD19(8B8-	see Table 59
	2B11) light chain

TABLE 68 — cDNA and amino acid sequences of monovalent DP47 untargeted split trimeric human 4-1BB ligand (71-254) Fc (kih) fusion with CH-CL cross and with charged residues (control B). SEQ ID

NO:	Description	Sequence
96	nucleotide sequence dimeric hu 4-1BBL	see Table 3
	(71-254) - CL* Fc knob chain
97	nucleotide sequence monomeric hu	see Table 3
	4-1BBL (71-254) - CH1*
79	nucleotide sequence DP47 Fc hole chain	see Table 18
80	nucleotide sequence DP47 light chain	see Table 18
98	Dimeric hu 4-1BBL (71-254) - CL* Fc	see Table 3
	knob chain
99	Monomeric hu	see Table 3
	4-1BBL (71-254) - CH1*
81	DP47 Fc hole chain	see Table 18
82	DP47 light chain	see Table 18
*charges residues

TABLE 69 — cDNA and amino acid sequences of bivalent DP47 untargeted split trimeric human 4-1BB ligand (71-254) Fc (kih) fusion (control C). SEQ ID

NO:	Description	Sequence
177	nucleotide sequence DP47 Fc hole chain	see Table 27
	fused to dimeric hu 4-1BBL (71-254)
178	nucleotide sequence DP47 Fc knob chain	see Table 27
	fused to monomeric hu 4-1BBL (71-254)
80	nucleotide sequence DP47 light chain	see Table 18
179	DP47 Fc hole chain fused to dimeric hu 4-	see Table 27
	1BBL (71-254)
180	DP47 Fc knob chain fused to monomeric	see Table 27
	hu 4-1BBL (71-254)
82	DP47 light chain	see Table 18

TABLE 70 — cDNA and amino acid sequences of monovalent DP47 untargeted split trimeric human 4-1BB ligand (71-248) Fc (kih) fusion with CH-CL cross and with charged residues (control D). SEQ ID

NO:	Description	Sequence
169	nucleotide sequence dimeric hu 4-1BBL	see Table 24
	(71-248) - CL* Fc knob chain
170	nucleotide sequence monomeric hu	see Table 24
	4-1BBL (71-248) - CH1*
79	nucleotide sequence DP47 Fc hole chain	see Table 18
80	nucleotide sequence DP47 light chain	see Table 18
119	Dimeric hu 4-1BBL (71-254) - CL* Fc	see Table 24
	knob chain
120	Monomeric hu	see Table 24
	4-1BBL (71-254) - CH1*
81	DP47 Fc hole chain	see Table 18
82	DP47 light chain	see Table 18
*charged residues

TABLE 71 — cDNA and amino acid sequences of monovalent DP47 untargeted split trimeric human 4-1BB ligand (71-248) Fc (kih) fusion with CH-CL cross and without charged residues (control E). SEQ ID

NO:	Description	Sequence
171	nucleotide sequence dimeric hu 4-	see Table 25
	1BBL (71-248) - CL Fc knob chain
172	nucleotide sequence monomeric hu	see Table 25
	4-1BBL (71-248) - CH1
79	nucleotide sequence DP47 Fc hole	see Table 18
	chain
80	nucleotide sequence DP47 light chain	see Table 18
173	Dimeric hu 4-1BBL (71-248) - CL	see Table 25
	Fc knob chain
174	Monomeric hu	see Table 25
	4-1BBL (71-248) - CH1
81	DP47 Fc hole chain	see Table 18
82	DP47 light chain	see Table 18

TABLE 72 — cDNA and amino acid sequences of anti-CD19 (8B8-018) huIgG1 PGLALA (control G) SEQ ID

NO:	Description	Sequence
315	nucleotide sequence	CAGGTCCAGCTGGTGCAGTCCGGCGCCGAGGT
	CD19 (8B8-018) heavy	CAAGAAACCCGGGGCTTCTGTGAAGGTTTCAT
	chain (huIgG1 PGLALA)	GCAAGGCAAGCGGATACACCTTCACCGACTAT
		ATCATGCATTGGGTCAGGCAGGCCCCTGGCCA
		AGGTCTCGAATGGATGGGCTACATTAACCCAT
		ATAATGATGGCTCCAAATACACCGAGAAGTTT
		CAGGGAAGAGTCACTATGACATCTGACACCAG
		TATCAGCACTGCTTACATGGAGCTGTCCCGCC
		TTCGGTCTGATGACACCGCAGTGTATTACTGT
		GCCAGGGGCACATATTACTACGGCTCAGCTCT
		GTTCGACTATTGGGGGCAGGGAACCACAGTAA
		CCGTGAGCTCCGCAAGTACTAAGGGCCCATCG
		GTCTTCCCCCTGGCACCCTCCTCCAAGAGCAC
		CTCTGGGGGCACAGCGGCCCTGGGCTGCCTGG
		TCAAGGACTACTTCCCCGAACCGGTGACGGTG
		TCGTGGAACTCAGGCGCCCTGACCAGCGGCGT
		GCACACCTTCCCGGCTGTCCTACAGTCCTCAG
		GACTCTACTCCCTCAGCAGCGTGGTGACCGTG
		CCCTCCAGCAGCTTGGGCACCCAGACCTACAT
		CTGCAACGTGAATCACAAGCCCAGCAACACCA
		AGGTGGACAAGAAAGTTGAGCCCAAATCTTGT
		GACAAAACTCACACATGCCCACCGTGCCCAGC
		ACCTGAAGCAGCTGGGGGACCGTCAGTCTTCC
		TCTTCCCCCCAAAACCCAAGGACACCCTCATG
		ATCTCCCGGACCCCTGAGGTCACATGCGTGGT
		GGTGGACGTGAGCCACGAAGACCCTGAGGTC
		AAGTTCAACTGGTACGTGGACGGCGTGGAGGT
		GCATAATGCCAAGACAAAGCCGCGGGAGGAG
		CAGTACAACAGCACGTACCGTGTGGTCAGCGT
		CCTCACCGTCCTGCACCAGGACTGGCTGAATG
		GCAAGGAGTACAAGTGCAAGGTCTCCAACAA
		AGCCCTCGGAGCCCCCATCGAGAAAACCATCT
		CCAAAGCCAAAGGGCAGCCCCGAGAACCACA
		GGTGTACACCCTGCCCCCATCCCGGGATGAGC
		TGACCAAGAACCAGGTCAGCCTGACCTGCCTG
		GTCAAAGGCTTCTATCCCAGCGACATCGCCGT
		GGAGTGGGAGAGCAATGGGCAGCCGGAGAAC
		AACTACAAGACCACGCCTCCCGTGCTGGACTC
		CGACGGCTCCTTCTTCCTCTACAGCAAGCTCAC
		CGTGGACAAGAGCAGGTGGCAGCAGGGGAAC
		GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG
		CACAACCACTACACGCAGAAGAGCCTCTCCCT
		GTCCCCGGGCAAA
204	nucleotide sequence	see Table 47
	CD19 (8B8-018) light
	chain
316	CD19 (8B8-018) heavy	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYI
	chain (huIgG1 PGLALA)	MHWVRQAPGQGLEWMGYINPYNDGSKYTEKF
		QGRVTMTSDTSISTAYMELSRLRSDDTAVYYCA
		RGTYYYGSALFDYWGQGTTVTVSSASTKGPSVF
		PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
		GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG
		TQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP
		PCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCV
		VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
		QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK
		ALGAPIEKTISKAKGQPREPQVYTLPPSRDELTK
		NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNHYTQKSLSLSPGK
206	CD19 (8B8-018) light	see Table 47
	chain

TABLE 73 — cDNA and amino acid sequences of germline control DP47 huIgG1 PGLALA (control F) SEQ ID

NO:	Description	Sequence
181	nucleotide sequence DP47	see Table 29
	heavy chain (hu IgG1
	PGLALA)
80	DP47 light chain	see Table 18
182	DP47 heavy chain (hu	see Table 29
	IgG1 PGLALA)
82	DP47 light chain	see Table 18

TABLE 76 — Biochemical analysis of control human IgG1 PGLALA

	Monomer [%]	Yield
Construct	(SEC)	[mg/l]
anti-CD19(8B8-018) huIgG1 PGLALA	100	36.6
germline DP47 human IgG1 PGLALA	100	50

TABLE 77 — Binding of CD19 targeted split trimeric 4-1BB ligand Fc fusion to recombinant human (hu) 4-1BB, cynomolgus (cy) 4-1BB and human (hu) CD19.

	Antigen	ka (1/Ms)	kd (1/s)	KD (M)
monovalent CD19(8B8-	hu 4-	7.2E+04	2.5E−02	3.4E−07
018) targeted split trimeric	1BB	(5.9E+03)	(1.0E−05)	(2.8E−08)
4-1BB ligand (71-248) Fc	cy 4-	1.2E+05	1.3E−02	1.1E−07
(kih) fusion containing CH-	1BB	(8.6E+03)	(1.8E−04)	(9.9E−09)
CL cross with charged	hu CD19	2.77E+04	2.67E−04	9.64E−09
residues
(construct 3.4)
bivalent CD19(8B8-018)	hu 4-	6.9E+04	2.4E−02	3.5E−07
targeted split trimeric 4-	1BB	(1.7E+03)	(1.5E−04)	(1.1E−08)
1BB ligand (71-248) Fc	cy 4-	1.1E+05	1.4E−02	1.3E−07
(kih) fusion	1BB	(7.7E+03)	(3.1E−04)	(1.3E−08)
(construct 3.6)	hu CD19	2.55E+04	2.69E−04	1.06E−08
monovalent DP47	hu 4-	7.3E+04	2.6E−02	3.5E−07
untargeted split trimeric	1BB	(3.9E+03)	(6.3E−04)	(1.0E−08)
human 4-1BB ligand (71-	cy 4-	1.2E+05	1.4E−02	1.2E−07
248) Fc (kih) fusion with	1BB	(1.9E+03)	(1.0E−04)	(2.9E−09)
CH-CL cross and with
charged residues
(control D)
anti-CD19(8B8-018)	hu CD19	2.12E+04	2.61E−04	1.23E−08
huIgG1 PGLALA

TABLE 78 — Binding on activated 4-1BB-expressing CD4+ T cells and CD8+ T cells

	EC 50 [nM]	EC 50 [nM]
Construct	4-1BB + CD8 +	4-1BB + CD4 +
Control B	0.05	0.26
Control C	0.02	0.30
Control D	0.04	0.28
Control E	0.13	1.22
3.1	0.03	0.28
3.3	0.01	0.29
3.4	0.15	2.04
3.5	0.04	1.03
3.6	0.05	0.21

TABLE 79 — Binding to CD19-expressing tumor cells

	EC 50 [nM]	EC 50 [nM]	EC 50 [nM]	EC 50 [nM]
Construct	SU-DHL-8	Nalm6	Toledo	OCI-Ly18
3.1	0.64	0.43	0.29	0.29
3.3	0.15	0.14	0.10	0.09
3.4	0.31	0.39	0.29	0.26
3.5	0.54	0.43	0.27	0.31
3.6	0.14	0.12	0.09	0.10
control G	0.09	0.10	0.06	0.07

TABLE 80 — Binding of different humanized variants of T84.66 IgGs to cells (EC50 values, based on binding curves shown in FIG. 39, calculated by Graph Pad Prism). EC50 (μg/ml)

Parental chimeric T84.66	0.99
Humanized variant 1	1.5
Humanized variant 2	8.6
Humanized variant 3	1.4
Humanized variant 4	3.1
Humanized variant 5	—
Humanized variant 6	—

TABLE 81 — Amino acid sequences of the variable domains of CEA clone T84.66-LCHA and its parental antibody T84.66 SEQ ID

Description	Sequence	NO:
CEA CDR-H1	DTYMH	321
CEA CDR-H2	RIDPANGNSKYVPKFQG	322
CEA CDR-H3	FGYYVSDYAMAY	323
CEA CDR-L1	RAGESVDIFGVGFLH	324
CEA CDR-L2	RASNRAT	325
CEA CDR-L3	QQTNEDPYT	326
Parental CEA	EVQLQQSGAELVEPGASVKLSCTASGFNIKDTYMHWVKQRPEQ	327
binder VH	GLEWIGRIDPANGNSKYVPKFQGKATITADTSSNTAYLQLTSLTS
	EDTAVYYCAPFGYYVSDYAMAYWGQGTSVTVSS
Parental CEA	DIVLTQSPASLAVSLGQRATMSCRAGESVDIFGVGFLHWYQQKP	328
binder VL	GQPPKWYRASNLESGIPVRFSGTGSRTDFTLIIDPVEADDVATY
	YCQQTNEDPYTFGGGTKLEIK
Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGFNIKDTYMHWVRQAPGQ	329
CEA binder	GLEWMGRIDPANGNSKYVPKFQGRVTITADTSTSTAYMELSSLR
CEA (T84.66-	SEDTAVYYCAPFGYYVSDYAMAYWGQGTLVTVSS
LCHA) VH
Humanized	EIVLTQSPATLSLSPGERATLSCRAGESVDIFGVGFLHWYQQKPG	330
CEA binder	QAPRLLIYRASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYY
CEA (T84.66-	CQQTNEDPYTFGQGTKLEIK
LCHA) VL

TABLE 82 — cDNA and amino acid sequences of monovalent CEA (T84.66-LCHA) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion containing CH-CL cross with charged residues (construct 5.1). *for charged residues SEQ ID

NO:	Description	Sequence
129	Nucleotide	see Table 3
	sequence Dimeric
	hu 4-1BBL (71-
	254)-CL* Fc
	knob chain
130	Nucleotide	see Table 3
	sequence
	Monomeric hu
	4-1BBL (71-254)-
	CH1*
331	Nucleotide	CAGGTGCAGCTGGTGCAGTCTGGCGCCGAAGTGAAGAA
	sequence anti-	ACCCGGCAGCAGCGTGAAGGTGTCCTGCAAGGCCAGCG
	CEA (T84.66-	GCTTCAACATCAAGGACACCTACATGCACTGGGTGCGCC
	LCHA) Fc hole	AGGCCCCTGGACAGGGACTGGAATGGATGGGCAGAATC
	chain	GACCCCGCCAACGGCAACAGCAAATACGTGCCCAAGTT
		CCAGGGCAGAGTGACCATCACCGCCGACACCAGCACCT
		CCACCGCCTACATGGAACTGAGCAGCCTGCGGAGCGAG
		GACACCGCCGTGTACTACTGTGCCCCCTTCGGCTACTAC
		GTGTCCGACTACGCCATGGCCTATTGGGGCCAGGGCAC
		ACTCGTGACCGTGTCCTCTGCTAGCACCAAGGGCCCCTC
		CGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCG
		GCGGCACAGCCGCTCTGGGCTGCCTGGTCAAGGACTACT
		TCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCC
		CTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAG
		AGTTCTGGCCTGTATAGCCTGAGCAGCGTGGTCACCGTG
		CCTTCTAGCAGCCTGGGCACCCAGACCTACATCTGCAAC
		GTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAA
		GGTGGAGCCCAAGAGCTGCGACAAAACTCACACATGCC
		CACCGTGCCCAGCACCTGAAGCTGCAGGGGGACCGTCA
		GTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATG
		ATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGAC
		GTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTA
		CGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC
		CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTC
		AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGC
		AAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGG
		CGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC
		AGCCCCGAGAACCACAGGTGTGCACCCTGCCCCCATCCC
		GGGATGAGCTGACCAAGAACCAGGTCAGCCTCTCGTGC
		GCAGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGA
		GTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGA
		CCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCC
		TCGTGAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAG
		CAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCT
		CTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCT
		CCGGGTAAA
332	Nucleotide	GAGATCGTGCTGACCCAGAGCCCTGCCACCCTGTCACTG
	sequence anti-	TCTCCAGGCGAGAGAGCCACCCTGAGCTGTAGAGCCGG
	CEA (T84.66-	CGAGAGCGTGGACATCTTCGGCGTGGGATTTCTGCACTG
	LCHA) light	GTATCAGCAGAAGCCCGGCCAGGCCCCCAGACTGCTGA
	chain	TCTACAGAGCCAGCAACCGGGCCACAGGCATCCCCGCC
		AGATTTTCTGGCTCTGGCAGCGGCACCGACTTCACCCTG
		ACAATCAGCAGCCTGGAACCCGAGGACTTCGCCGTGTA
		CTACTGCCAGCAGACCAACGAGGACCCCTACACCTTTGG
		CCAGGGCACCAAGCTGGAAATCAAGCGTACGGTGGCTG
		CACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTT
		GAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAA
		CTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGG
		ATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTC
		ACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAG
		CAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAAC
		ACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTG
		AGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTG
		T
115	Dimeric hu 4-	see Table 3
	1BBL (71-254)-
	CL* Fc knob
	chain
116	Monomeric hu	see Table 3
	4-1BBL (71-254)-
	CH1*
333	anti-CEA	QVQLVQSGAEVKKPGSSVKVSCKASGFNIKDTYMHWVRQ
	(T84.66-LCHA)	APGQGLEWMGRIDPANGNSKYVPKFQGRVTITADTSTSTA
	Fc hole chain	YMELSSLRSEDTAVYYCAPFGYYVSDYAMAYWGQGTLV
		TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV
		TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
		QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAA
		GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN
		W
		YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN
		GKEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRD
		ELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPP
		VLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNH
		YTQKSLSLSPGK
334	anti-CEA	EIVLTQSPATLSLSPGERATLSCRAGESVDIFGVGFLHWYQ
	(T84.66-LCHA)	QKPGQAPRLLIYRASNRATGIPARFSGSGSGTDFTLTISSLEP
	light chain	EDFAVYYCQQTNEDPYTFGQGTKLEIKRTVAAPSVFIFPPS
		DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
		ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQG
		LSSPVTKSFNRGEC

TABLE 83 — cDNA and amino acid sequences of monovalent CEA (T84.66-LCHA) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion containing CH-CL cross without charged residues (construct 5.2) SEQ ID

NO:	Description	Sequence
165	Nucleotide sequence dimeric	see Table 22
	ligand (71-254)- CL Fc knob
	chain
166	Nucleotide sequence monomeric	see Table 22
	hu4-1BBL (71-254) - CH1
331	Nucleotide sequence anti- CEA	see Table 82
	(T84.66-LCHA) Fc hole chain
332	Nucleotide sequence anti- CEA	see Table 82
	(T84.66-LCHA) light chain
117	Dimeric ligand (71-254) - CL Fc	see Table 22
	knob chain
118	Monomeric ligand (71-254) -CH1	see Table 22
333	anti- CEA (T84.66-LCHA) Fc	see Table 82
	hole chain
334	anti- CEA (T84.66-LCHA) light	see Table 82
	chain

TABLE 85 — cDNA and amino acid sequences of monovalent CEA(T84.66-LCHA) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion containing CH-CL cross with charged residues (construct 5.4). SEQ ID

NO:	Description	Sequence
169	Nucleotide sequence dimeric ligand	see Table 24
	(71-248) - CL* Fc knob chain
170	Nucleotide sequence monomeric hu	see Table 24
	4-1BBL (71-248) - CH1*
331	Nucleotide sequence anti-	see Table 82
	CEA(T84.66-LCHA) Fc hole chain
332	Nucleotide sequence anti-	see Table 82
	CEA(T84.66-LCHA) light chain
119	Dimeric ligand (71-248) - CL* Fc	see Table 24
	knob chain
120	Monomeric ligand (71-248)-CH1*	see Table 24
333	anti- CEA(T84.66-LCHA) Fc hole	see Table 62
	chain
334	anti- CEA(T84.66-LCHA) light chain	see Table 59
*charged residues

TABLE 86 — cDNA and amino acid sequences of monovalent CEA(T84.66- LCHA) targeted split trimeric 4-1BB ligand (71- 248) Fc (kih) fusion containing CH-CL cross without charged residues (construct 5.5). SEQ ID

NO:	Description	Sequence
171	Nucleotide sequence dimeric	see Table 25
	ligand (71-248) - CL Fc knob
	chain
172	Nucleotide sequence	see Table 25
	monomeric ligand (71-248)-
	CH1
331	Nucleotide sequence anti-	see Table 82
	CEA(T84.66-LCHA) Fc hole
	chain
332	Nucleotide sequence anti-	see Table 82
	CEA(T84.66-LCHA) light
	chain
173	Dimeric ligand (71-248) - CL	see Table 25
	Fc knob chain
174	Monomeric ligand (71-248)-	see Table 25
	CH1
333	anti-CEA(T84.66-LCHA) Fc	see Table 82
	hole chain
334	anti-CEA(T84.66-LCHA) light	see Table 82
	chain

TABLE 87 — cDNA and amino acid sequences of bivalent CEA (T84.66-LCHA) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion (construct 5.6) SEQ ID

NO:	Description	Sequence
339	Nucleotide	CAGGTGCAGCTGGTGCAGTCTGGCGCCGAAGTGAAGAA
	sequence anti-	ACCCGGCAGCAGCGTGAAGGTGTCCTGCAAGGCCAGCG
	CEA (T84.66-	GCTTCAACATCAAGGACACCTACATGCACTGGGTGCGCC
	LCHA) Fc hole	AGGCCCCTGGACAGGGACTGGAATGGATGGGCAGAATC
	dimeric 4-1BBL	GACCCCGCCAACGGCAACAGCAAATACGTGCCCAAGTT
	(71-248) chain	CCAGGGCAGAGTGACCATCACCGCCGACACCAGCACCT
		CCACCGCCTACATGGAACTGAGCAGCCTGCGGAGCGAG
		GACACCGCCGTGTACTACTGTGCCCCCTTCGGCTACTAC
		GTGTCCGACTACGCCATGGCCTATTGGGGCCAGGGCAC
		ACTCGTGACCGTGTCCTCTGCTAGCACCAAGGGCCCCTC
		CGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCG
		GCGGCACAGCCGCTCTGGGCTGCCTGGTCAAGGACTACT
		TCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCC
		CTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAG
		AGTTCTGGCCTGTATAGCCTGAGCAGCGTGGTCACCGTG
		CCTTCTAGCAGCCTGGGCACCCAGACCTACATCTGCAAC
		GTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAA
		GGTGGAGCCCAAGAGCTGCGACAAAACTCACACATGCC
		CACCGTGCCCAGCACCTGAAGCTGCAGGGGGACCGTCA
		GTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATG
		ATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGAC
		GTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTA
		CGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC
		CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTC
		AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGC
		AAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGG
		CGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC
		AGCCCCGAGAACCACAGGTGTGCACCCTGCCCCCATCCC
		GGGATGAGCTGACCAAGAACCAGGTCAGCCTCTCGTGC
		GCAGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGA
		GTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGA
		CCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCC
		TCGTGAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAG
		CAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCT
		CTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCT
		CCGGGTGGAGGCGGCGGAAGCGGAGGAGGAGGATCCA
		GAGAGGGCCCTGAGCTGAGCCCTGATGATCCTGCCGGA
		CTGCTGGACCTGCGGCAGGGAATGTTTGCCCAGCTGGTG
		GCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTGG
		TACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGGC
		GGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGGT
		GGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGGA
		ACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCTG
		TGTCTCTGGCCCTGCATCTGCAGCCTCTGAGATCTGCTG
		CTGGCGCCGCTGCTCTGGCACTGACAGTGGATCTGCCTC
		CTGCCAGCAGCGAGGCCCGGAATAGCGCATTTGGGTTTC
		AAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCTG
		GGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACGC
		CTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTGTT
		CAGAGTGACCCCCGAGATTCCAGCAGGCCTGGGAGGCG
		GCGGATCTGGCGGCGGAGGATCTAGAGAAGGACCCGAG
		CTGTCCCCCGACGATCCCGCTGGGCTGCTGGATCTGAGA
		CAGGGCATGTTCGCTCAGCTGGTGGCTCAGAATGTGCTG
		CTGATTGACGGACCTCTGAGCTGGTACTCCGACCCAGGG
		CTGGCAGGGGTGTCCCTGACTGGGGGACTGTCCTACAAA
		GAAGATACAAAAGAACTGGTGGTGGCTAAAGCTGGGGT
		GTACTATGTGTTTTTTCAGCTGGAACTGAGGCGGGTGGT
		GGCTGGGGAGGGCTCAGGATCTGTGTCCCTGGCTCTGCA
		TCTGCAGCCACTGCGCTCTGCAGCAGGGGCTGCAGCACT
		GGCCCTGACTGTGGACCTGCCCCCAGCTTCTTCCGAGGC
		CAGAAACAGCGCCTTCGGGTTCCAAGGACGCCTGCTGC
		ATCTGAGCGCCGGACAGCGCCTGGGAGTGCATCTGCAT
		ACTGAAGCCAGAGCCCGGCATGCTTGGCAGCTGACTCA
		GGGGGCAACTGTGCTGGGACTGTTTCGCGTGACACCTGA
		GATCCCAGCCGGGCTC
340	Nucleotide	CAGGTGCAGCTGGTGCAGTCTGGCGCCGAAGTGAAGAA
	sequence anti-	ACCCGGCAGCAGCGTGAAGGTGTCCTGCAAGGCCAGCG
	CEA (T84.66-	GCTTCAACATCAAGGACACCTACATGCACTGGGTGCGCC
	LCHA) Fc knob	AGGCCCCTGGACAGGGACTGGAATGGATGGGCAGAATC
	monomeric (71-	GACCCCGCCAACGGCAACAGCAAATACGTGCCCAAGTT
	248) 4-1BBL	CCAGGGCAGAGTGACCATCACCGCCGACACCAGCACCT
	chain	CCACCGCCTACATGGAACTGAGCAGCCTGCGGAGCGAG
		GACACCGCCGTGTACTACTGTGCCCCCTTCGGCTACTAC
		GTGTCCGACTACGCCATGGCCTATTGGGGCCAGGGCAC
		ACTCGTGACCGTGTCCTCTGCTAGCACCAAGGGCCCATC
		GGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGG
		GGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACT
		TCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCC
		CTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAG
		TCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTG
		CCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAAC
		GTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAA
		AGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCC
		ACCGTGCCCAGCACCTGAAGCTGCAGGGGGACCGTCAG
		TCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGA
		TCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACG
		TGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTAC
		GTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCC
		GCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCA
		GCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCA
		AGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGC
		GCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA
		GCCCCGAGAACCACAGGTGTACACCCTGCCCCCCTGCA
		GAGATGAGCTGACCAAGAACCAGGTGTCCCTGTGGTGT
		CTGGTCAAGGGCTTCTACCCCAGCGATATCGCCGTGGAG
		TGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGAC
		CACCCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCT
		GTACTCCAAACTGACCGTGGACAAGAGCCGGTGGCAGC
		AGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCC
		CTGCACAACCACTACACCCAGAAGTCCCTGAGCCTGAG
		CCCCGGCGGAGGCGGCGGAAGCGGAGGAGGAGGATCC
		AGAGAGGGCCCTGAGCTGAGCCCTGATGATCCTGCCGG
		ACTGCTGGACCTGCGGCAGGGAATGTTTGCCCAGCTGGT
		GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG
		GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG
		CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG
		TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG
		AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT
		GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGATCTGCT
		GCTGGCGCCGCTGCTCTGGCACTGACAGTGGATCTGCCT
		CCTGCCAGCAGCGAGGCCCGGAATAGCGCATTTGGGTTT
		CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT
		GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG
		CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG
		TTCAGAGTGACCCCCGAGATTCCTGCCGGGCTC
332	Nucleotide	see Table 82
	sequence anti-
	CEA (T84.66-
	LCHA) light
	chain
341	anti-CEA	QVQLVQSGAEVKKPGSSVKVSCKASGFNIKDTYMHWVRQ
	(T84.66-LCHA)	APGQGLEWMGRIDPANGNSKYVPKFQGRVTITADTSTSTA
	Fc hole dimeric	YMELSSLRSEDTAVYYCAPFGYYVSDYAMAYWGQGTLV
	4-1BBL (71-248)	TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV
	chain	TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
		QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAA
		GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN
		WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL
		NGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSR
		DELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTP
		PVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHN
		HYTQKSLSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLR
		QGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKE
		DTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHL
		QPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLS
		AGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPA
		GLGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQLVA
		QNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAK
		AGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA
		ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLH
		TEARARHAWQLTQGATVLGLFRVTPEIPAGL
342	anti-CEA	QVQLVQSGAEVKKPGSSVKVSCKASGFNIKDTYMHWVRQ
	(T84.66-LCHA)	APGQGLEWMGRIDPANGNSKYVPKFQGRVTITADTSTSTA
	Fc knob	YMELSSLRSEDTAVYYCAPFGYYVSDYAMAYWGQGTLV
	monomeric (71-	TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV
	248) 4-1BBL	TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
	chain	QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAA
		GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN
		WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL
		NGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPCR
		DELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTP
		PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN
		HYTQKSLSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLR
		QGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKE
		DTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHL
		QPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLS
		AGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPA
		GL
334	anti-CD19 (8B8-	see Table 82
	018) light chain

TABLE 88 — cDNA and amino acid sequences of monovalent CEA (T84.66) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion containing crossed CH-CL with charged residues (construct 5.7). *for charged residues SEQ ID

NO:	Description	Sequence
129	Nucleotide	see Table 3
	sequence Dimeric
	hu 4-1BBL (71-
	254)-CL* Fc
	knob chain
130	Nucleotide	see Table 3
	sequence
	Monomeric hu
	4-1BBL (71-254)-
	CH1*
343	Nucleotide	GAGGTGCAGCTGCAGCAGTCTGGCGCCGAACTGGTGGA
	sequence anti-	ACCTGGCGCCTCTGTGAAGCTGAGCTGTACCGCCAGCGG
	CEA (T84.66) Fc	CTTCAACATCAAGGACACCTACATGCACTGGGTCAAGC
	hole chain	AGCGGCCTGAGCAGGGCCTGGAATGGATCGGCAGAATC
		GACCCCGCCAACGGCAACAGCAAATACGTGCCCAAGTT
		CCAGGGCAAGGCCACCATCACCGCCGACACCAGCAGCA
		ACACAGCCTACCTGCAGCTGACCAGCCTGACCTCCGAG
		GACACCGCCGTGTACTACTGCGCCCCCTTCGGCTACTAC
		GTGTCCGACTACGCCATGGCCTATTGGGGCCAGGGCAC
		AAGCGTGACCGTGTCCTCTGCTAGCACCAAGGGCCCCTC
		CGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCG
		GCGGCACAGCCGCTCTGGGCTGCCTGGTCAAGGACTACT
		TCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCC
		CTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAG
		AGTTCTGGCCTGTATAGCCTGAGCAGCGTGGTCACCGTG
		CCTTCTAGCAGCCTGGGCACCCAGACCTACATCTGCAAC
		GTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAA
		GGTGGAGCCCAAGAGCTGCGACAAAACTCACACATGCC
		CACCGTGCCCAGCACCTGAAGCTGCAGGGGGACCGTCA
		GTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATG
		ATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGAC
		GTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTA
		CGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC
		CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTC
		AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGC
		AAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGG
		CGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC
		AGCCCCGAGAACCACAGGTGTGCACCCTGCCCCCATCCC
		GGGATGAGCTGACCAAGAACCAGGTCAGCCTCTCGTGC
		GCAGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGA
		GTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGA
		CCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCC
		TCGTGAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAG
		CAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCT
		CTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCT
		CCGGGTAAA
344	Nucleotide	GACATCGTGCTGACCCAGAGCCCTGCCTCTCTGGCCGTG
	sequence anti-	TCTCTGGGACAGAGGGCCACCATGTCTTGCAGAGCCGG
	CEA (T84.66)	CGAGAGCGTGGACATCTTCGGCGTGGGATTTCTGCACTG
	light chain	GTATCAGCAGAAGCCCGGCCAGCCCCCCAAGCTGCTGA
		TCTACAGAGCCAGCAACCTGGAAAGCGGCATCCCCGTG
		CGGTTTAGCGGCACCGGCAGCAGAACCGACTTCACCCT
		GATCATCGACCCCGTGGAAGCCGACGACGTGGCCACCT
		ACTACTGCCAGCAGACCAACGAGGACCCCTACACCTTTG
		GCGGAGGCACCAAGCTGGAAATCAAGCGTACGGTGGCT
		GCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAG
		TTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAAT
		AACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGT
		GGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTG
		TCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTC
		AGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAA
		ACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC
		TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAG
		TGT
115	Dimeric hu 4-	see Table 3
	1BBL (71-254)-
	CL* Fc knob
	chain
116	Monomeric hu	see Table 3
	4-1BBL (71-254)-
	CH1*
345	anti-CEA	EVQLQQSGAELVEPGASVKLSCTASGFNIKDTYMHWVKQ
	(T84.66) Fc hole	RPEQGLEWIGRIDPANGNSKYVPKFQGKATITADTSSNTAY
	chain	LQLTSLTSEDTAVYYCAPFGYYVSDYAMAYWGQGTSVTV
		SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV
		SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
		YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGG
		PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
		VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRDE
		LTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPV
		LDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHY
		TQKSLSLSPGK
346	anti-CEA	DIVLTQSPASLAVSLGQRATMSCRAGESVDIFGVGFLHWY
	(T84.66) light	QQKPGQPPKLLIYRASNLESGIPVRFSGTGSRTDFTLIIDPVE
	chain	ADDVATYYCQQTNEDPYTFGGGTKLEIKRTVAAPSVFIFPP
		SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS
		QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
		GLSSPVTKSFNRGEC

TABLE 89 — cDNA and amino acid sequences of bivalent CEA (T84.66) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) PGLALA fusion (construct 5.8) SEQ ID

NO:	Description	Sequence
347	Nucleotide	GAGGTGCAGCTGCAGCAGTCTGGCGCCGAACTGGTGGA
	sequence anti-	ACCTGGCGCCTCTGTGAAGCTGAGCTGTACCGCCAGCGG
	CEA (T84.66) Fc	CTTCAACATCAAGGACACCTACATGCACTGGGTCAAGC
	hole dimeric 4-	AGCGGCCTGAGCAGGGCCTGGAATGGATCGGCAGAATC
	1BBL (71-254)	GACCCCGCCAACGGCAACAGCAAATACGTGCCCAAGTT
	chain	CCAGGGCAAGGCCACCATCACCGCCGACACCAGCAGCA
		ACACAGCCTACCTGCAGCTGACCAGCCTGACCTCCGAG
		GACACCGCCGTGTACTACTGCGCCCCCTTCGGCTACTAC
		GTGTCCGACTACGCCATGGCCTATTGGGGCCAGGGCAC
		AAGCGTGACCGTGTCCTCTGCTAGCACCAAGGGCCCCTC
		CGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCG
		GCGGCACAGCCGCTCTGGGCTGCCTGGTCAAGGACTACT
		TCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCC
		CTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAG
		AGTTCTGGCCTGTATAGCCTGAGCAGCGTGGTCACCGTG
		CCTTCTAGCAGCCTGGGCACCCAGACCTACATCTGCAAC
		GTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAA
		GGTGGAGCCCAAGAGCTGCGACAAAACTCACACATGCC
		CACCGTGCCCAGCACCTGAAGCTGCAGGGGGACCGTCA
		GTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATG
		ATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGAC
		GTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTA
		CGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC
		CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTC
		AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGC
		AAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGG
		CGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC
		AGCCCCGAGAACCACAGGTGTGCACCCTGCCCCCATCCC
		GGGATGAGCTGACCAAGAACCAGGTCAGCCTCTCGTGC
		GCAGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGA
		GTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGA
		CCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCC
		TCGTGAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAG
		CAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCT
		CTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCT
		CCGGGTGGAGGCGGCGGAAGCGGAGGAGGAGGATCCA
		GAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGGA
		CTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGTG
		GCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTGG
		TACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGGC
		GGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGGT
		GGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGGA
		ACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCTG
		TGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCGCTG
		CTGGCGCTGCAGCTCTGGCACTGACAGTGGATCTGCCTC
		CTGCCAGCTCCGAGGCCCGGAATAGCGCATTTGGGTTTC
		AAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCTG
		GGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACGC
		CTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTGTT
		CAGAGTGACCCCCGAGATTCCAGCCGGCCTGCCTTCTCC
		AAGAAGCGAAGGCGGAGGCGGATCTGGCGGCGGAGGA
		TCTAGAGAGGGACCCGAACTGTCCCCTGACGATCCAGC
		CGGGCTGCTGGATCTGAGACAGGGAATGTTCGCCCAGCT
		GGTGGCTCAGAATGTGCTGCTGATTGACGGACCTCTGAG
		CTGGTACTCCGACCCAGGGCTGGCAGGGGTGTCCCTGAC
		TGGGGGACTGTCCTACAAAGAAGATACAAAAGAACTGG
		TGGTGGCTAAAGCTGGGGTGTACTATGTGTTTTTTCAGC
		TGGAACTGAGGCGGGTGGTGGCTGGGGAGGGCTCAGGA
		TCTGTGTCCCTGGCTCTGCATCTGCAGCCACTGCGCTCT
		GCTGCTGGCGCAGCTGCACTGGCTCTGACTGTGGACCTG
		CCACCAGCCTCTAGCGAGGCCAGAAACAGCGCCTTCGG
		GTTCCAAGGACGCCTGCTGCATCTGAGCGCCGGACAGC
		GCCTGGGAGTGCATCTGCATACTGAAGCCAGAGCCCGG
		CATGCTTGGCAGCTGACTCAGGGGGCAACTGTGCTGGG
		ACTGTTTCGCGTGACACCTGAGATCCCTGCCGGACTGCC
		AAGCCCTAGATCAGAA
348	Nucleotide	GAGGTGCAGCTGCAGCAGTCTGGCGCCGAACTGGTGGA
	sequence anti-	ACCTGGCGCCTCTGTGAAGCTGAGCTGTACCGCCAGCGG
	CEA (T84.66) Fc	CTTCAACATCAAGGACACCTACATGCACTGGGTCAAGC
	knob monomeric	AGCGGCCTGAGCAGGGCCTGGAATGGATCGGCAGAATC
	4-1BBL (72-254)	GACCCCGCCAACGGCAACAGCAAATACGTGCCCAAGTT
	chain	CCAGGGCAAGGCCACCATCACCGCCGACACCAGCAGCA
		ACACAGCCTACCTGCAGCTGACCAGCCTGACCTCCGAG
		GACACCGCCGTGTACTACTGCGCCCCCTTCGGCTACTAC
		GTGTCCGACTACGCCATGGCCTATTGGGGCCAGGGCAC
		AAGCGTGACCGTGTCCTCTGCTAGCACCAAGGGCCCATC
		GGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGG
		GGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACT
		TCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCC
		CTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAG
		TCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTG
		CCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAAC
		GTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAA
		AGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCC
		ACCGTGCCCAGCACCTGAAGCTGCAGGGGGACCGTCAG
		TCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGA
		TCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACG
		TGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTAC
		GTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCC
		GCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCA
		GCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCA
		AGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGC
		GCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA
		GCCCCGAGAACCACAGGTGTACACCCTGCCCCCCTGCA
		GAGATGAGCTGACCAAGAACCAGGTGTCCCTGTGGTGT
		CTGGTCAAGGGCTTCTACCCCAGCGATATCGCCGTGGAG
		TGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGAC
		CACCCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCT
		GTACTCCAAACTGACCGTGGACAAGAGCCGGTGGCAGC
		AGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCC
		CTGCACAACCACTACACCCAGAAGTCCCTGAGCCTGAG
		CCCCGGCGGAGGCGGCGGAAGCGGAGGAGGAGGATCC
		AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG
		ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT
		GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG
		GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG
		CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG
		TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG
		AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT
		GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCGCT
		GCTGGCGCTGCAGCTCTGGCACTGACAGTGGATCTGCCT
		CCTGCCAGCTCCGAGGCCCGGAATAGCGCATTTGGGTTT
		CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT
		GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG
		CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG
		TTCAGAGTGACCCCCGAGATTCCAGCCGGCCTGCCTTCT
		CCAAGAAGCGAA
344	Nucleotide	see Table 88
	sequence anti-
	CEA (T84.66)
	light chain
349	anti-	EVQLQQSGAELVEPGASVKLSCTASGFNIKDTYMHWVKQ
	CEA (T84.66) Fc	RPEQGLEWIGRIDPANGNSKYVPKFQGKATITADTSSNTAY
	hole dimeric 4-	LQLTSLTSEDTAVYYCAPFGYYVSDYAMAYWGQGTSVTV
	1BBL(71-254)	SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV
	chain	SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
		YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGG
		PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
		VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRDE
		LTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPV
		LDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHY
		TQKSLSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLRQG
		MFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDT
		KELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPL
		RSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQ
		RLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPS
		PRSEGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQLV
		AQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVA
		KAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGA
		AALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHL
		HTEARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSE
350	anti-	EVQLQQSGAELVEPGASVKLSCTASGFNIKDTYMHWVKQ
	CEA (T84.66) Fc	RPEQGLEWIGRIDPANGNSKYVPKFQGKATITADTSSNTAY
	knob monomeric	LQLTSLTSEDTAVYYCAPFGYYVSDYAMAYWGQGTSVTV
	4-1BBL (71-254)	SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV
	chain	SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
		YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGG
		PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
		VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPCRDE
		LTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
		LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY
		TQKSLSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLRQG
		MFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDT
		KELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPL
		RSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQ
		RLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPS
		PRSE
346	anti-	see Table 88
	CEA (T84.66)
	light chain

TABLE 92 — Nucleotide and amino acid sequences of hu NA3B3A2-avi-His SEQ ID

NO:	Antigen	Sequence
351	nucleotide	CAGCTGACCACCGAGTCCATGCCCTTCAACGTGGCCG
	sequence hu	AGGGCAAAGAGGTGCTGCTGCTGGTCCACAACCTGCC
	NA3B3A2-avi	CCAGCAGCTGTTCGGCTACAGCTGGTACAAGGGCGAG
	His	CGGGTGGACGGCAACCGGCAGATCGTGGGCTACGCCA
		TCGGCACCCAGCAGGCCACACCCGGCCCTGCCAATAG
		CGGCAGAGAGACAATCTACCCCAACGCCAGCCTGCTG
		ATCCAGAACGTGACCCAGAACGACACCGGCTTCTACA
		CACTCCAAGTCATCAAGAGCGACCTGGTCAACGAGGA
		AGCCACCGGCCAGTTCCACGTGTACCCCGAGCTGCCC
		AAGCCCAGCATCAGCAGCAACAACAGCAAGCCCGTGG
		AAGATAAGGACGCCGTGGCCTTTACCTGCGAGCCCGA
		GGCCCAGAACACCACCTACCTGTGGTGGGTCAACGGC
		CAGAGCCTGCCCGTGTCCCCCAGACTCCAGCTGAGCA
		ACGGCAACAGAACCCTGACCCTGTTCAACGTGACCCG
		GAATGACGCCAGAGCCTACGTGTGCGGCATCCAGAAC
		AGCGTGTCCGCCAACCGCAGCGACCCCGTGACCCTGG
		ATGTGCTGTACGGCCCCGACACCCCCATCATCAGCCCC
		CCTGACAGCAGCTACCTGAGCGGCGCCAACCTGAACC
		TGAGCTGCCACAGCGCCAGCAACCCCAGCCCTCAGTA
		CAGCTGGCGGATCAACGGCATCCCCCAGCAGCACACC
		CAGGTGCTGTTTATCGCCAAGATCACCCCCAACAACA
		ACGGCACCTACGCCTGCTTCGTGTCCAACCTGGCCACC
		GGCCGGAACAACAGCATCGTGAAGTCCATCACCGTGT
		CCGCCTCCCTGAGCCCCGTGGTGGCCAAGCCTCAGAT
		CAAGGCCAGCAAGACCACCGTGACCGGCGACAAGGA
		CAGCGTGAACCTGACCTGCTCCACCAACGATACCGGC
		ATCAGCATCCGGTGGTTCTTCAAGAATCAGTCCCTGCC
		CAGCAGCGAGCGGATGAAGCTGAGCCAGGGCAACAT
		CACCCTGTCCATCAACCCCGTGAAAAGAGAGGACGCC
		GGCACCTATTGGTGCGAGGTGTTCAACCCCATCAGCA
		AGAACCAGAGCGACCCCATCATGCTGAACGTGAACTA
		CAACGCCCTGCCCCAAGAAAACCTGATCAATGTTGAT
		CTGGAAGTGCTGTTCCAGGGCCCAGGCAGCGGCCTGA
		ACGACATCTTCGAAGCCCAGAAAATCGAGTGGCACGA
		GGCCAGAGCCCACCACCACCATCACCAC
352	human	QLTTESMPFNVAEGKEVLLLVHNLPQQLFGYSWYKGER
	NAB3A2-avi-	VDGNRQIVGYAIGTQQATPGPANSGRETIYPNASLLIQNV
	His	TQNDTGFYTLQVIKSDLVNEEATGQFHVYPELPKPSISSN
		NSKPVEDKDAVAFTCEPEAQNTTYLWWVNGQSLPVSPR
		LQLSNGNRTLTLFNVTRNDARAYVCGIQNSVSANRSDPV
		TLDVLYGPDTPIISPPDSSYLSGANLNLSCHSASNPSPQYS
		WRINGIPQQHTQVLFIAKITPNNNGTYACFVSNLATGRN
		NSIVKSITVSASLSPVVAKPQIKASKTTVTGDKDSVNLTC
		STNDTGISIRWFFKNQSLPSSERMKLSQGNITLSINPVKRE
		DAGTYWCEVFNPISKNQSDPIMLNVNYNALPQENLINVD
		LEVLFQGPGSGLNDIFEAQKIEWHEARAHHHHHH

TABLE 93 — Biochemical analysis of human NA3B3A2-avi-His

	Monomer [%]	Yield
Construct	(SEC)	[mg/l]
human NA3B3A2-avi-	88	14.1
His

TABLE 94 — Binding on activated 4-1BB-expressing CD4+ T cells and CD8+ T cells

	EC 50 [nM]	EC 50 [nM]
Construct	4-1BB + CD8 +	4-1BB + CD4 +
Control B	0.05	0.26
Control C	0.02	0.30
Control D	0.04	0.28
Control E	0.13	1.22
5.4	0.13	0.35
5.6	0.06	0.34
5.7	0.0004	0.36
5.8	0.17	0.38

TABLE 95 — Binding to CEA-expressing tumor cells

	EC 50 [nM]	EC 50 [nM]
Construct	MKN45-8	LS180
5.7	11.6	14.4

TABLE 96 — Binding to CEA-expressing tumor cells EC 50 [nM]

	MKN-45	EC 50 [nM]
Construct	no tumor cells	MKN45
5.4	3.1	0.34
5.6	2.05	0.21
5.7	0.85	0.05
5.8	1.52	0.45

TABLE 97 — cDNA and amino acid sequences of monovalent FAP (28H1) targeted split trimeric OX40 ligand Fc (kih) fusion containing CH-CL cross with charged residues (construct 6.1). *for charged residues SEQ ID

NO:	Description	Sequence
353	Nucleotide	CAGGTGTCCCACAGATACCCCAGAATCCAGAGCATCAA
	sequence Dimeric	GGTGCAGTTCACCGAGTACAAGAAAGAGAAGGGCTTCA
	hu OX40L (51-	TCCTGACCAGCCAGAAAGAGGACGAGATCATGAAGGTG
	183)-CL* Fc	CAGGACAACAGCGTGATCATCAACTGCGACGGCTTCTA
	knob chain	CCTGATCAGCCTGAAGGGCTACTTCAGCCAGGAAGTGG
		ACATCAGCCTGCACTACCAGAAGGACGAGGAACCCCTG
		TTCCAGCTGAAGAAAGTGCGGAGCGTGAACAGCCTGAT
		GGTGGCCAGCCTGACCTACAAGGACAAGGTGTACCTGA
		ACGTGACCACCGACAACACCAGCCTGGACGACTTCCAC
		GTGAACGGCGGCGAGCTGATCCTGATTCACCAGAACCC
		CGGCGAGTTCTGCGTGCTGGGAGGCGGAGGATCTGGCG
		GAGGCGGATCTCAGGTGTCACACCGCTACCCCCGGATTC
		AGTCCATTAAGGTGCAGTTTACAGAGTATAAGAAAGAA
		AAAGGCTTTATTCTGACTTCCCAGAAAGAAGATGAGATT
		ATGAAGGTGCAGGATAATTCTGTGATCATCAATTGTGAC
		GGCTTCTACCTGATCAGCCTGAAGGGCTACTTCAGCCAG
		GAAGTGGACATCAGCCTGCACTACCAGAAGGACGAGGA
		ACCCCTGTTCCAGCTGAAGAAAGTGCGGAGCGTGAACA
		GCCTGATGGTGGCCAGCCTGACCTACAAGGACAAGGTG
		TACCTGAACGTGACCACCGACAACACCAGCCTGGACGA
		CTTCCACGTGAACGGCGGCGAGCTGATCCTGATCCACCA
		GAACCCTGGCGAGTTCTGCGTGCTGGGAGGCGGAGGCT
		CCGGAGGGGGAGGATCTCGTACGGTGGCTGCACCATCT
		GTCTTTATCTTCCCACCCAGCGACCGGAAGCTGAAGTCT
		GGCACAGCCAGCGTCGTGTGCCTGCTGAATAACTTCTAC
		CCCCGCGAGGCCAAGGTGCAGTGGAAGGTGGACAATGC
		CCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGC
		AGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACC
		CTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGT
		GTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCC
		CGTGACCAAGAGCTTCAACCGGGGCGAGTGCGACAAGA
		CCCACACCTGTCCTCCATGCCCTGCCCCTGAAGCTGCTG
		GCGGCCCTAGCGTGTTCCTGTTCCCCCCAAAGCCCAAGG
		ACACCCTGATGATCAGCCGGACCCCTGAAGTGACCTGC
		GTGGTGGTGGATGTGTCCCACGAGGACCCTGAAGTGAA
		GTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAATG
		CCAAGACCAAGCCGCGGGAGGAGCAGTACAACAGCACG
		TACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGAC
		TGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAA
		CAAAGCCCTCGGCGCCCCCATCGAGAAAACCATCTCCA
		AAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACC
		CTGCCCCCATGCCGGGATGAGCTGACCAAGAACCAGGT
		CAGCCTGTGGTGCCTGGTCAAAGGCTTCTATCCCAGCGA
		CATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGA
		ACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGAC
		GGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAG
		AGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTG
		ATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAG
		CCTCTCCCTGTCTCCGGGTAAA
354	Nucleotide	CAGGTGTCCCACAGATACCCCAGAATCCAGAGCATCAA
	sequence	GGTGCAGTTCACCGAGTACAAGAAAGAGAAGGGCTTCA
	Monomeric hu	TCCTGACCAGCCAGAAAGAGGACGAGATCATGAAGGTG
	OX40L (51-183)-	CAGGACAACAGCGTGATCATCAACTGCGACGGCTTCTA
	CH1*	CCTGATCAGCCTGAAGGGCTACTTCAGCCAGGAAGTGG
		ACATCAGCCTGCACTACCAGAAGGACGAGGAACCCCTG
		TTCCAGCTGAAGAAAGTGCGGAGCGTGAACAGCCTGAT
		GGTGGCCAGCCTGACCTACAAGGACAAGGTGTACCTGA
		ACGTGACCACCGACAACACCAGCCTGGACGACTTCCAC
		GTGAACGGCGGCGAGCTGATCCTGATTCACCAGAACCC
		CGGCGAGTTCTGCGTGCTGGGAGGCGGAGGTTCCGGAG
		GCGGAGGATCTGCTAGCACAAAGGGCCCCAGCGTGTTC
		CCTCTGGCCCCTAGCAGCAAGAGCACATCTGGCGGAAC
		AGCCGCCCTGGGCTGCCTGGTGGAAGATTACTTCCCCGA
		GCCCGTGACCGTGTCCTGGAATTCTGGCGCCCTGACAAG
		CGGCGTGCACACCTTTCCAGCCGTGCTGCAGAGCAGCG
		GCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCA
		GCTCTCTGGGCACCCAGACCTACATCTGCAACGTGAACC
		ACAAGCCCAGCAACACCAAGGTGGACGAGAAGGTGGA
		ACCCAAGTCCTGC
68	Nucleotide	see Table 2
	sequence anti-
	FAP (28H1) Fc
	hole chain
69	Nucleotide	see Table 2
	sequence anti-
	FAP (28H1) light
	chain
355	Dimeric hu	QVSHRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMKVQDN
	OX40L (51-183)-	SVIINCDGFYLISLKGYFSQEVDISLHYQKDEEPLFQLKKVR
	CL* Fc knob	SVNSLMVASLTYKDKVYLNVTTDNTSLDDFHVNGGELILI
	chain	HQNPGEFCVLGGGGSGGGGSQVSHRYPRIQSIKVQFTEYK
		KEKGFILTSQKEDEIMKVQDNSVIINCDGFYLISLKGYFSQE
		VDISLHYQKDEEPLFQLKKVRSVNSLMVASLTYKDKVYLN
		VTTDNTSLDDFHVNGGELILIHQNPGEFCVLGGGGSGGGG
		SRTVAAPSVFIFPPSDRKLKSGTASVVCLLNNFYPREAKVQ
		WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYE
		KHKVYACEVTHQGLSSPVTKSFNRGECDKTHTCPPCPAPE
		AAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK
		FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLP
		PCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYK
		TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
		HNHYTQKSLSLSPGK
356	Monomeric hu	QVSHRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMKVQDN
	OX40L (51-183)-	SVIINCDGFYLISLKGYFSQEVDISLHYQKDEEPLFQLKKVR
	CH1*	SVNSLMVASLTYKDKVYLNVTTDNTSLDDFHVNGGELILI
		HQNPGEFCVLGGGGSGGGGSASTKGPSVFPLAPSSKSTSGG
		TAALGCLVEDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
		LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDEKVEPKS
		C
18	anti-FAP (28H1)	see Table 2
	Fc hole chain
19	anti-FAP (28H1)	see Table 2
	light chain

TABLE 98 — Biochemical analysis of CEA targeted split trimeric 4-1BB ligand Fc (kih) fusion.

	Monomer [%]	Yield
Construct	(SEC)	[mg/l]
monovalent FAP(28H1) targeted split	93.8	19.7
trimeric Ox40 ligand Fc fusion containing
CH-CL cross with charged residues
(construct 6.1)
germline DP47 human IgG1 PGLALA	100	50

description truncated at 500,000 characters

Stored text is truncated at the source; the tail of the description is not held.

Claims as granted

56 claims

Classifications

6 codes

IPC · International Patent Classification

Section A — Human necessities

A61K39/395
A61K38/00

Section C — Chemistry; metallurgy

C07K16/40
C07K14/705
C07K16/28
C07K16/30

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

2.7 y

999 days filing → grant

Office actions

non-final + final

Responses

1 RCE

Examiner

Robert S Landsman

art unit 1647 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 135 back · 12 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Chain of title

No assignments have been recorded for this application yet.